

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
3 July 2003 (03.07.2003)

PCT

(10) International Publication Number  
**WO 03/054162 A2**

- (51) International Patent Classification<sup>7</sup>: C12N
- (21) International Application Number: PCT/US02/41014
- (22) International Filing Date:  
19 December 2002 (19.12.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
10/029,397 20 December 2001 (20.12.2001) US
- (71) Applicant (*for all designated States except US*): AM-BION, INC. [US/US]; 2130 Woodward St., Suite 200, Austin, TX 78744-1832 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): MURPHY, George, L. [US/US]; 8825 Escabosa Dr., Austin, TX 78748 (US). WHITLEY, J., Penn [US/US]; 5203 Avenue F, Austin, TX 78751 (US).
- (74) Agent: SHISHIMA, Gina, N.; Fulbright & Jaworski L.L.P., Suite 2400, 600 Congress Avenue, Austin, TX 78701 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished upon receipt of that report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 03/054162 A2

(54) Title: METHOD AND SYSTEM FOR DEPLETING rRNA POPULATIONS

(57) Abstract: The present invention concerns a system for isolating, depleting, or separating a targeted nucleic acid, such as rRNA, from a sample comprising targeted and nontargeted nucleic acids. It effects a way of enriching for nontargeted nucleic acids, such as mRNAs. The invention further concerns methods of implementing the system and kits for implementing the system, which involves at least one bridging nucleic acid comprising 1) a targeting region complementary to a region on the targeted nucleic acid and 2) a bridging region complementary to the capture region of a capture nucleic acid that comprises a nonreactant structure. The nonreactant structure can be used to isolate the hybridizing molecules after incubation under conditions that allows hybridization.

## **DESCRIPTION**

### **METHOD AND SYSTEM FOR DEPLETING rRNA POPULATIONS**

#### **BACKGROUND OF THE INVENTION**

##### **1. Field of the Invention**

5           The present invention relates generally to the fields of molecular biology and microbial pathogenesis. More particularly, it concerns methods, compositions, and kits for isolating, depleting, separating a targeted nucleic acid population from other nucleic acid populations as a means for enriching those other nucleic acid population(s). More particularly, it concerns  
10       methods, compositions, and kits for enriching mRNA populations by depleting eukaryotic and/or prokaryotic rRNA from a sample using engineered bridging and capture nucleic acid molecules.

##### **2. Description of Related Art**

          The ongoing efforts in microbial genome sequencing will enable unprecedented advances in our understanding of microbes and host-microbe interactions. Dozens of prokaryotic  
15       genomes, including those of numerous human pathogens, have been completely sequenced, and many others are in progress. Consequently, a renewal of focus and energy has emerged in the fields of microbial evolution, microbial pathogenesis, and infectious diseases. The potential impact of genomics on these disciplines is the subject of several recent reviews (Cummings *et al.*, 2000; Cornelis *et al.*, 2001; Fox *et al.*, 2001; *Current Opinion in Microbiology*). For host-  
20       microbe interactions, the ability to measure the expression of every single gene in a microorganism will make possible studies of such complex interactions as the global regulation of virulence factors and the mechanisms of response to host cells and their microenvironment. Scientists will also be able to evaluate the complete repertoire of host cell gene expression in response to the pathogen. Undoubtedly, novel interactions and responses between microbes and  
25       their hosts will be discovered, leading to a more complete picture of infectious diseases and how to control them.

          In the past decade, researchers studying bacteria developed several novel approaches to evaluate global gene transcription in response to environmental stimuli, including host-microbe interactions. Prior to the era of genome sequencing, Chuang *et al.* (Chuang *et al.*, 1993) used an  
30       ordered set of *E. coli* lambda library clones to evaluate global transcription responses of *E. coli*. Other groups employed subtractive hybridization and differential screening to evaluate induction

of gene expression in *Mycobacterium avium* after phagocytosis by macrophages (Plum *et al.*, 1994) or in *Pyrococcus* grown under specific environmental conditions (Robinson *et al.*, 1994). Researchers further developed this approach with an elegant procedure for the selective capture of transcribed sequences (SCOTS) (Graham *et al.*, 1999). At the same time, many scientists  
5 bypassed library construction altogether and used using differential display (Liang *et al.*, 1995) to discover genes that are transcribed differently under various growth conditions. Although useful in certain circumstances, differential display is frequently a hit-or-miss prospect and gives no information on global transcription. More recently, serial analysis of gene expression (SAGE) (Velculescu *et al.*, 1995) emerged as a method for analyzing the complete transcriptome  
10 of a cell. SAGE, like differential display, can be useful but requires large amounts of nucleic acid sequencing. Not unexpectedly, for organisms whose genomes have been sequenced, array analysis is emerging as the method of choice for global gene expression studies with bacteria. Macroarrays (filter-based arrays) and microarrays (slide-based arrays) of complete genomes have made possible the simultaneous expression analysis of thousands of genes. The advent of  
15 microarray technology has already enabled analyses of the host response to interactions with pathogenic organisms (Cummings *et al.*, 2000). Similarly, microarray analysis and other methods have been used to evaluate gene expression in bacteria grown under different environmental conditions *in vitro*.

The application of array analysis to gene expression profiling in prokaryotes was an  
20 immediate outgrowth of similar studies with eukaryotic organisms, occurring only within the past two to three years. Infectious disease researchers have already begun applying microarray analysis to the study of complex host-microbe interactions. To date, such analyses of host-microbe interactions have been limited to the evaluation of host cell responses to bacteria or viruses. *Bordetella pertussis*, *Listeria monocytogenes*, *Neisseria meningitidis*, *Pseudomonas*  
25 *aeruginosa*, *Legionella pneumophila*, *Salmonella dublin*, and *Staphylococcus aureus* are among the bacterial pathogens whose effects on host cell gene expression have been evaluated with microarrays. Array analyses of eukaryotic host cell transcription are feasible because of the ability to isolate polyadenylated mRNAs from eukaryotic cells and to specifically label mRNAs by oligo dT-primed cDNA synthesis.

30 Although it has been alluded to in the literature (Cummings *et al.*, 2000; Rappuoli, 2000), complete genome array expression analyses of bacteria in response to interactions with host cells

have not been widely published, if at all. Studies that examine the global bacterial gene response in the presence of host cells will require the development of tools to enable the efficient isolation, enrichment, and labeling of bacterial mRNAs (Cummings *et al.*, 2000; Graham *et al.*, 1999; Gingeras *et al.*, 2000; Graham *et al.*, 2001).

5           However, technical limitations of current methods available for purification and evaluation of bacterial mRNAs preclude these types of whole genome analysis. To realize the full potential of the genomics revolution, methods for purifying mRNAs from total bacterial RNA populations and particularly from mixtures of host cell and bacterial RNA need to be developed.

10           Isolating sufficient quantities of high quality bacterial mRNA is perhaps the most demanding technical requirement impeding analyses of bacterial gene expression in the presence of host cells. A small percentage of bacterial mRNAs may be A-tailed, but these are targeted for degradation and tend to be unstable. As a result, the commonly used method for mRNA purification with eukaryotic cells, oligo-dT capture, is ineffective.

15           Only a few studies have described methods for enriching or purifying bacterial mRNAs. Several groups (Plum *et al.*, 1994; Robinson *et al.*, 1994; Su *et al.*, 1998) have used rRNA subtraction to enrich for bacterial mRNAs. These procedures involved hybridization of rRNAs to biotinylated plasmid containing rRNA genes or to biotinylated antisense rRNAs followed by streptavidin capture and removal. This yields some benefits, but it requires fairly large amounts  
20 of plasmids or antisense RNA. Biotinylation of large amounts of DNA or RNA is often tricky and can be prohibitively expensive if biotin-modified nucleotides are incorporated during antisense RNA synthesis. In general, these methods have not seen widespread use. As mentioned above, Graham and Clarke-Curtiss (Graham *et al.*, 1999) went further in enriching for mycobacterial mRNAs with SCOTS. The SCOTS procedure is effective for detecting genes  
25 specifically expressed in the presence of host cells but is hampered by being a multi-step procedure that requires production of normalized double-stranded cDNA, PCR, differential hybridization, and cDNA capture. In addition to these methods, researchers have developed methods to polyadenylate bacterial mRNAs, thereby allowing for their purification by oligo dT-capture. Amara and Vijaya (Amara *et al.*, 1997) demonstrated that mRNAs in purified  
30 polysomes can be specifically polyadenylated and purified by oligo-dT capture. Wendisch *et al.* (Wendisch *et al.*, 2001) showed that the same process can be carried out with crude cell extracts.



Several shortcomings are associated with the polyadenylation approach. Different mRNAs may be polyadenylated to different extents or not at all depending on the structure of their 5' and 3' ends (Feng *et al.*, 2000). Polyadenylation in a cell lysate, followed by purification of RNA, will require inactivation of cellular RNAses so that transcripts are not degraded during the polyadenylation reaction. Optimizing the reaction to work reproducibly in many different bacterial cell lysates would likely be very difficult. Despite many worthy attempts, simple and universal procedures for bacterial mRNA enrichment, especially in the presence of host cell RNA, remain elusive. Thus, there remains a continued need for improvements in mRNA enrichment and/or the depletion of other RNA populations.

10

### **SUMMARY OF THE INVENTION**

The present invention involves a system that allows for the isolation, separation, and depletion of a population of nucleic acid molecules. The system involves components that may be used to implement methods for isolating, separating, or depleting a targeted nucleic acid. Such components may also be included in kits of the invention.

15

In embodiments of the invention, a population of nucleic acids may be targeted for isolation, separation, or depletion. Such a nucleic acid is referred to as "targeted nucleic acid" or "targeted nucleic acid molecule." Alternatively, it may be referred to as a "nucleic acid target." In particular embodiments of the invention, the targeted nucleic acid is rRNA. In alternative embodiments, the targeted nucleic acid is mRNA, tRNA, or DNA including, cDNA and genomic DNA. The targeted nucleic acid may be in a sample, which is a composition that is suspected of containing the targeted nucleic acid. In some embodiments, the sample is obtained from or includes prokaryotes or eukaryotes or both. The sample may be cells, tissues, organs, and lysates, fractionations, or portions thereof. Furthermore, the targeted nucleic acid is targeted via a "targeting region" in the targeted nucleic acid. A "targeted region" refers to a region of the targeted nucleic acid that is complementary with the targeting region of a bridging nucleic acid and that allows the targeted nucleic acid to be separated from other non-targeted nucleic acid populations.

20

25

In embodiments in which the targeted nucleic acid is rRNA, the rRNA may be the 5S, 16S, or 23S rRNA from prokaryotes, though it may be any rRNA species from a prokaryotes. It is specifically contemplated that nucleic acids may be targeted in Gram positive bacteria and Gram negative bacteria. In further embodiments, the targeted rRNA is 5.8S, 17S or 18S, or 28S

30

rRNA (referred to as “types of rRNA”) from a eukaryote. It is further contemplated that tRNA may be a targeted nucleic acid population either by itself or in combination with any of the targeted nucleic acids described herein. A non-limiting list of targeted rRNAs from various organisms is provided in a later section and is contemplated to be part of the invention.

5 In embodiments of the invention, the system involves a bridging nucleic acid, a capture nucleic acid, and a targeted nucleic acid, as shown, for example, in FIG. 1. While in many embodiments of the invention it is contemplated that the bridging nucleic acid and the capture nucleic acid are oligonucleotides, it is specifically contemplated that they may be polynucleotides as well. Thus, any embodiment involving an oligonucleotide may be  
10 implemented with a polynucleotide. Bridging nucleic acids, capture nucleic acids, and targeted nucleic acids of the invention may include, be at least or be at most 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91,  
15 92, 93, 94, 95, 96, 97, 98, 99, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980,  
20 990, 1000 or more residues in length.

Furthermore, a “bridging nucleic acid” is a nucleic acid molecule that comprises a bridging region and a targeting region, while a “capture nucleic acid” is a nucleic acid molecule that comprises a capture region. It is contemplated that bridging, targeting, and capture regions of the invention may be, be at least or be at most 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,  
25 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450,  
30 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830,

840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, or 1000 residues in length.

A “bridging nucleic acid” refers to a molecule that includes nucleic acid residues or analogs and that includes at least one targeting region and at least one bridging region. A “targeting region” refers to a region of the molecule that is involved in targeting a particular nucleic acid or nucleic acid population and is thus complementary to all or part of the sequence of the targeted nucleic acid. It is further contemplated that more than one targeting region may be included in a bridging nucleic acid. The bridging nucleic acid may include or have up to 2, 3, 4, 5, 6, 7, 8, 9, 10, or more targeting regions. When there are multiple targeting regions, it is contemplated that the regions may be complementary to different, nonoverlapping sequences from the same targeted nucleic acid or they may be complementary to similar or overlapping sequences from the same targeted nucleic acid, or they may be complementary to sequences in different targeted nucleic acids. While mRNA may be targeted, it is specifically contemplated that mRNA is not targeted and thus the targeting region does not have a stretch of polypyrimidine residues, such as poly-T or poly-U to hybridize to the poly-A tail of eukaryotic mRNA. Also considered part of the invention is using single or multiple bridging nucleic acids to deplete an rRNA population. In some embodiments, a single bridging nucleic acid may contain one or more targeting regions that are complementary to different types of rRNA (“types” refer to sizes based on intact lengths). Thus, in some embodiments, the largest type of rRNA may be targeted (“largest” refers to longest nucleic acid molecule when intact, even though molecules that are no longer intact may also be targeted if they retain the sequence that is complementary to all or part of a targeting region). In still further embodiments, the second largest rRNA or the first and second largest rRNA types may be targeted by a single bridging nucleic acid with targeting regions to each or to more than one nucleic acid, each with a targeting region to a different type of rRNA. In still further embodiments, a bridging nucleic acid has a targeting region complementary to one or more of the following prokaryotic and eukaryotic rRNA types: 5S, 16S, 23S, 5.8S, 17S, 18S, and/or 28S. A bridging nucleic acid may target 1, 2, 3, 4, 5, 6, 7, or more types of rRNA, as well as any and all tRNA types, both eukaryotic and prokaryotic.

A “bridging region” in a bridging nucleic acid refers to a region that mediates an interaction with a capture nucleic acid. In further embodiments, the bridging region is a

polypurine or polypyrimidine stretch of residues. A bridging region can include a stretch of adenine or guanine residues or cytosine, uracil, or thymidine residues. In some embodiments, it is contemplated that more than one bridging region is included in a bridging nucleic acid, such as 2, 3, 4, 5, or more bridging regions.

5 A "capture nucleic acid" refers to a molecule that includes nucleotides or nucleotide analogs, a capture region, and a nonreacting structure. A "capture region" refers to a region that interacts with the bridging region of a bridging nucleic acid. In embodiments of the invention, the bridging region and the capture region are complementary to each other and hybridize to one another under conditions that allow for hybridization of complementary regions. In some  
10 embodiments of the invention, the capture region and bridging region are a stretch of complementary repeated nucleotides (complementary homopolymeric regions). For example, they may be homopolymeric A, T, G, C, or U. In other embodiments of the invention, however, the bridging and capture regions are any sequence, so long as they are complementary. In some embodiments of the invention, the capture region has a sequence that includes at least 5, 6, 7, 8,  
15 9, 10 or more contiguous nucleotides of SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, and SEQ ID NO:92 (collectively referred to as "SEQ ID NOs: 87-92"). In some embodiments, the capture regions comprises any of of SEQ ID NOs 87-92.

There may be more than one nonreacting structure attached, covalently or noncovalently, to a capture nucleic acid. There may be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more nonreacting structures  
20 as part of a capture nucleic acid.

A capture nucleic acid also includes a "nonreacting structure," which refers to a compound that does not chemically react with a nucleic acid. In some embodiments, a nonreacting structure is a magnetic bead or rod, which allows the capture nucleic acid, a bridging nucleic acid and a target nucleic acid to be isolated from a sample with a magnetic field, such as  
25 a magnetic stand. In still further embodiments, the nonreacting structure is a bead or other structure that can be physically captured, such as by using a basket, filter, or by centrifugation. It is contemplated that a bead may include plastic, glass, teflon, silica, a magnet or be magnetizeable, a metal such as a ferrous metal or gold, carbon, cellulose, latex, polystyrene, and other synthetic polymers, nylon, cellulose, nitrocellulose, polymethacrylate, polyvinylchloride,  
30 styrene-divinylbenzene, or any chemically-modified plastic or any other nonreacting structure. In still further embodiments, the nonreacting structure is biotin or iminobiotin. Biotin or

iminobiotin binds to avidin or streptavidin, which can be used to isolate the capture nucleic acid and any hybridizing molecules. Furthermore, in some embodiments of the invention, the nonreacting structure is cellulose or an analog thereof.

It is contemplated that the location of the targeting and bridging regions in the bridging nucleic acid may be at a variety of positions. The location of targeted regions in a targeted nucleic acid or a capture region in a capture nucleic acid may also vary. The location of any of these regions or nonreacting structure may be or be within 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000, 3100, 3200, 3300, 3400, 3500, 3600, 3700, 3800, 3900, 4000, 4100, 4200, 4300, 4400, 4500, 4600, 4700, 4800, 4900, 5000 or more nucleotides from the 3' and/or 5' end of the relevant nucleic acid ("relevant nucleic acid" refers to the nucleic acid in which the region is located). Moreover, it is contemplated that a region, such as a bridging, capture, targeted, or targeting region—as well as a nonreacting structure—may be at or within 100-5000 residues, 150-4000 residues, 200-3000 residues, 250-2000 residues, 300-1500 residues, 350-1000 residues, 400-900 residues, 450-800 residues, or 500-700 residues of the 5' or 3' end of the relevant nucleic acid.

Furthermore, it is also contemplated that the spacing between regions may vary. Regions in the same nucleic acid or a region and a nonreacting structure may be adjacent to one another or there may be residues between them or between each of them. The number of intervening residues may be the following or may be at least or at most of the following: 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590,

600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, or more nucleotides between them or each of them.

5           As for the location of the sequence to which the targeting region is complementary, termed "targeted region," this may be 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000, 3100, 3200, 3300, 3400, 3500, 3600, 3700, 3800, 3900, 4000, 4100, 4200, 4300, 4400, 4500, 4600, 4700, 4800, 4900, 5000 nucleotides or more from the 3' and/or 5' end of the targeted nucleic acid. It is specifically contemplated that the targeting region hybridizes to a sequence located between 100 and 5000, 150 and 4000, 200 and 3000, 250 and 2000, and 300 and 1000 residues of the 5' and/or 3' end of the targeted nucleic acid. It is also contemplated that the targeted region is at the 3' or 5' end of the targeted nucleic acid. Alternatively, the targeted region may not be within 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000, 3100, 3200, 3300, 3400, 3500, 3600, 3700, 3800, 3900, 4000, 4100, 4200, 4300, 4400, 4500, 4600, 4700, 4800, 4900, 5000 or more nucleotides from the termini of a targeted nucleic acid.

          In some embodiments, the targeting region comprises or is complementary to all or 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940,

950, 960, 970, 980, 990, 1000 or more contiguous nucleotides of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:72, or SEQ ID NO:73 (collectively referred to as "SEQ ID NOS:1-73"), as well as SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:91, SEQ ID NO:91, and SEQ ID NO:92 (collectively referred to as "SEQ ID NOS:1-92"). It is specifically contemplated that targeting regions of the invention comprise, in some embodiments, at least 5 contiguous nucleotides of SEQ ID NO:1-22; it is also contemplated that targeting regions of the invention are complementary to a sequence ("sequence" in the context of complementary regions refers to a sequence of at least 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, or more nucleotides in length) of SEQ ID NOS:23-86, which are sequences of rRNA molecules.

It will be understood that any embodiment discussed with respect to nucleotides applies also when nucleotide analogs are used. It is specifically contemplated that nucleotide analogs may be employed with respect to bridging and capture nucleic acids of the invention.

It is contemplated that nucleic acids of the invention include RNA, DNA, locked nucleic acid™ (LNA), iso-bases, and/or peptide mimetics. It is contemplated that all or part of nucleic acids of the invention may include such nucleic acid components.

The present invention further concerns methods of isolating and/or depleting nucleic acids from a sample. In some embodiments, methods include a) incubating a sample with a first

bridging nucleic acid comprising (1) at least one bridging region comprising at least 5 nucleic acid residues, under conditions allowing hybridization between the first targeting region and the targeted nucleic acid; b) incubating the first bridging nucleic acid with a capture nucleic acid comprising a nonreacting structure and a capture region comprising at least 5 nucleic acid residues, under conditions that allowing hybridization between the first bridging region and the capture region. In additional embodiments, one or more other steps may be included in combination with the method discussed above. Other steps involve isolating the targeted nucleic acid from the remainder of the sample; discarding the portion of the sample that hybridizes directly or indirectly to the capture nucleic acid (indirect hybridization refers to specific association of compounds that occurs through hybridization with a mediating compound, for example, indirect hybridization of a capture nucleic acid and a targeted nucleic acid via hybridization to a bridging nucleic acid); incubating the sample with additional bridging nucleic acids, under conditions allowing hybridization between the targeting region of the additional bridging nucleic acid and the targeted nucleic acid; implementing the method with respect to other targeted nucleic acids; washing the capture nucleic acid after incubation with the sample and the bridging nucleic acid; incubating the capture nucleic acid, bridging nucleic acid, and sample with elution buffer after isolating the targeted nucleic acid from the rest of the sample; eluting the targeted nucleic acid from the nonreactant structure; using the capture nucleic acid in a subsequent method involving a new sample; discarding the targeted nucleic acid after separating it from the sample; performing hybridizations between the bridging nucleic acid and the sample and the capture nucleic acid and the sample at the same temperatures or at different temperatures; performing the above hybridization steps at the same time, sequentially (one after the other or the other after the one); exposing the sample to a magnetic field or magnet, particularly when a magnetic bead or other object comprises all or part of the non-reacting structure of the capture nucleic acid; and incubating the sample with streptavidin or avidin, particularly if biotin or iminobiotin is used as a non-reacting structure.

In some embodiments of the invention, the sample, a bridging nucleic acid and/or a capture nucleic acid are incubated in a buffer, which, in some embodiments, includes TEAC or TMAC.

In methods of the invention involving more than one bridging nucleic acid, it is contemplated that the targeting region of the first bridging nucleic acid may be complementary to



a different sequence of a different targeted nucleic acid than a targeting region of another bridging nucleic acid. Alternatively, different bridging nucleic acids may have targeting regions that are complementary to the same targeted nucleic acid. In the latter case, it is further contemplated that the targeting regions be complementary to sequences that overlap one another or may be complementary to sequences in non-overlapping locations.

In cases in which targeting regions are complementary to different targeted nucleic acids, embodiments may involve targeting the largest rRNA molecule in a sample with one bridging nucleic acid and the second largest rRNA molecule in a sample with another bridging nucleic acid. In still further embodiments, another or third bridging nucleic acid will target the third largest rRNA molecule in a sample, while another or a fourth bridging nucleic acid will target the fourth largest rRNA molecule in a sample.

In another embodiment of the invention, there is a method for depleting rRNA from a sample comprising incubating the sample with (1) at least a first bridging oligonucleotide comprising a bridging region comprising a polypurine region of at least 5 residues in length and a targeting region comprising at least 5 contiguous residues complementary to an rRNA molecule in the sample and (2) a capture oligonucleotide comprising a magnetic bead and a capture region comprising a polypyrimidine region of at least 5 residues in length, under conditions allowing hybridization between the bridging oligonucleotide and the capture oligonucleotide and between the bridging oligonucleotide and the rRNA; b) incubating the sample with a magnetic bead; and c) isolating the magnetic bead. In still further embodiments, the first bridging oligonucleotide comprises a targeting region complementary to prokaryotic 23S rRNA. In still further embodiments, there is a second bridging oligonucleotide with a targeting region complementary to a different region of a prokaryotic 23S RNA than the first bridging oligonucleotide. In even further embodiments, there is a third and fourth bridging oligonucleotide each with a targeting region complementary to different sequences of a prokaryotic 16S rRNA.

As discussed earlier, a sample may be depleted or isolated as a way of enriching for the nontargeted nucleic acid, such as mRNA. In further embodiments of the invention, enriched mRNA can be used to prepare cDNA according to methods known to those of ordinary skill in the art, and as described herein. Thus, in cases in which mRNA is enriched as a result of methods of the invention, embodiments may further include discarding the portion of the sample

that hybridizes to the capture oligonucleotide. More specifically targeted rRNA may be discarded and the mRNA remaining in the sample may be used to produce cDNA molecules. cDNA molecules may be used in a variety of methods, including, but not limited to, library production, production of proteins, and for creating and screening arrays. Therefore, in some  
5       embodiments of the invention, cDNA made from mRNA enriched according to methods of the invention are attached to a solid support or surface so as to create a nucleic acid array. The term "nucleic acid array" refers to a plurality of target elements, wherein each target element comprising one or more nucleic acid molecules immobilized on one or more solid surfaces at discrete locations to which sample nucleic acids can be hybridized. The nonreacting solid  
10       surface or support may be any of a number of materials, including plastic, glass, or nylon. In some embodiments, the solid support is a plate. The plate may have wells that contain the target elements. Plates may have 2, 3, 4, 5, 6, 7, 8, 9, 10 or more wells ("multi-well"), and up to at least 96 or 192 wells. In some embodiments of the invention, the sample nucleic acids comprise cDNAs made by depleting a sample of rRNA, according to methods of the invention. Those  
15       embodiments may further involve contacting a nucleic acid array with the cDNA. Alternatively, cDNA made according to the invention may be used as target elements on an array. In any of these embodiments of the invention, it is specifically contemplated that enriched mRNA may be amplified into RNA or DNA by techniques known to those of skill in the art and then used in methods of the invention, such as to probe or screen an array.

20       The present invention also concerns kits that include compositions of the invention to implement the methods discussed herein. These kits can be used for the depletion, isolation, or purification of nucleic acids. Kits contain these compositions in a suitable container means.

In some embodiments, a kit includes 1) at least one capture oligonucleotide comprising a capture region and a magnetic bead; and 2) at least a first bridging oligonucleotide comprising i)  
25       at least one bridging region complementary to all or part of the capture region of the capture oligonucleotide and ii) at least one targeting region comprising 10 contiguous nucleic acids complementary to an rRNA.

In additional embodiments, there is a second bridging oligonucleotide comprising i) at least one bridging region complementary to all or part of the capture region of the capture  
30       oligonucleotide and ii) at least one targeting region comprising 10 contiguous nucleic acids complementary to an rRNA. In some kits, the targeting region of the second bridging

oligonucleotide is complementary to the same rRNA as the targeting region of the first bridging oligonucleotide, while in other embodiments, these are complementary to different rRNAs. Further embodiments involve kits in which the targeting region of the first bridging oligonucleotide is complementary to the largest rRNA of a prokaryote or eukaryote. In other  
5     embodiments, the second bridging oligonucleotide has a targeting region that is complementary to either the largest rRNA of a prokaryote or eukaryote or the second largest rRNA of a prokaryote or eukaryote. It is specifically contemplated that kits may include one or more bridging oligonucleotides targeting prokaryotic rRNA (16S, 23S, or both) *and* one or more bridging oligonucleotides targeting eukaryotic rRNA (18S, 28S, or both); thus, a kit may be used  
10    for depleting both eukaryotic and prokaryotic rRNA, in some embodiments.

Kits may also include a third, fourth, fifth, sixth, seventh, eighth, ninth, tenth or more bridging oligonucleotides with targeting region complementary to the same or different rRNAs as the targeting regions of the first and second bridging oligonucleotides. It is contemplated that the targeting regions of the bridging oligonucleotides in kits of the invention may be  
15    complementary to prokaryote 16S rRNA, prokaryote 23S rRNA, prokaryote 5S rRNA, eukaryote 17S or 18S rRNA, eukaryote 28SrRNA, and/or eukaryote 5.8S rRNA. It is further contemplated that targeting regions of bridging oligonucleotides in kits may have all or part of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ  
20    ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, or SEQ ID NO:22 (collectively referred to as "SEQ ID NOS:1-22"). Alternatively, kits may include targeting regions as discussed above with respect to SEQ ID NOS:23-86, *i.e.* targeting regions complementary to a sequence from SEQ ID NOS:23-86. Kits of the invention may also include one or more of the following: binding buffer with TMAC,  
25    binding buffer with TEAC, magnetic stand, wash solution, nuclease-free water; RNase inhibitors, glycogen, control RNA, sodium acetate, ammonium acetate, streptavidin beads, avidin beads, magnetic beads, beads of any nonreacting structure--including those discussed above--capture basket; capture filters, RNA markers, nuclease-free containers such as tubes and tips, and any other composition described herein.

It is contemplated that kits of the invention may be used to implement methods of the invention, that methods of the invention may be implemented with compositions of the invention, and that kits may include any composition of the invention.

It is further contemplated that kits, methods, and compositions of the invention may  
5 effect a depletion of a targeted nucleic acid in a sample by reducing its amount in the sample by  
at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99, 99.1,  
99.2, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, 99.9 or more percent.

Kits of the invention also include materials for creating a nucleic acid array and probing a  
nucleic acid array. Any of the kits discussed above may also include a solid support for  
10 preparing a nucleic acid array.

The use of the word "a" or "an" when used in conjunction with the term "comprising" in  
the claims and/or the specification may mean "one," but it is also consistent with the meaning of  
"one or more," "at least one," and "one or more than one." When the term "at least" is used in  
the context of bridging, targeting, or capture regions, as well as for capture and bridging  
15 oligonucleotides, it is contemplated that there is an upper limit of 20 for practical purposes, even  
though more such regions or oligonucleotides could be implemented with the invention.  
Furthermore, it should be understood that a number (cardinal or ordinal) used in the context of  
compositions of the invention refers to a "kind" of that composition; thus, "a first  
oligonucleotide" in the context of a "second oligonucleotide" refers to "one of that kind of  
20 oligonucleotide," and not one single oligonucleotide molecule.

Other objects, features and advantages of the present invention will become apparent  
from the following detailed description. It should be understood, however, that the detailed  
description and the specific examples, while indicating specific embodiments of the invention,  
are given by way of illustration only, since various changes and modifications within the spirit  
25 and scope of the invention will become apparent to those skilled in the art from this detailed  
description.

**BRIEF DESCRIPTION OF THE DRAWINGS**

The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.

**FIG. 1.** Depiction of molecules in system. A bridging oligonucleotide is shown with a targeting region and a bridging region. The targeting region is complementary to a targeted region in the targeted nucleic acid, which is an rRNA molecule. The bridging region is complementary to the capture region in the capture oligonucleotide, which is attached, by way of example, to a magnetic bead as a nonreacting structure.

**FIG. 2A-1 to A-14 and FIG. 2B-1 to B-27.** Sequence comparison of different rRNAs from different bacteria to *E. coli* rRNA with MegAlign sequence analysis software version 4.05 from DNA Star, Incorporated. **A.** The 5' end of the sequence is shown on the first page of the figure in FIG. 2A-1 and continues until the last page of the figure, FIG. 2A-14, in which the 3' end of the same sequence is shown. Shown is a sequence comparison of 16S rRNA of listed prokaryotic organisms to 16S rRNA from *E. coli* (SEQ ID NO:34). The sequences are the 16S rRNA from the following organisms: *B. subtilis* (SEQ ID NO:23); *B. anthracis* (SEQ ID NO. 24); *E. faecalis* (SEQ ID NO. 25); *L. lactis* (SEQ ID NO. 26); *L. monocyt* (SEQ ID NO. 27); *S. aureus* (SEQ ID NO. 28); *S. mutans* (SEQ ID NO. 29); *S. pneumon* (SEQ ID NO. 30); *S. pyogenes* (SEQ ID NO. 31); *M. avian* (SEQ ID NO. 32); *M. tuberculosis* (SEQ ID NO. 33); *K. pneumoniae* (SEQ ID NO. 35); *A. actino* (SEQ ID NO. 36); *H. influenzae* (SEQ ID NO. 37); *E. bronchiseptica* (SEQ ID NO. 38); *B. parapertussis* (SEQ ID NO. 39); *B. pertussis* (SEQ ID NO. 40); *B. cepacia* (SEQ ID NO. 41); *B. mallei* (SEQ ID NO. 42); *B. pseudomallei* (SEQ ID NO. 43); *N. gonorrhoeae* (SEQ ID NO. 44); *N. mening* (SEQ ID NO. 45); *P. aeruginosa* (SEQ ID NO. 46); *V. cholerae* (SEQ ID NO. 47); and *Y. enterocolitica* (SEQ ID NO. 48). **B.** The 5' end of the sequence is shown on the first page of the figure in FIG. 2B-1 and continues until the last page of the figure, FIG. 2B-27, in which the 3' end of the same sequence is shown. Shown is a sequence comparison of 23S rRNA of listed prokaryotic organisms to 23S rRNA from *E. coli* (SEQ ID NO:60). The sequences are the 23S rRNA from the following organisms: *B. subtilis* (SEQ ID NO:49); *B. anthracis* (SEQ ID NO. 50); *E. facaelis* (SEQ ID NO. 51); *L. lactis* (SEQ ID

NO. 52); *L. monocytogenes* (SEQ ID NO. 53); *S. aureus* (SEQ ID NO. 54); *S. mutans* (SEQ ID NO. 55); *S. pneumoniae* (SEQ ID NO. 56); *S. pyogenes* (SEQ ID NO. 57); *M. avium* (SEQ ID NO. 58); *M. tuberculosis* (SEQ ID NO. 59); *K. pneumoniae* (SEQ ID NO. 61); *H. influenzae* (SEQ ID NO. 62); *B. bronchiseptica* (SEQ ID NO. 63); *B. parapertussis* (SEQ ID NO. 64); *B.*  
5 *pertussis* (SEQ ID NO. 65); *B. cepacia* (SEQ ID NO. 66); *E. mallei* (SEQ ID NO. 67); *E. pseudomallei* (SEQ ID NO. 68); *N. gonorrhoeae* (SEQ ID NO. 69); *N. meningitidis* (SEQ ID NO. 70); *P. aeruginosa* (SEQ ID NO. 71); *V. cholerae* (SEQ ID NO. 72); *Y. enterocolitica* (SEQ ID NO. 73).

**FIG. 3.** Electropherograms of RNA from a control reaction. *E. coli* total RNA  
10 was purified with RNAwiz™ (Ambion) and carried through the rRNA depletion procedure as described in Example 2, except that bridging nucleic acids were left out of the reaction. A sample of the RNA was analyzed with the RNA 6000 Lab Chip Kit® (Caliper Technologies Corp.) using the Agilent 2100 Bioanalyzer (Agilent Technologies). The electropherogram shown was generated with Agilent 2100 Bioanalyzer Bio Sizing software (Version A.02.01).

15 **FIG. 4.** Electropherograms of RNA from an experimental reaction after ribosomal RNA depletion. *E. coli* total RNA was purified with RNAwiz™ (Ambion) and carried through the rRNA depletion procedure as described in Example 2. A sample of the RNA was analyzed as described in the legend to FIG. 3.

**FIG. 5A-B.** Electropherograms of RNA from experiments. **A.** Agilent 2100  
20 Bioanalyzer electropherogram of a sample from a control reaction performed as described in Example 5, but with no bridging oligonucleotides. The sample contains *E. coli* and rat liver total RNA. The RNA sample was analyzed with the RNA 6000 Lab Chip Kit® (Caliper Technologies Corp.) using the Agilent 2100 Bioanalyzer (Agilent Technologies). The electropherogram shown was generated with Agilent 2100 Bioanalyzer Bio Sizing software (Version A.02.01). **B.**  
25 Agilent 2100 Bioanalyzer electropherogram of a sample from an experimental reaction performed as described in Example 5 with bridging oligonucleotides. The sample is depleted of *E. coli* 16S and 23S rRNA and rat liver 18S and 28S rRNA. The RNA sample was analyzed with the RNA 6000 Lab Chip Kit® (Caliper Technologies Corp.) using the Agilent 2100 Bioanalyzer (Agilent Technologies). The electropherogram shown was generated with Agilent  
30 2100 Bioanalyzer Bio Sizing software (Version A.02.01).

**FIG. 6A-B.** Electropherograms of RNA from experiments. **A.** Agilent 2100 Bioanalyzer electropherogram of a sample from a control reaction performed as described in Example 6, but with no bridging oligonucleotides. The sample contains human liver total RNA. The RNA sample was analyzed with the RNA 6000 Lab Chip Kit<sup>®</sup> (Caliper Technologies Corp.) using the Agilent 2100 Bioanalyzer (Agilent Technologies). The electropherogram shown was generated with Agilent 2100 Bioanalyzer Bio Sizing software (Version A.02.01). **B.** Agilent 2100 Bioanalyzer electropherogram of a sample from an experimental reaction performed as described in Example 6 with bridging oligonucleotides. The sample is depleted of human 18S and 28S rRNA. The RNA sample was analyzed with the RNA 6000 Lab Chip Kit<sup>®</sup> (Caliper Technologies Corp.) using the Agilent 2100 Bioanalyzer (Agilent Technologies). The electropherogram shown was generated with Agilent 2100 Bioanalyzer Bio Sizing software (Version A.02.01).

**FIG. 7A-B.** Electropherograms of RNA from experiments. **A.** Agilent 2100 Bioanalyzer electropherogram of a sample from a control reaction performed as described in Example 7, but with no bridging oligonucleotides. The sample contains rat liver total RNA. The RNA sample was analyzed with the RNA 6000 Lab Chip Kit<sup>®</sup> (Caliper Technologies Corp.) using the Agilent 2100 Bioanalyzer (Agilent Technologies). The electropherogram shown was generated with Agilent 2100 Bioanalyzer Bio Sizing software (Version A.02.01). **B.** Agilent 2100 Bioanalyzer electropherogram of a sample from an experimental reaction performed as described in Example 6 with bridging oligonucleotides. The sample is depleted of rat 18S and 28S rRNA. The RNA sample was analyzed with the RNA 6000 Lab Chip Kit<sup>®</sup> (Caliper Technologies Corp.) using the Agilent 2100 Bioanalyzer (Agilent Technologies). The electropherogram shown was generated with Agilent 2100 Bioanalyzer Bio Sizing software (Version A.02.01).

**FIG. 8A-B.** Electropherograms of RNA from experiments. **A.** Agilent 2100 Bioanalyzer electropherogram of a sample from a control reaction performed as described in Example 6, but with no bridging oligonucleotides. The sample contains mouse liver total RNA. The RNA sample was analyzed with the RNA 6000 Lab Chip Kit<sup>®</sup> (Caliper Technologies Corp.) using the Agilent 2100 Bioanalyzer (Agilent Technologies). The electropherogram shown was generated with Agilent 2100 Bioanalyzer Bio Sizing software (Version A.02.01). **B.** Agilent 2100 Bioanalyzer electropherogram of a sample from an experimental reaction performed as described in Example 8 with bridging oligonucleotides. The sample is depleted of mouse 18S and 28S

rRNA. The RNA sample was analyzed with the RNA 6000 Lab Chip Kit<sup>®</sup> (Caliper Technologies Corp.) using the Agilent 2100 Bioanalyzer (Agilent Technologies). The electropherogram shown was generated with Agilent 2100 Bioanalyzer Bio Sizing software (Version A.02.01).

- 5 **FIG. 9A-B.** Electropherograms of RNA from experiments. **A.** Agilent 2100 Bioanalyzer electropherogram of a sample from a control reaction performed as described in Example 11 with no bridging oligonucleotides. The sample contains human total RNA (50 µg) and *E. coli* total RNA (500 ng). The RNA sample was analyzed with the RNA 6000 Lab Chip Kit<sup>®</sup> (Caliper Technologies Corp.) using the Agilent 2100 Bioanalyzer (Agilent Technologies). The  
10 electropherogram shown was generated with Agilent 2100 Bioanalyzer Bio Sizing software (Version A.02.01). **B.** Agilent 2100 Bioanalyzer electropherogram of a sample from an experimental reaction performed as described in Example 11 with bridging oligonucleotides. The sample is depleted of human 18S and 28S rRNA, but *E. coli* total RNA remains in the sample. The RNA sample was analyzed with the RNA 6000 Lab Chip Kit<sup>®</sup> (Caliper  
15 Technologies Corp.) using the Agilent 2100 Bioanalyzer (Agilent Technologies). The electropherogram shown was generated with Agilent 2100 Bioanalyzer Bio Sizing software (Version A.02.01).

- FIG. 10A-C.** Electropherograms of RNA from experiments. **A.** Agilent 2100 Bioanalyzer  
20 electropherogram of a sample from a control reaction with no bridging oligonucleotides performed as described in Example 12. The sample contains rat liver total RNA (25 µg) and *E. coli* total RNA (2 µg). The RNA sample was analyzed with the RNA 6000 Lab Chip Kit<sup>®</sup> (Caliper Technologies Corp.) using the Agilent 2100 Bioanalyzer (Agilent Technologies). The electropherogram shown was generated with Agilent 2100 Bioanalyzer Bio Sizing software  
25 (Version A.02.01). **B.** Agilent 2100 Bioanalyzer electropherogram of a sample from an experimental reaction performed as described in Example 12 with bridging oligonucleotides. The sample is depleted of rat 18S and 28S rRNA, but *E. coli* total RNA remains in the sample. The RNA sample was analyzed with the RNA 6000 Lab Chip Kit<sup>®</sup> (Caliper Technologies Corp.) using the Agilent 2100 Bioanalyzer (Agilent Technologies). The electropherogram shown was  
30 generated with Agilent 2100 Bioanalyzer Bio Sizing software (Version A.02.01). **C.** Agilent



2100 Bioanalyzer electropherogram of a sample from an experimental reaction performed as described in Example 12 with bridging oligonucleotides. The sample is depleted of rat 18S and 28S rRNA and *E. coli* 16S and 23S rRNA. The RNA sample was analyzed with the RNA 6000 Lab Chip Kit<sup>®</sup> (Caliper Technologies Corp.) using the Agilent 2100 Bioanalyzer (Agilent Technologies). The electropherogram shown was generated with Agilent 2100 Bioanalyzer Bio Sizing software (Version A.02.01).

**FIG. 11A-B.** *E. coli* gene arrays probed with cDNA from experiments. Experimental reactions were performed as described in Example 13. RNA samples were used to generate radiolabeled cDNA for use as probes with replicate portions of Sigma-Genosys Panorama<sup>™</sup> *E. coli* gene arrays. A. *E. coli* gene array probed with a sample from a control reaction. The sample contains human total RNA (25 µg) and *E. coli* total RNA (2 µg). B. *E. coli* gene array probed with an RNA sample that was depleted of human 18S and 28S rRNA and *E. coli* 16S and 23S rRNA.

**FIG. 12A-B.** Electropherograms of RNA from experiments. A. Agilent 2100 Bioanalyzer electropherogram of a sample from a control reaction performed as described in Examples 1 and 2 with no bridging oligonucleotides. The sample contains *Campylobacter fetus* total RNA (10 µg). The RNA sample was analyzed with the RNA 6000 Lab Chip Kit<sup>®</sup> (Caliper Technologies Corp.) using the Agilent 2100 Bioanalyzer (Agilent Technologies). The electropherogram shown was generated with Agilent 2100 Bioanalyzer Bio Sizing software (Version A.02.01). B. Agilent 2100 Bioanalyzer electropherogram of a sample from an experimental reaction with 10 µg of *Campylobacter fetus* total RNA that employed the bridging oligonucleotides d16S-807, d16S-1092, d23S-479CH, and d23S-2511. The sample is depleted of 16S rRNA, 23S rRNA fragment (1260 nt), and 23S rRNA fragment (1667 nt). The RNA sample was analyzed with the RNA 6000 Lab Chip Kit<sup>®</sup> (Caliper Technologies Corp.) using the Agilent 2100 Bioanalyzer (Agilent Technologies). The electropherogram shown was generated with Agilent 2100 Bioanalyzer Bio Sizing software (Version A.02.01).

**FIG. 13A-B.** Electropherograms of RNA from experiments. A. Agilent 2100 Bioanalyzer electropherogram of a sample from a control reaction performed as described in Examples 1 and 2 with no bridging oligonucleotides. The sample contains *Rhodobacter sphaeroides* total RNA (10 µg). The RNA sample was analyzed with the RNA 6000 Lab Chip Kit<sup>®</sup> (Caliper

Technologies Corp.) using the Agilent 2100 Bioanalyzer (Agilent Technologies). The electropherogram shown was generated with Agilent 2100 Bioanalyzer Bio Sizing software (Version A.02.01). B. Agilent 2100 Bioanalyzer electropherogram of a sample from an experimental reaction with 10 µg of *Rhodobacter sphaeroides* total RNA that employed the bridging oligonucleotides d16S-537 (16 pmol), d16S-1114R(16 pmol), d23S-479CH (16 pmol), d23S-1954 (16 pmol), and d23S-2511 (16 pmol). The sample is depleted of the 16S rRNA and the 23S rRNA fragment that co-migrates with the 16S rRNA. The sample is also depleted of the 23S rRNA fragment (1260 nt). The RNA sample was analyzed with the RNA 6000 Lab Chip Kit® (Caliper Technologies Corp.) using the Agilent 2100 Bioanalyzer (Agilent Technologies). The electropherogram shown was generated with Agilent 2100 Bioanalyzer Bio Sizing software (Version A.02.01).

**FIG. 14A-B.** Electropherograms of RNA from experiments. A. Agilent 2100 Bioanalyzer electropherogram of a sample from a control reaction performed as described in Examples 1 and 2 with no bridging oligonucleotides. The sample contains *Anabaena sp.* total RNA (10 µg). The RNA sample was analyzed with the RNA 6000 Lab Chip Kit® (Caliper Technologies Corp.) using the Agilent 2100 Bioanalyzer (Agilent Technologies). The electropherogram shown was generated with Agilent 2100 Bioanalyzer Bio Sizing software (Version A.02.01). B. Agilent 2100 Bioanalyzer electropherogram of a sample from an experimental reaction with 10 µg of *Anabaena sp.* total RNA that employed the bridging oligonucleotides d16S-364 (12.5 pmol), d16S-1087CY (12.5 pmol), d23S-485 (20 pmol), and d23S-1954 (35 pmol). The sample is depleted of 16S rRNA and the 23S rRNA fragments at 520 nt, 2090 nt, and 2470 nt. The RNA sample was analyzed with the RNA 6000 Lab Chip Kit® (Caliper Technologies Corp.) using the Agilent 2100 Bioanalyzer (Agilent Technologies). The electropherogram shown was generated with Agilent 2100 Bioanalyzer Bio Sizing software (Version A.02.01).

### **DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS**

The present invention concerns a system for isolating, depleting, or identifying specific, targeted nucleic acid populations, such as rRNA in a sample, in some cases for the purpose of enriching for other nucleic acid populations. The targeted nucleic acid, components of the system, and the methods for implementing the system, as well as variations thereof, are provided below.

## I. Targeted Nucleic Acid

The present invention concerns targeting a particular nucleic acid population (*i.e.*, mRNA, rRNA, tRNA, genomic DNA) or targeting types of a nucleic acid population, such as individual tRNAs, rRNAs (5S, 16S, or 23S rRNA from prokaryotes; 5.8S, 17S or 18S, or 28S from eukaryotes), or specific mRNAs. A nucleic acid is targeted by using a bridging nucleic acid that has a targeting region—a region complementary to all or part of the targeted nucleic acid.

In some embodiments, the invention is specifically concerned with depleting or isolating rRNA from other nucleic acids (“non-targeted nucleic acids” or “enriched population”). The 5S, 16S, and/or 23S rRNA from a prokaryote may be the targeted nucleic acid. Also, the 5.8S, 17S (observed in yeast) or 18S, and/or 28S from a eukaryote may be the targeted nucleic acid. Alternatively, rRNAs from both prokaryotes and eukaryotes may be targeted, such as with a sample that has eukaryotic host cells infected with a prokaryotic organism. The sequences for ribosomal RNAs are well known to those of ordinary skill in the art and can be readily found in sequence databases such as GenBank ([www.ncbi.nlm.nih.gov/](http://www.ncbi.nlm.nih.gov/)) or are published. Nucleic acids may be targeted by targeting regions that are complementary to all or part of the targeted nucleic acid. Targeted nucleic acids may be, be at least, or be at most 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000, 3100, 3200, 3300, 3400, 3500, 3600, 3700, 3800, 3900, 4000, 4100, 4200, 4300, 4400, 4500, 4600, 4700, 4800, 4900, 5000, 5100, 5200, 5300, 5400, 5500, 5600, 5700, 5800, 5900, 6000, 6100, 6200, 6300, 6400, 6500, 6600, 6700, 6800, 6900, 7000, 7100, 7200, 7300, 7400, 7500, 7600, 7700, 7800, 7900, 8000, 8100, 8200, 8300, 8400, 8500, 8600, 8700, 8800, 8900, 9000, 9100, 9200, 9300, 9400, 9500, 9600, 9700, 9800, 9900, 10000, or more nucleotides in length. Furthermore, any region of at least five contiguous nucleotides in the targeted nucleic acid may be used as the targeted region—that is, the region that is complementary to the targeting region of a bridging nucleic acid. Also, there may be more than one targeted region in a targeted nucleic acid. There may be, be at least, or be at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or

more targeted regions in a targeted nucleic acid. A targeted region may be a region in a targeted nucleic acid that has greater than 70%, 80%, or 90% homology with a sequence from a different targeted nucleic acid. In some embodiments, the targeted region from a targeted nucleic acid is identical to a sequence in a different targeted nucleic acid. For example, 23S rRNA of various prokaryotes may be targeted using a targeted region common to a group of organisms, such as Gram negative bacteria or a subset of such bacteria. Alternatively, a targeted region may be a sequence unique to a particular targeted nucleic acid. However, for purposes of this application, a "targeted region" is not a poly-A region, such as a poly-A tail of an eukaryotic mRNA. Additional information regarding targeted rRNAs is provided below. This information is provided as an example of targeted nucleic acids. However, it is contemplated that there may be sequence variations from individual organism to organism and these sequences provided as simply an example of one sequenced nucleic acid, even though such variations exist in nature. It is contemplated that these variations may also be targeted, and this may or may not require changes to a targeting nucleic acid or to the hybridization conditions, depending on the variation, which one of ordinary skill in the art could evaluate and determine.

A number of patents concern a targeted nucleic acid, for example, U.S. Patent Nos. 4,486,539; 4,563,419; 4,751,177; 4,868,105; 5,200,314; 5,273,882; 5,288,609; 5,457,025; 5,500,356; 5,589,335; 5,702,896; 5,714,324; 5,723,597; 5,759,777; 5,897,783; 6,013,440; 6,060,246; 6,090,548; 6,110,678; 6,203,978; 6,221,581; 6,228,580; and WO 01/32672, all of which are specifically incorporated herein by reference.

#### A. Prokaryotic rRNA

Prokaryotic rRNA can be a targeted nucleic acid of the invention. The following examples are provided, but the invention is not limited solely to these organisms and sequences (GenBank accession number provided and/or region within sequence that corresponds to the targeted rRNA):

##### 1. Superkingdom Archaea (archaeobacteria)

<i>Aeropyrum pernix</i>	
16S	D83259
<i>Aeropyrum pernix</i> NC_000854	
APErRNA05 (16S)	1218763-1220185
APErRNA03 (23S)	1213627-1218039
<i>Methanococcus jannaschii</i>	
16S	M59126

	<i>Methanococcus jannaschii</i> NC_000909	
	MJrmA16S	157985-159459
	MJrmA23S	154759-157648
5	<i>Halobacterium marismortui</i>	
	23S	X13738
	<i>Halobacterium sp. NRC-1</i> NC_002607	
	rrs (16S)	1875505-1876977
	rrlA (23S)	1877506-1880411
10	<i>Thermoplasma acidophilum</i>	
	23S	M32298
	<i>Thermoplasma acidophilum</i> NC_002578	
	16S	1475300-1475770
2.	<b>Superkingdom <u>Eubacteria</u> (eubacteria)</b>	
a.	<b>Firmicutes (Gram-positive bacteria)</b>	
15	i) <b>Bacillus/Clostridium group (low G+C gram-positive bacteria)</b>	
	<i>Listeria innocua</i> Clip 11262 NC_003212	
	16S	260527-262081
20	23S	262327-265257
	<i>Listeria monocytogenes</i> strain EGD NC_003210	
	16S	237466-239020
	23S	239265-242195
25	<i>Bacillus subtilis</i> NC000964	
	RrnO 16S	9809-11361
	RrnA 23S	11707-14634
30	<i>Bacillus anthracis</i>	
	16S (1508nt)	AF155950
	23S (2922nt)	AF267877
	<i>Bacillus thuringiensis</i>	
35	16S (1486nt)	D16281
	23S (2923nt)	AF267880
	<i>Staphylococcus aureus</i> strain Mu50 NC_002758	
	16S	530479-532033
40	23S	532398-535231
	<i>Staphylococcus aureus</i> N315 NC_002745	
	SarRNA01 16S	506138-507692
	SarRNA02 23S	508166-510999
45	<i>Clostridium acetobutylicum</i> ATCC824 NC_003030	
	16SarRNA	9710-11219
	23SarRNA	11398-14303
50	<i>Clostridium difficile</i>	
	16S (1470nt)	X73450

	<i>Clostridium perfringens</i>	
	16S	M69264 (499-2294)
	<i>Mycoplasma genitalium</i> G37 L43967	
5	MgrmA16S	170009-171527
	MgrmA23S	171730-174463
	<i>Mycoplasma pneumoniae</i> NC_000912	
10	16S	118312-119824
	23S	120057-122961
	<i>Mycoplasma pulmonis</i> NC_002771	
15	16S	813583-815113
	23S	810563-813297
	<i>Streptococcus pneumoniae</i> R6 NC_003098	
	RRNA16S-1	15161-16674
	RRNA23S-1	16945-19846
20	<i>Streptococcus pneumoniae</i> TIGR4 AE005672	
	SprmA16S	15394-16806
	SprmA23S	17142-20043
	<i>Streptococcus pyogenes</i> AE004092	
25	16S	17170-18504
	23S	19037-21937
	<i>Streptococcus mutans</i>	
30	16S (1334nt)	X58303
	23S	AF139599 (1940-4840)
	<i>Lactococcus lactis</i>	
35	16S	X64887 (508-2055)
	23S	X64887 (2360-5257)
	<i>Enterococcus faecalis</i>	
	16S (1449nt)	Y18293
	23S (2912nt)	AJ295306
40	ii) <b>Actinobacteria (high G+C gram-positive bacteria)</b>	
	<i>Mycobacterium leprae</i> strain TN NC_002677	
	Rrs16S	1341144-1342692
	Rrl23S	1342976-1346100
45	<i>Mycobacterium tuberculosis</i> CDC 1551 NC_002755	
	MtrmA16S	1471388-1472923
	MtrmA23S	1473199-1476336
	<i>Mycobacterium avium</i>	
50	16S (1372nt)	M61673
	23S	X74494 (295-3401)

	<i>Corynebacterium glutamicum</i>	
	16S (1479nt)	Z46753
5	<i>Rhodococcus equi</i>	
	16S (1478nt)	X80614
	<b>b. Spirochaetales (spirochetes)</b>	
	<i>Borrelia burgdorferi</i> AE000783	
10	RrlB 16S	444581-446118
	RrlB 23S	438590-441508
	<i>Treponema pallidum</i> AE000520	
15	TprmaA16S	230162-231656
	TprmaA23S	231950-234850
	<i>Borrelia burgdorferi</i>	
	16S	AE001147 (9459-10996)
	23S	AE001147 (212-3145)
20	<b>c. Thermotogales</b>	
	<i>Thermotoga maritima</i> AE000512	
	TmrnaA16S	188968-190526
	TmrnaA23S	190766-193787
25	<b>d. Thermus/Deinococcus group</b>	
	<i>Deinococcus radiodurans</i> R1 NC_001263	
	DrrmaA16S	2285518-2287019
	DrrmaA23S	2245319-2246194
30	<i>Deinococcus radiodurans</i>	
	16S	AE002076 (7275-8776)
	23S	AE001886 (8829-10771)
	<b>e. Chlamydiales (chlamydias)</b>	
35	<i>Chlamydia trachomatis</i> AE001273	
	16SrRNA1	854128-855677
	23SrRNA1	855993-858862
	<i>Chlamydomonas pneumoniae</i> AR39 NC_002179	
40	CprmA16S	1069329-1070785
	CprmA23S	1066159-1069022
	<i>Chlamydomonas psittaci</i>	
45	16S	U68447 (1-1553)
	23S	U68447 (1778-4721)
	<b>f. Proteobacteria (purple bacteria)</b>	
	<b>i) Alpha subdivision</b>	
	<i>Rickettsia conorii</i> Malish 7 NC_003103	

27

	Rrs16S	884601-886108
	Rrl23S	281797-284557
5	<i>Rickettsia prowazekii</i> strain Madrid E	AJ235269
	Rrs16S	772263-773769
	Rrl23S	257853-260613
10	<i>Rickettsia typhi</i>	
	16S (1444nt)	M20499
	23S	Y13133 (956-3716)
	<i>Ehrlichia bovis</i>	
	16S (1488nt)	U03775
15	<i>Agrobacterium tumefaciens</i> C58	AE007870
	16S	768991-770427
	23S	765313-767565
20	<i>Brucella melitensis</i>	
	16S	AF220148 (645-2129)
	23S	AF220148 (2896-3024..3204-5807)
25	<i>Rhizobium rhizogenes</i>	
	16S (1369nt)	D13945
	<b>ii) Beta subdivision</b>	
	<i>Neisseria meningitides</i> strain MC58	AE002098
30	NmrrnaA16S	60971-62514
	NmrrnaA23S	63178-66068
	<i>Bordetella bronchiseptica</i>	
	16S (1532nt)	X57026
	23S (2865nt)	X70371
35	<i>Bordetella parapertussis</i>	
	16S (1464nt)	U04949
	23S (2865nt)	X68368
40	<i>Bordetella pertussis</i>	
	16S (1464nt)	U04950
45	<i>Burkholderi mallei</i>	
	16S (1488nt)	AF110188
	23S (2882nt)	Y17183
	<i>Burkholderi pseudomallei</i>	
	16S (1488nt)	U91839
	23S (2882nt)	Y17184
50	<i>Neisseria gonorrhoeae</i>	
	16S (1544nt)	X07714
	23S (2890nt)	X67293



iii) **Gamma group***Buchnera* sp. APS NC\_002528

Rrs 16S 274065-275524

Rrl 23S 539539-542451

*Escherichia coli* K12 U00096

RrsH 16S 223771-225312

RrlH 23S 225759-228662

*Escherichia coli* 0157:H7 NC\_002695

RrsH 16S 227102-228643

RrlH 23S 229090-231992

*Salmonella enterica* serovar Typhi NC\_003198

16S 287479-289020

23S 289375-292380

*Salmonella typhimurium* LT2 NC\_003197

RrsH16S 289189-290732

RrlH23S 291244-294336

*Yersinia pestis* NC\_003143

16S 12292-13763

23S 14272-17178

*Klebsiella pneumoniae*

16S (1534nt) X87276

23S (2903nt) X87284

*Yersinia enterocolitica*

16S (1484nt) Z49830

23S (2906nt) U77925

*Proteus vulgaris*

16S (2067nt) X07652

*Shigella flexneri*

16S (1468nt) X80679

*Shigella sonnei*

16S (1467nt) X80726

*Shigella dysenterica*

16S (1487nt) X96966

*Haemophilus influenzae* Rd L42023

HirmE16S 1511137-1512634

HirmE23S 123801-126697

*Pasteurella multocida*

16S (1543nt) M35018

	<i>Actinobacillus actinomycetemcomitans</i>	
	16S (1485nt)	M75037
5	<i>Actinobacillus pleuropneumoniae</i>	
	16S	D30032 (83-1625)
	<i>Haemophilus somnus</i>	
10	16S (1483nt)	M75046
	<i>Legionella pneumophila</i>	
	16S (1544nt)	M59157
	<i>Mannheimia haemolytica</i>	
15	16S (1472nt)	U57072
	<i>Vibrio cholerae</i> chromosomal	NC_002505
	16Sa rRNA	53823-55357
20	23Sa rRNA	55784-58670
	<i>Vibrio parahaemolyticus</i>	
	16S (1499nt)	M59161
	<i>Coxiella burnetii</i>	
25	16S (1484nt)	M21291
	23S	X79704 (1620-3350)
	<i>Aeromonas hydrophila</i>	
30	16S (1538nt)	X87271
	<i>Aeromonas salmonicida</i>	
	16S (1502nt)	X60405
	<i>Francisella tularensis</i>	
35	16S (1517nt)	Z21931
	<i>Moraxella catarrhalis</i>	
	16S (1511nt)	U10876
40	<i>Pseudomonas aeruginosa</i>	AE004091
	16S	722096-726631
	23S	724103-726993
	<i>Pseudomonas putida</i>	
45	16S (1527nt)	D84020
	<b>iv) Delta/Epsilon subdivisions</b>	
	<i>Campylobacter jejuni</i>	AL111168
50	16S	39249-40761
	23S	41568-44457

*Helicobacter pylori* 26695 NC\_000915  
 HPrmB16S 1511137-1512634  
 HPrmB23S 1473918-1476893

5                   g.    **Cyanobacteria**

*Synechocystis* sp. PCC 6803 NC\_000911  
 Rm16Sa 2452187-2453675  
 Rm23Sa 2448839-2451721

10                   *Synechococcus* sp. (*Anacystis nidulans*)  
                       16S X03538 (1432-2918)  
                       23S X00512 (251-3126)

15                   h.    **CFB/Green sulfur bacteria group**

*Porphyromonas gingivalis*  
                       16S (1474nt) L16492

**B.    Eukaryotic rRNA**

20           Targeted nucleic acids of the invention may also be one or more types of eukaryotic rRNAs. Eukaryotes include, but are not limited to: mammals, fish, birds, amphibians, fungi, and plants. The following provides sequences for some of these targeted nucleic acids. It is contemplated that other eukaryotic rRNA sequences can be readily obtained by one of ordinary skill in the art, and thus, the invention includes, but is not limited to, the sequences shown below.

25           **Superkingdom Eukaryota (eucaryotes)**

*Homo sapiens* (human)  
                       18S M10098  
                       18S K03432  
                       18S X03205  
 30                   28S M11167

*Mus musculus*  
                       18S X00686  
                       28S X00525

35                   *Rattus norvegicus*  
                       18S M11188  
                       18S X01117

40                   *Rattus norvegicus* V01270.1  
                       18S 1-1874  
                       28S 3862-8647

## II. Isolation and/or Depletion System Nucleic Acids

The present invention concerns compositions comprising a nucleic acid or a nucleic acid analog in a system or kit to deplete, isolate, or separate a nucleic acid population from other nucleic acid populations, for which enrichment may be desirable. It concerns a bridging nucleic acid and a capture nucleic acid to deplete, isolate, or separate out a targeted nucleic acid, as discussed above.

### A. Bridging Nucleic Acids

Bridging nucleic acids of the invention comprise a bridging region and a targeting region. As discussed in other sections, the location of these regions may be throughout the molecule, which may be of a variety of lengths. The bridging nucleic acid may comprise RNA, DNA, both, or analogs of either or both.

The bridging region comprises a sequence that is complementary to at least five contiguous nucleotides in the capture nucleic acid. It is contemplated that that this region may be a homogenous sequence, that is, have the same nucleotide repeated across its length, such as a repeat of A, C, G, T, or U residues. However, to avoid hybridizing with a poly-A tailed mRNA in a sample comprising eukaryotic nucleic acids, it is contemplated that most embodiments will not have a poly-U or poly-T bridging region when dealing with such samples having poly-A tailed RNA. In some embodiments, the bridging region is a poly-C region and the capture region is a poly-G region, or vice versa. In other embodiments, the bridging region will be a random sequence that is complementary to the capture region (or the capture region will be random and the bridging region will be complementary to it). In further embodiments, the bridging region will have a designed sequence that is not homopolymeric but that is complementary to the capture region or vice versa. Sequences may be determined empirically. In many embodiments, it is preferred that this will be a random sequence or a defined sequence that is not a homopolymer. Some sequences will be determined empirically during evaluation in the assay.

### B. Capture Nucleic Acids

Capture nucleic acids of the invention comprise a capture region and a nonreacting structure that allows the capture nucleic acid, any molecules specifically binding or hybridizing to the capture nucleic acid—such as the bridging nucleic acid—and any molecules specifically binding or hybridizing to the bridging nucleic acid—such as the targeted nucleic acid—to be isolated away from other nucleic acid populations.

The capture nucleic acid may comprise RNA, DNA, both, or analogs of either or both. However, in some embodiments of the invention, it is specifically contemplated to be homopolymeric (only one type of nucleotide residue in molecule, such as poly-C), though in other embodiments, it is specifically contemplated not to be homopolymeric and be  
5 heteropolymeric, as described for bridging regions.

### 1. Capture Regions

The main requirement for bridging and capture nucleic acid sequences is that they are complementary to one another. The capture region may be a poly-pyrimidine or poly-purine region comprising at least 5 nucleic acid residues. In addition, it may be heteropolymeric, either  
10 a random sequence or a designed sequence that is complementary to the bridging region of the nucleic acid with which it should hybridize.

In addition to the capture oligos already described herein, the following are also considered for use with the present invention:

15 NRS-5'-TAACCTGGTCGTAAC-3' (SEQ ID NO:87)  
NRS-5'-CCCCCCCCCCCCC-3' (SEQ ID NO:88)  
NRS-5'-GCCCCTAACCTCGTCG (SEQ ID NO:89)  
20 NRS-5'-CGGCCCTAGCCGGGTCGTACCTCCGG (SEQ ID NO:90)  
NRS-5'-CGGCCCTAACCTGGTCGTAACCTCCGG (SEQ ID NO:91)  
25 NRS-5'-AGGCTTCGATCCCGGGATCCGCG (SEQ ID NO:92)

As discussed below, "NRS" refers to a non-reacting structure.

### 2. Nonreacting Structures (NRS)

A nonreacting structure is a compound or structure that will not react chemically with nucleic acids, and in some embodiments, with any molecule that may be in a sample.  
30 Nonreacting structures may comprise plastic, glass, teflon, silica, a magnet, a metal such as gold, carbon, cellulose, latex, polystyrene, and other synthetic polymers, nylon, cellulose, nitrocellulose, polymethacrylate, polyvinylchloride, styrene-divinylbenzene, or any chemically-

modified plastic. They may also be porous or non-porous materials. The structure may also be a particle of any shape that allows the targeted nucleic acid to be isolated, depleted, or separated. It may be a sphere, such as a bead, or a rod, or a flat-shaped structure, such as a plate with wells. Also, it is contemplated that the structure may be isolated by physical means or electromagnetic means. For example, a magnetic field may be used to attract a non-reacting structure that includes a magnet. The magnetic field may be in a stand or it may simply be placed on the side of a tube with the sample and a capture nucleic acid that is magnetized. Examples of physical ways to separate nucleic acids with their specifically hybridizing compounds are well known to those of skill in the art. A basket or other filter means may be employed to separate the capture nucleic acid and its hybridizing compounds (direct and indirect). The non-reacting structure and sample with nucleic acids of the invention may be centrifuged, filtered, dialyzed, or captured (with a magnet). When the structure is centrifuged it may be pelleted or passed through a centrifugible filter apparatus. The structure may also be filtered, including filtration using a pressure-driven system. Many such structures are available commercially and may be utilized herewith. Other examples can be found in WO 86/05815, WO90/06045, U.S. Patent 5,945,525, all of which are specifically incorporated by reference.

Cellulose is a structural polymer derived from vascular plants. Chemically, it is a linear polymer of the monosaccharide glucose, using  $\beta$ , 1-4 linkages. Cellulose can be provided commercially, including from the Whatman company, and can be chemically sheared or chemically modified to create preparations of a more fibrous or particulate nature. CF-1 cellulose from Whatman is an example that can be implemented in the present invention.

Synthetic plastic or glass beads may be employed in the context of the invention. The beads may be complexed with avidin or streptavidin and they may also be magnetized. The complexed streptavidin can be used to capture biotin linked to an oligo-dT or -U or poly (dT) or poly(U) moiety, either before or after hybridization to the poly(A) tails of mRNA. Alternatively, the oligo/poly(dT/U) moiety can be attached to the beads directly through chemical coupling. The beads may be collected using gravity- or pressure-based systems and/or filtration devices. If the beads are magnetized, a magnet can be used to separate the beads from the rest of the sample. The magnet may be employed with a stand or a stick or other type of physical structure to facilitate isolation.

Other components include isolation apparatuses such as filtration devices, including spin filters or spin columns.

### C. Nucleic Acid Compositions

Embodiments of the present invention concern bridging, capture, and targeted nucleic acids. In particular aspects, a targeted nucleic acid encodes for or comprises a transcribed nucleic acid. In other aspects, a bridging nucleic acid comprises a targeting region that comprises a nucleic acid segment having the sequence of all or part of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:72, or SEQ ID NO:73 (collectively referred to as "SEQ ID NOS:1-73"), as well as SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, and SEQ ID NO:92 (collectively referred to as "SEQ ID NOS:1-92"). In particular aspects, a targeted nucleic acid encodes a protein, polypeptide, peptide. Nucleic acids of the invention comprise RNA, DNA, analogs of RNA, analogs of DNA, or a combination thereof.

The term "nucleic acid" is well known in the art. A "nucleic acid" as used herein will generally refer to a molecule (*i.e.*, a strand) of DNA, RNA or a derivative or analog thereof, comprising a nucleobase. A nucleobase includes, for example, a naturally occurring purine or pyrimidine base found in DNA (*e.g.*, an adenine "A," a guanine "G," a thymine "T" or a cytosine "C") or RNA (*e.g.*, an A, a G, an uracil "U" or a C). The term "nucleic acid" encompass the

terms "oligonucleotide" and "polynucleotide," each as a subgenus of the term "nucleic acid." The term "oligonucleotide" refers to a molecule of between about 3 and about 100 nucleobases in length. The term "polynucleotide" refers to at least one molecule of greater than about 100 nucleobases in length.

5           These definitions generally refer to a single-stranded molecule, but in specific embodiments will also encompass an additional strand that is partially, substantially or fully complementary to the single-stranded molecule. Thus, a nucleic acid may encompass a double-stranded molecule or a triple-stranded molecule that comprises one or more complementary strand(s) or "complement(s)" of a particular sequence comprising a molecule. As used herein, a  
10       single stranded nucleic acid may be denoted by the prefix "ss," a double stranded nucleic acid by the prefix "ds," and a triple stranded nucleic acid by the prefix "ts."

### 1.       Nucleobases

          As used herein a "nucleobase" refers to a heterocyclic base, such as for example a naturally occurring nucleobase (*i.e.*, an A, T, G, C or U) found in at least one naturally occurring  
15       nucleic acid (*i.e.*, DNA and RNA), and naturally or non-naturally occurring derivative(s) and analogs of such a nucleobase. A nucleobase generally can form one or more hydrogen bonds ("anneal" or "hybridize") with at least one naturally occurring nucleobase in manner that may substitute for naturally occurring nucleobase pairing (*e.g.*, the hydrogen bonding between A and T, G and C, and A and U).

20       "Purine" and/or "pyrimidine" nucleobase(s) encompass naturally occurring purine and/or pyrimidine nucleobases and also derivative(s) and analog(s) thereof, including but not limited to, those of a purine or pyrimidine substituted by one or more of an alkyl, caboxyalkyl, amino, hydroxyl, halogen (*i.e.*, fluoro, chloro, bromo, or iodo), thiol or alkylthiol moiety. Preferred alkyl (*e.g.*, alkyl, caboxyalkyl, etc.) moieties comprise of from about 1, about 2, about 3, about 4,  
25       about 5, to about 6 carbon atoms. Other non-limiting examples of a purine or pyrimidine include a deazapurine, a 2,6-diaminopurine, a 5-fluorouracil, a xanthine, a hypoxanthine, a 8-bromoguanine, a 8-chloroguanine, a bromothymine, a 8-aminoguanine, a 8-hydroxyguanine, a 8-methylguanine, a 8-thioguanine, an azaguanine, a 2-aminopurine, a 5-ethylcytosine, a 5-methylcyosine, a 5-bromouracil, a 5-ethyluracil, a 5-iodouracil, a 5-chlorouracil, a 5-propyluracil, a thiouracil, a 2-methyladenine, a methylthioadenine, a N,N-diemethyladenine, an  
30       azaadenines, a 8-bromoadenine, a 8-hydroxyadenine, a 6-hydroxyaminopurine, a 6-thiopurine, a



4-(6-aminohexyl/cytosine), and the like. A table of non-limiting, purine and pyrimidine derivatives and analogs is also provided herein below.

<b><u>Table 1-Purine and Pyrimidine Derivatives or Analogs</u></b>			
<b><u>Abbr.</u></b>	<b><u>Modified base description</u></b>	<b><u>Abbr.</u></b>	<b><u>Modified base description</u></b>
ac4c	4-acetylcytidine	Mam5s2u	5-methoxyaminomethyl-2-thiouridine
Chm5u	5-(carboxyhydroxymethyl)uridine	Man q	Beta,D-mannosylqueosine
Cm	2'-O-methylcytidine	Mcm5s2u	5-methoxycarbonylmethyl-2-thiouridine
Cmm5s2u	5-carboxymethylamino-methyl-2-thioridine	Mcm5u	5-methoxycarbonylmethyluridine
Cmm5u	5-carboxymethylaminomethyluridine	Mo5u	5-methoxyuridine
D	Dihydrouridine	Ms2i6a	2-methylthio-N6-isopentenyladenosine
Fm	2'-O-methylpseudouridine	Ms2t6a	N-((9-beta-D-ribofuranosyl-2-methylthiopurine-6-yl)carbamoyl)threonine
Gal q	Beta,D-galactosylqueosine	Mt6a	N-((9-beta-D-ribofuranosylpurine-6-yl)N-methyl-carbamoyl)threonine
Gm	2'-O-methylguanosine	Mv	Uridine-5-oxyacetic acid methylester
I	Inosine	o5u	Uridine-5-oxyacetic acid (v)
I6a	N6-isopentenyladenosine	Osyw	Wybutoxosine
m1a	1-methyladenosine	P	Pseudouridine

<b>Table 1-Purine and Pyrimidine Derivatives or Analogs</b>			
<b><u>Abbr.</u></b>	<b><u>Modified base description</u></b>	<b><u>Abbr.</u></b>	<b><u>Modified base description</u></b>
m1f	1-methylpseudouridine	Q	Queosine
m1g	1-methylguanosine	s2c	2-thiocytidine
m1I	1-methylinosine	s2t	5-methyl-2-thiouridine
m22g	2,2-dimethylguanosine	s2u	2-thiouridine
m2a	2-methyladenosine	s4u	4-thiouridine
m2g	2-methylguanosine	T	5-methyluridine
m3c	3-methylcytidine	t6a	N-((9-beta-D-ribofuranosylpurine-6-yl)carbamoyl)threonine
m5c	5-methylcytidine	Tm	2'-O-methyl-5-methyluridine
m6a	N6-methyladenosine	Um	2'-O-methyluridine
m7g	7-methylguanosine	Yw	Wybutosine
Mam5u	5-methylaminomethyluridine	X	3-(3-amino-3-carboxypropyl)uridine, (acp3)u

A nucleobase may be comprised of a nucleoside or nucleotide, using any chemical or natural synthesis method described herein or known to one of ordinary skill in the art.

## 2. Nucleosides

As used herein, a "nucleoside" refers to an individual chemical unit comprising a nucleobase covalently attached to a nucleobase linker moiety. A non-limiting example of a "nucleobase linker moiety" is a sugar comprising 5-carbon atoms (*i.e.*, a "5-carbon sugar"), including but not limited to a deoxyribose, a ribose, an arabinose, or a derivative or an analog of a 5-carbon sugar. Non-limiting examples of a derivative or an analog of a 5-carbon sugar include a 2'-fluoro-2'-deoxyribose or a carbocyclic sugar where a carbon is substituted for an oxygen atom in the sugar ring.

Different types of covalent attachment(s) of a nucleobase to a nucleobase linker moiety are known in the art. By way of non-limiting example, a nucleoside comprising a purine (*i.e.*, A

or G) or a 7-deazapurine nucleobase typically covalently attaches the 9 position of a purine or a 7-deazapurine to the 1'-position of a 5-carbon sugar. In another non-limiting example, a nucleoside comprising a pyrimidine nucleobase (*i.e.*, C, T or U) typically covalently attaches a 1 position of a pyrimidine to a 1'-position of a 5-carbon sugar.

### 5                    3.        Nucleotides

As used herein, a "nucleotide" refers to a nucleoside further comprising a "backbone moiety". A backbone moiety generally covalently attaches a nucleotide to another molecule comprising a nucleotide, or to another nucleotide to form a nucleic acid. The "backbone moiety" in naturally occurring nucleotides typically comprises a phosphorus moiety, which is covalently  
10 attached to a 5-carbon sugar. The attachment of the backbone moiety typically occurs at either the 3'- or 5'-position of the 5-carbon sugar. However, other types of attachments are known in the art, particularly when a nucleotide comprises derivatives or analogs of a naturally occurring 5-carbon sugar or phosphorus moiety.

### 4.        Nucleic Acid Analogs

15 A nucleic acid may comprise, or be composed entirely of, a derivative or analog of a nucleobase, a nucleobase linker moiety and/or backbone moiety that may be present in a naturally occurring nucleic acid. As used herein a "derivative" refers to a chemically modified or altered form of a naturally occurring molecule, while the terms "mimic" or "analog" refer to a molecule that may or may not structurally resemble a naturally occurring molecule or moiety,  
20 but possesses similar functions. As used herein, a "moiety" generally refers to a smaller chemical or molecular component of a larger chemical or molecular structure. Nucleobase, nucleoside and nucleotide analogs or derivatives are well known in the art, and have been described (see for example, Scheit, 1980, incorporated herein by reference).

Additional non-limiting examples of nucleosides, nucleotides or nucleic acids comprising  
25 5-carbon sugar and/or backbone moiety derivatives or analogs, include those in U.S. Patent No. 5,681,947 which describes oligonucleotides comprising purine derivatives that form triple helixes with and/or prevent expression of dsDNA; U.S. Patents 5,652,099 and 5,763,167 which describe nucleic acids incorporating fluorescent analogs of nucleosides found in DNA or RNA, particularly for use as fluorescent nucleic acids probes; U.S. Patent 5,614,617 which describes  
30 oligonucleotide analogs with substitutions on pyrimidine rings that possess enhanced nuclease stability; U.S. Patents 5,670,663, 5,872,232 and 5,859,221 which describe oligonucleotide

analogs with modified 5-carbon sugars (*i.e.*, modified 2'-deoxyfuranosyl moieties) used in nucleic acid detection; U.S. Patent 5,446,137 which describes oligonucleotides comprising at least one 5-carbon sugar moiety substituted at the 4' position with a substituent other than hydrogen that can be used in hybridization assays; U.S. Patent 5,886,165 which describes oligonucleotides with both deoxyribonucleotides with 3'-5' internucleotide linkages and ribonucleotides with 2'-5' internucleotide linkages; U.S. Patent 5,714,606 which describes a modified internucleotide linkage wherein a 3'-position oxygen of the internucleotide linkage is replaced by a carbon to enhance the nuclease resistance of nucleic acids; U.S. Patent 5,672,697 which describes oligonucleotides containing one or more 5' methylene phosphonate internucleotide linkages that enhance nuclease resistance; U.S. Patents 5,466,786 and 5,792,847 which describe the linkage of a substituent moiety, which may comprise a drug or label to the 2' carbon of an oligonucleotide to provide enhanced nuclease stability and ability to deliver drugs or detection moieties; U.S. Patent 5,223,618 which describes oligonucleotide analogs with a 2 or 3 carbon backbone linkage attaching the 4' position and 3' position of adjacent 5-carbon sugar moiety to enhanced cellular uptake, resistance to nucleases and hybridization to target RNA; U.S. Patent 5,470,967 which describes oligonucleotides comprising at least one sulfamate or sulfamide internucleotide linkage that are useful as nucleic acid hybridization probe; U.S. Patents 5,378,825, 5,777,092, 5,623,070, 5,610,289 and 5,602,240 which describe oligonucleotides with three or four atom linker moiety replacing phosphodiester backbone moiety used for improved nuclease resistance, cellular uptake and regulating RNA expression; U.S. Patent 5,858,988 which describes hydrophobic carrier agent attached to the 2'-O position of oligonucleotides to enhanced their membrane permeability and stability; U.S. Patent 5,214,136, which describes oligonucleotides conjugated to anthraquinone at the 5' terminus that possess enhanced hybridization to DNA or RNA; enhanced stability to nucleases; U.S. Patent 5,700,922 which describes PNA-DNA-PNA chimeras wherein the DNA comprises 2'-deoxy-erythro-pentofuranosyl nucleotides for enhanced nuclease resistance, binding affinity, and ability to activate RNase H; and U.S. Patent 5,708,154 which describes RNA linked to a DNA to form a DNA-RNA hybrid. Other analogs that may be used with compositions of the invention include U.S. Patent 5,216,141 (discussing oligonucleotide analogs containing sulfur linkages), U.S. Patent 5,432,272 (concerning oligonucleotides having nucleotides with heterocyclic bases), and U.S. Patents 6,001,983, 6,037,120, 6,140,496 (involving oligonucleotides with non-standard bases), all of which are incorporated by reference.

## 5. Polyether and Peptide Nucleic Acids and Locked Nucleic Acids

In certain embodiments, it is contemplated that a nucleic acid comprising a derivative or analog of a nucleoside or nucleotide may be used in the methods and compositions of the invention. A non-limiting example is a "polyether nucleic acid", described in U.S. Patent Serial  
5 No. 5,908,845, incorporated herein by reference. In a polyether nucleic acid, one or more nucleobases are linked to chiral carbon atoms in a polyether backbone.

Another non-limiting example is a "peptide nucleic acid", also known as a "PNA", "peptide-based nucleic acid analog" or "PENAM", described in U.S. Patent Serial Nos. 5,786,461, 5,891,625, 5,773,571, 5,766,855, 5,736,336, 5,719,262, 5,714,331, 5,539,082, and  
10 WO 92/20702, each of which is incorporated herein by reference. Peptide nucleic acids generally have enhanced sequence specificity, binding properties, and resistance to enzymatic degradation in comparison to molecules such as DNA and RNA (Egholm *et al.*, 1993; PCT/EP/01219). A peptide nucleic acid generally comprises one or more nucleotides or nucleosides that comprise a nucleobase moiety, a nucleobase linker moiety that is not a 5-carbon  
15 sugar, and/or a backbone moiety that is not a phosphate backbone moiety. Examples of nucleobase linker moieties described for PNAs include aza nitrogen atoms, amido and/or ureido tethers (see for example, U.S. Patent No. 5,539,082). Examples of backbone moieties described for PNAs include an aminoethylglycine, polyamide, polyethyl, polythioamide, polysulfonamide or polysulfonamide backbone moiety.

In certain embodiments, a nucleic acid analogue such as a peptide nucleic acid may be used to inhibit nucleic acid amplification, such as in PCR, to reduce false positives and discriminate between single base mutants, as described in U.S. Patent Serial No. 5,891,625. Other modifications and uses of nucleic acid analogs are known in the art, and are encompassed by the bridging and capture nucleic acids of the invention. In a non-limiting example, U.S.  
20 Patent 5,786,461 describes PNAs with amino acid side chains attached to the PNA backbone to enhance solubility of the molecule. In another example, the cellular uptake property of PNAs is increased by attachment of a lipophilic group. Several alkylamino moieties used to enhance cellular uptake of a PNA are described in U.S. Patent Nos. 5,766,855, 5,719,262, 5,714,331 and 5,736,336, which describe PNAs comprising naturally and non-naturally occurring nucleobases  
25 and alkylamine side chains that provide improvements in sequence specificity, solubility and/or binding affinity relative to a naturally occurring nucleic acid.  
30

Another non-limiting example is a locked nucleic acid or "LNA." An LNA monomer is a bicyclic compound that is structurally similar to RNA nucleosides. LNAs have a furanose conformation that is restricted by a methylene linker that connects the 2'-O position to the 4'-C position, as described in Koshkin *et al.*, 1998a and 1998b and Wahlestedt *et al.*, 2000.

## 5                    6.        Preparation of Nucleic Acids

A nucleic acid may be made by any technique known to one of ordinary skill in the art, such as for example, chemical synthesis, enzymatic production or biological production. Non-limiting examples of a synthetic nucleic acid (*e.g.*, a synthetic oligonucleotide), include a nucleic acid made by *in vitro* chemical synthesis using phosphotriester, phosphite or phosphoramidite chemistry and solid phase techniques such as described in EP 266,032, incorporated herein by  
10 reference, or via deoxynucleoside H-phosphonate intermediates as described by Froehler *et al.*, 1986 and U.S. Patent No. 5,705,629, each incorporated herein by reference. In the methods of the present invention, one or more oligonucleotide may be used. Various different mechanisms of oligonucleotide synthesis have been disclosed in for example, U.S. Patents.  
15 4,659,774, 4,816,571, 5,141,813, 5,264,566, 4,959,463, 5,428,148, 5,554,744, 5,574,146, 5,602,244, each of which is incorporated herein by reference.

A non-limiting example of an enzymatically produced nucleic acid include one produced by enzymes in amplification reactions such as PCR<sup>TM</sup> (see for example, U.S. Patent 4,683,202 and U.S. Patent 4,682,195, each incorporated herein by reference), or the synthesis of an  
20 oligonucleotide described in U.S. Patent No. 5,645,897, incorporated herein by reference. A non-limiting example of a biologically produced nucleic acid includes a recombinant nucleic acid produced (*i.e.*, replicated) in a living cell, such as a recombinant DNA vector replicated in bacteria (see for example, Sambrook *et al.* 1989, incorporated herein by reference).

## 25                    7.        Purification of Nucleic Acids

A nucleic acid may be purified on polyacrylamide gels, cesium chloride centrifugation gradients, or by any other means known to one of ordinary skill in the art (see for example, Sambrook *et al.*, 1989, incorporated herein by reference).

In certain aspect, the present invention concerns a nucleic acid that is an isolated nucleic acid. As used herein, the term "isolated nucleic acid" refers to a nucleic acid molecule (*e.g.*, an  
30 RNA or DNA molecule) that has been isolated free of, or is otherwise free of, the bulk of the

total genomic and transcribed nucleic acids of one or more cells. In certain embodiments, "isolated nucleic acid" refers to a nucleic acid that has been isolated free of, or is otherwise free of, bulk of cellular components or in vitro reaction components such as for example, macromolecules such as lipids or proteins, small biological molecules, and the like.

## 5 8. Nucleic Acid Segments

In certain embodiments, the nucleic acid comprises a nucleic acid segment. As used herein, the term "nucleic acid segment," are smaller fragments of a nucleic acid, such as for non-limiting example, those that correspond to targeted, targeting, bridging, and capture regions. Thus, a "nucleic acid segment" may comprise any part of a gene sequence, of from about 2  
10 nucleotides to the full length of a targeted nucleic acid, capture nucleic acid, or bridging nucleic acid.

Various nucleic acid segments may be designed based on a particular nucleic acid sequence, and may be of any length. By assigning numeric values to a sequence, for example, the first residue is 1, the second residue is 2, *etc.*, an algorithm defining all nucleic acid segments can be created:

15 n to n + y

where  $n$  is an integer from 1 to the last number of the sequence and  $y$  is the length of the nucleic acid segment minus one, where  $n + y$  does not exceed the last number of the sequence. Thus, for a 10-mer, the nucleic acid segments correspond to bases 1 to 10, 2 to 11, 3 to 12 ... and so on. For a 15-mer, the nucleic acid segments correspond to bases 1 to 15, 2 to 16, 3 to 17 ... and so on. For a 20-mer, the nucleic acid segments correspond to bases 1 to 20, 2 to 21, 3 to 22 ... and so on. In certain embodiments, the nucleic acid segment may be a probe or primer. As used herein, a "probe" generally refers to a nucleic acid used in a detection method or composition. As used herein, a "primer" generally refers to a nucleic acid used in an extension or amplification method or composition.

25                      9.    **Nucleic Acid Complements**

The present invention also encompasses a nucleic acid that is complementary to a other nucleic acids of the invention and targeted nucleic acids. More specifically, a targeting region in a bridging nucleic acid is complementary to the targeted region of the targeted nucleic acid and a bridging region of the bridging nucleic acid is complementary to a capture region of a capture nucleic acid. In particular embodiments the invention encompasses a nucleic acid or a nucleic

acid segment identical or complementary to all or part of the sequences set forth in SEQ ID NOS:1-92. A nucleic acid is "complement(s)" or is "complementary" to another nucleic acid when it is capable of base-pairing with another nucleic acid according to the standard Watson-Crick, Hoogsteen or reverse Hoogsteen binding complementarity rules. Unless otherwise  
5 specified, a nucleic acid region is "complementary" to another nucleic acid region if there is at least 70, 80%, 90% or 100% Watson-Crick base-pairing (A:T or A:U, C:G) between or between at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430,  
10 440, 450, 460, 470, 480, 490, 500 or more contiguous nucleic acid bases of the regions. As used herein "another nucleic acid" may refer to a separate molecule or a spatial separated sequence of the same molecule.

As used herein, the term "complementary" or "complement(s)" also refers to a nucleic acid comprising a sequence of consecutive nucleobases or semiconsecutive nucleobases  
15 (*e.g.*, one or more nucleobase moieties are not present in the molecule) capable of hybridizing to another nucleic acid strand or duplex even if less than all the nucleobases do not base pair with a counterpart nucleobase. In certain embodiments, a "complementary" nucleic acid comprises a sequence in which at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,  
20 98%, 99% or 100%, and any range derivable therein, of the nucleobase sequence is capable of base-pairing with a single or double stranded nucleic acid molecule during hybridization, as described in the Examples. In certain embodiments, the term "complementary" refers to a nucleic acid that may hybridize to another nucleic acid strand or duplex under conditions described in the Examples, as would be understood by one of ordinary skill in the art.

25 In certain embodiments, a "partly complementary" nucleic acid comprises a sequence that may hybridize in low stringency conditions to a single or double stranded nucleic acid, or contains a sequence in which less than about 70% of the nucleobase sequence is capable of base-pairing with a single or double stranded nucleic acid molecule during hybridization.

## 10. Hybridization

30 As used herein, "hybridization", "hybridizes" or "capable of hybridizing" is understood to mean the forming of a double or triple stranded molecule or a molecule with partial double or



triple stranded nature. The term "anneal" as used herein is synonymous with "hybridize." The term "hybridization", "hybridize(s)" or "capable of hybridizing" encompasses the terms "stringent condition(s)" or "high stringency" and the terms "low stringency" or "low stringency condition(s)."

5 As used herein "stringent condition(s)" or "high stringency" are those conditions that allow hybridization between or within one or more nucleic acid strand(s) containing complementary sequence(s), but precludes hybridization of random sequences. Stringent conditions tolerate little, if any, mismatch between a nucleic acid and a target strand. Such conditions are well known to those of ordinary skill in the art, and are preferred for applications  
10 requiring high selectivity. Non-limiting applications include isolating a nucleic acid, such as a gene or a nucleic acid segment thereof, or detecting at least one specific mRNA transcript or a nucleic acid segment thereof, and the like.

Stringent conditions may comprise low salt and/or high temperature conditions, such as provided by about 0.02 M to about 0.15 M NaCl at temperatures of about 50°C to about 70°C.  
15 Alternatively, stringent conditions may be determined largely by temperature in the presence of a TMAC solution with a defined molarity such as 3M TMAC. For example, in 3 M TMAC, stringent conditions include the following: for complementary nucleic acids with a length of 15 bp, a temperature of 45 °C to 55 °C; for complementary nucleotides with a length of 27 bases, a temperature of 65 °C to 75 °C; and, for complementary nucleotides with a length of >200  
20 nucleotides, a temperature of 90 °C to 95°C. The publication of Wood *et al.*, 1985, which is specifically incorporated by reference, provides examples of these parameters. It is understood that the temperature and ionic strength of a desired stringency are determined in part by the length of the particular nucleic acid(s), the length and nucleobase content of the target sequence(s), the charge composition of the nucleic acid(s), and to the presence or concentration  
25 of formamide, tetramethylammonium chloride or other solvent(s) in a hybridization mixture.

It is also understood that these ranges, compositions and conditions for hybridization are mentioned by way of non-limiting examples only, and that the desired stringency for a particular hybridization reaction is often determined empirically by comparison to one or more positive or negative controls. Depending on the application envisioned it is preferred to employ varying  
30 conditions of hybridization to achieve varying degrees of selectivity of a nucleic acid towards a target sequence. In a non-limiting example, identification or isolation of a related target nucleic

acid that does not hybridize to a nucleic acid under stringent conditions may be achieved by hybridization at low temperature and/or high ionic strength. Such conditions are termed "low stringency" or "low stringency conditions", and non-limiting examples of low stringency include hybridization performed at about 0.15 M to about 0.9 M NaCl at a temperature range of about 20°C to about 50°C. Of course, it is within the skill of one in the art to further modify the low or high stringency conditions to suite a particular application.

### 11. Oligonucleotide Synthesis

Oligonucleotide synthesis is performed according to standard methods. See, for example, Itakura and Riggs (1980). Additionally, U.S. Patent 4,704,362; U.S. Patent 5,221,619, U.S. Patent 5,583,013 each describe various methods of preparing synthetic structural genes.

Oligonucleotide synthesis is well known to those of skill in the art. Various different mechanisms of oligonucleotide synthesis have been disclosed in for example, U.S. Patents. 4,659,774, 4,816,571, 5,141,813, 5,264,566, 4,959,463, 5,428,148, 5,554,744, 5,574,146, 5,602,244, each of which is incorporated herein by reference.

Basically, chemical synthesis can be achieved by the diester method, the triester method polynucleotides phosphorylase method and by solid-phase chemistry. These methods are discussed in further detail below.

**Diester method.** The diester method was the first to be developed to a usable state, primarily by Khorana and co-workers. (Khorana, 1979). The basic step is the joining of two suitably protected deoxynucleotides to form a dideoxynucleotide containing a phosphodiester bond. The diester method is well established and has been used to synthesize DNA molecules (Khorana, 1979).

**Triester method.** The main difference between the diester and triester methods is the presence in the latter of an extra protecting group on the phosphate atoms of the reactants and products (Itakura *et al.*, 1975). The phosphate protecting group is usually a chlorophenyl group, which renders the nucleotides and polynucleotide intermediates soluble in organic solvents. Therefore purification's are done in chloroform solutions. Other improvements in the method include (i) the block coupling of trimers and larger oligomers, (ii) the extensive use of high-

performance liquid chromatography for the purification of both intermediate and final products, and (iii) solid-phase synthesis.

**Polynucleotide phosphorylase method.** This is an enzymatic method of DNA synthesis that can be used to synthesize many useful oligodeoxynucleotides (Gillam *et al.*, 1978; Gillam *et al.*, 1979). Under controlled conditions, polynucleotide phosphorylase adds predominantly a single nucleotide to a short oligodeoxynucleotide. Chromatographic purification allows the desired single adduct to be obtained. At least a trimer is required to start the procedure, and this primer must be obtained by some other method. The polynucleotide phosphorylase method works and has the advantage that the procedures involved are familiar to most biochemists.

**Solid-phase methods.** Drawing on the technology developed for the solid-phase synthesis of polypeptides, it has been possible to attach the initial nucleotide to solid support material and proceed with the stepwise addition of nucleotides. All mixing and washing steps are simplified, and the procedure becomes amenable to automation. These syntheses are now routinely carried out using automatic DNA synthesizers.

Phosphoramidite chemistry (Beaucage, and Lyer, 1992) has become by far the most widely used coupling chemistry for the synthesis of oligonucleotides. As is well known to those skilled in the art, phosphoramidite synthesis of oligonucleotides involves activation of nucleoside phosphoramidite monomer precursors by reaction with an activating agent to form activated intermediates, followed by sequential addition of the activated intermediates to the growing oligonucleotide chain (generally anchored at one end to a suitable solid support) to form the oligonucleotide product.

## 12. Expression Vectors

Other ways of creating nucleic acids of the invention include the use of a recombinant vector created through the application of recombinant nucleic acid technology known to those of skill in the art or as described herein. A recombinant vector may comprise a bridging or capture nucleic acid, particularly one that is a polynucleotide, as opposed to an oligonucleotide. An expression vector can be used create nucleic acids that are lengthy, for example, containing multiple targeting regions or relatively lengthy targeting regions, such as those greater than 100 residues in length.

The term "vector" is used to refer to a carrier nucleic acid molecule into which a nucleic acid sequence can be inserted for introduction into a cell where it can be replicated. A nucleic acid sequence can be "exogenous," which means that it is foreign to the cell into which the vector is being introduced or that the sequence is homologous to a sequence in the cell but in a position within the host cell nucleic acid in which the sequence is ordinarily not found. Vectors include plasmids, cosmids, viruses (bacteriophage, animal viruses, and plant viruses), and artificial chromosomes (e.g., YACs). One of skill in the art would be well equipped to construct a vector through standard recombinant techniques (see, for example, Sambrook *et al.*, 2001 and Ausubel *et al.*, 1994, both incorporated herein by reference).

The term "expression vector" refers to any type of genetic construct comprising a nucleic acid coding for a RNA capable of being transcribed. Expression vectors can contain a variety of "control sequences," which refer to nucleic acid sequences necessary for the transcription and possibly translation of an operable linked coding sequence in a particular host cell. In addition to control sequences that govern transcription (promoters and enhancers) and translation, vectors and expression vectors may contain nucleic acid sequences that serve other functions as well that are well known to those of skill in the art, such as screenable and selectable markers, ribosome binding site, multiple cloning sites, splicing sites, poly A sequences, origins of replication, and other sequences that allow expression in different hosts.

Numerous expression systems exist that comprise at least a part or all of the compositions discussed above. Prokaryote- and/or eukaryote-based systems can be employed for use with the present invention to produce nucleic acid sequences, or their cognate polypeptides, proteins and peptides. Many such systems are commercially and widely available.

The nucleotide and protein, polypeptide and peptide sequences for various genes have been previously disclosed, and may be found at computerized databases known to those of ordinary skill in the art. For example, the nucleotide sequences of rRNAs of various organisms are readily available. One such database is the National Center for Biotechnology Information's Genbank and GenPept databases (<http://www.ncbi.nlm.nih.gov/>). The coding regions for all or part of these known genes may be amplified and/or expressed using the techniques disclosed herein or by any technique that would be known to those of ordinary skill in the art.

### 13. Nucleic Acid Arrays

Because the present invention provides efficient methods of enriching in mRNA, which can be used to make cDNA, the present invention extends to the use of cDNAs with arrays. The term "array" as used herein refers to a systematic arrangement of nucleic acid. For example, a cDNA population that is representative of a desired source (e.g., human adult brain) is divided up into the minimum number of pools in which a desired screening procedure can be utilized to detect a cDNA and which can be distributed into a single multi-well plate. Arrays may be of an aqueous suspension of a cDNA population obtainable from a desired mRNA source, comprising: a multi-well plate containing a plurality of individual wells, each individual well containing an aqueous suspension of a different content of a cDNA population. The cDNA population may include cDNA of a predetermined size. Furthermore, the cDNA population in all the wells of the plate may be representative of substantially all mRNAs of a predetermined size from a source. Examples of arrays, their uses, and implementation of them can be found in U.S. Patent Nos. 6,329,209, 6,329,140, 6,324,479, 6,322,971, 6,316,193, 6,309,823, 5,412,087, 5,445,934, and 5,744,305, which are herein incorporated by reference.

The number of cDNA clones array on a plate may vary. For example, a population of cDNA from a desired source can have about 200,000-6,000,000 cDNAs, about 200,000-2,000,000, 300,000-700,000, about 400,000-600,000, or about 500,000 cDNAs, and combinations thereof. Such a population can be distributed into a small set of multi-well plates, such as a single 96-well plate or a single 384-well plate. For instance, when about 1000-10,000 cDNAs, preferably about 3,500-7,000, more preferably about 5,000, from a population are present in a single well of a 96-well or 384-well plate, PCR can be utilized to clone a single, target gene using a set of primers.

The term a "nucleic acid array" refers to a plurality of target elements, each target element comprising one or more nucleic acid molecules immobilized on one or more solid surfaces to which sample nucleic acids can be hybridized. The nucleic acids of a target element can contain sequence(s) from specific genes or clones, e.g. from the regions identified here. Other target elements will contain, for instance, reference sequences. Target elements of various dimensions can be used in the arrays of the invention. Generally, smaller, target elements are preferred. Typically, a target element will be less than about 1 cm in diameter. Generally element sizes are from 1  $\mu$ m to about 3 mm, between about 5  $\mu$ m and about 1 mm. The target elements

of the arrays may be arranged on the solid surface at different densities. The target element densities will depend upon a number of factors, such as the nature of the label, the solid support, and the like. One of skill will recognize that each target element may comprise a mixture of nucleic acids of different lengths and sequences. Thus, for example, a target element may contain  
5 more than one copy of a cloned piece of DNA, and each copy may be broken into fragments of different lengths. The length and complexity of the nucleic acid fixed onto the target element is not critical to the invention. One of skill can adjust these factors to provide optimum hybridization and signal production for a given hybridization procedure, and to provide the required resolution among different genes or genomic locations. In various embodiments, target  
10 element sequences will have a complexity between about 1 kb and about 1 Mb, between about 10 kb to about 500 kb, between about 200 to about 500 kb, and from about 50 kb to about 150 kb.

Microarrays are known in the art and consist of a surface to which probes that correspond in sequence to gene products (e.g., cDNAs, mRNAs, cRNAs, polypeptides, and fragments  
15 thereof), can be specifically hybridized or bound at a known position. In one embodiment, the microarray is an array (i.e., a matrix) in which each position represents a discrete binding site for a product encoded by a gene (e.g., a protein or RNA), and in which binding sites are present for products of most or almost all of the genes in the organism's genome. In a preferred embodiment, the "binding site" (hereinafter, "site") is a nucleic acid or nucleic acid analogue to which a  
20 particular cognate cDNA can specifically hybridize. The nucleic acid or analogue of the binding site can be, e.g., a synthetic oligomer, a full-length cDNA, a less-than full length cDNA, or a gene fragment.

A microarray may contains binding sites for products of all or almost all genes in the target organism's genome, but such comprehensiveness is not necessarily required. Usually the  
25 microarray will have binding sites corresponding to at least about 50% of the genes in the genome, often at least about 75%, more often at least about 85%, even more often more than about 90%, and most often at least about 99%. Preferably, the microarray has binding sites for genes relevant to the action of a drug of interest or in a biological pathway of interest. A "gene" is identified as an open reading frame (ORF) of preferably at least 50, 75, or 99 amino acids  
30 from which a messenger RNA is transcribed in the organism (e.g., if a single cell) or in some cell in a multicellular organism. The number of genes in a genome can be estimated from the number

of mRNAs expressed by the organism, or by extrapolation from a well-characterized portion of the genome. When the genome of the organism of interest has been sequenced, the number of ORFs can be determined and mRNA coding regions identified by analysis of the DNA sequence.

5 The nucleic acid or analogue are attached to a solid support, which may be made from glass, plastic (e.g., polypropylene, nylon), polyacrylamide, nitrocellulose, or other materials. A preferred method for attaching the nucleic acids to a surface is by printing on glass plates, as is described generally by Schena *et al.*, 1995a. *See also* DeRisi *et al.*, 1996; Shalon *et al.*, 1996; Schena *et al.*, 1995b. Each of these articles is incorporated by reference in its entirety.

10 Other methods for making microarrays, e.g., by masking (Maskos *et al.*, 1992), may also be used. In principal, any type of array, for example, dot blots on a nylon hybridization membrane (see Sambrook *et al.*, 1989, which is incorporated in its entirety for all purposes), could be used, although, as will be recognized by those of skill in the art, very small arrays will be preferred because hybridization volumes will be smaller.

15 Labeled cDNA is prepared from mRNA by oligo dT-primed or random-primed reverse transcription, both of which are well known in the art (see e.g., Klug *et al.*, 1987). Reverse transcription may be carried out in the presence of a dNTP conjugated to a detectable label, most preferably a fluorescently labeled dNTP. Alternatively, isolated mRNA can be converted to labeled antisense RNA synthesized by in vitro transcription of double-stranded cDNA in the presence of labeled dNTPs (Lockhart *et al.*, 1996, which is incorporated by reference in its  
20 entirety for all purposes). In alternative embodiments, the cDNA or RNA probe can be synthesized in the absence of detectable label and may be labeled subsequently, e.g., by incorporating biotinylated dNTPs or rNTP, or some similar means (e.g., photo-cross-linking a psoralen derivative of biotin to RNAs), followed by addition of labeled streptavidin (e.g., phycoerythrin-conjugated streptavidin) or the equivalent.

25 Fluorescently-labeled probes can be used, including suitable fluorophores such as fluorescein, lissamine, phycoerythrin, rhodamine (Perkin Elmer Cetus), Cy2, Cy3, Cy3.5, Cy5, Cy5.5, Cy7, FluorX (Amersham) and others (see, e.g., Kricka, 1992). It will be appreciated that pairs of fluorophores are chosen that have distinct emission spectra so that they can be easily distinguished. In another embodiment, a label other than a fluorescent label is used. For example,  
30 a radioactive label, or a pair of radioactive labels with distinct emission spectra, can be used (see

Zhao et al., 1995; Pietu et al., 1996). However, because of scattering of radioactive particles, and the consequent requirement for widely spaced binding sites, use of radioisotopes is a less-preferred embodiment.

In one embodiment, labeled cDNA is synthesized by incubating a mixture containing 0.5 mM dGTP, dATP and dCTP plus 0.1 mM dTTP plus fluorescent deoxyribonucleotides (e.g., 0.1 mM Rhodamine 110 UTP (Perkin Elmer Cetus) or 0.1 mM Cy3 dUTP (Amersham)) with reverse transcriptase (e.g., SuperScript™, Invitrogen Inc.) at 42°C for 60 min.

### III. Methods for Isolating and Depleting Targeted Nucleic Acids

Methods of the invention involve preparing a sample comprising a targeted nucleic acid, preparing a bridging nucleic acid, preparing a capture nucleic acid, incubating the sample with the bridging nucleic acid, incubating the sample with a capture nucleic acid, incubating the bridging nucleic acid with the capture nucleic acid, incubating compounds under conditions allowing for hybridization among complementary regions, washing the sample and/or the capture and/or bridging nucleic acids, and isolating the capture nucleic acids and any accompanying compounds (compounds that bind or hybridize directly or indirectly to the capture nucleic acids). Steps of the invention are not required to be in a particular order and thus, the invention covers methods in which the order of the steps varies.

Hybridization conditions are discussed earlier. Wash conditions may involve temperatures between 20°C and 75°C, between 25°C and 70°C, between 30°C and 65°C, between 35°C and 60°C, between 40°C and 55°C, between 45°C and 50°C, or at temperatures within the ranges specified.

Buffer conditions for hybridization of nucleic acid compositions are well known to those of skill in the art. It is specifically contemplated that isostabilizing agents may be employed in hybridization and wash buffers in methods of the invention. U.S. Ser. No. 09/854,412 describes the use of tetramethylammonium chloride (TMAC) and tetraethylammonium chloride (TEAC) in such buffers; this application is specifically incorporated by reference herein. The concentration of an isostabilizing agent in a hybridization (binding) buffer may be between about 1.0 M and about 5.0 M, is about 4.0 M, or is about 2.0 M. Also specifically contemplated is a wash solution with an isostabilizing agent concentration of between about 0.1 M and 3.0 M, including 0.1 M increments within the range. Wash buffers may or may not contain Tris. However, in



some embodiments of the invention, the wash solution consists of water and no other salts or buffers. In some embodiments of the invention, the hybridizing or wash buffer may include guanidinium isothiocyanate, though in some embodiments this chemical is specifically contemplated to be absent. The concentration of guanidinium may be between about 0.4 M and about 3.0 M

A solution or buffer to elute targeted nucleic acids from the hybridizing nucleic acids (indirect or direct) may be implemented in some kits and methods of the invention. The elution buffer or solution can be an aqueous solution lacking salt, such as TE or water. Elution may occur at room temperature or it may occur at temperatures between 15°C and 100°C, between 20°C and 95°C, between 25°C and 90°C, between 30°C and 85°C, between 35°C and 80°C, between 40°C and 75°C, between 45°C and 70°C, between 50°C and 65°C, between 55°C and 60°C, or at temperatures within the ranges specified.

#### **A. Quantitation of RNA**

##### **1. Assessing RNA yield by UV absorbance**

The concentration and purity of RNA can be determined by diluting an aliquot of the preparation (usually a 1:50 to 1:100 dilution) in TE (10 mM Tris-HCl pH 8, 1 mM EDTA) or water, and reading the absorbance in a spectrophotometer at 260 nm and 280 nm.

An  $A_{260}$  of 1 is equivalent to 40  $\mu\text{g}$  RNA/ml. The concentration ( $\mu\text{g}/\text{ml}$ ) of RNA is therefore calculated by multiplying the  $A_{260}$  X dilution factor X 40  $\mu\text{g}/\text{ml}$ . The following is a typical example:

The typical yield from 10  $\mu\text{g}$  total RNA is 3 - 5  $\mu\text{g}$ . If the sample is re-suspended in 25  $\mu\text{l}$ , this means that the concentration will vary between 120  $\text{ng}/\mu\text{l}$  and 200  $\text{ng}/\mu\text{l}$ . One  $\mu\text{l}$  of the prep is diluted 1:50 into 49  $\mu\text{l}$  of TE. The  $A_{260} = 0.1$ . RNA concentration =  $0.1 \times 50 \times 40 \mu\text{g}/\text{ml} = 200 \mu\text{g}/\text{ml}$  or 0.2  $\mu\text{g}/\mu\text{l}$ . Since there are 24  $\mu\text{l}$  of the prep remaining after using 1  $\mu\text{l}$  to measure the concentration, the total amount of remaining RNA is  $24 \mu\text{l} \times 0.2 \mu\text{g}/\mu\text{l} = 4.8 \mu\text{g}$ .

##### **2. Assessing RNA yield with RiboGreen®**

Molecular Probes' RiboGreen® fluorescence-based assay for RNA quantitation can be employed to measure RNA concentration.

## **B. Denaturing Agarose Gel Electrophoresis**

Many mRNAs form extensive secondary structure. Ribosomal RNA depletion may be evaluated by agarose gel electrophoresis. Because of this, it is best to use a denaturing gel system to analyze RNA samples. A positive control should be included on the gel so that any  
5 unusual results can be attributed to a problem with the gel or a problem with the RNA under analysis. RNA molecular weight markers, an RNA sample known to be intact, or both, can be used for this purpose. It is also a good idea to include a sample of the starting RNA that was used in the enrichment procedure.

Ambion's NorthernMax™ reagents for Northern Blotting include everything needed for  
10 denaturing agarose gel electrophoresis. These products are optimized for ease of use, safety, and low background, and they include detailed instructions for use. An alternative to using the NorthernMax reagents is to use a procedure described in "Current Protocols in Molecular Biology", Section 4.9 (Ausubel et al., eds.), hereby incorporated by reference. It is more difficult and time-consuming than the Northern-Max method, but it gives similar results.

## **C. Agilent 2100 Bioanalyzer**

### **1. Evaluating rRNA Removal with the RNA 6000 LabChip**

An effective method for evaluating rRNA removal utilizes RNA analysis with the Caliper RNA 6000 LabChip Kit and the Agilent 2100 Bioanalyzer. Follow the instructions provided with the RNA 6000 LabChip Kit for RNA analysis. This system performs best with RNA  
20 solutions at concentrations between 50 and 250 ng/μl. Loading 1 μl of a typical enriched RNA sample is usually adequate for good performance.

### **2. Expected Results**

In enriched mRNA samples from prokaryotes, the 16S and 23S rRNA peaks will be absent or present in only very small amounts. The peak calling feature of the software may fail  
25 to identify the peaks containing small quantities of leftover 16S and 23S rRNAs. A peak corresponding to 5S and tRNAs may be present depending on how the total RNA was initially purified. If RNA was purified by a glass fiber filter method prior to enrichment, this peak will be smaller. The size and shape of the 5S rRNA-tRNA peak is unchanged by some embodiments.

#### IV. KITS

Any of the compositions described herein may be comprised in a kit. In a non-limiting example, a bridging nucleic acid and a capture nucleic acid may be comprised in a kit. The kits will thus comprise, in suitable container means, a bridging nucleic acid and a capture nucleic of  
5 the present invention. It may also include one or more buffers, such as hybridization buffer or a wash buffer, compounds for preparing the sample, and components for isolating the capture nucleic acid via the nonreacting structure. Other kits of the invention may include components for making a nucleic acid array, and thus, may include, for example, a solid support.

The kits may comprise suitably aliquoted nucleic acid compositions of the present  
10 invention, whether labeled or unlabeled, as may be used to isolate, deplete, or separate a targeted nucleic acid. The components of the kits may be packaged either in aqueous media or in lyophilized form. The container means of the kits will generally include at least one vial, test tube, flask, bottle, syringe or other container means, into which a component may be placed, and preferably, suitably aliquoted. Where there are more than one component in the kit (bridging  
15 and capture nucleic acids may be packaged together), the kit also will generally contain a second, third or other additional container into which the additional components may be separately placed. However, various combinations of components may be comprised in a vial. The kits of the present invention also will typically include a means for containing the nucleic acids, and any other reagent containers in close confinement for commercial sale. Such containers may include  
20 injection or blow-molded plastic containers into which the desired vials are retained.

When the components of the kit are provided in one and/or more liquid solutions, the liquid solution is an aqueous solution, with a sterile aqueous solution being particularly preferred.

However, the components of the kit may be provided as dried powder(s). When reagents  
25 and/or components are provided as a dry powder, the powder can be reconstituted by the addition of a suitable solvent. It is envisioned that the solvent may also be provided in another container means.

The container means will generally include at least one vial, test tube, flask, bottle, syringe and/or other container means, into which the nucleic acid formulations are placed,

preferably, suitably allocated. The kits may also comprise a second container means for containing a sterile, pharmaceutically acceptable buffer and/or other diluent.

The kits of the present invention will also typically include a means for containing the vials in close confinement for commercial sale, such as, e.g., injection and/or blow-molded plastic containers into which the desired vials are retained.

Such kits may also include components that facilitate isolation of the targeting molecule, such as filters, beads, or a magnetic stand. Such kits generally will comprise, in suitable means, distinct containers for each individual reagent or solution as well as for the targeting agent.

A kit will also include instructions for employing the kit components as well the use of any other reagent not included in the kit. Instructions may include variations that can be implemented.

Kits of the invention may also include one or more of the following, in addition to a capture nucleic acid and a bridging nucleic acid:

- 1) Control RNA (*E. coli* or other appropriate RNA);
- 2) Nuclease-free water;
- 3) RNase-free containers, such as 1.5 ml tubes;
- 4) RNase-free elution tubes;
- 5) glycogen;
- 6) ethanol;
- 7) sodium acetate;
- 8) ammonium acetate;
- 9) magnetic stand or other magnetic field;
- 10) agarose;
- 11) nucleic acid size marker;
- 12) RNase-free tube tips;
- 13) and RNase or DNase inhibitors.

#### IV. Examples

The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

Furthermore, these examples are provided as one of many ways of implementing the claimed method and using the compositions of the invention. It is contemplated that the invention is not limited to the specific conditions set forth below, but that the conditions below provide examples of how to implement the invention.

#### EXAMPLE 1:

##### Materials

The following materials were used in the methods described herein for the selective removal of 16S and 23S rRNA and/or 18S and 28S rRNA, and hence mRNA enrichment, from total RNA. All steps are performed at room temperature unless otherwise indicated.

##### *1. Bridging Nucleic Acids*

In the following examples, the bridging regions are the poly-A stretches in the respective oligonucleotides.

Targeting regions for prokaryotic 16S and 23S rRNAs were designed based on a sequence comparison of different rRNAs from different bacteria to *E. coli* rRNA with MegAlign sequence analysis software version 4.05 from DNA Star, Incorporated (FIG. 2). The targeting regions are shown, in the examples below, 3' of the bridging regions. Thus, the targeting region encompasses the remaining, non-bridging region of each molecule described below. SEQ ID NOs are provided for the targeting regions of the bridging nucleic acids provided below (*i.e.*, sequence of bridging regions not included in SEQ ID NO.).

##### 16S prokaryotic rRNA bridging oligonucleotides

**d16S-358** (SEQ ID NO:1)

5'-AAAAAAAAAAAAAAAAAACTGCTGCCTCCCGTAGGAGTCT-3'

**d16S-537** (SEQ ID NO:2)

5'-AAAAAAAAAAAAAAAAAACGTATTACCGCGGCTGCTGGCAC-3'

5

**d16S-548** (SEQ ID NO:3)

5'-AAAAAAAAAAAAAAAAACGCCAGTAATTCCGATTAACGC-3'

**d16S-807** (SEQ ID NO:4)

10 5'-AAAAAAAAAAAAAAAAAATGGACTACCAGGGTATCTAATCC-3'

**d16S-1092** (SEQ ID NO:5)

5'-AAAAAAAAAAAAAAAAAAGGGTTGCGCTCGTTGCGGGACTT-3'

15 **d16S-3'** (SEQ ID NO:6)

5'-AAAAAAAAAAAAAAAAAATAAGGAGGTGATCCAACCGCAGG-3'

**23S prokaryotic rRNA bridging oligonucleotides**

**d23S-488** (SEQ ID NO:7)

20 5'-AAAAAAAAAAAAAAAAAAGGTTCTTTTTCACTCCCCTCGCC-3'

**d23S-581** (SEQ ID NO:8)

5'-AAAAAAAAAAAAAAAAAAGACCCATTATACAAAAGGTACGC-3'

25 **d23S-1118** (SEQ ID NO:9)

5'-AAAAAAAAAAAAAAAAAAGCCCCGTTACATCTTCCGCGCAG-3'

**d23S-1926** (SEQ ID NO:10)

5'-AAAAAAAAAAAAAAAAAACGACAAGGAATTCGCTACCTTA-3'

30

**d23S-1954** (SEQ ID NO:11)

5'-AAAAAAAAAAAAAAAAAACTTACCCGACAAGGAATTCGC-3'

**d23S-2511** (SEQ ID NO:12)

35 5'-AAAAAAAAAAAAAAAAAAGAGCCGACATCGAGGTGCCAAAC-3'

**d23S-3'** (SEQ ID NO:13)

5'-AAAAAAAAAAAAAAAAAAGGTTAAGCCTCACGGTTCATT-3'

40 **d23S-1704** (SEQ ID NO:15)

5'-AAAAAAAAAAAAAAAAAACCCCTTCTCCCGAAGTTACGGGG-3'

**d23S-1105** (SEQ ID NO:16)

5'-AAAAAAAAAAAAAAAAAAGTGAGCTATTACGCTTTCTTT-3'

45

RNA oligo bridging oligonucleotide**r23S-3'** (SEQ ID NO:14)5'-AAAAAAAAAAAAAAAAAGGUUAAGCGUCACGGUUCAUU-(inverted (dT))-3'  
(inverted refers to bases attached 3' to 3')

5

Eukaryotic 18S rRNA bridging oligonucleotides**d18S-3711** (SEQ ID NO:17)

AAA AAA AAA AAA AAA AAA TAC CGG CCG TGC GTA CTT AGA CA

10 **d18S-4238** (SEQ ID NO:18)

AAA AAA AAA AAA AAA AAA TGC CCT CCA ATG GAT CCT CGT TA

**d18S-5482** (SEQ ID NO:19)

AAA AAA AAA AAA AAA AAA CTA CGG AAA CCT TGT TAC GAC TT

15

Eukaryotic 28S rRNA bridging oligonucleotides**d28S-11599** (SEQ ID NO:20)

AAA AAA AAA AAA AAA AAA GAG CAC TGG GCA GAA ATC ACA TC

20

**d28S-7979** (SEQ ID NO:21)

AAA AAA AAA AAA AAA AAA GTT TCT TTT CCT CCG CTG ACT AA

**d28S-12533** (SEQ ID NO:22)

25 AAA AAA AAA AAA AAA AAA TCC TCA GCC AAG CAC ATA CAC CA

2. *Binding Buffer* (also referred to as hybridization buffer)  
3 M TMAC, 10 mM Tris, (pH 7.0)

30

3. *Bridging Nucleic Acid Mixture*

Mixtures of 16S, 23S, 18S, and/or 28S bridging oligonucleotides were used. All oligonucleotides were purchased from IDT and purified from polyacrylamide gels.

4. *Capture Nucleic Acid (Oligo(dT) MagBeads)*  
Seradyn MGOL #2815-2103.

35

5. *Wash Solution*

2 M TMAC, 6.67 mM Tris (pH 7.0) (this is a dilution of binding buffer).

**EXAMPLE 2:**  
**Methods for rRNA Depletion from Prokaryotic Total RNA**

The following methods are provided by way of example for practicing methods of the invention. They have been performed and shown to effect methods of the invention. The invention is not intended to be limited to these protocols, and it is specifically contemplated that variations of the methods below may be employed that fall within the scope of the invention if they effect depletion, isolation, or separation of a targeted nucleic acid, particularly rRNA.

This example demonstrates the depletion of 16S and 23S rRNA from *E. coli* total RNA.

10 *RNA/Bridging Nucleic Acid Mixture Annealing*

RNA (10 µg/15 µl) was added to 200 µl of binding buffer. The bridging nucleic acid mixture consisted of d16S-807 (5 µM), d16S-1092 (5 µM), d23S-1954 (5 µM), d23S-2511 (5 µM). The bridging nucleic acid mixture (4 µl) was added to the RNA and the mixture was incubated at 70°C for 10 minutes and then shifted to 37°C for 30 minutes.

15 Thirty minutes was found to be an adequate time for the annealing step. Longer time periods can be used with no adverse effects. Between fifteen and 120 minutes have been used successfully in the methods of the invention.

*Preparation of Capture Nucleic Acid*

Capture nucleic acid (Oligo (dT) MagBeads, Seradyn) in storage buffer was mixed and 50 µl was removed to a separate tube. A magnetic stand was applied to the side of the tube to capture the magnetic beads and the supernatant was removed. The capture nucleic acid was equilibrated one time with distilled, deionized water (50 µl) and once with binding buffer (50 µl). The captured nucleic acid was captured again with a magnetic stand, and the binding buffer wash was removed. The magnetic beads were resuspended in 50 µl of binding buffer.

25 *rRNA Capture*

Following the 30 minute annealing of RNA with the bridging nucleic acid mixture, the capture nucleic acid was added and the mixture was incubated at room temperature for 15 minutes. A magnetic stand was then applied to the tube to capture the magnetic beads. The supernatant containing mRNA, 5S rRNA, and tRNAs was removed to another tube and saved.

30 An optional washing step was performed next. The magnetic beads were washed with Wash



Solution (100  $\mu$ l) and captured again. The wash supernatant was removed and added to the original supernatant.

Fifteen minutes was found to be an adequate time for rRNA capture. Longer time periods can be used with no adverse effects. rRNA capture likely occurs rapidly, and capture  
5 times of 5 minutes – 60 minutes have been used successfully in the methods of the invention.

#### *Precipitating mRNA*

mRNA, 5S rRNA, and tRNAs were precipitated by adding 1/10 volume of 3M NaOAc (pH 5.5) and 3 volumes of 100% EtOH and incubating at  $-20^{\circ}\text{C}$  for 60 minutes. The precipitated RNA was pelleted in a microfuge, washed with 70% EtOH, and resuspended in TE  
10 (pH 8.0).

#### *Analysis of Purified mRNA*

Purified mRNA was analyzed with the Caliper RNA 6000 LabChip kit on an Agilent Bioanalyzer. Purified RNA was compared with a control *E. coli* total RNA sample that was  
15 carried through the reaction as described above, except that the Bridging Nucleic Acid Mixture was left out. This assay system uses electrophoretic and electrokinetic separation in a capillary electrophoresis type system. The rRNAs appear as peaks on an electropherogram (FIG. 3). The percentage of a rRNA present in the sample is calculated from the area under the peak.

Under the protocol conditions described above, the 5S + tRNA peak area is essentially  
20 the same in the control and in experimental samples. The % of 16S or 23S rRNA removed was calculated using the ratios of  $16\text{S}_{\text{peak area}}/5\text{S}_{\text{peak area}}$  and  $23\text{S}_{\text{peak area}}/5\text{S}_{\text{peak area}}$ . Enriched and control RNAs with similar 5S + tRNA peak areas were compared.

% 16S rRNA removed =

$$\frac{(16\text{S}_{\text{peak area}}/5\text{S}_{\text{peak area}})_{\text{no oligos control}} - (16\text{S}_{\text{peak area}}/5\text{S}_{\text{peak area}})_{\text{experimental}}}{(16\text{S}_{\text{peak area}}/5\text{S}_{\text{peak area}})_{\text{no oligos control}}} \times 100$$

25

A corresponding formula was used to calculate % 23S rRNA removed.

Electropherograms of RNA from a control reaction and from an experimental reaction after ribosomal RNA depletion are shown in FIG. 3 and FIG. 4.

**EXAMPLE 3:****Evaluations of Efficacy with Prokaryotic Targets**

The materials and methods of Examples 1 and 2 were employed to determine the efficiency of removal of 16S rRNA or 23S rRNA or both from *E. coli* total RNA. Changes in the parameters of the experiments are noted when appropriate. These experiments were performed to evaluate the efficacy of various bridging nucleic acids and reaction conditions.

The following results are from reactions that employed 10 µg of *E. coli* total RNA, 40 pmol of total 16S rRNA bridging nucleic acid, 40 pmol of total 23S rRNA bridging nucleic acid, and 50 µl of capture nucleic acid described in Example 1.

<b>Bridging Nucleic Acid 16S/23S</b>	<b>% 16S Removed average of 2 reactions</b>	<b>% 23S Removed average of 2 reactions</b>
d16S-358/d23S-2511	96.48285	89.86496
d16S-537/d23S-1954	97.47974	91.32074
d16S-537/d23S-2511	97.48704	91.216
d16S-807/d23S-1954	95.79126	89.85388
d16S-807/d23S-2511	95.25362	91.06399
d16S-1092/d23S-1118	97.91265	96.50658
d16S-1092/d23S-1954	96.7473	89.40605
d16S-1092/d23S-2511	97.61689	91.5964
d16S-358/d23S-1954	96.74434	88.07242
d16S1092/d23S-1954 (20 pmol) d23S-2511 (20 pmol)	97.19134	98.44728

The following results are from reactions that employed 10 µg of *E. coli* total RNA, 26 pmol of 16S rRNA bridging nucleic acid, 26 pmol of 23S rRNA bridging nucleic acid, and 35 µl of capture nucleic acid described in Example 1.

<b>Bridging Nucleic Acid 16S/23S</b>	<b>% 16S Removed average of 2 reactions</b>	<b>% 23S Removed average of 2 reactions</b>
d16S-1092/d23S-1118	97.38534	95.02083
d16S-1092/d23S-1957	97.8291	90.798

The following results are from reactions that employed 10  $\mu$ g of *E. coli* total RNA, 75 pmol of 16S rRNA bridging nucleic acid, 75 pmol of 23S rRNA bridging nucleic acid, and 100  $\mu$ l of capture nucleic acid described in Example 1.

<b>Bridging Nucleic Acid 16S.....23S</b>	<b>% 16S Removed average of 2 reactions</b>	<b>% 23S Removed average of 2 reactions</b>
d16S-1092.....d23S-1118	99.14812	99.11895
d16S-1092.....d23S-1954	98.79938	98.45245
d16S-1092.....d23S-2511	99.00567	98.84033

- 5 The following results are from reactions that employed 10  $\mu$ g of *E. coli* total RNA, 37.5 pmol of 16S rRNA bridging nucleic acid, 37.5 pmol of 23S rRNA bridging nucleic acid, and 50  $\mu$ l of capture nucleic acid described in Example 1.

<b>Bridging Nucleic Acid 16S/23S</b>	<b>% 16S Removed average of 2 reactions</b>	<b>% 23S Removed average of 2 reactions</b>
d16S-1092/d23S-1118	98.95563	98.28748
d16S-1092/d23S-1954	97.83593	94.84438

- 10 The following results are from reactions that employed 10  $\mu$ g of *E. coli* total RNA, 75 pmol of 16S rRNA bridging nucleic acid or 75 pmol of 23S rRNA bridging nucleic acid with 75  $\mu$ l of capture nucleic acid described in Example 1.

<b>Bridging Nucleic Acid 16S/23S</b>	<b>% 16S Removed</b>	<b>% 23S Removed</b>
n.a./d23S-581	-	98.98529
n.a./d23S-581	-	98.87251
n.a./d23S-1118	-	93.62175
n.a./d23S-1118	-	91.4927
n.a./d23S-1954	-	98.68262
n.a./d23S-1954	-	99.03237
n.a./d23S-2511	-	99.31982
n.a./d23S-2511	-	99.13291
d16S-358/n.a.	97.65586	-
d16S-358/n.a.	97.51393	-
d16S-537/n.a.	99.16427	-
d16S-537/n.a.	98.92345	-
d16S-807/n.a.	98.0661	-
d16S-807/n.a.	98.14292	-

n.a. = not applicable

The following results are from reactions that employed 5  $\mu$ g of *E. coli* total RNA, 25 pmol of each 16S rRNA or 23S rRNA bridging nucleic acid, and 25  $\mu$ l of capture nucleic acid described in Example 1. The rRNA/bridging nucleic acid annealing reaction was for 60 minutes at 37°C.

<b>Bridging Nucleic Acid 16S/23S</b>	<b>% 16S Removed</b>	<b>% 23S Removed</b>
n.a./d23S-488	-	~100
n.a./d23S-1118	-	~100
d16S-3'/d23S-488	89.024	94.228
d16S-548/d23S-488	~100	93.718
d16S-1092/d23S-488	~100	92.652

The following results are from reactions that employed 5  $\mu$ g of *E. coli* total RNA, 16S rRNA bridging nucleic acid as indicated, 23S rRNA bridging nucleic acid as indicated, and 25  $\mu$ l of capture nucleic acid described in Example 1. The rRNA/bridging nucleic acid annealing reaction was for 120 minutes at 37°C.

<b>Bridging Nucleic Acid 16S/23S</b>	<b>% 16S Removed</b>	<b>% 23S Removed</b>
d16S-3' (25 pmol)/n.a.	89.137	-
d16S-548 (25 pmol)/n.a.	~100	-
d16S-1092 (25 pmol)/n.a.	~100	-
d16S-3' (25 pmol) d16S-548 (25 pmol)/n.a.	~100	-
d16S-3' (25 pmol) d16S-1092 (25 pmol)/n.a.	~100	-
d16S-548 (25 pmol) d16S-1092 (25 pmol)/n.a.	~100	-
d16S-548 (25 pmol)/ d23S-3' (25 pmol)	~100	~100
d16S-1092 (25 pmol)/ d23S-3' (25 pmol)	~100	~100
d16S-3' (25 pmol)/ d23S-3' (25 pmol)	92	~100

**EXAMPLE 4:**  
**The Effect of Washing the Capture Nucleic Acid**

The purpose of this experiment was to determine if washing the capture nucleic acid and combining the wash with the purified mRNA had an effect on the presence of rRNA in the purified mRNA sample. Reactions employed 10  $\mu$ g of *E. coli* total RNA, 75 pmol d16S-1092, 75 pmol of d23S-d1118, and 100  $\mu$ l of capture nucleic acid described in Example 1. The rRNA/bridging nucleic acid annealing reaction proceeded for 60 min at 37°C. After the nucleic acid capture step, the capture nucleic acid (with bound rRNA) was resuspended and washed with 100  $\mu$ l of the indicated solution at room temperature for 5 minutes. The capture nucleic acid was re-captured with a magnetic stand and the supernatant was removed and combined with mRNA in the supernatant from the first capture. mRNA in the combined supernatants were precipitated with ethanol and evaluated with RNA 6000 Lab Chip assay for the presence of rRNAs. The percent of rRNA removal for the entire process is indicated in the table below.

Wash	% 16S Removed	% 23S Removed
0.4 M TMAC	66.061	66.175
1.0 M TMAC	95.810	96.708
1.5 M TMAC	~100	~100
2.0 M TMAC	~100	~100

These results demonstrate that lowering the molarity of the TMAC wash solution increases the stringency of the rRNA capture reaction when the temperature is held constant at room temperature. The results also demonstrate that washing the capture nucleic acid magnetic beads with 1.5 and 2.0 M TMAC does not remove rRNA from the capture nucleic acid.

**EXAMPLE 5:**  
**Evaluation of Efficacy with Prokaryotic and Eukaryotic rRNA Targets**

The purpose of this example was to evaluate efficacy of the methods of the invention for depleting 16S rRNA, 18S rRNA, 23S rRNA, and 28S rRNA from mixtures of prokaryotic and eukaryotic total RNA. Depletion methods were verified using various mammalian samples, including rat livers.

Equal amounts (2.5  $\mu$ g) of *E. coli* total RNA and rat liver total RNA were mixed prior to the mRNA enrichment procedure. The bridging oligonucleotides employed were:

5  
d16S-1092 (10 pmol)  
d16S- 807 (10 pmol)  
d23S-1954 (10 pmol)  
d23S-2511 (10 pmol)  
d18S-3711 (20 pmol)  
d28S-11599 (20 pmol)

The reaction used 50  $\mu$ l of capture nucleic acid as described in Example 1. No wash step was employed. Otherwise the reaction was performed according to methods in Example 2. The results are shown in FIG. 5A and 5B. Note that all rRNAs were depleted except the 5S and 5.8S rRNAs for which no bridging oligonucleotides were added.

#### EXAMPLE 6:

##### Evaluation of Efficacy with Human rRNA Targets

Additional experiments were done using human samples to evaluate the extent of human rRNA depletion using the bridging oligonucleotides shown below. Depletion of 18S rRNA and 28S rRNA was observed from human liver total RNA. rRNAs were depleted from human liver total RNA (5  $\mu$ g). The bridging oligonucleotides employed were:

20  
d18S-3711 (40 pmol)  
d28S-11599 (40 pmol)

The reaction used 50  $\mu$ l of capture nucleic acid as described in Example 1. No wash step was employed. Otherwise the reaction was performed according to Example 2.

The results are shown in FIG. 6A and 6B. Note that all rRNAs (18S, 28S) were depleted except the 5S and 5.8S rRNAs for which no bridging oligonucleotides were added.

#### 25 EXAMPLE 7:

##### Evaluation of Efficacy with Rat rRNA Targets

Additional experiments were done using rat samples to evaluate the extent of rat rRNA depletion using the bridging oligonucleotides shown below. Depletion of 18S rRNA and 28S rRNA was observed from rat liver total RNA. rRNAs were depleted from rat liver total RNA (5  $\mu$ g). The bridging oligonucleotides employed were:

30  
d18S-3711R-polyA (40 pmol)  
d28S-11599R-polyA (40 pmol)

The reaction used 50  $\mu$ l of capture nucleic acid as described in Example 1. No wash step was employed. Otherwise the reaction was performed according to Example 2.

The results are shown in FIG. 7A and 7B. Note that all rRNAs (18S, 28S) were depleted except the 5S and 5.8S rRNAs for which no bridging oligonucleotides were added.

5

**EXAMPLE 8:****Evaluation of Efficacy with Mouse rRNA Targets**

Additional experiments were done using mouse samples to evaluate the extent of rat rRNA depletion using the bridging oligonucleotides shown below. Depletion of 18S rRNA and 28S rRNA was observed from mouse liver total RNA (5  $\mu$ g). The bridging oligonucleotides employed were:

d18S-3711R-polyA (40 pmol)

d28S-11599R-polyA (40 pmol)

The reaction used 50  $\mu$ l of capture nucleic acid as described in Example 1. No wash step was employed. Otherwise the reaction was performed according to Example 2.

The results are shown in FIG. 8A and 8B. Note that all rRNAs (18S, 28S) were depleted except the 5S and 5.8S rRNAs for which no bridging oligonucleotides were added.

**EXAMPLE 9:****Use of Purified *E. coli* mRNA in Gene Array Expression Analysis**

mRNA was purified from total *E. coli* RNA (10  $\mu$ g) using the methods of the invention as described in Example 2. A control reaction was also performed in which the bridging nucleic acid mixture was omitted from the reaction. Control total RNA and purified mRNA (1.5  $\mu$ g) were added to 70 pmol random hexamers in a final volume of 7.25  $\mu$ l. The mixture was heated at 70°C for 10 minutes, then transferred to ice for 3 minutes. The following components were added to each reaction:

5 $\mu$ l	cDNA 1 <sup>st</sup> strand synthesis buffer (Invitrogen)
2.5 $\mu$ l	0.1 M DTT
1.25 $\mu$ l	10 mM dATP

1.25 $\mu$ l	10 mM dGTP
1.25 $\mu$ l	10 mM dTTP
5 $\mu$ l	10 mCi/ml $^{33}$ P-dCTP (Perkin Elmer-NEN)
1 $\mu$ l	Superscript II reverse transcriptase (Invitrogen) 200 U/ $\mu$ l

5

The reactions were incubated at 42°C for 120 minutes. Unincorporated nucleotides were removed from the reactions with a Qiaquick PCR cleanup column (Qiagen). The labeled cDNAs ( $3 \times 10^7$  cpm/blot) were used to probe replicate portions of Panorama™ *E. coli* gene arrays, using hybridization buffers supplied by the array manufacturer (Sigma-Genosys). The arrays were washed and exposed to film. This example demonstrates a dramatic increase in hybridization signal (sensitivity) on gene arrays when labeled cDNA is prepared from bacterial mRNA, purified according to the methods of the invention, rather than from total RNA.

10

#### EXAMPLE 10:

##### Instructions for Use with Kit

The following instructions have been followed with a kit of the invention described below for the successful depletion of 16S and 23S rRNA from a sample comprising prokaryotic RNA populations. Bridging oligonucleotides with targeting regions complementary to 18S and 28S rRNA may be employed according to the method below to effect a similar result (as in Examples 5-8).

##### 20 *Materials Provided with a Kit Embodiment*

30 $\mu$ l	Control RNA
1.2 ml	Capture Nucleic Acid [as in Example 1]
7 ml	Binding Buffer [as in Example 1]
95 $\mu$ l	Bridging Oligonucleotide Mix [as in Example 2]
25 2.4 ml	Wash Solution [as in Example 1]
1.75 ml	Nuclease-free Water
50 ea	RNase-free 1.5 ml tubes
25 ea	RNase-free 2ml Elution tubes
200 $\mu$ l	Glycogen (5 mg/ml)
30 875 $\mu$ l	3 M NaOAc



*Experimental Parameters***A. RNA Source**

This mRNA enrichment procedure is designed to work with purified total RNA from many different bacteria, including both gram-positive and gram-negative species. The procedure was optimized with total *E. coli* RNA and has been found to remove 90-99% of the rRNA from *Bacillus subtilis*, *Staphylococcus aureus*, *Prochlorococcus* sp., *Neisseria meningitidis*, and *Pseudomonas aeruginosa*, for example. It is contemplated that any eubacterial species may be targeted using the methods and compositions of the invention.

This procedure is designed so that small RNAs (including tRNA and 5S rRNA) remain in the enriched mRNA population. However, if the loss of very small RNA species (<200 base) will not be an issue, the initial isolation of total RNA should be performed with Ambion's RNAQUEOUS KIT. The RNAQUEOUS KIT will remove most small RNA species and provide the highest possible level of mRNA enrichment. If small RNAs are of interest to the user, it is best to avoid glass fiber filter-based purification.

**B. Precipitate RNA to remove salt and concentrate if necessary**

Total RNA prepared from a solid-phase extraction method such as RNAQUEOUS can be used immediately after elution because such samples are unlikely to have high levels of salt. On the other hand, RNA isolated by methods that include organic extractions, for example using the products RNAWIZ, TRIZOL or ToTALLY RNA, may have a substantial amount of residual salt. If RNA from these types of procedures has been precipitated only a single time, we recommend doing a second alcohol precipitation and 70% EtOH wash to remove residual salt before starting the enrichment procedure.

The recommended maximum amount of RNA per reaction is 10  $\mu$ g and the recommended maximum volume for the RNA is 15  $\mu$ l. If the RNA sample is too dilute, it will be necessary to precipitate and concentrate the RNA to at least 10  $\mu$ g/15  $\mu$ l. Precipitate the RNA with:

- 0.1 volume 5 M Ammonium Acetate or 3 M sodium acetate
- 1  $\mu$ l Glycogen (The glycogen acts as a carrier to increase precipitation efficiency from dilute RNA solutions; it is unnecessary for solutions with 200  $\mu$ g RNA/ml)
- 2.5 volumes 100% ethanol

- a. Leave the precipitation mixture at  $-20^{\circ}\text{C}$  overnight, or quick-freeze it in either ethanol and dry ice, or in a  $-70^{\circ}\text{C}$  freezer for 30 minutes.
- b. Recover the RNA by centrifugation at  $12,000 \times g$  for 30 minutes at  $4^{\circ}\text{C}$ .
- 5 c. Carefully remove and discard the supernatant. The RNA pellet may not adhere tightly to the walls of the tubes, so we suggest removing the supernatant by gentle aspiration with a fine-tipped pipette.
- d. Centrifuge the tube briefly a second time, and aspirate any additional fluid that collects with a fine-tipped pipette.
- 10 e. Add 1 ml 70% ethanol, and vortex the tube a few times. Repellet the RNA by microcentrifuging, for 10 minutes at  $4^{\circ}\text{C}$ . Remove supernatant carefully as in steps c and d above.

RNA should be dissolved in TE or Ambion's THE RNA STORAGE SOLUTION. It is important to accurately quantitate RNA so as not to overload the system. Ambion recommends  
15 using the RiboGreen RNA Quantitation Assay and Kit (Molecular Probes) or a high quality, calibrated spectrophotometer.

**C. Save an aliquot of your total RNA**

If possible, retain a small aliquot ( $\sim 1\text{--}2 \mu\text{g}$ ) of the total RNA used for comparison with enriched mRNA by gel electrophoresis after the procedure is finished.

20 *Instructions*

**A. Anneal RNA and Bridging Oligonucleotide Mix**

**1. Add RNA to Binding buffer**

Add total RNA (up to  $10 \mu\text{g}$  total RNA in a maximum volume of  $15 \mu\text{l}$ ) to  $200 \mu\text{l}$  Binding Buffer in a 1.5 ml tube provided with the kit. Close the tube and tap or vortex gently to mix.

25 **2. Add Bridging Oligonucleotide Mix to RNA**

Add  $4.0 \mu\text{l}$  of the Bridging Oligonucleotide Mix to the RNA in Binding Buffer. Close the tube and tap or vortex gently to mix. Pulse in a microcentrifuge very briefly to get mixture to bottom of tube.

**3. Incubate reactions at 70°C for 10 minutes.**

Incubating the mixture at 70°C for 10 minutes denatures secondary structures in RNA, including the 16S and 23S rRNAs, allowing for maximal hybridization of the bridging oligonucleotides to the rRNAs.

5                   **4. Incubate reactions at 37°C for 1 hour.**

Incubating the mixture at 37°C for 1 hour allows for binding of the bridging oligonucleotides to the 16S and 23S rRNA. The Binding Buffer has been optimized to function specifically and efficiently at this temperature.

**B. Prepare the Capture Nucleic Acid**

10           During the 1 hour RNA<sup>Bridging</sup> Oligonucleotide Mix annealing step, prepare the Capture Nucleic Acid. The Capture Nucleic Acid is in a 1% (10 mg/ml) suspension, vortex the tube briefly before pipetting to be sure they are well suspended.

**1. Aliquot the Capture Nucleic Acid**

For each 10 µg reaction remove 50 µl Capture Oligos to a 1.5 ml tube. Capture Nucleic  
15   Acid for up to 10 reactions can be processed in a single 1.5 ml tube.

**2. Wash the Capture Nucleic Acid once with water and once with Binding Buffer**

a.       Capture the beads (Capture Nucleic Acid) by placing the tube on the Magnetic  
20   Stand. Leave the tube on the stand until all of the Capture Nucleic Acid is arranged inside the tube near the magnet. This will take ~3 minutes for microfuge tubes.

b.       Carefully remove the supernatant by aspiration, leaving the beads in the tube, and discard the supernatant.

c.       Add Nuclease Free Water to the captured beads at a ratio of 50 µl/50 µl beads).

25       d.       Remove the tube from the Magnetic Stand, resuspend the beads by gently vortexing briefly, recapture the beads with a Magnetic Stand, carefully aspirate the supernatant, leaving the beads in the tube, and discard the supernatant.

e.       Add Binding Buffer to the captured beads at a ratio of 50 µl/50 µl beads).

- f. Repeat step d.

**3. Resuspend the Capture Nucleic Acid in Binding Buffer**

- a. Add Binding Buffer to the captured beads at a ratio of 50  $\mu$ l/50  $\mu$ l beads).
- b. Remove the tube from the Magnetic Stand, resuspend the beads by gently tapping  
5 the tube or very gentle vortexing.
- c. Pulse spin in a microcentrifuge to get liquid to the bottom of the tube.

**C. Capture the rRNA with Capture Nucleic Acid and Recover the Enriched mRNA**

10 **1. Add Capture Nucleic Acid (50  $\mu$ l/rxn) to RNA/Bridging Oligonucleotide Mix and incubate at RT for 15 minutes.**

- a. After the 1 hour incubation at 37°C (Step A.4) remove tubes to room temperature (RT) and immediately add 50  $\mu$ l of the washed and equilibrated beads (Capture Nucleic Acid, from Step B.3c) to each purification reaction. Very gently vortex or tap tube to mix briefly and pulse spin in a microcentrifuge to get liquid to the bottom of the tube.
- 15 b. Incubate 15 minutes at RT. During this step the oligonucleotide sequence on the Capture Nucleic Acid anneals to the bridging oligonucleotides. The bridging oligonucleotides remain hybridized to the 16S and 23S rRNAs. The hybridization "sandwich" of bridging oligonucleotide and capture oligonucleotide (via the capture region on the capture oligo and the bridging region on the bridging oligo) is formed at this step.

20 **2. Recover the supernatant containing the enriched mRNA.**

- a. Capture the beads by placing the tube on the Magnetic Stand. Leave the tube on the stand until all of the beads are arranged inside the tube near the magnet. This will take ~3 minutes for microfuge tubes. Allow the beads to be completely captured by the magnet for at least 3 minutes.
- 25 b. Remove the supernatant by aspiration, being careful not to dislodge the beads. Put the supernatant into a 2 ml nipple bottom tube on ice and save. Do not be overly concerned if there seems to be beads in the removed supernatant. The excess can be removed at the end of the procedure. The supernatant contains the enriched mRNA sample.

**3. Wash the Oligo MagBeads with Wash Solution and recover the wash.**

- a. Add Wash Solution to the captured beads at a ratio of 100  $\mu$ l Wash Solution/50  $\mu$ l beads.
  - b. Remove the tube from the Magnetic Stand, resuspend the beads by gently vortexing briefly.
  - c. Incubate at RT for 5 minutes.
  - d. Recapture the beads with the Magnetic Stand as in step C.2a. Allow the beads to be completely captured by the magnet for at least 3 minutes.
  - e. Remove the supernatant by aspiration, being careful not to dislodge the beads.
- 10 Put this supernatant in the 2 ml nipple bottom tube on ice with that from step C.2b.

**D. Precipitate and resuspend the enriched mRNA in the supernatant.****1. Perform an EtOH precipitation on the collected supernatant.**

- a. Add 1/10 Volume 3M NaOAc (35  $\mu$ l) and 5 mg/ml glycogen to a final concentration of 100 $\mu$ g/ml (7  $\mu$ l) to the supernatant from step C.3.e. (the supernatant volume should be ~350  $\mu$ l).
- b. Briefly vortex the sample to mix.
- c. Add 3 Vol. ice cold 100% EtOH (1175  $\mu$ l) and mix well by vortexing the sample.
- d. Precipitate the sample at  $-20^{\circ}\text{C}$  for at least 1 hour.
- e. Centrifuge the sample for 30 min. @ 13,000 rpm.
- f. Carefully decant the supernatant.
- g. Add 750ml ice cold 70% EtOH, vortex briefly, and centrifuge for 5 min. @ 13,000 rpm. Decant the supernatant.
- h. Repeat step D.1.g.

i. After decanting the supernatant spin briefly to collect. Remove the remaining supernatant with a pipettor, being careful not to dislodge the pellet. Air dry for 5 min.

**2. Resuspend the enriched mRNA in an appropriate buffer.**

- a. After the pellet has air dried for no more than 5 min. add 2  $\mu$ l TE pH 8.0 (RNA STORAGE SOLUTION, 1 mM EDTA or Nuclease-Free ddH<sub>2</sub>O could be substituted).
- b. Allow the RNA to resuspend for 15 min. at room temperature. Vortex the sample vigorously to resuspend. Collect the sample by brief centrifugation. NOTE: If the pellet refuses to go into solution the sample can be incubated for 5 min. @ 70°C. This should help resuspend the pellet. NOTE: Often there will be beads remaining in the sample after the precipitation (This will cause the RNA solution to appear brownish in color). This can be remedied by applying the sample to the Magnetic stand for ~3 min. and removing the supernatant to a new tube.

**E. Compatibility with respect to other microorganisms**

Based on experimental evidence and sequence information, the following organisms should be compatible (removal of 16S rRNA and of 23S rRNA) with the oligos identified in Example 1 (non-control oligos): *Acidithiobacillus ferrooxidans*, *Acinetobacter calcoaceticus*, *Actinobacillus actinomycetemcomitans*, *Aeromonas hydrophila*, *Agrobacterium tumefaciens*, *Alcaligenes faecalis*, *Bacillus alcalophilus*, *Bacillus anthracis*, *Bacillus cereus*, *Bacillus halodurans*, *Bacillus licheniformis*, *Bacillus mycoides*, *Bacillus subtilis*, *Bacillus thuringiensis*, *Bartonella bacilliformis*, *Bordetella avium*, *Bordetella bronchiseptica*, *Bordetella parapertussis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Bradyrhizobium japonicum*, *Bradyrhizobium lupini*, *Brevundimonas diminuta*, *Brucella melitensis*, *Brucella melitensis* biovar suis, *Buchnera aphidicola*, *Buchnera* sp. APS, *Burkholderia cepacia*, *Burkholderia mallei*, *Burkholderia pseudomallei*, *Caulobacter crescentus*, *Chlamydia muridarum*, *Chlamydia suis*, *Chlamydia trachomatis*, *Chlamydophila abortus*, *Chlamydophila caviae*, *Chlamydophila felis*, *Chlamydophila pecorum*, *Chlamydophila pneumoniae*, *Chlamydophila psittaci*, *Chlorobium limicola*, *Chlorobium tepidum*, *Citrobacter freundii*, *Clostridium acetobutylicum*, *Clostridium difficile*, *Clostridium histolyticum*, *Corynebacterium diphtheriae*, *Corynebacterium glutamicum*, *Cytophaga hutchisonii*, *Desulfovibrio vulgaris*, *Dichelobacter nodosus*, *Enterococcus asini*, *Enterococcus avium*, *Enterococcus casseliflavus*, *Enterococcus cecorum*, *Enterococcus*

*columbae*, *Enterococcus dispar*, *Enterococcus durans*, *Enterococcus faecalis*, *Enterococcus faecium*, *Enterococcus flavescens*, *Enterococcus gallinarum*, *Enterococcus hirae*, *Enterococcus malodoratus*, *Enterococcus mundtii*, *Enterococcus pseudoavium*, *Enterococcus raffinosus*, *Enterococcus saccharolyticus*, *Enterococcus sulfureus*, *Erwinia chrysanthemi*, *Escherichia coli*,  
5 *Fibrobacter succinogenes*, *Frankia* sp., *Fusobacterium nucleatum*, *Geobacillus stearothermophilus*, *Geobacter sulfurreducens*, *Gluconacetobacter europaeus*, *Gluconacetobacter intermedius*, *Gluconacetobacter xylinus*, *Haemophilus ducreyi*, *Haemophilus influenzae*, *Klebsiella pneumoniae*, *Lactobacillus amylolyticus*, *Lactobacillus delbrueckii*, *Lactococcus lactis*, *Leuconostoc carnosum*, *Leuconostoc lactis*, *Leuconostoc mesenteroides*,  
10 *Listeria grayi*, *Listeria innocua*, *Listeria ivanovii*, *Listeria monocytogenes*, *Listeria seeligeri*, *Melissococcus plutonius*, *Micrococcus luteus*, *Mycobacterium avium*, *Mycobacterium avium* supsp. *Paratuberculosis*, *Mycobacterium bovis*, *Mycobacterium kansasii*, *Mycobacterium leprae*, *Mycobacterium phlei*, *Mycobacterium smegmatis*, *Mycobacterium tuberculosis*, *Myxococcus xanthus*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nitrosomonas europaea*, *Pasteurella*  
15 *multocida*, *Peptococcus niger*, *Plesiomonas shigelloides*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Ralstonia pickettii*, *Ralstonia solanacearum*, *Renibacterium salmoninarum*, *Rhizobium vitis*, *Rhodococcus erythropolis*, *Rhodococcus fascians*, *Rhodopseudomonas palustris*, *Rhodospirillum rubrum*, *Rickettsia akari*, *Rickettsia australis*, *Rickettsia bellii*, *Rickettsia canadensis*, *Rickettsia conorii*, *Rickettsia montanensis*,  
20 *Rickettsia parkeri*, *Rickettsia prowazekii*, *Rickettsia rhipicephali*, *Rickettsia rickettsii*, *Rickettsia sibirica*, *Rickettsia typhi*, *Salmonella bongori*, *Salmonella enterica*, *Salmonella enteritidis*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shewanella putrefaciens*, *Sinorhizobium meliloti*, *Sporosarcina globispora*, *Staphylococcus aureus*, *Staphylococcus carnosus*, *Staphylococcus condimenti*, *Staphylococcus epidermidis*, *Stigmatella aurantiaca*,  
25 *Streptococcus equi*, *Streptococcus gordonii*, *Streptococcus macedonicus*, *Streptococcus mitis*, *Streptococcus mutans*, *Streptococcus oralis*, *Streptococcus parauberis*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Streptococcus thermophilus*, *Streptococcus uberis*, *Streptomyces ambofaciens*, *Streptomyces coelicolor*, *Streptomyces griseus*, *Streptomyces lividans*, *Streptomyces nodosus*, *Streptomyces rimosus*, *Thermoanaerobacter tengcongensis*,  
30 *Thermobifida fusca*, *Thermomonospora chromogena*, *Thiobacillus ferrooxidans*, *Trteponema denticola*, *Treponema pallidum*, *Vibrio cholerae*, *Yersinia enterocolitica*, *Yersinia pestis*, *Xanthomonas campestris*, *Xanthomonas axonopodis* pv. *Citri*, and *Xylella fastidiosa*.

Based on experimental evidence and sequence information, the following organisms should be partially compatible (removal of 23S rRNA and of 50-100% 16S rRNA) with oligos identified in Example 1 (non-control): *Azotobacter vinelandii*, *Bacteroides fragilis*, *Carboxydothermus hydrogenoformans*, *Clostridium tyrobutyricum*, *Desulfovibrio vulgaris*,  
 5 *Dictyoglomus thermophilum*, *Enterococcus solitarius*, *Erysipelothrix rhusiopathiae*, *Erysipelothrix tonsillarum*, *Flexibacter flexilis*, *Legionella pneumophila*, *Leptospira interrogans*, *Leucothrix mucor*, *Listeria welshimeri*, *Methylococcus capsulatus*, *Myroides odoratus*, *Oenococcus oeni*, *Paracoccus denitrificans*, *Pectinatus frisingensis*, *Porphyromonas gingivalis*, *Prevotella intermedia*, *Silicibacter pomeroyi*, *Tannerella forsythensis*, *Tetragenococcus*  
 10 *halophilus*, *Thermobispora bispora*, *Thermus thermophilus* and, *Thiomonas cuprina*

Based on experimental evidence and sequence information, the following organisms should be partially compatible (removal of 16S rRNA and 50-100% of 23S rRNA) with oligos identified in Example 1 (non-control): *Burkholderia fungorum*, *Clostridium perfringens*, *Desulfitobacterium hafniense*, *Magnetospirillum magnetotacticum*, *Mesorhizobium loti*,  
 15 *Nannocystis exedens*, *Novosphingobium aromaticivorans*, *Parachlamydia acanthamoebae*, *Ruminobacter amylophilus*, *Ruminococcus albus*, *Tropheryma whipplei*, and *Wolbachia endosymbiont* of *Drosophila melanogaster*.

Based on experimental data and sequence information, the following organisms are believed to be incompatible with the oligos in Example 1: *Archaeobacteria*, *Campylobacter spp.*,  
 20 *Chloroflexus aurantiacus*, *Cyanobacteria*, *Dehalococcoides ethenogenes*, *Deinococcus radiodurans*, *Fervidobacterium islandicum*, *Helicobacter pylori*, *Mycoplasma spp.*, *Pirellula marina*, *Propionibacterium freundenreichii*, *Simkania negevensis*, *Thermotoga maritima*, and *Ureaplasma urealyticum*.

#### EXAMPLE 11:

#### 25 Methods for Eukaryotic rRNA Depletion from Mixed Human/*E. coli* Total RNA

These experiments were performed to demonstrate the depletion of 18S and 28S rRNAs from a mixture of prokaryotic and eukaryotic total RNA. Materials from Example 1 were used in the following experiments, except where noted.

#### 30 *RNA/Bridging Nucleic Acid Mixture Annealing*



RNA (50 µg human total / 0.5 µg *E. coli* total) in 30 µl TE pH8.0 was added to 300 µl of binding buffer (The binding buffer in this example contains 0.02% Triton-X 100 which has been shown to reduce non-specific interactions between nucleic acids target and the capture nucleic acid). The bridging nucleic acid mixture consisted of d18S-3711, d18S-4238, d18S-5482, d28S-7979, d28S-11599 and d28S-12533 (each of these bridging oligonucleotides is at a final concentration of 3.33 µM). The bridging nucleic acid mixture (20 µl) was added to the RNA and the mixture was incubated at 70°C for 10 minutes and then shifted to 37°C for 1 hour.

#### *Preparation of Capture Nucleic Acid*

Capture nucleic acid (Oligo (dT) MagBeads, Seradyn) in storage buffer was mixed and 250 µl was removed to a separate tube. A magnetic stand was applied to the side of the tube to capture the magnetic beads and the supernatant was removed. The capture nucleic acid was equilibrated one time with distilled, deionized water (250 µl) and once with binding buffer (250 µl). The captured nucleic acid was captured again with a magnetic stand, and the binding buffer wash was removed. The magnetic beads were stored on ice until used in the next step (rRNA Capture).

#### *rRNA Capture*

Following the 1 hour annealing of RNA with the bridging nucleic acid mixture, the RNA-bridging oligonucleotide mixture was added to the capture nucleic acid (see Preparation of Capture Nucleic Acid), and the mixture was incubated at 37°C for 15 minutes. A magnetic stand was applied to the tube to capture the magnetic beads. The supernatant containing *E. coli* total RNA was removed to another tube and saved. An optional washing step was performed. The magnetic beads were washed with Wash Solution (100 µl) and captured again. The wash supernatant was removed and added to the original supernatant.

Fifteen minutes was found to be an adequate length of time for rRNA capture. Longer time periods can be used with no adverse effects. rRNA capture occurs rapidly, and capture times of 5 – 60 minutes have been used successfully in the methods of the invention.

#### *Precipitating RNA*

*E. coli* total RNA was precipitated by adding 1/10 volume of 3 M NaOAc (pH 5.5) and 3 volumes of 100% EtOH and incubating at -20°C for 60 minutes. The precipitated RNA was pelleted in a microfuge, washed with 70% EtOH, and resuspended in TE (pH 8.0).

*Analysis of Purified RNA*

Purified RNA was analyzed with the Caliper RNA 6000 LabChip kit on an Agilent Bioanalyzer. Purified RNA was compared with a control total RNA sample that was carried through the reaction as described above, except that the Bridging Nucleic Acid Mixture was omitted (FIG. 9). The percentage of a rRNA present in the sample is calculated from the area under the peak. The percentage removal of the 18S and 28S rRNAs was calculated as described in Example 2 for removal of 16S and 23S rRNAs.

Electropherograms of RNA from a control reaction and from an experimental reaction after ribosomal RNA depletion are shown in FIG. 9.

10

**EXAMPLE 12:****Evaluation of efficacy with Mixed Prokaryotic and Eukaryotic rRNA Targets**

The purpose of this experiment was to determine if one could, first remove the eukaryotic RNA and subsequently remove the prokaryotic rRNAs from a mixture of the two total RNAs. The materials and methods of Examples 1, 2 and 11 were used, except where noted. Depletion methods were verified using various mammalian samples, including rat liver total RNA, and both *E. coli* and *Bacillus subtilis* total RNA.

25 µg rat liver total RNA and 2 µg *E. coli* total RNA were mixed prior to the RNA enrichment procedure. The bridging oligonucleotides employed were: d16S-807, d16S-1092, d23S-1954, d23S-2511, d18S-3711, d18S-4238, d18S-5482, d28S-7979, d28S-11599, and d28S-12533.

The reactions began with procedures similar to Example 11, except for the following changes. 10 µl bridging nucleic acid mixture and 125 µl capture nucleic acid were used to remove the mammalian 18S and 28S rRNAs. Following the wash step, the wash solution and the unbound fraction containing the bacterial RNA were combined. The precipitation step was not performed. Instead the bacterial 16S and 23S rRNA was removed as in Example 2, with the following modifications. The bridging nucleic acid mixture (4 µl) containing d16S-807, d16S-1092, d23S-1954, and d23S-2511 was added directly to the combined wash and unbound

fractions containing the bacterial RNA. The remainder of the procedure for 16S and 23S rRNA followed the methods from Example 2.

Electropherograms of RNA from a control reaction with no bridging nucleic acids (FIG. 10A), from a reaction following 18S and 28S rRNA removal (FIG. 10B), and from a reaction following subsequent removal of 16S and 23S rRNA (FIG. 10C) are shown in FIG. 10.

#### EXAMPLE 13:

#### Use of Purified *E. coli* mRNA from Mixed Eukaryotic/Prokaryotic Samples in Gene Array

#### Expression Analysis

mRNA was purified from total *E. coli* RNA (2 µg) in a background of human total RNA (25 µg) using the methods of the invention as described in Example 12 (16S, 23S, 18S and 28S rRNAs were all depleted from the sample). A control reaction was also performed in which the bridging nucleic acid mixtures were omitted from the reaction. Control total RNA (8.4 µg) and purified mRNA (1.0 µg) were added to 160 pmol random decamers in a final volume of 24.5 µl. These RNA amounts represent equal fractions of the control and purified RNA samples after the procedure is complete. The mixture was heated at 70°C for 10 minutes, then transferred to ice for 3 minutes. The following components were added to each reaction:

12 µl	cDNA 1 <sup>st</sup> strand synthesis buffer (Invitrogen)
6 µl	0.1 M DTT
3 µl	10 mM dATP
3 µl	10 mM dGTP
3 µl	10 mM dTTP
5 µl	10 mCi/ml <sup>33</sup> P-dCTP (Perkin Elmer-NEN)
1 µl	RNase Inhibitor (cloned)

The reaction was then incubated at room temperature for 10 minutes, and the following component was added:

2 µl Superscript II reverse transcriptase (Invitrogen) 200 U/µl

The reactions were incubated at 42°C for 120 minutes. Unincorporated nucleotides were removed from the reactions with a Qiaquick PCR™ cleanup column (Qiagen). RNA present in the cDNA probes was hydrolyzed by incubation at 65°C for 10 minutes in .05 N NaOH. The probes were subsequently neutralized with 0.05 M HCl. The labeled cDNAs (5 x 10<sup>7</sup> cpm/blot) were used to probe replicate portions of Panorama™ *E. coli* gene arrays, using hybridization buffers supplied by the array manufacturer (Sigma-Genosys). The arrays were washed and exposed to film. This example demonstrates a dramatic increase in hybridization signal (sensitivity) on gene arrays when labeled cDNA is prepared from enriched bacterial mRNA, purified according to the methods of the invention, rather than from the mixed prokaryotic and eukaryotic total RNA.

#### Example 14:

##### Evaluations of Efficacy with non-*E.coli* Prokaryotic Targets

The materials and methods of Examples 1 and 2 were employed in the Examples below except where noted. These experiments were performed to evaluate the efficacy of various bridging nucleic acids with different bacterial species.

Additional targeting regions for prokaryotic 16S and 23S rRNAs were designed. The targeting regions are shown, in the examples below, 3' of the bridging regions. Thus, the targeting region encompasses the remaining, non-bridging region of each molecule described below. SEQ ID NOs are provided for the targeting regions of the bridging nucleic acids provided below (*i.e.*, sequence of bridging regions not included in SEQ ID NO.). Furthermore, the oligos have been further designated with a suffix at the end of the oligo number. CY refers to cyanobacteria; P refers to pseudomonas; R refers to rhodobacter; and CH refers to campylobacter/helicobacter.

##### 16S prokaryotic rRNA bridging oligonucleotides

d16S-1114P  
5'-AAAAAAAAAAAAAAAAAAGGGTTGCGCTCGTTACGGGACTT-3' (SEQ ID NO:74)

d16S-1114R  
5'-AAAAAAAAAAAAAAAAAAGGGTTGCGCTCGTTGCCGGACTT-3' (SEQ ID NO:75)

d16S-364  
5'-AAAAAAAAAAAAAAAAAATCCCCACTGCTGCCTCCCGTAGG-3' (SEQ ID NO:76)

d16S-1087

5'-AAAAAAAAAAAAAAAAAAACAACATCTCACGACACGAGCTGA-3' (SEQ ID NO:77)

d16S-364CY

5'-AAAAAAAAAAAAAAAAAAATCCCCACTGCTGCCTCCCGTAGG-3' (SEQ ID NO:78)

d16S-534CY

5'-AAAAAAAAAAAAAAAAAAATTACCGCGGCTGCTGGCACGGA-3' (SEQ ID NO:79)

d16S-928CY

10 5'-AAAAAAAAAAAAAAAAAAACCCCGTCAATTCCTTTGAGTTTC-3' (SEQ ID NO:80)

d16S-1087CY

5'-AAAAAAAAAAAAAAAAAAACAACATCTCACGACACGAGCTGA-3' (SEQ ID NO:81)

15

23S prokaryotic rRNA bridging oligonucleotides

d23S-479RCH

5'-AAAAAAAAAAAAAAAAAAATTTACCTTTCCCTCACGGTACT-3' (SEQ ID NO:82)

20

d23S-485

5'-AAAAAAAAAAAAAAAAAAAGGTTCTTTTCACCTTTCCCTCGC-3' (SEQ ID NO:83)

d23S-518 CH

5'-AAAAAAAAAAAAAAAAAAATGGTTTCAGGTTCTATTTCACTC-3' (SEQ ID NO:84)

25

d23S-1954 CH

5'-AAAAAAAAAAAAAAAAAAATTTAACCGACAAGGAATTTTCGC-3' (SEQ ID NO:85)

d23S-485CY

30 5'-AAAAAAAAAAAAAAAAAAAGGTTCTTTTCACCTTTCCCTCGC-3' (SEQ ID NO:86)

The following results are from reactions that employed 10 µg of *Pseudomonas aeruginosa* total RNA, 40 pmol of 16S bridging nucleic acid and 40 pmol of 23S bridging nucleic acid, and 50 µl of capture nucleic acid described in Example 1.

35

Bridging Nucleic Acid 16S/23S	% 16S Removed average of 2 reactions	% 23S Removed average of 2 reactions
d16S-807 (20 pmol), d16S-1092 (20 pmol) d23S-1954 (20 pmol), d23S-2511 (20 pmol)	90.1%	99.5%
d16S-807 (20 pmol), d16S-1114P (20 pmol) d23S-1954 (20 pmol), d23S-2511 (20 pmol)	97.0%	99.4%

The following results are from reactions that employed 10 µg of *Bacillus subtilis* total RNA, 40 pmol of 16S bridging nucleic acid and 40 pmol of 23S bridging nucleic acid, and 50 µl of capture nucleic acid described in Example 1.

Bridging Nucleic Acid 16S/23S	% 16S Removed average of 2 reactions	% 23S Removed average of 2 reactions
d16S-807 (20 pmol), d16S-1092 (20 pmol) d23S-1954 (20 pmol), d23S-2511 (20 pmol)	98.2%	96.2%

5

The following results are from reactions that employed 10 µg of *Campylobacter fetus* total RNA, 40 pmol of 16S bridging nucleic acid and 40 pmol of 23S bridging nucleic acid, and 50 µl of capture nucleic acid described in Example 1. The *Campylobacter fetus* 23S rRNA is processed into two fragments (FIG. 12).

Bridging Nucleic Acid 16S/23S	% 16S Removed average of 2 reactions	% 23S (1260 nt fragment) Removed average of 2 reactions	% 23S (1667 nt fragment) Removed average of 2 reactions
d16S-807 (20 pmol), d16S-1092 (20 pmol) d23S-479CH (20 pmol), d23S-2511 (20 pmol)	97.3%	97.7%	89.3%
d16S-807 (20 pmol), d16S-1092 (20 pmol) d23S-518CH (20 pmol), d23S-2511 (20 pmol)	95.9%	96.7%	89.5%

10

The following results are from reactions that employed 10 µg of *Rhodobacter sphaeroides* total RNA, 40 pmol of 16S bridging nucleic acid and 40 pmol of 23S bridging nucleic acid, and 50 µl of capture nucleic acid, as described in Example 1 unless otherwise noted. The *Rhodobacter sphaeroides* 23S rRNA is processed into two fragments (FIG. 13). One  
15 fragment migrates with the 16S rRNA.

<b>Bridging Nucleic Acid 16S/23S</b>	<b>% 16S + 23S fragment (1600 nt) Removed average of 2 reactions</b>	<b>% 23S Removed average of 2 reactions</b>
d16S-807 (20 pmol), d16S-1092 (20 pmol) d23S-479CH (20 pmol), d23S-2511 (20 pmol)	81.6%	96.8%
d16S-807 (20 pmol), d16S-1092 (20 pmol) d23S-518CH (20 pmol), d23S-2511 (20 pmol)	95.9%	96.7%
d16S-537 (20 pmol), d16S-1114R(20 pmol) d23S-479CH (20 pmol), d23S-2511 (20 pmol)	89.3%	96.1%
d16S-537 (20 pmol), d16S-1114R(20 pmol) d23S-479CH (20 pmol), d23S-1954 (20 pmol), d23S-2511 (20 pmol)	97.0%	96.4%
d16S-807 (20 pmol), d16S-1114R(20 pmol) d23S-479CH (20 pmol), d23S-2511 (20 pmol)	83.1%	96.5%
d16S-807 (20 pmol), d16S-1114R(20 pmol) d23S-479CH (20 pmol), d23S-1954 (20 pmol) d23S-2511 (20 pmol)	90.2%	95.9%
d16S-537 (20 pmol), d16S-807 (20 pmol), d16S-1114R(20 pmol) d23S-479CH (20 pmol), d23S-1954 (20 pmol) d23S-2511 (20 pmol)	96.7%	94.9%
d16S-537 (20 pmol), d16S-1114R(20 pmol) d23S-479CH (20 pmol), d23S-1954 (20 pmol) d23S-2511 (20 pmol)	95.0%	90.2%
d16S-537 (20 pmol), d16S-1114R(20 pmol) d23S-479CH (20 pmol), d23S-1954 (20 pmol) d23S-2511 (20 pmol)	95.2%	89.8%

The results demonstrate that bridging nucleic acids will function with various species. This example also demonstrates functionality based on sequence comparison, *i.e.*, that a bridging oligonucleotide will function with rRNAs in different organisms based on sequence identity

5 between the oligonucleotide and the rRNA of the organism.

#### *Evaluations of Efficacy with Cyanobacteria Targets*

The materials and methods of Examples 1 and 2 were employed except where noted. These experiments were performed to evaluate the efficacy of various bridging nucleic acids with different bacterial species.

10 The following results are from reactions that employed 10 µg of *Anabaena spp.* total RNA, the indicated amounts of the bridging nucleic acids, and 50 µl of capture nucleic acid described in Example 1. The *Anabaena sp.* 23S rRNA and 23S rRNAs from other cyanobacteria may be processed into several fragments (FIG. 14).

Bridging Nucleic Acid 16S/23S	% 16S Removed average of 2 reactions	% 23S Removed average of 2 reactions		
		520 nt fragment	2090 nt fragment	2470 nt fragment
d16S-364CY (20 pmol), d16S-928CY (20 pmol)	94.3	NA	NA	NA
d16S-364CY (20 pmol), d16S-1087CY (20 pmol)	93.1	NA	NA	NA
d16S-928CY (20 pmol), d16S-1087CY (20 pmol)	93.7	NA	NA	NA
d23S-485 (20 pmol), d23S-1954 (20 pmol)	NA	98.6	94.1	99.5
d23S-485 (20 pmol), d23S-2511 (20 pmol)	NA	98.4	95.7	99.5
d16S-364CY (20 pmol), d16S-928CY (20 pmol) d23S-485, (20 pmol), d23S-1954 (20 pmol)	99.5	96.5	84.7	97.7
d16S-364CY (20 pmol), d16S-928CY (20 pmol) d23S-485, (20 pmol), d23S-2511 (20 pmol)	99.2	96.3	87.2	98.5
d16S-364CY (20 pmol), d16S-1087CY (20 pmol) d23S-485 (20 pmol), d23S-1954 (20 pmol)	99.7	98.6	88.3	98.3
d16S-364CY (20 pmol), d16S-1087CY (20 pmol) d23S-485 (20 pmol), d23S-2511 (20 pmol)	99.7	99.2	89.2	99.1
d16S-928CY (20 pmol), d16S-1087CY (20 pmol) d23S-485 (20 pmol), d23S-2511 (20 pmol)	96.9	97.6	86.8	98.9
d16S-364 (20 pmol), d16S-1087CY (20 pmol) d23S-485 (20 pmol), d23S-1954 (20 pmol)	99.2	98.2	88.1	97.7
d16S-364 (17.5 pmol), d16S-1087CY (17.5 pmol) d23S-485 (20 pmol), d23S-1954 (25 pmol)	99.8	98.8	88.4	98.5
d16S-364 (15 pmol), d16S-1087CY (15 pmol) d23S-485 (20 pmol), d23S-1954 (30 pmol)	99.8	99.1	90.6	98.3
d16S-364 (12.5 pmol), d16S-1087CY (12.5 pmol) d23S-485 (20 pmol), d23S-1954 (35 pmol)	99.9	98.7	92.5	98.9



Bridging Nucleic Acid 16S/23S	% 16S Removed average of 2 reactions	% 23S Removed average of 2 reactions		
		520 nt fragment	2090 nt fragment	2470 nt fragment
d16S-364 (10 pmol), d16S- 1087CY (10 pmol) d23S-485 (20 pmol), d23S- 1954 (40 pmol)	99.9	98.9	90.6	98.6

\* \* \* \* \*

5 All of the compositions and methods disclosed and claimed herein can be made and  
executed without undue experimentation in light of the present disclosure. While the  
compositions and methods of this invention have been described in terms of preferred  
embodiments, it will be apparent to those of skill in the art that variations may be applied to the  
compositions and/or methods and in the steps or in the sequence of steps of the method described  
herein without departing from the concept, spirit and scope of the invention. More specifically,  
10 it will be apparent that certain agents that are both chemically and physiologically related may be  
substituted for the agents described herein while the same or similar results would be achieved.  
All such similar substitutes and modifications apparent to those skilled in the art are deemed to  
be within the spirit, scope and concept of the invention as defined by the appended claims.

**REFERENCES**

The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.

5 U.S. Application No. 09/854,412

U.S. Patent No. 4,486,539

U.S. Patent No. 4,563,419

U.S. Patent No. 4,659,774

10 U.S. Patent No. 4,682,195

U.S. Patent No. 4,683,202

U.S. Patent No. 4,751,177

U.S. Patent No. 4,816,571

U.S. Patent No. 4,868,105

15 U.S. Patent No. 4,894,325

U.S. Patent No. 4,959,463

U.S. Patent No. 5,124,246

U.S. Patent No. 5,141,813

U.S. Patent No. 5,200,314

20 U.S. Patent No. 5,214,136

U.S. Patent No. 5,216,141

U.S. Patent No. 5,223,618

U.S. Patent No. 5,264,566

U.S. Patent No. 5,273,882

25 U.S. Patent No. 5,288,609

U.S. Patent No. 5,378,825

U.S. Patent No. 5,412,087

U.S. Patent No. 5,428,148

U.S. Patent No. 5,432,272

30 U.S. Patent No. 5,445,934

U.S. Patent No. 5,446,137

U.S. Patent No. 5,457,025

- U.S. Patent No. 5,466,786  
U.S. Patent No. 5,470,967  
U.S. Patent No. 5,500,356  
U.S. Patent No. 5,539,082  
5 U.S. Patent No. 5,554,744  
U.S. Patent No. 5,574,146  
U.S. Patent No. 5,589,335  
U.S. Patent No. 5,602,240  
U.S. Patent No. 5,602,244  
10 U.S. Patent No. 5,610,289  
U.S. Patent No. 5,614,617  
U.S. Patent No. 5,623,070  
U.S. Patent No. 5,645,897  
U.S. Patent No. 5,652,099  
15 U.S. Patent No. 5,670,663  
U.S. Patent No. 5,672,697  
U.S. Patent No. 5,681,947  
U.S. Patent No. 5,700,922  
U.S. Patent No. 5,702,896  
20 U.S. Patent No. 5,708,154  
U.S. Patent No. 5,709,629  
U.S. Patent No. 5,714,324  
U.S. Patent No. 5,714,331  
U.S. Patent No. 5,714,606  
25 U.S. Patent No. 5,719,262  
U.S. Patent No. 5,723,597  
U.S. Patent No. 5,736,336  
U.S. Patent No. 5,744,305  
U.S. Patent No. 5,759,777  
30 U.S. Patent No. 5,763,167  
U.S. Patent No. 5,766,855  
U.S. Patent No. 5,773,571

- U.S. Patent No. 5,777,092  
U.S. Patent No. 5,786,461  
U.S. Patent No. 5,792,847  
U.S. Patent No. 5,858,988  
5 U.S. Patent No. 5,859,221  
U.S. Patent No. 5,872,232  
U.S. Patent No. 5,886,165  
U.S. Patent No. 5,891,625  
U.S. Patent No. 5,897,783  
10 U.S. Patent No. 5,908,845  
U.S. Patent No. 5,945,525  
U.S. Patent No. 6,001,983  
U.S. Patent No. 6,013,440  
U.S. Patent No. 6,037,120  
15 U.S. Patent No. 6,060,246  
U.S. Patent No. 6,090,548  
U.S. Patent No. 6,110,678  
U.S. Patent No. 6,140,496  
U.S. Patent No. 6,203,978  
20 U.S. Patent No. 6,221,581  
U.S. Patent No. 6,228,580  
U.S. Patent No. 6,309,823  
U.S. Patent No. 6,316,193  
U.S. Patent No. 6,322,971  
25 U.S. Patent No. 6,324,479  
U.S. Patent No. 6,329,140  
U.S. Patent No. 6,329,209
- 30 EP 266,032  
PCT/EP/01219  
PCT/US00/29865

WO 01/32672

WO 86/05815

WO90/06045

WO 92/20702

5

The entire issue of *Current Opinion in Microbiology*, Volume 4, February 2001.

Amara *et al.*, *Nucl. Acids Res.* 25:3465-3470, 1997.

Arfin *et al.*, *J. Biol. Chem.* 275:29672-29684.

- 10 Ausubel *et al.*, In: *Current Protocols in Molecular Biology*, John, Wiley & Sons, Inc, New York, 1994.

Beaucage, *Methods Mol. Biol.* 20:33-61, 1993.

Chuang *et al.*, *J. Bacteriol.* 175:2026-2036, 1993.

Coombes *et al.*, *Infect. Immun.* 69:1420-1427, 2001.

- 15 Cornelis *et al.*, *Curr. Opin. Microbiol.* 4:13-15, 2001.

Cummings *et al.*, *Emerg. Inf. Dis.* 6:513-524, 2000.

DeRisi *et al.*, *Nature Genetics* 14:457-460, 1996.

Detweller *et al.*, *Proc. Natl. Acad. Sci. USA* 98:5850-5855, 2001.

Egholm *et al.*, *Nature* 365(6446):566-568, 1993.

- 20 Feng *et al.*, *Proc. Natl. Acad. Sci. USA* 97:6415-6420, 2000.

Fox, J.L. *et al.*, *ASM News* 67:247-252, 2001.

Froehler *et al.*, *Nucleic Acids Res.*, 14(13):5399-5407, 1986.

Gillam *et al.*, *J. Biol. Chem.* 253(8):2532-9, 1978.

Gillam *et al.*, *Gene* 8(1):99-106, 1979.

- 25 Gingeras *et al.*, *ASM News* 66:463-469, 2000.

Graham *et al.*, *Curr. Opin. Microbiol.* 4:65-70, 2001.

Graham *et al.*, *Proc. Natl. Acad. Sci. USA* 96:11554-11559, 1999.

Ichikawa *et al.*, *Proc. Natl. Acad. Sci. USA* 97:9659-9664, 2000.

Itakura *et al.*, *J. Am. Chem. Soc.* 97(25):7327-32, 1975.

- 30 Kagnoff *et al.*, *Curr. Opin. Microbiol.* 4:246-250, 2001.

Khorana, *Science* 203(4381):614-25, 1979.

Klug *et al.*, *Methods Enzymol.* 152:316-325, 1987.

- Koshkin *et al.*, *Tetrahedron* 54:3607-3630, 1998.
- Koshkin *et al.*, *J. Am. Chem. Soc.* 120:13252-13253, 1998.
- Kricka, *Nonisotopic DNA Probe Techniques*, Academic Press, San Diego, California, 1992.
- Liang *et al.*, *Methods Enzymol.* 254:304-321, 1995.
- 5 Lockhart *et al.*, *Nature Biotech.* 14:1675, 1996.
- Maskos *et al.*, *Nuc. Acids. Res.* 20:1679-1684, 1992.
- Neidhardt *et al.*, in *Escherichia coli* and *Salmonella* (Neidhardt, FC, Ed.), Vol. 1, pp.13-16, ASM Press, Washington, DC, 1996.
- Newton *et al.*, *J Comput. Biol.* 8:37-52, 2001.
- 10 Pietu *et al.*, *Genome Res.* 6:492, 1996.
- Plum, *et al.*, *Infect. Immun.* 62:476-483, 1994.
- Rappuoli, R. *Proc. Natl. Acad. Sci. USA* 97:13467-13469, 2000.
- Robinson *et al.*, *Gene* 148:137-141, 1994.
- Rosenberger *et al.*, *J. Immunol.* 164:5894-5904, 2000.
- 15 Sambrook *et al.*, In: *Molecular Cloning: A Laboratory Manual*, 2d Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.
- Sambrook *et al.*, In: *Molecular Cloning: A Laboratory Manual*, 3rd Ed., Cold Spring Harbor Press, Cold Spring Harbor, NY, 2001.
- Schena *et al.*, *Science* 270:467-470, 1995a.
- 20 Schena *et al.*, *Proc. Natl. Acad. Sci. USA* 93:10539-11286, 1995b.
- Shalon *et al.*, *Genome Res.* 6:639-645, 1996.
- Su *et al.*, *Molec. Biotechnol.* 10:83-85, 1998.
- Velculescu *et al.*, *Science* 270:484-487, 1995.
- Wahlestedt *et al.*, *PNAS* 97:5633-5638, 2000.
- 25 Wei *et al.*, *J. Bacteriol.* 183:545-556, 2001.
- Wendisch, *et al.*, *Anal. Biochem.* 290:205-213, 2001.
- Wood *et al.*, *Proc. Natl. Acad. Sci. USA.* 82:1585-1588, 1985.
- Yoshida *et al.*, *Nucl. Acids Res.* 29:683-692, 2001.
- Zhao *et al.*, *Gene* 156:207, 1995.

**CLAIMS**

1. A method for depleting or isolating a targeted nucleic acid from a sample comprising:
  - a) incubating the sample with a first bridging oligonucleotide comprising (1) at least one bridging region comprising at least 5 nucleic acid residues and (2) at least one targeting region comprising at least 5 nucleic acid residues, under conditions allowing hybridization between the first targeting region and the targeted nucleic acid;
  - b) incubating the first bridging oligonucleotide with a capture oligonucleotide comprising a nonreacting structure and a capture region comprising at least 5 nucleic acid residues, under conditions allowing hybridization between the bridging region and the capture region; and
  - c) isolating the targeted nucleic acid from the remainder of the sample.
2. The method of claim 1 wherein the targeted nucleic acid is rRNA.
3. The method of claim 2, wherein the rRNA is prokaryotic 16S, prokaryotic 23S, eukaryotic 17S or 18S, or eukaryotic 28S rRNA.
4. The method of claim 3, wherein the rRNA comprises the sequence of SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, or SEQ ID NO:86.

5. The method of claim 1, wherein the sample comprises eukaryotic nucleic acid.
6. The method of claim 1, wherein the sample comprises prokaryotic nucleic acid.
- 5 7. The method of claim 6, wherein the prokaryotic nucleic acid is from a gram positive bacterium.
8. The method of claim 6, wherein the prokaryotic nucleic acid is from a gram negative bacterium.
- 10 9. The method of claim 1, wherein the bridging region, targeting region, or capture region comprises at least 10 nucleic acid residues.
10. The method of claim 9, wherein the bridging region, targeting region, or capture region  
15 comprises at least 15 nucleic acid residues.
11. The method of claim 10, wherein the bridging region, targeting region, or capture region comprises at least 20 nucleic acid residues.
- 20 12. The method of claim 1, wherein the bridging region or the capture region is polypurine or polypyrimidine.
13. The method of claim 12, wherein the bridging region is polypurine and the capture region is polypyrimidine.
- 25 14. The method of claim 1, further comprising incubating the sample with a second bridging oligonucleotide comprising (1) at least one bridging region comprising at least 5 nucleic acid residues and (2) at least one targeting region comprising at least 5 nucleic acid residues, under conditions allowing hybridization between the targeting region of the second bridging  
30 oligonucleotide and the targeted nucleic acid.



15. The method of claim 14, wherein the targeting region of the first bridging oligonucleotide is complementary to the sequence of a targeted nucleic acid and the targeting region of the second bridging oligonucleotide is complementary to a different sequence of a targeted nucleic acid.

5

16. The method of claim 15, wherein the targeting region of the first bridging oligonucleotide and the targeting region of the second bridging oligonucleotide are complementary to the same targeted nucleic acid.

10 17. The method of claim 15, wherein the targeting region of the first bridging oligonucleotide and the targeting region of the second bridging oligonucleotide are complementary to different targeted nucleic acids.

15 18. The method of claim 17, wherein the targeting region of the first bridging oligonucleotide is complementary to a sequence of the largest rRNA molecule and the targeting region of the second bridging oligonucleotide is complementary to a sequence of the second largest rRNA molecule in the sample.

20 19. The method of claim 14, wherein the targeting region of the first or second bridging oligonucleotide hybridizes to a sequence located between 100 and 5000 residues of the 5' or 3' end of the targeted nucleic acid.

25 20. The method of claim 19, wherein the targeting region of the first or second bridging oligonucleotide hybridizes to a sequence located between 150 and 4000 residues of the 5' or 3' end of the targeted nucleic acid.

30 21. The method of claim 20, wherein the targeting region of the first or second bridging oligonucleotide hybridizes to a sequence located between 200 and 3000 residues of the 5' or 3' end of the targeted nucleic acid.

22. The method of claim 21, wherein the targeting region of the first or second bridging oligonucleotide hybridizes to a sequence located between 250 and 2000 residues of the 5' or 3' end of the targeted nucleic acid.
- 5 23. The method of claim 22, wherein the targeting region of the first or second bridging oligonucleotide hybridizes to a sequence located between 300 and 1500 residues of the 5' or 3' end of the targeted nucleic acid.
24. The method of claim 23, wherein the targeting region of the first or second bridging  
10 oligonucleotide hybridizes to a sequence located between 350 and 1000 residues of the 5' or 3' end of the targeted nucleic acid.
25. The method of claim 24, wherein targeting region of the first or second bridging oligonucleotide hybridizes to a sequence located between 400 and 900 residues of the 5' or 3'  
15 end of the targeted nucleic acid.
26. The method of claim 25, wherein the targeting region of the first or second bridging oligonucleotide hybridizes to a sequence located between 450 and 800 residues of the 5' or 3' end of the targeted nucleic acid.  
20
27. The method of claim 26, wherein the targeting region of the first or second bridging oligonucleotide hybridizes to a sequence located between 500 and 700 residues of the 5' or 3' end of the targeted nucleic acid.
- 25 28. The method of claim 14, wherein the targeting region of the first or second bridging oligonucleotide hybridizes to a sequence at the 3' or 5' end of the targeted nucleic acid.
29. The method of claim 14, wherein the targeting region of the first or second bridging oligonucleotide hybridizes to a sequence not within 100 residues from the 3' or 5' end of the  
30 targeted nucleic acid.

30. The method of claim 14, wherein targeting region of the first or second bridging oligonucleotide hybridizes to a sequence not within 200 residues from the 3' or 5' end of the targeted nucleic acid.
- 5 31. The method of claim 14, wherein the targeting region of the first or second bridging oligonucleotide hybridizes to a sequence not within 400 residues from the 3' or 5' ends of the targeted nucleic acid.
32. The method of claim 14, wherein the targeting region of the first or second bridging  
10 oligonucleotide comprises SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID  
15 NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, or SEQ ID NO:86.
33. The method of claim 1, wherein the bridging oligonucleotide comprises a second  
20 targeting region comprising at least 5 nucleic acid residues complementary to a different sequence than the sequence to which the first targeting region is complementary.
34. The method of claim 33, wherein the first targeting region is complementary to a different targeting nucleic acid than the second targeting region is.
- 25 35. The method of claim 1, wherein the first bridging oligonucleotide comprises two bridging regions.
36. The method of claim 1, wherein the bridging oligonucleotide or the capture  
oligonucleotide is RNA, DNA, LNA, iso-bases, or a peptide nucleic acid.  
30
37. The method of claim 1, further comprising washing the capture oligonucleotide after incubation with the sample and the bridging oligonucleotide.

38. The method of claim 1, wherein a) and b) are performed at the same temperature.
39. The method of claim 1, wherein a) and b) are performed at a different temperature.
- 5 40. The method of claim 38, wherein a) and b) are performed at the same time.
41. The method of claim 1, wherein the nonreacting structure comprises a bead comprising plastic, glass, teflon, silica, a magnet, cellulose, latex, polystyrene, nylon, cellulose,  
10 nitrocellulose, polymethacrylate, polyvinylchloride, or styrene-divinylbenzene
42. The method of claim 41, wherein isolating the targeted nucleic acid away from the sample comprises exposing the sample with the capture oligonucleotide to a magnetic field.
- 15 43. The method of claim 1, wherein the nonreacting structure is cellulose.
44. The method of claim 1, wherein the nonreacting structure is biotin.
45. The method of claim 44, wherein isolating the targeted nucleic acid comprises incubating  
20 the sample with streptavidin or avidin.
46. The method of claim 1, wherein the sample, capture oligonucleotide, and bridging oligonucleotide are incubated in a buffer comprising TMAC or TEAC.
- 25 47. The method of claim 1, further comprising:  
d) discarding the portion of the sample that hybridizes to the capture oligonucleotide.
48. The method of claim 2, further comprising:  
30 d) discarding the targeted rRNA nucleic acid; and  
e) producing cDNA using mRNA in the remainder of the sample.

49. The method of claim 2, further comprising:
  - d) amplifying nucleic acids in the remainder of the sample, wherein the remainder of the sample is enriched for mRNA.
- 5 50. The method of claim 49., further comprising:
  - e) using the amplified nucleic acids to probe a nucleic acid array.
51. The method of claim 48, further comprising:
  - f) attaching the cDNA to a solid support, wherein a nucleic acid array is created.
- 10 52. The method of claim 51, wherein the solid support is plastic, glass, or nylon.
53. The method of claim 52, wherein the solid support is a plate.
- 15 54. The method of claim 53, wherein the plate is a multiple-well plate.
55. The method of claim 48, further comprising:
  - f) contacting a nucleic acid array with the cDNA.
- 20 56. The method of claim 1, further comprising incubating the sample with a second bridging oligonucleotide comprising (1) at least one bridging region comprising at least 5 nucleic acid residues and (2) at least one targeting region comprising at least 5 nucleic acid residues, under conditions allowing hybridization between the targeting region of the second bridging oligonucleotide and a second targeted nucleic acid.
- 25 57. The method of claim 56, further comprising incubating the sample with a third bridging oligonucleotide comprising (1) at least one bridging region comprising at least 5 nucleic acid residues and (2) at least one targeting region comprising at least 5 nucleic acid residues, under conditions allowing hybridization between the targeting region of the third bridging
- 30 oligonucleotide and a third targeted nucleic acid.

58. The method of claim 57, further comprising incubating the sample with a fourth bridging oligonucleotide comprising (1) at least one bridging region comprising at least 5 nucleic acid residues and (2) at least one targeting region comprising at least 5 nucleic acid residues, under conditions allowing hybridization between the targeting region of the fourth bridging  
5 oligonucleotide and a fourth targeted nucleic acid.

59. The method of claim 56, wherein prokaryotic and eukaryotic rRNAs are targeted nucleic acids.

10 60. A method for depleting rRNA from a sample comprising:  
a) incubating the sample with at least a first (1) bridging oligonucleotide comprising a bridging region comprising a poly-purine region of at least 5 residues and a targeting region comprising at least 5 contiguous nucleic acid residues complementary to a sequence of an rRNA molecule and a (2) capture  
15 oligonucleotide comprising a magnetic bead and a capture region comprising a poly-pyrimidine region of at least 5 residues, under conditions to allow hybridization between the bridging oligonucleotide and the capture oligonucleotide and the bridging oligonucleotide and the rRNA;  
b) incubating the sample with a magnetic bead; and  
20 c) isolating the magnetic bead.

61. A kit, in a suitable container means, comprising:  
a) a capture oligonucleotide comprising a capture region and a magnetic bead; and  
b) at least a first bridging oligonucleotide comprising (1) at least one bridging region  
25 complementary to all or part of the capture region of the capture oligonucleotide and a (2) at least one targeting region comprising 10 contiguous nucleic acids complementary to a sequence of an rRNA.

62. The kit of claim 61, wherein the first bridging oligonucleotide comprises a second  
30 targeting region.

63. The kit of claim 62, wherein the first and second targeting regions have the same nucleic acid sequence.

64. The kit of claim 62, wherein the first and second targeting regions have different nucleic acid sequences.

65. The kit of claim 64, wherein the first targeting region is complementary to a sequence of an eukaryotic rRNA and the second targeting region is complementary to a sequence of a prokaryotic rRNA.

66. The kit of claim 64, wherein the first targeting region is complementary to a sequence of an eukaryotic rRNA and the second targeting region is complementary to a sequence of a different eukaryotic rRNA than the first targeting region.

67. The kit of claim 64, wherein the first targeting region is complementary to a sequence of a prokaryotic rRNA and the second targeting region is complementary to a sequence of a different prokaryotic rRNA than the first targeting region.

68. The kit of claim 61, further comprising a second bridging oligonucleotide comprising (1) at least one bridging region complementary to all or part of the capture region of the capture oligonucleotide and a (2) at least one targeting region comprising 10 contiguous nucleic acids complementary to a sequence of an rRNA.

69. The kit of claim 68, wherein the targeting region of the second bridging oligonucleotide is complementary to a sequence of the same rRNA as the first targeting region.

70. The kit of claim 68, wherein the targeting region of the first bridging oligonucleotide is complementary to a sequence of the largest rRNA and the targeting region of the second bridging oligonucleotide is complementary to a sequence of the second largest rRNA in the sample.

71. The kit of claim 68, wherein the targeting region of the first bridging oligonucleotide is complementary to a sequence of an eukaryotic rRNA and the targeting region of the bridging oligonucleotide is complementary to a sequence of a prokaryotic rRNA.
- 5 72. The kit of claim 70, wherein the targeting region of the first bridging oligonucleotide is complementary to a sequence of an eukaryotic 28S rRNA and the targeting region of the second bridging oligonucleotide is complementary to a sequence of a eukaryotic 17S or 18S rRNA.
- 10 73. The kit of claim 70, wherein the targeting region of the first bridging oligonucleotide is complementary to a sequence of a prokaryotic 23S rRNA and the targeting region of the second bridging oligonucleotide is complementary to a sequence of a prokaryotic 16S rRNA.
- 15 74. The kit of claim 70, wherein the targeting region of the first bridging oligonucleotide is complementary to a sequence of an eukaryotic 28S rRNA and the targeting region of the second bridging oligonucleotide is complementary to a sequence of a prokaryotic 23S rRNA.
- 20 75. The kit of claim 68, further comprising a third bridging oligonucleotide comprising (1) at least one bridging region complementary to all or part of the capture region of the capture oligonucleotide and a (2) at least one targeting region comprising 10 contiguous nucleic acids complementary to a sequence of an rRNA.
- 25 76. The kit of claim 75, wherein the targeting region of the third bridging oligonucleotide is complementary to a sequence of a prokaryotic 23S rRNA.
- 30 77. The kit of claim 75, wherein the targeting region of the third bridging oligonucleotide is complementary to a sequence of a eukaryotic 18S rRNA.
78. The kit of claim 75, further comprising a fourth bridging oligonucleotide comprising (1) at least one bridging region complementary to all or part of the capture region of the capture oligonucleotide and a (2) at least one targeting region comprising 10 contiguous nucleic acids complementary to a sequence of an rRNA.



79. The kit of claim 78, wherein (i) the targeting region of the first bridging oligonucleotide is complementary to a sequence of a prokaryotic 16S rRNA, (ii) the targeting region of the second bridging oligonucleotide is complementary to a sequence of a prokaryotic 23S rRNA, (iii) the targeting region of the third bridging oligonucleotide is complementary to a sequence of a eukaryotic 18S rRNA, and (iv) the targeting region of the fourth bridging oligonucleotide is complementary to a sequence of a eukaryotic 28S rRNA,
80. The kit of claim 61, wherein the first targeting region of the bridging oligonucleotide comprises SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, or SEQ ID NO:86.
81. The kit of claim 61, further comprising a buffer comprising TMAC or TEAC.
82. The kit of claim 61, further comprising a magnetic stand.
83. The kit of claim 61, further comprising:  
c) a solid support for preparing a nucleic acid array.
84. A bridging oligonucleotide comprising a (1) bridging region comprising a polypyrimidine or polypurine stretch and a (2) targeting region comprising at least 10 contiguous nucleic acid residues complementary to a sequence of an rRNA.
85. The oligonucleotide of claim 84, wherein the rRNA is eukaryotic.
86. The oligonucleotide of claim 85, wherein the rRNA is the 28S rRNA.
87. The oligonucleotide of claim 84, wherein the rRNA is prokaryotic.

88. The oligonucleotide of claim 87, wherein the rRNA is the 23S rRNA.
89. A method for depleting or isolating a targeted rRNA from a sample comprising:
- 5 a) obtaining the kit of claim 61;
- b) incubating the sample with the bridging oligonucleotide under conditions allowing hybridization between the targeting region and the targeted rRNA;
- c) incubating the bridging oligonucleotide with the capture oligonucleotide under conditions allowing hybridization between the bridging region and the capture region; and
- 10 d) isolating the targeted rRNA from the remainder of the sample by incubating the sample with a magnetic field.
90. The method of claim 89, further comprising:
- 15 e) obtaining the remainder of the sample enriched for mRNA;
- f) preparing cDNA from the mRNA.
91. The method of claim 90, further comprising:
- g) constructing a nucleic acid array with the cDNA.
- 20 92. The method of claim 89, wherein the mRNA or prepared cDNA is amplified.
93. The method of claim 92, wherein the cDNA is used to probe a nucleic acid array.





FIG. 1

Alignment Report of Gram +&- 16S align.MEG, using Clustal method with Weighted residue weight table.  
Tuesday, November 27, 2001 4:14 PM



**FIG. 2A-1**

Alignment Report of Gram +&- 16S align.MEG, using Clustal method with Weighted residue weight table,  
Tuesday, November 27, 2001 4:14 PM

	70	80	90	100	110	120	130	140	150	160	170
Subtilisin16S.SEQ	..G..--G..	..AT..G--G..	..C..-..AGT..	..C..-..AGT..	..C..-..AGT..	..C..-..AGT..	..C..-..AGT..	..C..-..AGT..	..C..-..AGT..	..C..-..AGT..	..C..-..AGT..
Bantracis16.SEQ	..G..--G..	..TO..ATTA..	..G..--G..	..C..-..AGT..	..C..-..AGT..	..C..-..AGT..	..C..-..AGT..	..C..-..AGT..	..C..-..AGT..	..C..-..AGT..	..C..-..AGT..
Zfaecalis16S.SEQ	..A..TT..--G..A..	..AGG..--G..A..	..AGG..--G..A..	..AGG..--G..A..	..AGG..--G..A..	..AGG..--G..A..	..AGG..--G..A..	..AGG..--G..A..	..AGG..--G..A..	..AGG..--G..A..	..AGG..--G..A..
Llactis16S.SEQ	T..G..C..G..AG..TTG..	..GTA..--GTA..	..TAC..--TAC..	..GTA..--GTA..	..GTA..--GTA..	..GTA..--GTA..	..GTA..--GTA..	..GTA..--GTA..	..GTA..--GTA..	..GTA..--GTA..	..GTA..--GTA..
Leuonocytis16S.SEQ	..G..--G..	..G..AGCA..--G..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..
Saureus16S.SEQ	..G..--G..	..G..AGCA..--G..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..
Spneumon16S.SEQ	G..G..CA..G..AG..C..CTGT..	..AGCAGT..	..AGCAGT..	..AGCAGT..	..AGCAGT..	..AGCAGT..	..AGCAGT..	..AGCAGT..	..AGCAGT..	..AGCAGT..	..AGCAGT..
Spneumon16S.SEQ	A..C..G..AG..AGGAGT..	..T..	..T..	..T..	..T..	..T..	..T..	..T..	..T..	..T..	..T..
Navium16S.SEQ	..G..--G..	..G..AGCA..--G..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..
Ncbi16S.SEQ	..G..--G..	..G..AGCA..--G..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..
Zcoll 0157 16S.SEQ	..G..--G..	..G..AGCA..--G..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..
Kpneumon16S.SEQ	..G..--G..	..G..AGCA..--G..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..
Actinob16S.SEQ	..G..--G..	..G..AGCA..--G..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..
Minifluensae 16S.SEQ	..G..--G..	..G..AGCA..--G..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..
Bronchiseptica 16S.SEQ	..G..--G..	..G..AGCA..--G..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..
Spartapertussis16S.SEQ	..G..--G..	..G..AGCA..--G..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..
Spartusis 16S.SEQ	..G..--G..	..G..AGCA..--G..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..
Bespectia 16S.SEQ	..G..--G..	..G..AGCA..--G..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..
Buallid 16S.SEQ	..G..--G..	..G..AGCA..--G..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..
Bpseudomallei 16S.SEQ	..G..--G..	..G..AGCA..--G..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..
Ngonorrhoeae 16S.SEQ	..G..--G..	..G..AGCA..--G..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..
Nmening 16S.SEQ	..G..--G..	..G..AGCA..--G..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..
Paeruginosa 16S.SEQ	..G..--G..	..G..AGCA..--G..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..
Vcholeerae 16S.SEQ	..G..--G..	..G..AGCA..--G..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..
Yenterocolitica 16S.SEQ	..G..--G..	..G..AGCA..--G..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..	..CT..CCAAAGT..

FIG. 2A-2

**FIG. 2A-3**

Alignment Report of Gram +&- 16S align.MEG, using Clustal method with Weighted residue weight table.  
Tuesday, November 27, 2001 4:14 PM

	290	300	310	320	330	340	350	360	370	380	390	400
Seubtilis16S.SEQ	...C.AC	...G..T.G	...G..T.G	...G..T.G	...C..C..C	...C..C..C	...A..C.C.G	...A..C.C.G	...A..A..T	...C.G..A.C	...C.G..A.C	...C.G..A.C
Bacthacis16.SEQ	...C.AC	...G..T.G	...G..T.G	...G..T.G	...C..C..C	...C..C..C	...A..C.C.G	...A..C.C.G	...A..A..T	...C.G..A.C	...C.G..A.C	...C.G..A.C
Exaetalis 16S.SEQ	...C.AC	...G..T.G	...G..T.G	...G..T.G	...C..C..C	...C..C..C	...A..C.C.G	...A..C.C.G	...A..A..T	...C.G..A.C	...C.G..A.C	...C.G..A.C
Llactis 16S.SEQ	...C.AC	...G..T.G	...G..T.G	...G..T.G	...C..C..C	...C..C..C	...A..C.C.G	...A..C.C.G	...A..A..T	...C.G..A.C	...C.G..A.C	...C.G..A.C
Lmonocyt16S.SEQ	...C.AC	...G..T.G	...G..T.G	...G..T.G	...C..C..C	...C..C..C	...A..C.C.G	...A..C.C.G	...A..A..T	...C.G..A.C	...C.G..A.C	...C.G..A.C
Saureus16S.SEQ	...C.AC	...G..T.G	...G..T.G	...G..T.G	...C..C..C	...C..C..C	...A..C.C.G	...A..C.C.G	...A..A..T	...C.G..A.C	...C.G..A.C	...C.G..A.C
Smutans16S.SEQ	...C.AC	...G..T.G	...G..T.G	...G..T.G	...C..C..C	...C..C..C	...A..C.C.G	...A..C.C.G	...A..A..T	...C.G..A.C	...C.G..A.C	...C.G..A.C
Spneumoni16S.SEQ	...C.AC	...G..T.G	...G..T.G	...G..T.G	...C..C..C	...C..C..C	...A..C.C.G	...A..C.C.G	...A..A..T	...C.G..A.C	...C.G..A.C	...C.G..A.C
Spvgenes16S.SEQ	...C.AC	...G..T.G	...G..T.G	...G..T.G	...C..C..C	...C..C..C	...A..C.C.G	...A..C.C.G	...A..A..T	...C.G..A.C	...C.G..A.C	...C.G..A.C
Maviual16S.SEQ	...C.AC	...G..T.G	...G..T.G	...G..T.G	...C..C..C	...C..C..C	...A..C.C.G	...A..C.C.G	...A..A..T	...C.G..A.C	...C.G..A.C	...C.G..A.C
Ntbi16S.SEQ	...C.C	...G..T.G	...G..T.G	...G..T.G	...C..C..C	...C..C..C	...A..C.C.G	...A..C.C.G	...A..A..T	...C.G..A.C	...C.G..A.C	...C.G..A.C
Ecoli 0157 16S.SEQ	...C.C	...G..T.G	...G..T.G	...G..T.G	...C..C..C	...C..C..C	...A..C.C.G	...A..C.C.G	...A..A..T	...C.G..A.C	...C.G..A.C	...C.G..A.C
Xpneumoniae 16S.SEQ	...C.C	...G..T.G	...G..T.G	...G..T.G	...C..C..C	...C..C..C	...A..C.C.G	...A..C.C.G	...A..A..T	...C.G..A.C	...C.G..A.C	...C.G..A.C
Lactis16S.SEQ	...C.C	...G..T.G	...G..T.G	...G..T.G	...C..C..C	...C..C..C	...A..C.C.G	...A..C.C.G	...A..A..T	...C.G..A.C	...C.G..A.C	...C.G..A.C
Hinfluenzae 16S.SEQ	...C.C	...G..T.G	...G..T.G	...G..T.G	...C..C..C	...C..C..C	...A..C.C.G	...A..C.C.G	...A..A..T	...C.G..A.C	...C.G..A.C	...C.G..A.C
Abnorchiseptica 16S.SEQ	...C.C	...G..T.G	...G..T.G	...G..T.G	...C..C..C	...C..C..C	...A..C.C.G	...A..C.C.G	...A..A..T	...C.G..A.C	...C.G..A.C	...C.G..A.C
Spapartusis16S.SEQ	...C.C	...G..T.G	...G..T.G	...G..T.G	...C..C..C	...C..C..C	...A..C.C.G	...A..C.C.G	...A..A..T	...C.G..A.C	...C.G..A.C	...C.G..A.C
Spportusis 16S.SEQ	...C.C	...G..T.G	...G..T.G	...G..T.G	...C..C..C	...C..C..C	...A..C.C.G	...A..C.C.G	...A..A..T	...C.G..A.C	...C.G..A.C	...C.G..A.C
Scopacia 16S.SEQ	...C.C	...G..T.G	...G..T.G	...G..T.G	...C..C..C	...C..C..C	...A..C.C.G	...A..C.C.G	...A..A..T	...C.G..A.C	...C.G..A.C	...C.G..A.C
Smallei 16S.SEQ	...C.C	...G..T.G	...G..T.G	...G..T.G	...C..C..C	...C..C..C	...A..C.C.G	...A..C.C.G	...A..A..T	...C.G..A.C	...C.G..A.C	...C.G..A.C
Epseudomallei 16S.SEQ	...C.C	...G..T.G	...G..T.G	...G..T.G	...C..C..C	...C..C..C	...A..C.C.G	...A..C.C.G	...A..A..T	...C.G..A.C	...C.G..A.C	...C.G..A.C
Xngorhoese 16S.SEQ	...C.C	...G..T.G	...G..T.G	...G..T.G	...C..C..C	...C..C..C	...A..C.C.G	...A..C.C.G	...A..A..T	...C.G..A.C	...C.G..A.C	...C.G..A.C
Nmoning 16S.SEQ	...C.C	...G..T.G	...G..T.G	...G..T.G	...C..C..C	...C..C..C	...A..C.C.G	...A..C.C.G	...A..A..T	...C.G..A.C	...C.G..A.C	...C.G..A.C
Paeruginosa 16S.SEQ	...C.C	...G..T.G	...G..T.G	...G..T.G	...C..C..C	...C..C..C	...A..C.C.G	...A..C.C.G	...A..A..T	...C.G..A.C	...C.G..A.C	...C.G..A.C
Vcholerae 16S.SEQ	...C.C	...G..T.G	...G..T.G	...G..T.G	...C..C..C	...C..C..C	...A..C.C.G	...A..C.C.G	...A..A..T	...C.G..A.C	...C.G..A.C	...C.G..A.C
Yentatocitica 16S.SEQ	...C.C	...G..T.G	...G..T.G	...G..T.G	...C..C..C	...C..C..C	...A..C.C.G	...A..C.C.G	...A..A..T	...C.G..A.C	...C.G..A.C	...C.G..A.C

FIG. 2A-4

Alignment Report of Gram +&- 16S align.MEG, using Clustal method with Weighted residue weight table.  
Tuesday, November 27, 2001 4:14 PM

	410	420	430	440	450	460	470	480	49	500	510	520
<i>Baebactillus</i> 16S.SEQ	AG...T...	TT...	A.C...	CT..G.TGTTA..	A...CAA.T.C-CTGTCG...	GGGCG.TA.C...	G...	TAA.CAG.A.GC...				524
<i>Banthracis</i> 16S.SEQ	AG...T...	T...	C...	ACT..G.TGTTA..	A...CAA.TGCT..GT.G...	AGC.G..A.C...	G...	TAA.CAG.A.GC...				522
<i>Ziaecalis</i> 16S.SEQ	AG...	TT...	A.C...	ACT..G.TGTTA..	A...CAA...CUTT...	A.C.GAAC--TC.CC...	G...	T.TAA.CAG.A.GC...				512
<i>Llactis</i> 16S.SEQ	AG...	TT...	A.C...	ACT..G.TG.TA.A..	A...CUTT..GTG.G...	GG..-AGC.CATCA.G...	G...	A.TAC.CAG.A.G.G...				531
<i>Monocytis</i> 16S.SEQ	AG...	TT...	A.C...	ACT..G.TGTTA..	A...CAA...TA.G..A.C..-CC..TC.C...	TC.C...	G...	T.TAA.CAG.A.GC...				541
<i>Saureus</i> 16S.SEQ	AG...	T...	A.C...	ACT..G.T.TTA..	A...CATATGTT...	A.C.GTGC--A.ATC...	G...	TATCAG.A.GC...				531
<i>Smutans</i> 16S.SEQ	AG...	TT...	A.C...	CT..G.TGTTA..TC.A...	CCT.TGTG.G...	GG..-AG..CA.A..G...	G...	G.TTA.CAG.A.G.G...				531
<i>Spneumon</i> 16S.SEQ	AG...	TT...	A.C...	CT..G.TGTTA..	A...CCTA.TGTG.G...	GG..-AG..CA.A..TG...	G...	T.TTA.CAG.A.G.G...				518
<i>SPyogenes</i> 16S.SEQ	AG...	TT...	A.C...	CT..G.TGTTA..	A...TGAT.GTGG...	GG..-AA.CCA.CA.G...	G...	A.TAA.CAG.A.G.G...				436
<i>Maviuni</i> 16S.SEQ	GGG..T..C...	CCT...	C.ATC..C...	T--CCCG...	T--CCCG...	CT.GG...	G...	G.GTG...				472
<i>Ecoli</i> 0157 16S.SEQ	CT..T..C...	CCT...	C.ATC..C...	T--CCCG...	T--CCCG...	CT.GG...	G...	G.GTG...				513
<i>Kpneumoniae</i> 16S.SEQ	TATTAAGAGGCGCTTCGGTGTGTAAGTACTTTCAGCGCGAGGA--GGGATTAAGTAACTTAATCTTCTCTATTAAGCTTACCC--CCAGAGAGCAGCCGCTAACTCGGTCCAGCA											533
<i>Acetivols</i> 16S.SEQ	G...											
<i>Kinflluensae</i> 16S.SEQ	A...											
<i>Shronchiseptica</i> 16S.SEQ	A...											
<i>Spaparatus</i> 16S.SEQ	CC..T...											
<i>Spertusis</i> 16S.SEQ	CC..T...											
<i>Scopacia</i> 16S.SEQ	G...											
<i>Spseudomallei</i> 16S.SEQ	G...											
<i>Nygnorrhoeae</i> 16S.SEQ	C...											
<i>Nanning</i> 16S.SEQ	C...											
<i>Paeruginosa</i> 16S.SEQ	G...											
<i>Vcholerae</i> 16S.SEQ	G...											
<i>Yenterecolitica</i> 16S.SEQ	G...											

FIG. 2A-5



Alignment Report of Gram +&- 16S align.MEG, using Clustal method with Weighted residue weight table.  
Tuesday, November 27, 2001 4:14 PM

	530	540	550	560	570	580	590	600	610	620	630	640
<i>Beutellia</i> 16S.S2Q	.....T..TG..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..
<i>Banthracis</i> 16S.S2Q	.....T..TG..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..
<i>Bfaecalis</i> 16S.S2Q	.....T..TG..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..
<i>Llactis</i> 16S.S2Q	.....T..TG..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..
<i>Lnococyt</i> 16S.S2Q	.....T..TG..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..
<i>Saureus</i> 16S.S2Q	.....T..TG..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..
<i>Smutans</i> 16S.S2Q	.....T..TG..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..
<i>Spneumon</i> 16S.S2Q	.....T..TG..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..
<i>Spvogena</i> 16S.S2Q	.....T..TG..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..
<i>Navium</i> 16S.S2Q	.....T..TG..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..
<i>Ntbls</i> 16S.S2Q	.....T..TG..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..
<i>Ecoli</i> 0157 16S.S2Q	.....T..TG..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..
<i>Xpneumoniae</i> 16S.S2Q	.....T..TG..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..
<i>Lactinol</i> 16S.S2Q	.....T..TG..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..
<i>Hinfluenzae</i> 16S.S2Q	.....T..TG..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..
<i>Bronchiseptica</i> 16S.S2Q	.....T..TG..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..
<i>Spapertusis</i> 16S.S2Q	.....T..TG..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..
<i>Spertusis</i> 16S.S2Q	.....T..TG..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..
<i>Scopacia</i> 16S.S2Q	.....T..TG..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..
<i>Smallei</i> 16S.S2Q	.....T..TG..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..
<i>Spseudomallei</i> 16S.S2Q	.....T..TG..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..
<i>Ngonorhose</i> 16S.S2Q	.....T..TG..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..
<i>Nmening</i> 16S.S2Q	.....T..TG..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..
<i>Paeruginosa</i> 16S.S2Q	.....T..TG..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..
<i>Vcholeraz</i> 16S.S2Q	.....T..TG..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..
<i>Venterocolitica</i> 16S.S2Q	.....T..TG..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..	.....T..TC..

FIG. 2A-6

Alignment Report of Gram +&- 16S align.MEG, using Clustal method with Weighted residue weight table.  
Tuesday, November 27, 2001 4:14 PM

[illegible]

**FIG. 2A-7**

Alignment Report of Gram +&- 16S align.MEG, using Clustal method with Weighted residue weight table.  
Tuesday, November 27, 2001 4:14 PM

	770	780	790	800	810	820	830	840	850	860	870	880
Bsubtilis16S.SEQ	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....
Banthracis16S.SEQ	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....
Zfaecalis16S.SEQ	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....
Llactis16S.SEQ	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....
Lmonocytis16S.SEQ	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....
Saureus16S.SEQ	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....
Smittans16S.SEQ	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....
Spneumon16S.SEQ	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....
SPyogenes16S.SEQ	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....
Haviu16S.SEQ	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....
Mtblis16S.SEQ	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....
Eccli 0157 16S.SEQ	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....
Xpneumon16S.SEQ	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....
Lactinol16S.SEQ	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....
Xinfluen16S.SEQ	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....
Bbronchiseptica16S.SEQ	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....
Bparapartus16S.SEQ	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....
Bcepacis16S.SEQ	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....
Bmailei16S.SEQ	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....
Bpseudomallei16S.SEQ	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....
Bgonorrhoeae16S.SEQ	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....
Bmening16S.SEQ	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....
Bparvulnosa16S.SEQ	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....
Bcholerae16S.SEQ	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....
Benterocolitica16S.SEQ	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....G.....

FIG. 2A-8

Alignment Report of Gram +&- 16S align.MEG, using Clustal method with Weighted residue weight table.  
Tuesday, November 27, 2001 4:14 PM

	890	900	910	920	930	940	950	960	970	980	990	1000
Baebti16S.S2Q	.....T.....	AC.G.....	.....G.....	.....G.....	.....T.....	.....A.....	.....A.....	.....A.....	.....A.....	.....A.....	.....A.....	.....T 1000
Banthrac16.S2Q	.....C.G.....	.....G.....	.....G.....	.....G.....	.....G.....	.....A.....	.....A.....	.....A.....	.....A.....	.....A.....	.....A.....	.....T 1000
Elaecalis 16S.S2Q	.....A.....	.....G.....	.....G.....	.....G.....	.....G.....	.....A.....	.....A.....	.....A.....	.....A.....	.....A.....	.....A.....	.....T 990
Llactis 16S.S2Q	.....A.....	.....G.....	.....G.....	.....G.....	.....G.....	.....A.....	.....A.....	.....A.....	.....A.....	.....A.....	.....A.....	.....T 1007
Lmonocyt16S.S2Q	.....A.....	.....G.....	.....G.....	.....G.....	.....G.....	.....A.....	.....A.....	.....A.....	.....A.....	.....A.....	.....A.....	.....T 1018
Saureus16S.S2Q	.....A.....	.....G.....	.....G.....	.....G.....	.....A.....	.....A.....	.....A.....	.....A.....	.....A.....	.....A.....	.....A.....	.....T 1009
Smutsans16S.S2Q	.....A.....	.....G.....	.....G.....	.....G.....	.....A.....	.....A.....	.....A.....	.....A.....	.....A.....	.....A.....	.....A.....	.....C 1008
Spaemon16S.S2Q	.....A.....	.....G.....	.....G.....	.....G.....	.....A.....	.....A.....	.....A.....	.....A.....	.....A.....	.....A.....	.....A.....	.....C 995
Spvogenes16S.S2Q	.....A.....	.....G.....	.....G.....	.....G.....	.....A.....	.....A.....	.....A.....	.....A.....	.....A.....	.....A.....	.....A.....	.....C 903
Mavi16S.S2Q	.....N.....	.....C.....	.....G.....	.....G.....	.....N.....	.....C.....	.....A.....	.....A.....	.....A.....	.....A.....	.....A.....	.....GT.....G 951
Mtbl16S.S2Q	.....C.....	.....C.....	.....G.....	.....G.....	.....C.....	.....C.....	.....A.....	.....A.....	.....A.....	.....A.....	.....A.....	.....GT.....G 992
Zcoli 0157 16S.S2Q	.....C.....	.....C.....	.....G.....	.....G.....	.....C.....	.....C.....	.....A.....	.....A.....	.....A.....	.....A.....	.....A.....	.....GT.....G 992
Kneumonias 16S.S2Q	.....C.....	.....C.....	.....G.....	.....G.....	.....C.....	.....C.....	.....A.....	.....A.....	.....A.....	.....A.....	.....A.....	.....GT.....G 992
Aactinol16S.S2Q	.....C.....	.....C.....	.....G.....	.....G.....	.....C.....	.....C.....	.....A.....	.....A.....	.....A.....	.....A.....	.....A.....	.....GT.....G 992
Kinfluenzae 16S.S2Q	.....C.....	.....C.....	.....G.....	.....G.....	.....C.....	.....C.....	.....A.....	.....A.....	.....A.....	.....A.....	.....A.....	.....GT.....G 992
Abbronchi16S.S2Q	.....T.....	.....A.....	.....G.....	.....G.....	.....A.....	.....A.....	.....TG.....	.....A.....	.....A.....	.....A.....	.....A.....	.....GT 998
Spapar16S.S2Q	.....T.....	.....A.....	.....G.....	.....G.....	.....A.....	.....A.....	.....TG.....	.....A.....	.....A.....	.....A.....	.....A.....	.....GT 994
Spapartus16S.S2Q	.....T.....	.....A.....	.....G.....	.....G.....	.....A.....	.....A.....	.....TG.....	.....A.....	.....A.....	.....A.....	.....A.....	.....GT 966
Spapartus16S.S2Q	.....T.....	.....A.....	.....G.....	.....G.....	.....A.....	.....A.....	.....TG.....	.....A.....	.....A.....	.....A.....	.....A.....	.....GT 992
Scapacia 16S.S2Q	.....T.....	.....A.....	.....G.....	.....G.....	.....A.....	.....A.....	.....TG.....	.....A.....	.....A.....	.....A.....	.....A.....	.....GT 995
Smalle1 16S.S2Q	.....T.....	.....A.....	.....G.....	.....G.....	.....A.....	.....A.....	.....TG.....	.....A.....	.....A.....	.....A.....	.....A.....	.....GT 968
Spseudomalle1 16S.S2Q	.....T.....	.....A.....	.....G.....	.....G.....	.....A.....	.....A.....	.....TG.....	.....A.....	.....A.....	.....A.....	.....A.....	.....GT 1047
Ngonorthosae 16S.S2Q	.....T.....	.....A.....	.....G.....	.....G.....	.....A.....	.....A.....	.....TG.....	.....A.....	.....A.....	.....A.....	.....A.....	.....GT 1001
Nmaning 16S.S2Q	.....T.....	.....A.....	.....G.....	.....G.....	.....A.....	.....A.....	.....TG.....	.....A.....	.....A.....	.....A.....	.....A.....	.....GT 1001
Paeruginosa 16S.S2Q	.....T.....	.....A.....	.....G.....	.....G.....	.....A.....	.....A.....	.....TG.....	.....A.....	.....A.....	.....A.....	.....A.....	.....GT 995
Vcholerse 16S.S2Q	.....T.....	.....A.....	.....G.....	.....G.....	.....A.....	.....A.....	.....TG.....	.....A.....	.....A.....	.....A.....	.....A.....	.....GT 998
Yenterocolitica 16S.S2Q	.....T.....	.....A.....	.....G.....	.....G.....	.....A.....	.....A.....	.....TG.....	.....A.....	.....A.....	.....A.....	.....A.....	.....GT 1000

FIG. 2A-9

**FIG. 2A-10**

**FIG. 2A-11**

Alignment Report of Gram +8- 16S align.MEG, using Clustal method with Weighted residue weight table.  
Tuesday, November 27, 2001 4:14 PM

	1240	1250	1260	1270	1280	1290	1300	1310	1320	1330	1340	1350
Baebillia16S.SEQ	.....ACAGA.....	G.C.....	AAC.....	GTT.....	CA.T.C.A.C.....	TCGT.....TC.....	T.....	C.C.....	G.G.....	CT.....		C.1351
Banthracis16.SEQ	.....ACCG.....	CT..A.CAC.....	GTCG.....	TA.T..A.....	ACGT.....TC.....	T.....	T.....	T..G.....	C.A.....	CT.....		C.1354
Efaecalis16S.SEQ	.....GAAG.....	C..TC..T.GAC.....	GT..T..AA.T..T.....	CTTC.....TC.....	T.....	C.G.....			C.G.....	C.....		C.1344
Llactis16S.SEQ	.....ATCG.....	C..TC.....	GACA.T..TCTTT.....	TA.T..T.....	ACAT.....TC.....	T.....	T.....	T..G.....	C.A.....	C.....		C.1361
Leonocyt16S.SEQ	.....ADAG.....	G.TC.....	AGC.....	GTCG.....	TA.T.C.A.....	ACTAT.....TC.....	T.....	T..G.....	C.A.....	C.....		C.1369
Saureus16S.SEQ	.....ACA.....	G.C.....	AAC.....	GT.....	AA.T.C.A.....	TGT.....TC.....	T.....	T.....	A.....	CT.....		A.1365
Smuts16S.SEQ	.....TCCG.....	C..TT.....	G.OG.T..CO.....	TA.T..T..G.....	CCGA.....TC.....	T.....	G.....		C.....			C.1362
Spneumon16S.SEQ	.....TCCG.....	C..TC..A.O.G.T..CO.....	TA.T..T.....	CCA.....TC.....	T.....	T..G.....			C.A.....	C.....		C.1349
Spyogenes16S.SEQ	.....TCCG.....	C..TC..A.O.G.T..CO.....	TA.T..T.....	CCA.....TC.....	T.....	T..G.....			C.A.....	C.....		C.1257
Navium16S.SEQ	.....CCG.....	G.CT.....	TCC.TA.....	GTT.....	A.T.CTT.....	CCG.....TC.....	T.....	T..G.....	C.....	G.....		CA.1306
Mt16S.SEQ	.....CCG.....	G.CT.....	TCC.TA.....	GTT.....	A.T.CTT.....	CCG.....TC.....	T.....	T..G.....	C.....	G.....		CA.1306
Ecoli o157 16S.SEQ	CAATGCGCCTACAGAGGACCTCCGAGGACGACGACCTC-ATTAAGTGGCTGTAGTCCGATTCGAGTCTCGAACTGCACTGAAATCCCTAGTAACTCG	.....AT.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	CA.1346
Kpneumonias 16S.SEQ	.....T.....	G.O.G.T.A.C.A.CA.....	TCGG.....T.A.T..-G.....	TA.....TA.....	.....	.....	.....	.....	.....	.....	.....	A.1347
Lactinol16S.SEQ	.....T.....	G.O.G.....	ACCT.....	GTCG.....	A.T.....	TA.....TA.....	.....	.....	.....	.....	.....	C.1351
Minifluensae 16S.SEQ	.....TCCCG.....	G.O.TC..C.A.C.....	G.OG.....CA.T.C.-G.....	CCCGA.....	.....	.....	.....	.....	G.O.....	.....	.....	C.1353
Bronchiseptica 16S.SEQ	.....TCCCG.....	G.O.TC..C.A.C.....	G.OG.....CA.T.C.-G.....	CCCGA.....	.....	.....	.....	.....	G.O.....	.....	.....	C.1345
Spartapertussis16S.SEQ	.....TCCCG.....	G.O.TC..C.A.C.....	G.OG.....CA.T.C.-G.....	CCCGA.....	.....	.....	.....	.....	G.O.....	.....	.....	C.1317
Bpirtussis 16S.SEQ	.....TCCCG.....	G.O.TT.NC.A.C.....	G.OG.....CA.T.C.-G.....	CCCG.....N.....	.....	.....	.....	.....	G.O.....	.....	.....	C.1343
Bcepacia 16S.SEQ	.....TCCGA.....	G.O.TT.C.A.C.....	G.OG.....TA.T.C.-G.....	ACC.A.....	.....	.....	.....	.....	G.O.....	CT.....	.....	C.1346
Emallei 16S.SEQ	.....TCCGA.....	G.O.TC..C.A.C.....	G.OG.....CA.T.C.-G.....	ACCGA.....	.....	.....	.....	.....	G.O.....	CT.....	.....	C.1319
Bpseudomallei 16S.SEQ	.....TCCGA.....	G.O.TC..C.A.C.....	G.OG.....CA.T.C.-G.....	ACCGA.....	.....	.....	.....	.....	G.O.....	CT.....	.....	C.1319
Pgonorrhoeae 16S.SEQ	.....TCCG.....	G.O.T..C.A.C.....	CCCG.....CA.T..-C.....	ACCGA.....	.....	.....	.....	.....	G.O.....	.....	.....	C.1398
Nmening 16S.SEQ	.....TCCG.....	G.O.T..C.A.C.....	CCCG.....CA.T..-C.....	ACCGA.....	.....	.....	.....	.....	G.O.....	.....	.....	CA.1355
Paeruginosa 16S.SEQ	.....TCCG.....	G.O.TT..C.A.C.....	T.OG.....TA.T.C.-	ACCGA.....	.....	.....	.....	.....	G.O.....	.....	.....	CA.1355
Vcholerae 16S.SEQ	.....T.....	G.O.G.C.....	TAC.....	GTCG.....	T.A.T..-C.....	TA.....TA.....	.....	.....	G.O.....	.....	.....	1350
Yentarcollisica 16S.SEQ	.....AG.....	.....T.....	.....A.....	.....CT.....	.....	.....	.....	.....	.....	.....	.....	CA.1354
												A.1356

FIG. 2A-12

[illegible]



Alignment Report of Gram +&- 16S align.MEG, using Clustal method with Weighted residue weight table.  
Tuesday, November 27, 2001 4:14 PM

	1480	1490	1500	1510	1520	1530	1540	
Subtilisin16S.SEQ	.G..CAG....T.....	.G.....G.....	.G.....G.....	.G.....G.....	.G.....G.....	.G.....G.....	.G.....G.....	1427
Banthracis16.SEQ	AA..CCG.....	AA..CCG.....	AA..CCG.....	AA..CCG.....	AA..CCG.....	AA..CCG.....	AA..CCG.....	1544
Escherichia16S.SEQ	.G..CAG..A..T.....	.G..CAG..A..T.....	.G..CAG..A..T.....	.G..CAG..A..T.....	.G..CAG..A..T.....	.G..CAG..A..T.....	.G..CAG..A..T.....	1449
Lactis16S.SEQ	.G..CAA....T.....	.G..CAA....T.....	.G..CAA....T.....	.G..CAA....T.....	.G..CAA....T.....	.G..CAA....T.....	.G..CAA....T.....	1548
Monocyt16S.SEQ	.G..CG....T.....	.G..CG....T.....	.G..CG....T.....	.G..CG....T.....	.G..CG....T.....	.G..CG....T.....	.G..CG....T.....	1524
Saureus16S.SEQ	.G..AG....T.....	.G..AG....T.....	.G..AG....T.....	.G..AG....T.....	.G..AG....T.....	.G..AG....T.....	.G..AG....T.....	1555
Smuts16S.SEQ	.G..AG....T.....	.G..AG....T.....	.G..AG....T.....	.G..AG....T.....	.G..AG....T.....	.G..AG....T.....	.G..AG....T.....	1551
Spneumon16S.SEQ	.G..AG....T.....	.G..AG....T.....	.G..AG....T.....	.G..AG....T.....	.G..AG....T.....	.G..AG....T.....	.G..AG....T.....	1515
Spvogenes16S.SEQ	.G..AG....T.....	.G..AG....T.....	.G..AG....T.....	.G..AG....T.....	.G..AG....T.....	.G..AG....T.....	.G..AG....T.....	1335
Maviun16S.SEQ	.G..AG....T.....	.G..AG....T.....	.G..AG....T.....	.G..AG....T.....	.G..AG....T.....	.G..AG....T.....	.G..AG....T.....	1465
Mtbl16S.SEQ	.G..AG....T.....	.G..AG....T.....	.G..AG....T.....	.G..AG....T.....	.G..AG....T.....	.G..AG....T.....	.G..AG....T.....	1536
Ecoli o157 16S.SEQ	GTGATTCATCACTGGGGTGAAGTGTACACAGCT-AACCGTAAG	GTGATTCATCACTGGGGTGAAGTGTACACAGCT-AACCGTAAG	GTGATTCATCACTGGGGTGAAGTGTACACAGCT-AACCGTAAG	GTGATTCATCACTGGGGTGAAGTGTACACAGCT-AACCGTAAG	GTGATTCATCACTGGGGTGAAGTGTACACAGCT-AACCGTAAG	GTGATTCATCACTGGGGTGAAGTGTACACAGCT-AACCGTAAG	GTGATTCATCACTGGGGTGAAGTGTACACAGCT-AACCGTAAG	1542
Kpneumonise 16S.SEQ	.....N.....	.....N.....	.....N.....	.....N.....	.....N.....	.....N.....	.....N.....	1534
Actinob16S.SEQ	A.....	A.....	A.....	A.....	A.....	A.....	A.....	1485
Kinfluenzae 16S.SEQ	A.....	A.....	A.....	A.....	A.....	A.....	A.....	1487
Bbrnchiseptica 16S.SEQ	A.....	A.....	A.....	A.....	A.....	A.....	A.....	1532
Sparapertussis16S.SEQ	A.....	A.....	A.....	A.....	A.....	A.....	A.....	1485
Spertussis 16S.SEQ	A.....	A.....	A.....	A.....	A.....	A.....	A.....	1464
Beopacia 16S.SEQ	A.....	A.....	A.....	A.....	A.....	A.....	A.....	1535
Bmallei 16S.SEQ	A.....	A.....	A.....	A.....	A.....	A.....	A.....	1488
Spseudomallei 16S.SEQ	A.....	A.....	A.....	A.....	A.....	A.....	A.....	1610
Ngonorthosae 16S.SEQ	A..C.....	A..C.....	A..C.....	A..C.....	A..C.....	A..C.....	A..C.....	1544
Rnaning 16S.SEQ	A..C.....	A..C.....	A..C.....	A..C.....	A..C.....	A..C.....	A..C.....	1544
Paeruginosa 16S.SEQ	A.....	A.....	A.....	A.....	A.....	A.....	A.....	1537
Vcholeraz 16S.SEQ	A.....	A.....	A.....	A.....	A.....	A.....	A.....	1467
Yenterocolitica 16S.SEQ	.....NN.N.	.....NN.N.	.....NN.N.	.....NN.N.	.....NN.N.	.....NN.N.	.....NN.N.	1485

Decoration 'Decoration #1': Hide (as '.') residues that match Ecoli o157 16S.SEQ exactly.

FIG. 2A-14

# Alignment Report of Gram +&- 23S align.MEG, using Clustal method with Weighted residue weight table.

Tuesday, November 27, 2001 4:14 PM

	10	20	30	40	50	60	70	80	90	100	110
Bubtllis 23S.SEQ	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG
Banthracis 23S.SEQ	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG
Elacalis 23S.SEQ	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG
Lmonocytogenes 23S.SEQ	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG
Saureus 23S.SEQ	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG
Smutans 23S.SEQ	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG
Spneumonias 23S.SEQ	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG
Spvogenes 23S.SEQ	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG
Mavium 23S.SEQ	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG
Mtuberculosis 23S.SEQ	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG
Zcoll 23S.SEQ	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG
Koneumonias 23S.SEQ	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG
Minfluenzae 23S.SEQ	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG
Bbrochiseptica 23S.SEQ	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG
Bparapartusis 23S.SEQ	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG
Bpertussis 23S.SEQ	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG
Bcepacia 23S.SEQ	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG
Bmailei 23S.SEQ	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG
Bpseudomallei 23S.SEQ	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG
Bgonorrhoeae 23S.SEQ	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG
Bneminigitidis 23S.SEQ	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG
Baeruginosa 23S.SEQ	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG
Bcholerae 23S.SEQ	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG
Benterocolitica 23S.SEQ	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG	TT.GA...G.CG

FIG. 2B-1

Alignment Report of Gram +&- 23S align.MEG, using Clustal method with Weighted residue weight table.  
 Tuesday, November 27, 2001 4:14 PM

	120	130	14	150	160	17	180	190	200	210	220																	
Beubtilis 23S.SEQ	.....	CCACTGG	ANT	GAGTGG	.....	CA	T	.....	ATA	G	GA	.....	AG	.....	C	.....	G	.....	G	.....	A	230						
Banthracis 23S.SEQ	.....	CCA	AGG	ANT	GT	TGG	.....	C	T	.....	A	.....	GTAA	CGA	A	AG	.....	CA	.....	.....	.....	G	.....	A	230			
Bmacialis 23S.SEQ	.....	G	.....	A	CTT	ATAGG	T	T	CTT	C	G	.....	A	.....	C	GA	T	GA	.....	T	.....	.....	.....	GA	.....	A	230	
Llactis 23S.SEQ	C	.....	A	.....	CT	GC	A	TAG	AGT	TCA	G	G	.....	A	.....	C	CA	GTAA	TA	.....	CCA	.....	GA	.....	GT	.....	A	237
Laonocytogenes 23S.SEQ	.....	G	.....	C	A	CTT	AGTGG	T	G	.....	C	CG	.....	A	.....	CGTG	CCA	AG	.....	CA	.....	.....	.....	GA	.....	A	230	
Saureus 23S.SEQ	.....	CA	AG	AT	.....	TGT	GA	TG	.....	A	.....	CA	TA	C	CA	AC	.....	C	A	.....	.....	.....	.....	GA	.....	A	231	
Smittans 23S.SEQ	A	.....	ACA	CG	ANT	C	TGT	.....	CA	.....	T	A	.....	TA	G	CA	AG	CCA	T	.....	C	.....	.....	GA	.....	A	231	
Spneumonias 23S.SEQ	.....	G	.....	ACA	CG	ATAC	TGT	C	CA	C	T	T	.....	A	.....	ATG	G	G	.....	AG	CCA	T	.....	.....	.....	.....	A	224
SPVogenes 23S.SEQ	G	.....	G	CA	TG	ANT	CA	TGTC	CA	G	.....	T	A	.....	CA	G	CA	AG	CCA	T	.....	.....	.....	.....	.....	.....	A	224
Navium 23S.SEQ	.....	G	.....	CAC	AG	ANT	.....	GTGT	C	CG	T	.....	AT	.....	GTGCGGAG	T	.....	GC	.....	.....	.....	.....	.....	.....	.....	.....	A	237
Mtuberculosis 23S.SEQ	.....	CAC	AG	ANT	.....	GTG	C	CG	T	.....	AT	.....	GTGCGGAG	T	.....	GC	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	A	230
Eccli 23S.SEQ	TTCCGATGCGGAAACCCAGTGTG	ATTC	GTCA	CACTATCA	TACTGATCCATAGGT	.....	TAATGAGGCGGACCGCGGAGTGAACATCTTAACTACCCCGGAGGAAAGAAATCAAC	228																				
Kpneumonias 23S.SEQ	G	.....	CA	.....	TG	.....	G	.....	A	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	A	228
Hinfluenzae 23S.SEQ	A	.....	AGATGAG	AAATCT	.....	AC	G	.....	T	.....	C	.....	GT	.....	A	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	A	232
Bbrochiseptica 23S.SEQ	.....	CG	CAA	.....	G	CG	.....	CG	CG	.....	A	.....	CC	AGTG	.....	T	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	A	224
Bparapartus 23S.SEQ	.....	CG	CAA	.....	G	CG	.....	CG	CG	.....	A	.....	CC	AGTG	.....	T	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	A	223
Bpartus 23S.SEQ	A	.....	CG	CAA	.....	G	CG	.....	CG	CG	.....	A	.....	CC	AGTG	.....	T	.....	.....	.....	.....	.....	.....	.....	.....	.....	A	223
Bcepacia 23S.SEQ	G	.....	C	CC	T	.....	TGG	G	.....	CA	CG	.....	A	.....	CC	ATGC	A	.....	GC	T	.....	.....	.....	.....	.....	.....	A	224
Bmallei 23S.SEQ	G	.....	G	CCG	T	.....	TGG	TC	.....	C	AG	.....	A	.....	C	.....	G	.....	GC	T	.....	.....	.....	.....	.....	.....	A	225
Bpseudomallei 23S.SEQ	G	.....	G	CCG	T	.....	TGG	TC	.....	C	AG	.....	A	.....	C	.....	G	.....	GC	T	.....	.....	.....	.....	.....	.....	A	225
Ngonorrhoeas 23S.SEQ	G	.....	C	CC	T	.....	TGTG	G	.....	C	A	GT	.....	A	.....	CT	.....	GA	.....	C	A	.....	.....	.....	.....	.....	A	228
Neminigititidis 23S.SEQ	.....	C	CC	T	.....	TGTG	G	.....	C	A	GT	.....	A	.....	CT	.....	GA	.....	C	A	.....	.....	.....	.....	.....	.....	A	227
Paeruginosa 23S.SEQ	C	T	.....	G	.....	CCTA	G	AA	OCT	CG	.....	T	GT	.....	CC	A	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	A	228
Vcholerae 23S.SEQ	.....	ACT	C	AA	C	.....	GT	CTG	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	A	226
Yanterocolitica 23S.SEQ	.....	CA	.....	TG	.....	TOCATGG	.....	A	.....	CC	ATCCA	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	.....	A	228

FIG. 2B-2



[illegible]

**FIG. 2B-4**

Alignment Report of Gram +&- 23S align.MEG, using Clustal method with Weighted residue weight table.  
Tuesday, November 27, 2001 4:14 PM

	380	390	400	410	420	430	440	450	460	470	480	490
<i>Baebtilis</i> 23S.SEQ	A	..	..	..	..	..	..	..	..	..	..	..
<i>Banthracis</i> 23S.SEQ	A	..	..	..	..	..	..	..	..	..	..	..
<i>Elizabeth</i> 23S.SEQ	A	..	..	..	..	..	..	..	..	..	..	..
<i>Lactis</i> 23S.SEQ	A	..	..	..	..	..	..	..	..	..	..	..
<i>Leuconocytogenes</i> 23S.SEQ	A	..	..	..	..	..	..	..	..	..	..	..
<i>Saureus</i> 23S.SEQ	A	..	..	..	..	..	..	..	..	..	..	..
<i>Smutans</i> 23S.SEQ	A	..	..	..	..	..	..	..	..	..	..	..
<i>Spneumonise</i> 23S.SEQ	A	..	..	..	..	..	..	..	..	..	..	..
<i>Spvogenes</i> 23S.SEQ	A	..	..	..	..	..	..	..	..	..	..	..
<i>Mavium</i> 23S.SEQ	A	..	..	..	..	..	..	..	..	..	..	..
<i>Metuberculosie</i> 23S.SEQ	A	..	..	..	..	..	..	..	..	..	..	..
<i>Ecoli</i> 23S.SEQ	A	..	..	..	..	..	..	..	..	..	..	..
<i>Xpneumonise</i> 23S.SEQ	A	..	..	..	..	..	..	..	..	..	..	..
<i>Hinfluenzae</i> 23S.SEQ	A	..	..	..	..	..	..	..	..	..	..	..
<i>Brochiseptica</i> 23S.SEQ	A	..	..	..	..	..	..	..	..	..	..	..
<i>Spapertusis</i> 23S.SEQ	A	..	..	..	..	..	..	..	..	..	..	..
<i>Spertusis</i> 23S.SEQ	A	..	..	..	..	..	..	..	..	..	..	..
<i>Beopacia</i> 23S.SEQ	A	..	..	..	..	..	..	..	..	..	..	..
<i>Bsallei</i> 23S.SEQ	A	..	..	..	..	..	..	..	..	..	..	..
<i>Bpsudomallei</i> 23S.SEQ	A	..	..	..	..	..	..	..	..	..	..	..
<i>Ngonorrhoeae</i> 23S.SEQ	A	..	..	..	..	..	..	..	..	..	..	..
<i>Neminigitidis</i> 23S.SEQ	A	..	..	..	..	..	..	..	..	..	..	..
<i>Paeruginosa</i> 23S.SEQ	A	..	..	..	..	..	..	..	..	..	..	..
<i>Vcholarae</i> 23S.SEQ	A	..	..	..	..	..	..	..	..	..	..	..
<i>Yenterocolitica</i> 23S.SEQ	A	..	..	..	..	..	..	..	..	..	..	..

FIG. 2B-5



Alignment Report of Gram +&- 23S align.MEG, using Clustal method with Weighted residue weight table.  
Tuesday, November 27, 2001 4:14 PM

	10	20	30	40	50	60	70	80	90
Bautille 235.SEQ	.....G.A.....	.....G.T.C.....	.....C.C.....	.....G.TA.....	.....CAT.....	.....G.....	.....ACGT.....	.....TCG.....	.....C.....TC 742
Banthracis 235.SEQ	.....G.T.....	.....G.C.....	.....C.C.....	.....G.TA.....	.....T.....	.....T.....	.....ACGT.....	.....TCG.....	.....C.....TC 743
Elacaelis 235.SEQ	.....GT.....	.....G.AC.....	.....C.C.....	.....G.TA.....	.....AT.....	.....G.....	.....ACGT.....	.....TCG.....	.....C.....TC 736
Llactis 235.SEQ	.....OTT.....	.....G.AC.....	.....T.....	.....G.TA.....	.....ACT.....	.....T.....	.....AT.....	.....T.A.G.....	.....A.....TC 731
Leonocytogenes 235.SEQ	.....G.G.....	.....A.A.C.....	.....T.C.....	.....G.TA.....	.....CAT.....	.....A.....	.....NA.....	.....TCG.....	.....C.....TC 743
Saureus 235.SEQ	.....G.A.T.A.T.....	.....T.C.....	.....G.....	.....G.TA.....	.....T.....	.....T.....	.....ATT.....	.....TCG.....	.....C.....TC 742
Smutans 235.SEQ	.....OTT.....	.....G.AC.....	.....T.....	.....G.TA.....	.....G.T.....	.....A.....	.....ACGT.....	.....A.G.....	.....AA.....C.....A 728
Spnemoniae 235.SEQ	.....OTT.....	.....G.AC.....	.....T.....	.....G.TA.....	.....CCT.....	.....T.....	.....AT.....	.....T.A.G.....	.....AT.....C.....C.....A 729
Spyogenes 235.SEQ	.....OTT.....	.....G.AC.....	.....T.....	.....TA.....	.....C.....	.....T.....	.....AT.....	.....T.T.G.....	.....AT.....C.....C.....A 730
Mavium 235.SEQ	.....C.....	.....TCG.....	.....T.....	.....C.C.....	.....G.TA.....	.....CATCCG.....	.....TTTCG.....	.....GT.....	.....G.....C.....C.....C 806
Mtuberculosia 235.SEQ	.....C.....	.....T.G.G.....	.....T.....	.....C.C.....	.....G.TA.....	.....ACCCACGCGCAGACGCGCGTGTAT.....	.....G.....	.....GT.....T.C.G.....	.....G.....G.....C.....C 826
Ecoli 235.SEQ	.....GTTA.....	.....CGA.....	.....GCG.....	.....GCG.....	.....GTTA.....	.....ACCCACGCGCAGACGCGCGTGTAT.....	.....G.....	.....GT.....T.C.G.....	.....G.....G.....C.....C 826
Knemumoniae 235.SEQ	.....T.....	.....T.....	.....C.....	.....T.....	.....T.....	.....ACGT.....	.....G.....	.....GT.....T.C.G.....	.....G.....G.....C.....C 697
Kinfluenzae 235.SEQ	.....T.....	.....T.....	.....C.....	.....T.....	.....T.....	.....ACGT.....	.....G.....	.....GT.....T.C.G.....	.....G.....G.....C.....C 695
Bbrochiseptica 235.SEQ	.....T.....	.....T.....	.....C.....	.....T.....	.....T.....	.....ACGT.....	.....G.....	.....GT.....T.C.G.....	.....G.....G.....C.....C 695
Sparapertusis 235.SEQ	.....T.....	.....T.....	.....C.....	.....T.....	.....T.....	.....ACGT.....	.....G.....	.....GT.....T.C.G.....	.....G.....G.....C.....C 687
Sparapertusis 235.SEQ	.....T.....	.....T.....	.....C.....	.....T.....	.....T.....	.....ACGT.....	.....G.....	.....GT.....T.C.G.....	.....G.....G.....C.....C 688
Bcopacia 235.SEQ	.....T.....	.....T.....	.....C.....	.....T.....	.....T.....	.....ACGT.....	.....G.....	.....GT.....T.C.G.....	.....G.....G.....C.....C 688
Bmalid 235.SEQ	.....T.....	.....T.....	.....C.....	.....T.....	.....T.....	.....ACGT.....	.....G.....	.....GT.....T.C.G.....	.....G.....G.....C.....C 691
Bpseudomallid 235.SEQ	.....T.....	.....T.....	.....C.....	.....T.....	.....T.....	.....ACGT.....	.....G.....	.....GT.....T.C.G.....	.....G.....G.....C.....C 691
Bpseudomallid 235.SEQ	.....T.....	.....T.....	.....C.....	.....T.....	.....T.....	.....ACGT.....	.....G.....	.....GT.....T.C.G.....	.....G.....G.....C.....C 693
Bpseudomallid 235.SEQ	.....T.....	.....T.....	.....C.....	.....T.....	.....T.....	.....ACGT.....	.....G.....	.....GT.....T.C.G.....	.....G.....G.....C.....C 693
Bpseudomallid 235.SEQ	.....T.....	.....T.....	.....C.....	.....T.....	.....T.....	.....ACGT.....	.....G.....	.....GT.....T.C.G.....	.....G.....G.....C.....C 693
Bpseudomallid 235.SEQ	.....T.....	.....T.....	.....C.....	.....T.....	.....T.....	.....ACGT.....	.....G.....	.....GT.....T.C.G.....	.....G.....G.....C.....C 693
Bpseudomallid 235.S	.....T.....	.....T.....	.....C.....	.....T.....	.....T.....	.....ACGT.....	.....G.....	.....GT.....T.C.G.....	.....G.....G.....C.....C 687

**FIG. 2B-7**



[illegible]

**FIG. 2B-8**

Alignment Report of Gram +&- 23S align.MEG, using Clustal method with Weighted residue weight table.  
Tuesday, November 27, 2001 4:14 PM

[illegible]

**FIG. 2B-9**

Alignment Report of Gram +& 23S align.MEG, using Clustal method with Weighted residue weight table.  
Tuesday, November 27, 2001 4:14 PM

[illegible]

**FIG. 2B-10**

**FIG. 2B-11**

**FIG. 2B-12**

**FIG. 2B-13**

Alignment Report of Gram -& 23S align.MEG, using Clustal method with Weighted residue weight table.  
Tuesday, November 27, 2001 4:14 PM

[illegible]

**FIG. 2B-14**

Alignment Report of Gram +&- 23S align.MEG, using Clustal method with Weighted residue weight table.  
Tuesday, November 27, 2001 4:14 PM

	1490	1500	1510	1520	1530	
Ba subtilis 23S.SEQ	T.GCAAAAT	.....TTTC-----CC.A--G.C--CT	.....G...CG.A--TATA	.....G...CG.A--TATA	.....G...CG.A--TATA	1585
Banthracis 23S.SEQ	T.A.AAGT	.....CTTA-----TGG.G--CT	.....CT	.....CG..-AGTCC-TTAT	.....CG..-AGTCC-TTAT	1592
Staphylococcus 23S.SEQ	TTGAG.AG.TT	...G.T-TT.C-----TCT.T--ACA.TT	.....ACA.TT	.....C.CG..CG.AAT-AATA	.....C.CG..CG.AAT-AATA	1584
Lactis 23S.SEQ	..TAAAGTAT.T	.....G.A-TTTC-----TCT.T--CAT	.....CAT	.....CG..A..AC-TAC	.....CG..A..AC-TAC	1568
Monocytogenes 23S.SEQ	T.AAAGT	.....CTTC-----TC.CG--CA	.....CA	.....CG..A.G.A--TTAA	.....CG..A.G.A--TTAA	1591
Saureus 23S.SEQ	T.AG.AAT	.....CT.C-----TGG.T--CT	.....CT	.....CG..AGAC-TTGT	.....CG..AGAC-TTGT	1586
Smutans 23S.SEQ	..AGACTG.T	.....G.T-T.GT-----TCTG--CCCA.CA	.....CCCA.CA	.....C.CG..CG.AG-TTAA	.....C.CG..CG.AG-TTAA	1565
Spneumonias 23S.SEQ	..TGAATG.T	.....G.T-T.T-----TCTAT--CAT	.....CAT	.....CG..CG.AG-TTAA	.....CG..CG.AG-TTAA	1569
Spysogenes 23S.SEQ	..TAAAGT.T	.....G.T-T.TC-----TTTAT--CAT	.....CAT	.....CG..CG.A--TTTA	.....CG..CG.A--TTTA	1571
Mavium 23S.SEQ	ATGCGGTG.C	..CG.A.CGTTACCATC.GTGGT.TA	.....G...AA.CCGGTGAG--AGAGC	..TAG.CA.A.C.GTC	..CTGACTAATCTGAGAGGTGATGATGAGCCGTT.A	1754
Mtuberculosis 23S.SEQ	..AGCGGTG.C	..CG.GTTA.CGTTACCATC.GTGGT.TA	.....G...AA.CCGGTGAGAGAGC	..TAG.CA.A.C.GTC	..CTGACTAATCTGAGAGGTGATGAGCCGTT.A	1776
Ecoli 23S.SEQ	CGTTTTCGAGCC	..ATGCGGAA	.....ATC--AGCGTGGCGGTG	.....ATGAGAGGCACTAC--G	.....ATGAGAGGCACTAC--G	1538
Xpneumonias 23S.SEQ	...G.....T	.....T	.....T	.....T	.....T	1536
Hinfluenzae 23S.SEQ	..AG.TT	.....C-T-----TCC.T--CA.A..AGA	.....CA.A..AGA	.....T	.....T	1545
Bbrochiaeptica 23S.SEQ	..AGCGTT	.....GCGC-----GA--G.AT.AAG.T	.....G.AT.AAG.T	.....CG..CG.AGTC	.....CG..CG.AGTC	1522
Bparapertusis 23S.SEQ	..AGCGTT	.....GCGC-----GA--G.AT.AAG.T	.....G.AT.AAG.T	.....CG..CG.AGTC	.....CG..CG.AGTC	1523
Bpertusis 23S.SEQ	..AGCGTT	.....GCGC-----GA--G.AT.AAG.T	.....G.AT.AAG.T	.....CG..CG.AGTC	.....CG..CG.AGTC	1523
Bcepacla 23S.SEQ	..AGCGTT	.....GCGC-----C.G--G.AT.AAG.T	.....G.AT.AAG.T	.....CG..CG.AGTC	.....CG..CG.AGTC	1526
Bsmalli 23S.SEQ	..AGCGTT	.....GCGC-----C.G--G.AT.AAG.T	.....G.AT.AAG.T	.....CG..CG.AGTC	.....CG..CG.AGTC	1529
Bpseudomallei 23S.SEQ	..AGCGTT	.....GCGC-----C.G--G.AT.AAG.T	.....G.AT.AAG.T	.....CG..CG.AGTC	.....CG..CG.AGTC	1529
Ngonorrhoeae 23S.SEQ	..AGACTT	.....GTTT-----TCT--CA.C..AA	.....CA.C..AA	.....CG..CG.AGTC	.....CG..CG.AGTC	1529
Neminigitidis 23S.SEQ	..AGACTT	.....GTTT-----TCT--CA.C..AA	.....CA.C..AA	.....CG..CG.AGTC	.....CG..CG.AGTC	1529
Paeruginosa 23S.SEQ	..AGACTT	.....GTTT-----TCT--CA.C..AA	.....CA.C..AA	.....CG..CG.AGTC	.....CG..CG.AGTC	1529
Vcholerae 23S.SEQ	..AGACTT	.....GTTT-----TCT--CA.C..AA	.....CA.C..AA	.....CG..CG.AGTC	.....CG..CG.AGTC	1529
Yenterocolitica 23S.SEQ	..AGACTT	.....GTTT-----TCT--CA.C..AA	.....CA.C..AA	.....CG..CG.AGTC	.....CG..CG.AGTC	1529

FIG. 2B-15



[illegible]

**FIG. 2B-17**

[illegible]

**FIG. 2B-18**

Alignment Report of Gram +&- 23S align.MEG, using Clustal method with Weighted residue weight table.  
Tuesday, November 27, 2001 4:14 PM

	1900	1910	1920	1930	1940	1950	1960	1970	1980	1990	2000	2010	
Baibtilia 23S.SEQ	A												2041
Banthracis 23S.SEQ	A												2037
Efaecalis 23S.SEQ	A												2027
Llaectis 23S.SEQ	A												2017
Lmonocytogenes 23S.SEQ	A												2047
Saureus 23S.SEQ	A												2041
Smutans 23S.SEQ	A												2014
Spneumoniae 23S.SEQ	A												2016
Spyogenes 23S.SEQ	A												2017
Mavium 23S.SEQ	A												2230
Mtuberculosis 23S.SEQ	A												2252
Ecoli 23S.SEQ	A												2013
Xpneumoniae 23S.SEQ	A												2019
Hinfluenzae 23S.SEQ	A												1982
Bbrochiaeptica 23S.SEQ	A												1983
Sporepertussis 23S.SEQ	A												1983
Bcepsia 23S.SEQ	A												1988
Bmallei 23S.SEQ	A												1991
Bpseudomallei 23S.SEQ	A												1991
Ngonorhoeae 23S.SEQ	A												2002
Neminigitidis 23S.SEQ	A												2001
Paeruginosa 23S.SEQ	A												2001
Vcholerae 23S.SEQ	A												1996
Yenterocolitica 23S.SEQ	A												2016

FIG. 2B-19

Alignment Report of Gram +8- 23S align.MEG, using Clustal method with Weighted residue weight table.  
Tuesday, November 27, 2001 4:14 PM

	2020	2030	2040	2050	2060	2070	2080	2090	2100	2110	2120	2130
Baebilla 23S.SEQ	..AT.G.AC	..GT	..A.G	..G.G	..G.G	..G.G	..G.C	..T.T	..TG	..GTA.AGCT	..AC	..C..G.. 2161
Banthracie 23S.SEQ	..AT.G.AC	..GT	..A.G	..G.G	..G.G	..G.G	..G.C	..T.T	..TG	..GTA.AGCT	..AC	..C..G.. 2161
Bfacellie 23S.SEQ	..TT.G.AC	..GT	..A.G	..A.G	..A.G	..A.G	..G.C	..T.T	..TG	..GTA.AGCT	..AC	..C..G.. 2167
Llactis 23S.SEQ	..TT.G.AC	..GT	..A.G	..A.G	..A.G	..A.G	..G.C	..T.T	..TG	..GTA.AGCT	..AC	..C..G.. 2167
Lmonocytogenes 23S.SEQ	..AT.G.AC	..GT	..A.G	..A.G	..A.G	..A.G	..G.C	..T.T	..TG	..GTA.AGCT	..AC	..C..G.. 2167
Saureus 23S.SEQ	..AT.G.AC	..GT	..A.G	..A.G	..A.G	..A.G	..G.C	..T.T	..TG	..GTA.AGCT	..AC	..C..G.. 2167
Smuteus 23S.SEQ	..TT.G.AC	..GT	..A.G	..A.G	..A.G	..A.G	..G.C	..T.T	..TG	..GTA.AGCT	..AC	..C..G.. 2161
Spneumonise 23S.SEQ	..TT.G.AC	..GT	..A.G	..A.G	..A.G	..A.G	..G.C	..T.T	..TG	..GTA.AGCT	..AC	..C..G.. 2134
Spyogenes 23S.SEQ	..TT.G.AC	..GT	..A.G	..A.G	..A.G	..A.G	..G.C	..T.T	..TG	..GTA.AGCT	..AC	..C..G.. 2136
Maviun 23S.SEQ	..C..ACGA	..A	..G	..G	..G	..G	..C	..A	..GT	..GTA.AGCT	..AC	..C..G.. 2137
Neubarculosis 23S.SEQ	..C..ACGA	..A	..G	..G	..G	..G	..C	..A	..GT	..GTA.AGCT	..AC	..C..G.. 2137
Ecoli 23S.SEQ	..C..ACGA	..A	..G	..G	..G	..G	..C	..A	..GT	..GTA.AGCT	..AC	..C..G.. 2137
Kneumonise 23S.SEQ	..C..ACGA	..A	..G	..G	..G	..G	..C	..A	..GT	..GTA.AGCT	..AC	..C..G.. 2137
Minfluenzae 23S.SEQ	..C..ACGA	..A	..G	..G	..G	..G	..C	..A	..GT	..GTA.AGCT	..AC	..C..G.. 2137
Bbrochiseptica 23S.SEQ	..C..ACGA	..A	..G	..G	..G	..G	..C	..A	..GT	..GTA.AGCT	..AC	..C..G.. 2137
Bparapertusis 23S.SEQ	..C..ACGA	..A	..G	..G	..G	..G	..C	..A	..GT	..GTA.AGCT	..AC	..C..G.. 2137
Bpertusis 23S.SEQ	..C..ACGA	..A	..G	..G	..G	..G	..C	..A	..GT	..GTA.AGCT	..AC	..C..G.. 2137
Bcepacia 23S.SEQ	..C..ACGA	..A	..G	..G	..G	..G	..C	..A	..GT	..GTA.AGCT	..AC	..C..G.. 2137
Bmallei 23S.SEQ	..C..ACGA	..A	..G	..G	..G	..G	..C	..A	..GT	..GTA.AGCT	..AC	..C..G.. 2137
Bpseudomallei 23S.SEQ	..C..ACGA	..A	..G	..G	..G	..G	..C	..A	..GT	..GTA.AGCT	..AC	..C..G.. 2137
Ngonorrhoeae 23S.SEQ	..C..ACGA	..A	..G	..G	..G	..G	..C	..A	..GT	..GTA.AGCT	..AC	..C..G.. 2137
Neminigitidis 23S.SEQ	..C..ACGA	..A	..G	..G	..G	..G	..C	..A	..GT	..GTA.AGCT	..AC	..C..G.. 2137
Paeruginosa 23S.SEQ	..C..ACGA	..A	..G	..G	..G	..G	..C	..A	..GT	..GTA.AGCT	..AC	..C..G.. 2137
Vcholerae 23S.SEQ	..C..ACGA	..A	..G	..G	..G	..G	..C	..A	..GT	..GTA.AGCT	..AC	..C..G.. 2137
Yentaroellicia 23S.SEQ	..C..ACGA	..A	..G	..G	..G	..G	..C	..A	..GT	..GTA.AGCT	..AC	..C..G.. 2137

FIG. 2B-20

	2140	2150	2160	2170	2180	2190	2200	2210	2220	2230	2240	2250
<i>Beaubittis</i> 238.SBQ	ACC.-AG.....CT.-GGT.....G.AT.GG.GG.....T.....GGCTGTAA.....CC.....CCCCCG.C.T.-G..CGG.GA.....A.....C.....	2278										
<i>Banthracis</i> 238.SBQ	ACC.-AG.....T.CT.-GGT.....G.CTGG.GG.....G.....GACTGTAA.....AA.....C.AGGGTC.T.-G.....C.AGGCG.GA.....A.....C.....	2274										
<i>Bifacialis</i> 238.SBQ	GAAC.-A.....T.-T.-GCA.....G.CTGG.GG.....T.....GTG.TA.GA.CCC.....CC.C..AC.A.-.GT.....G.GA.....A.A.....C.....	2264										
<i>Llactis</i> 238.SBQ	ADA.....T.-T.-TATT.....G.TTG.GG.....T.....G.C.TA.G.T.AC.....CC.CTGG.A.A.-.G.CCAG.GA.....AC..AC.....C.....	2254										
<i>Limnocytophaga</i> 238.SBQ	ACTT.-TG.....T..CA.-ACCA.....A.TGG.GG.....T.....GGCTGTAA.GACCA.....CC.CCA.GC.T.-G.CG.TGG.GA.....A.....C.....	2284										
<i>Saureus</i> 238.SBQ	AGCT.-AG.....T.CT.-AGCT.....G.CTGG.GG.....T.....AGCTGTG.....GGT.....CC.C..AC.T.-.GT.....G.GA.....A..C..C.....	2278										
<i>Smutans</i> 238.SBQ	AGT.-A.....T.-T.-AC.T.....G.TTG.GG.....T.....GTG..A.G.C.AC.....CC.C..TAGGT.....ATCTAC.GA.....AC..C.....	2251										
<i>Spneumoniae</i> 238.SBQ	GAUC.....T.-GAA.....A.CTG.GG.....T.....GTG.TA.G.CCAG.....CCA.TAG.....CTA.C.GA.....AC..C.....	2253										
<i>Spyrogens</i> 238.SBQ	CTTC.....T.-GAAT.....G.TTG.GG.....T.....GTG.TA.G.C.AC.....CCA.TAG.T.-.CTA.C.GA.....AC..C.....	2254										
<i>Mavium</i> 238.SBQ	CA.-CA.....T.-TG.-T.....T.TTG.....T.....T.GACTGTAA.....GACAC.....C.A.C.T.-.G.T.CA.....A.....C.....	2466										
<i>Mtuberculosis</i> 238.SBQ	ACC.-C.....TG.GG.-T.....T.TTG.....T.....T.GACTGTAA.....GACA.....C.C.C.A.-.G.T.AG.....C..C.....A.....	2489										
<i>Bcoli</i> 238.SBQ	AQ-TGTGAGCCGCTGTCAAT-GAGCCGACCTGTAAATACACCTTTAATTTGTATGTTCTTAACCTGACACCTGTAA-TCGGGTGTGCGACATCTCTGTGTATTGTACTGG	2250										
<i>Kpneumoniae</i> 238.SBQ	-C.....G.-.....A.....T.G.C.C.C.-G.....	2250										
<i>Hinfluenzae</i> 238.SBQ	-CMGT.....ATGG.-.....G.....C.....A.....TACCA.-A.T.....CT.....	2256										
<i>Bbrochiseptica</i> 238.SBQ	CTC.-A.T.....AT.-GAG.....AT.....GGTT.....CG.....C.T.GT.....T.-.A.C.G.....CA.....A..C.....	2219										
<i>Bparapertusis</i> 238.SBQ	CTC.-A.T.....AT.-GAG.....AT.....GGTT.....CG.....C.T.GT.....T.-.A.C.G.....CA.....A..C.....	2220										
<i>Bportusis</i> 238.SBQ	CTC.-A.T.....AT.-GAG.....AT.....GGTT.....CG.....C.T.GT.....T.-.A.C.G.....CA.....A..C.....	2220										
<i>Bcepacia</i> 238.SBQ	ACC.-A.....T.-T.-GGT.....T.....GGTT.....G.....C.T.G.....-C.G.....CA.....A..C.....	2225										
<i>Bmalei</i> 238.SBQ	ACC.-A.T.....T.-T.-GGT.....T.....GGTT.....G.....C.T.G.....-C.G.....CA.....A..C.....	2228										
<i>Bpseudomallei</i> 238.SBQ	ACC.-A.....T.-T.-GGT.....T.....GGTT.....G.....C.T.G.....-C.G.....CA.....A..C.....	2238										
<i>Ngonorrhoeae</i> 238.SBQ	CA.-A.....TUT.....T.T.....GGTG.C.....G.....CCA.....C.-.C.G.....C.CA.....A..C.....	2239										
<i>Neminigitidis</i> 238.SBQ	CA.-A.....TUT.....T.T.....GGTG.C.....G.....CCA.....C.-.C.G.....C.CA.....A..C.....	2238										
<i>Paeruginosa</i> 238.SBQ	-C.....TC.G.-.....AT.....GGT.....C.....G.....GGT.....TCT.GT.....A.C.A.....A.....C.....	2238										
<i>Vcholerae</i> 238.SBQ	AC.-.....T.-G.T.....T.....GT.....T.A.....T.-.A.....A.....C.....	2233										
<i>Yenterocolitica</i> 238.SBQ	-.....T.....A.....TC.C.....A.-.G.A.....A.....A.....	2233										

[illegible]

[illegible]

**FIG. 2B-23**



Alignment Report of Gram +&- 23S align.MEG, using Clustal method with Weighted residue weight table.  
Tuesday, November 27, 2001 4:15 PM

	2490	2500	2510	2520	2530	2540	2550	2560	2570	2580	2590	2600
Baebtilla 23S.SEQ	.....	.....	.....	.....	T..C.....	.....	TG.....	CA.....	C.....	C.....	C.....	2637
Banthracis 23S.SEQ	.....	.....	.....	G.....	T..C.....	.....	TG.....	CA.....	C.....	C.....	C.....	2632
Zfacaella 23S.SEQ	.....	.....	.....	G.....	T..C.....	.....	TG.....	CA.....	C.....	C.....	C.....	2621
Llaetia 23S.SEQ	.....	.....	.....	G.....	T..C.....	.....	TG.....	CA.....	C.....	C.....	C.....	2610
Leuonocytogenes 23S.SEQ	.....	.....	.....	G.....	T..C.....	.....	TG.....	CA.....	C.....	C.....	C.....	2642
Saureus 23S.SEQ	.....	.....	.....	G.....	T..C.....	.....	TG.....	CA.....	C.....	C.....	C.....	2636
Smutans 23S.SEQ	.....	.....	.....	G.....	T..C.....	.....	TG.....	CA.....	C.....	C.....	C.....	2609
Spneumonae 23S.SEQ	.....	.....	.....	G.....	T..C.....	.....	TG.....	CA.....	C.....	C.....	C.....	2611
Spvogenes 23S.SEQ	.....	.....	.....	G.....	T..C.....	.....	TG.....	CA.....	C.....	C.....	C.....	2612
Mavium 23S.SEQ	.....	.....	.....	G.....	T..C.....	.....	TG.....	CA.....	C.....	C.....	C.....	2624
Mtuberculosis 23S.SEQ	.....	.....	.....	G.....	T..C.....	.....	TG.....	CA.....	C.....	C.....	C.....	2847
Scelli 23S.SEQ	.....	.....	.....	G.....	T..C.....	.....	TG.....	CA.....	C.....	C.....	C.....	2608
Kpneumonae 23S.SEQ	.....	.....	.....	G.....	T..C.....	.....	TG.....	CA.....	C.....	C.....	C.....	2608
Kinflluensae 23S.SEQ	.....	.....	.....	G.....	T..C.....	.....	TG.....	CA.....	C.....	C.....	C.....	2614
Abrochiseptica 23S.SEQ	.....	.....	.....	G.....	T..C.....	.....	TG.....	CA.....	C.....	C.....	C.....	2569
Spaparatusis 23S.SEQ	.....	.....	.....	G.....	T..C.....	.....	TG.....	CA.....	C.....	C.....	C.....	2571
Spertusis 23S.SEQ	.....	.....	.....	G.....	T..C.....	.....	TG.....	CA.....	C.....	C.....	C.....	2570
Bcepacia 23S.SEQ	.....	.....	.....	G.....	T..C.....	.....	TG.....	CA.....	C.....	C.....	C.....	2583
Bnellei 23S.SEQ	.....	.....	.....	G.....	T..C.....	.....	TG.....	CA.....	C.....	C.....	C.....	2586
Spseudomallei 23S.SEQ	.....	.....	.....	G.....	T..C.....	.....	TG.....	CA.....	C.....	C.....	C.....	2586
Ngonorrhoeae 23S.SEQ	.....	.....	.....	G.....	T..C.....	.....	TG.....	CA.....	C.....	C.....	C.....	2597
Neminiigitidis 23S.SEQ	.....	.....	.....	G.....	T..C.....	.....	TG.....	CA.....	C.....	C.....	C.....	2596
Paeruginosa 23S.SEQ	.....	.....	.....	G.....	T..C.....	.....	TG.....	CA.....	C.....	C.....	C.....	2596
Vcholerac 23S.SEQ	.....	.....	.....	G.....	T..C.....	.....	TG.....	CA.....	C.....	C.....	C.....	2591
Yenterocolitica 23S.SEQ	.....	.....	.....	G.....	T..C.....	.....	TG.....	CA.....	C.....	C.....	C.....	2611

FIG. 2B-24

Alignment Report of Gram +8- 23S align.MEG, using Clustal method with Weighted residue weight table.  
Tuesday, November 27, 2001 4:15 PM

	2610	2620	2630	40	2650	2660	2670	2680	2690	2700	2710	2720
Beutellia 23S.SEQ	.....C.T.C.	.....A.TT.	.....A.	.....A.	.....TC.T.	.....GA.	.....C.G.	.....A.CA.	.....TC.	.....G.	.....TC.	.....TG
Banthracis 23S.SEQ	.....C.T.	.....TA.	.....A.TT.	.....A.	.....TC.T.	.....CA.	.....C.G.	.....A.CA.	.....TC.	.....G.	.....TA.	.....TG
Efaecalis 23S.SEQ	.....C.T.C.	.....T.	.....A.TT.	.....A.	.....TC.T.	.....GA.	.....TT.C.G.	.....A.CA.	.....TC.	.....G.	.....T.	.....TG
Lactis 23S.SEQ	.....C.T.C.	.....TA.	.....TA.TT.	.....A.	.....TC.T.	.....GA.	.....TT.C.G.	.....A.CA.	.....TC.	.....G.	.....G.	.....TG
Imonocytogenes 23S.SEQ	.....C.T.C.	.....A.	.....A.TT.	.....A.	.....TC.T.	.....GA.	.....A.C.G.	.....A.CA.	.....TC.	.....G.	.....G.	.....TG
Saureus 23S.SEQ	.....C.T.	.....TA.	.....A.TT.	.....A.	.....TC.T.	.....GA.	.....AT.C.T.	.....A.CA.	.....TC.	.....G.	.....TA.	.....TG
Smutans 23S.SEQ	.....C.T.C.	.....A.	.....A.TT.	.....A.	.....TC.T.	.....GA.	.....TT.C.G.	.....A.CA.	.....TC.	.....G.	.....TA.	.....TG
Spneumoniae 23S.SEQ	.....C.T.C.	.....TA.	.....A.TT.	.....A.	.....TC.T.	.....GA.	.....TT.C.G.	.....A.CA.	.....TC.	.....G.	.....TA.	.....TG
Spnyogenes 23S.SEQ	.....C.T.C.	.....TA.	.....A.TT.	.....A.	.....TC.T.	.....GA.	.....TT.C.G.	.....A.CA.	.....TC.	.....G.	.....TA.	.....TG
Navium 23S.SEQ	.....C.T.C.	.....TCA.	.....A.CT.	.....A.	.....TC.	.....GAC.	.....A.C.T.	.....A.CA.	.....CC.	.....G.	.....G.	.....TG
Mtuberculosis 23S.SEQ	.....C.T.C.	.....TCA.	.....A.CT.	.....A.	.....TC.	.....GAC.	.....A.C.T.	.....A.CA.	.....CC.	.....G.	.....G.	.....TG
Ecoli 23S.SEQ	.....C.T.C.	.....TCA.	.....A.CT.	.....A.	.....TC.	.....GAC.	.....A.C.T.	.....A.CA.	.....CC.	.....G.	.....G.	.....TG
Kpneumoniae 23S.SEQ	.....C.T.C.	.....TCA.	.....A.CT.	.....A.	.....TC.	.....GAC.	.....A.C.T.	.....A.CA.	.....CC.	.....G.	.....G.	.....TG
Rinfluenzae 23S.SEQ	.....C.T.C.	.....TCA.	.....A.CT.	.....A.	.....TC.	.....GAC.	.....A.C.T.	.....A.CA.	.....CC.	.....G.	.....G.	.....TG
Brochiseptica 23S.SEQ	.....C.T.C.	.....TCA.	.....A.CT.	.....A.	.....TC.	.....GAC.	.....A.C.T.	.....A.CA.	.....CC.	.....G.	.....G.	.....TG
Bparapertussis 23S.SEQ	.....C.T.C.	.....TCA.	.....A.CT.	.....A.	.....TC.	.....GAC.	.....A.C.T.	.....A.CA.	.....CC.	.....G.	.....G.	.....TG
Bpertussis 23S.SEQ	.....C.T.C.	.....TCA.	.....A.CT.	.....A.	.....TC.	.....GAC.	.....A.C.T.	.....A.CA.	.....CC.	.....G.	.....G.	.....TG
Bcepacia 23S.SEQ	.....C.T.C.	.....TCA.	.....A.CT.	.....A.	.....TC.	.....GAC.	.....A.C.T.	.....A.CA.	.....CC.	.....G.	.....G.	.....TG
Bmaliei 23S.SEQ	.....C.T.C.	.....TCA.	.....A.CT.	.....A.	.....TC.	.....GAC.	.....A.C.T.	.....A.CA.	.....CC.	.....G.	.....G.	.....TG
Bpseudomallei 23S.SEQ	.....C.T.C.	.....TCA.	.....A.CT.	.....A.	.....TC.	.....GAC.	.....A.C.T.	.....A.CA.	.....CC.	.....G.	.....G.	.....TG
Ngonorrhoeae 23S.SEQ	.....C.T.C.	.....TCA.	.....A.CT.	.....A.	.....TC.	.....GAC.	.....A.C.T.	.....A.CA.	.....CC.	.....G.	.....G.	.....TG
Nemigitidis 23S.SEQ	.....C.T.C.	.....TCA.	.....A.CT.	.....A.	.....TC.	.....GAC.	.....A.C.T.	.....A.CA.	.....CC.	.....G.	.....G.	.....TG
Paeruginosa 23S.SEQ	.....C.T.C.	.....TCA.	.....A.CT.	.....A.	.....TC.	.....GAC.	.....A.C.T.	.....A.CA.	.....CC.	.....G.	.....G.	.....TG
Vcholerae 23S.SEQ	.....C.T.C.	.....TCA.	.....A.CT.	.....A.	.....TC.	.....GAC.	.....A.C.T.	.....A.CA.	.....CC.	.....G.	.....G.	.....TG
Yenterocolitica 23S.SEQ	.....C.T.C.	.....TCA.	.....A.CT.	.....A.	.....TC.	.....GAC.	.....A.C.T.	.....A.CA.	.....CC.	.....G.	.....G.	.....TG

FIG. 2B-25

Alignment Report of Gram +&- 23S align.MEG, using Clustal method with Weighted residue weight table.  
Tuesday, November 27, 2001 4:15 PM

	2730	2740	2750	2760	2770	2780	2790	2800	2810	2820	2830	2840
<i>Baebtilis</i> 23S.SEQ	.....C.G.....	.....T.....	.....G.OCC.....	.....T.A.....	.....A.T.....	.....ATT.....	.....CC-A.G.AGT.....	.....ATC.C.GA.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....
<i>Banthracis</i> 23S.SEQ	.....G.....	.....G.....	.....G.OCC.....	.....T.A.....	.....A.T.....	.....ATT.....	.....CC-A.G.AGT.....	.....ATC.C.GA.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....
<i>Elacalis</i> 23S.SEQ	.....G.....	.....G.....	.....G.OCC.....	.....T.A.....	.....A.T.....	.....ATT.....	.....CC-A.G.AGT.....	.....ATC.C.GA.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....
<i>Llaetis</i> 23S.SEQ	.....G.....	.....G.....	.....G.OCC.....	.....T.A.....	.....A.T.....	.....ATT.....	.....CC-A.G.AGT.....	.....ATC.C.GA.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....
<i>Leonocytogenes</i> 23S.SEQ	.....G.....	.....G.....	.....G.OCC.....	.....T.A.....	.....A.T.....	.....ATT.....	.....CC-A.G.AGT.....	.....ATC.C.GA.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....
<i>Saureus</i> 23S.SEQ	.....G.....	.....G.....	.....G.OCC.....	.....T.A.....	.....A.T.....	.....ATT.....	.....CC-A.G.AGT.....	.....ATC.C.GA.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....
<i>Smutans</i> 23S.SEQ	.....G.....	.....G.....	.....G.OCC.....	.....T.A.....	.....A.T.....	.....ATT.....	.....CC-A.G.AGT.....	.....ATC.C.GA.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....
<i>Spneumonias</i> 23S.SEQ	.....G.....	.....G.....	.....G.OCC.....	.....T.A.....	.....A.T.....	.....ATT.....	.....CC-A.G.AGT.....	.....ATC.C.GA.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....
<i>Spvogenes</i> 23S.SEQ	.....G.....	.....G.....	.....G.OCC.....	.....T.A.....	.....A.T.....	.....ATT.....	.....CC-A.G.AGT.....	.....ATC.C.GA.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....
<i>Mavium</i> 23S.SEQ	.....G.....	.....G.....	.....G.OCC.....	.....T.A.....	.....A.T.....	.....ATT.....	.....CC-A.G.AGT.....	.....ATC.C.GA.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....
<i>Neuberculosia</i> 23S.SEQ	.....G.....	.....G.....	.....G.OCC.....	.....T.A.....	.....A.T.....	.....ATT.....	.....CC-A.G.AGT.....	.....ATC.C.GA.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....
<i>Ecoli</i> 23S.SEQ	.....G.....	.....G.....	.....G.OCC.....	.....T.A.....	.....A.T.....	.....ATT.....	.....CC-A.G.AGT.....	.....ATC.C.GA.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....
<i>Kpneumonias</i> 23S.SEQ	.....G.....	.....G.....	.....G.OCC.....	.....T.A.....	.....A.T.....	.....ATT.....	.....CC-A.G.AGT.....	.....ATC.C.GA.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....
<i>Hinfluenzae</i> 23S.SEQ	.....G.....	.....G.....	.....G.OCC.....	.....T.A.....	.....A.T.....	.....ATT.....	.....CC-A.G.AGT.....	.....ATC.C.GA.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....
<i>Bbrochisepctica</i> 23S.SEQ	.....G.....	.....G.....	.....G.OCC.....	.....T.A.....	.....A.T.....	.....ATT.....	.....CC-A.G.AGT.....	.....ATC.C.GA.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....
<i>Bparapertussis</i> 23S.SEQ	.....G.....	.....G.....	.....G.OCC.....	.....T.A.....	.....A.T.....	.....ATT.....	.....CC-A.G.AGT.....	.....ATC.C.GA.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....
<i>Bpertussis</i> 23S.SEQ	.....G.....	.....G.....	.....G.OCC.....	.....T.A.....	.....A.T.....	.....ATT.....	.....CC-A.G.AGT.....	.....ATC.C.GA.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....
<i>Beopacia</i> 23S.SEQ	.....G.....	.....G.....	.....G.OCC.....	.....T.A.....	.....A.T.....	.....ATT.....	.....CC-A.G.AGT.....	.....ATC.C.GA.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....
<i>Smallei</i> 23S.SEQ	.....G.....	.....G.....	.....G.OCC.....	.....T.A.....	.....A.T.....	.....ATT.....	.....CC-A.G.AGT.....	.....ATC.C.GA.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....
<i>Bpseudomallei</i> 23S.SEQ	.....G.....	.....G.....	.....G.OCC.....	.....T.A.....	.....A.T.....	.....ATT.....	.....CC-A.G.AGT.....	.....ATC.C.GA.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....
<i>Ngonorrhoeae</i> 23S.SEQ	.....G.....	.....G.....	.....G.OCC.....	.....T.A.....	.....A.T.....	.....ATT.....	.....CC-A.G.AGT.....	.....ATC.C.GA.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....
<i>Neminiigitidis</i> 23S.SEQ	.....G.....	.....G.....	.....G.OCC.....	.....T.A.....	.....A.T.....	.....ATT.....	.....CC-A.G.AGT.....	.....ATC.C.GA.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....
<i>Paeruginosa</i> 23S.SEQ	.....G.....	.....G.....	.....G.OCC.....	.....T.A.....	.....A.T.....	.....ATT.....	.....CC-A.G.AGT.....	.....ATC.C.GA.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....
<i>Vcholeriae</i> 23S.SEQ	.....G.....	.....G.....	.....G.OCC.....	.....T.A.....	.....A.T.....	.....ATT.....	.....CC-A.G.AGT.....	.....ATC.C.GA.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....
<i>Yenterocolitica</i> 23S.SEQ	.....G.....	.....G.....	.....G.OCC.....	.....T.A.....	.....A.T.....	.....ATT.....	.....CC-A.G.AGT.....	.....ATC.C.GA.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....	.....T.TC.G.....

FIG. 2B-26

Alignment Report of Gram +&- 23S align.MEG, using Clustal method with Weighted residue weight table.  
Tuesday, November 27, 2001 4:15 PM

	2850	2860	2870	2880	2890	2900	
Baebtilis 23S.SEQ	G...T.TG..A.CA.A.G...	G..A.A...	CG.T..AG.A...	.....A-T			2927
Banthracis 23S.SEQ	G...ATG.T.CAT..G...	G.GAA...	AG.T..AG.A...	.....A-T			2922
Efaecalis 23S.SEQ	G...OCT.T..AGT.G...	CG..AA...	COCT..AG.A...	.....A-A			2912
Lactis 23S.SEQ	G...A.TT...GA.T.G...	CG..AA...	COCT..AG.A...	.....A-A			2898
Lacnocytopages 23S.SEQ	G...T.T...A.A.G...	CG..AA...	CG.T..AG.A...	.....A-A			2912
Saureus 23S.SEQ	G...ATG.T.CAT..G...	G.GAA...	AG.T..AG.A...	.....A-A			2923
Smutans 23S.SEQ	G...TT.T.GA...GA...	CG..AA...	COCT..AG.A...	.....A-A			2900
Spneumonise 23S.SEQ	G...T.TG...CA.A.GT...	CG..TAA...	AGCT..AG.A...	.....A-A			2902
SPYoganes 23S.SEQ	G...T.T...A.A.GT...	CG..TAA...	AGCT..AG.A...	.....A-A			2901
Navium 23S.SEQ	G...T...TA...A.CC...	CG..T.C...	CTCG...A.A...				3107
Ntuberculosis 23S.SEQ	G...T...TA...G.GT...	CG..T..G...	COGG...A.A...	.....A-A			3138
Ecoli 23S.SEQ	GTAGCCACGACATGCTGTGAC	TACCGTACTATGACCGTGA	CGCTTAACTT				2903
Kpneumonise 23S.SEQ	.....T.A.T.GT.A...	.....AA...	TOC...A...				2903
Hinfluenzae 23S.SEQ	.....T.A...TA...	.....A...	TOC...	.....T.C.			2897
Bbrochiseptica 23S.SEQ	G...T.A...TA...	.....A...	TOC...	.....G.T.C.			2865
Bparapertussis 23S.SEQ	G...T.A...TA...	.....A...	TOC...	.....G.T.C.			2865
Bportussis 23S.SEQ	G...T.A...TA...	.....A...	TOC...	.....G.T.C.			2864
Bcepacia 23S.SEQ	.....TA...C...	.....T.A...	TOC...	.....G.T.C.			2878
Bmallei 23S.SEQ	.....TA...C...	.....A...	TOC...	.....G.T.C.A			2882
Bpseudomallei 23S.SEQ	.....TA...C...	.....A...	TOC...	.....G.T.C.A			2882
Bgonorrhoeae 23S.SEQ	G...G.TA.C...GA...	.....CA...	TOC...	.....G.T.C.A			2890
Bmeningitidis 23S.SEQ	G...G.TA.C...GA...	.....CA...	TOC...	.....G.T.C.			2891
Bparuginosa 23S.SEQ	.....TT.T.G...	.....A...	TOC...	.....G..A.			2891
Bcholerse 23S.SEQ	.....TT.T.G...	.....T...	TOC...	.....A.			2886
Benterocolitica 23S.SEQ	.....GATTTG...						2906

Decoration 'Decoration #1': Hide (as '.') residues that match Ecoli 23S.SEQ exactly.




FIG. 3




FIG. 4




FIG. 5A




FIG. 5B




FIG. 6A




FIG. 6B






FIG. 7A




FIG. 7B




FIG. 8A




FIG. 8B




FIG. 9A




FIG. 9B

50/54




FIG. 10A




FIG. 10B




FIG. 10C




FIG. 11A



FIG. 11B




FIG. 12A




FIG. 12B




FIG. 13A




FIG. 13B




FIG 14A.




FIG 14B.



## SEQUENCE LISTING

<110> MURPHY, GEORGE L.  
WHITLEY, J. PENN

5 <120> METHOD AND SYSTEM FOR DEPLETING rRNA POPULATIONS

<130> AMBI:076WO

10 <140> UNKNOWN  
<141> 2002-12-20

<150> 10/029,397  
<151> 2001-12-20

15 <160> 92

<170> PatentIn Ver. 2.1

20 <210> 1  
<211> 22  
<212> DNA  
<213> Artificial Sequence

25 <220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

30 <400> 1  
ctgctgcctc ccgtaggagt ct 22

<210> 2  
<211> 23

35 <212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

40 <400> 2  
cgtattaccg cggctgctgg cac 23

45 <210> 3  
<211> 23  
<212> DNA  
<213> Artificial Sequence

50 <220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

55 <400> 3  
cgcccagtaa ttccgattaa cgc 23

5       <210> 4  
      <211> 23  
      <212> DNA  
      <213> Artificial Sequence

10       <220>  
      <223> Description of Artificial Sequence: Synthetic  
          Primer

      <400> 4  
      tggactacca gggatatctaa tcc 23

15       <210> 5  
      <211> 23  
      <212> DNA  
      <213> Artificial Sequence

20       <220>  
      <223> Description of Artificial Sequence: Synthetic  
          Primer

25       <400> 5  
      gggttgcgct cggtgcggga ctt 23

30       <210> 6  
      <211> 23  
      <212> DNA  
      <213> Artificial Sequence

35       <220>  
      <223> Description of Artificial Sequence: Synthetic  
          Primer

40       <400> 6  
      taaggaggtg atccaaccgc agg 23

45       <210> 7  
      <211> 23  
      <212> DNA  
      <213> Artificial Sequence

50       <220>  
      <223> Description of Artificial Sequence: Synthetic  
          Primer

      <400> 7  
      ggttcttttt cactcccctc gcc 23

55       <210> 8  
      <211> 23

<212> DNA  
<213> Artificial Sequence

5 <220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

10 <400> 8  
gacccattat acaaaaggta cgc 23

15 <210> 9  
<211> 23  
<212> DNA  
<213> Artificial Sequence

20 <220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

<400> 9  
gccccgttac atcttccgcg cag 23

25 <210> 10  
<211> 23  
<212> DNA  
<213> Artificial Sequence

30 <220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

35 <400> 10  
cgacaaggaa ttctgctacc tta 23

40 <210> 11  
<211> 22  
<212> DNA  
<213> Artificial Sequence

45 <220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

50 <400> 11  
cttaccgcgac aaggaatttc gc 22

55 <210> 12  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Primer

5 <400> 12  
gagccgacat cgaggtgcc aac 23

10 <210> 13  
<211> 21  
<212> DNA  
<213> Artificial Sequence

15 <220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

20 <400> 13  
ggttaagcct cacggttcat t 21

25 <210> 14  
<211> 14  
<212> DNA  
<213> Artificial Sequence

30 <220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

35 <400> 14  
ggaagcgcac ggca 14

40 <210> 15  
<211> 23  
<212> DNA  
<213> Artificial Sequence

45 <220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

50 <400> 15  
ccccttctcc cgaagttacg ggg 23

55 <210> 16  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

<400> 16

gtgagctatt acgctttctt t 21

5 <210> 17  
<211> 23  
<212> DNA  
<213> Artificial Sequence

10 <220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

15 <400> 17  
taccggccgt gcgtacttag aca 23

20 <210> 18  
<211> 23  
<212> DNA  
<213> Artificial Sequence

25 <220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

30 <400> 18  
tgccctccaa tggatcctcg tta 23

35 <210> 19  
<211> 23  
<212> DNA  
<213> Artificial Sequence

40 <220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

45 <400> 19  
ctacggaaac cttgttacga ctt 23

50 <210> 20  
<211> 23  
<212> DNA  
<213> Artificial Sequence

55 <220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

<400> 20  
gagcactggg cagaaatcac atc 23

<210> 21

<211> 23  
 <212> DNA  
 <213> Artificial Sequence

5 <220>  
 <223> Description of Artificial Sequence: Synthetic  
 Primer

<400> 21  
 10 gtttcttttc ctccgctgac taa 23

<210> 22  
 <211> 23  
 15 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 20 Primer

<400> 22  
 tcctcagcca agcacatata cca 23

25 <210> 23  
 <211> 1427  
 <212> DNA  
 <213> Bacillus subtilis

30 <220>  
 <221> modified\_base  
 <222> (554)..(873)  
 <223> N = A, C, G or T/U

35 <400> 23  
 gagagtttga tcctggctca ggacgaacgc tggcggcgtg cctaatacat gcaagtcgag 60  
 cggacagatg ggaacttgct ccctgatgtt agcggcggac gggtgagtaa cacgtgggta 120  
 40 acctgcctgt aagactggga taactccggg aaaccggggc taataccgga tggttgtttg 180  
 aaccgcatgg ttcaaacata aaaggtggct tcggctacca cttacagatg gaccgcggc 240  
 gcattagcta gttggtgagg taacggctca ccaaggcaac gatgcgtagc cgacctgaga 300  
 gggatgatcg ccacactggg actgagacac ggcccagact cctacgggag gcagcagtag 360  
 ggaatcttcc gcaatggacg aaagtctgac ggagcaacgc cgcgtgagtg atgaaggttt 420  
 tcggatcgta aagctctgtt gttagggaag aacaagtacc gttcgaatag ggcggtacct 480  
 45 tgacgggtacc taaccagaaa gccacggcta actacgtgcc agcagccgcg gtaatacgta 540  
 ggtggcaagc gttntccgga attattgggc gtaaagggct cgcaggcggg ttcttaagtc 600  
 tgatgtgaaa gccccgggct caaccgggga gggtcattgg aaactgggga acttgagtgc 660  
 agaagaggag agtggaaattc cacgtgtngc ggtgaaatgc gtagagatgt ggaggaacac 720  
 cagtggcgaa ggcgactctc tggctctgta ctgacgctga ggagcgaaag cgtggggagc 780  
 50 gaacaggatt agataccctg gtagtccacg ccgtaaacga tgagtgctaa gtgttagggg 840  
 gtttccgccc cttagtgtct cagtaacgca tttagcactc cgcctgggga gtacggtcgc 900  
 aagactgaaa ctcaaaggaa ttgacggggg ccgcacaagc ggtggagcat gtggtttaat 960  
 tcgaagcaac gcgaagaacc ttaccaggtc ttgacatcct ctgacaatcc tagagatagg 1020  
 acgtcttcgg gggcagagtg acaggtggtg catggttgct gtcagctcgt gtcgtgagat 1080  
 55 gttgggttaa gtcccgaac gagcgcaacc ctggatctta gttgccagca ttcagttggg 1140  
 cactctaagg tgactgcccg tgacaaaacc gaggaagggt gggatgacgt caaatcatca 1200

5      tgcccccttat   gacctgggct   acacacgtgc   tacaatggac   agaacaaagg   gcagcgaaac   1260  
       cgcgagggtta   agccaatccc   acaaatctgt   tctcagttcg   gatcgcagtc   tgcaactcga   1320  
       ctgctgtgaag   ctggaatcgc   tagtaatcgc   ggatcagcat   gccgcggtga   atacgttccc   1380  
       gggccttgta   cacaccgccc   gtcacaccac   gagagtttgt   aacacccc   1427

10      <210> 24  
       <211> 1544  
       <212> DNA  
       <213> *Bacillus anthracis*

15      <400> 24  
       gtttgatcct   ggctcaggat   gaacgctggc   ggctgacct   atacatgcaa   gtcgagcgaa   60  
       tggaattaaga   gcttgctcct   atgaagttag   cggcgagcgg   gtgagtaaca   cgtgggtaac   120  
       ctgcccataa   gactgggata   actccgggaa   accggggcta   ataccggata   acattttgaa   180  
       ccgcatgggt   cgaaattgaa   aggcggcttc   ggctgtcact   tatggatgga   cccgcgtcgc   240  
       attagctagt   tgggtgaggt   acggctcacc   aaggcaacga   tgcgtagccg   acctgagagg   300  
       gtgatcggcc   acactgggac   tgagacacgg   cccagactcc   tacgggaggg   agcagtaggg   360  
       aatcttccgc   aatggacgaa   agtctgacgg   agcaacgccg   cgtgagtgat   gaaggctttc   420  
 20      gggtcgtaaa   actctgttgt   tagggaagaa   caagtgtctg   ttgaataagc   tggcaccttg   480  
       acgggtaccta   accagaaagc   cacggctaac   tacgtgccag   cagccgcggg   aatacgtagg   540  
       tggcaagcgt   tatccggaat   tattgggcgt   aaagcgcgcg   caggtgggtt   cttaagtctg   600  
       atgtgaaagc   ccacggctca   accgtggagg   gtcattggaa   actgggagac   ttgagtgcag   660  
       aagaggaaag   tggaaattcca   tgtgtagcgg   tgaatatgct   agagatatgg   aggaacacca   720  
 25      gtggcgaaag   cgactttctg   gtctgtaact   gacactgagg   cgcgaaagcg   tggggagcaa   780  
       acaggattag   ataccctggt   agtccacgcc   gtaaaccgat   agtgctaagt   gttagagggt   840  
       ttccgcctct   tagtgctgaa   gttaacgcat   taagcactcc   gcctggggag   tacggccgca   900  
       aggctgaaac   tcaaaggaat   tgacgggggc   ccgcacaagc   ggtggagcat   gtggtttaat   960  
       tcgaagcaac   gcgaagaacc   ttaccaggct   ttgacatcct   ctgacaacc   tagagatagg   1020  
 30      gcttctcctt   cgggagcaga   gtgacagggt   gtgcatgggt   gtcgtcagct   cgtgtcgtga   1080  
       gatgttggtt   taagtccgcg   aacgagcgca   acccttgatc   ttagtgtcca   tcattaagtt   1140  
       gggcactcta   aggtgactgc   cggtgacaaa   ccggaggaag   gtggggatga   cgtcaaatca   1200  
       tcatgcccct   tatgacctgg   gctacacacg   tgctacaatg   gacggtacaa   agagctgcaa   1260  
       gacgcgagg   tggagctaat   ctcataaaac   cgttctcagt   tcggattgta   ggctgcaact   1320  
 35      cgctacatg   aagctggaat   cgctagtaat   cgcggatcag   catgccgcgg   tgaatacgtt   1380  
       cccgggcctt   gtacacaccg   cccgtcacac   cacgagagtt   tgtaacaccc   gaagtcgggt   1440  
       gggtaacctt   tttggagcca   gccgcctaag   gtgggacaga   tgattggggg   gaagtcgtaa   1500  
       caaggtagcc   gtatcggaag   gtgcggctgg   atcacctcct   ttct   1544

40      <210> 25  
       <211> 1449  
       <212> DNA  
       <213> *Enterococcus faecalis*

45      <400> 25  
       cgaacgctgg   cggcgtgcct   aatacatgca   agtcgaacgc   ttcttttctc   ccgagtgtct   60  
       gcactcaatt   ggaaagagga   gtggcggacg   ggtgagtaac   acgtgggtaa   cctaccatc   120  
       agagggggat   aacacttgga   aacagggtgt   aataccgcat   aacagtttat   gccgcattgg   180  
 50      ataagagtga   aaggcgcttt   cgggtgtcgc   tgatggatgg   acccgcggtg   cattagctag   240  
       ttggtgaggt   aacggctcac   caaggccacg   atgcatagcc   gacctgagag   ggtgatcggc   300  
       cacactggga   ctgagacacg   gccagactc   ctacgggagg   cagcagtagg   gaatcttcgg   360  
       caatggacga   aagtctgacc   gagcaacgcc   gcgtgagtga   agaaggtttt   cggatcgtaa   420  
       aactctgttg   ttagagaaga   acaaggacgt   tagtaactga   acgtcccctg   acggtatcta   480  
 55      accagaaagc   cacggctaac   tacgtgccag   cagccgcggg   aatacgtagg   tggcaagcgt   540  
       tgtccggatt   tattgggcgt   aaagcgagcg   caggcgggtt   cttaagtctg   atgtgaaagc   600

```

ccccggetca accggggagg gtcattggaa actgggagac ttgagtgcag aagaggagag 660
tggaattcca tgtgtagcgg tgaaatgcgt agatatatgg aggaacacca gtggcgaagg 720
cggtctctctg gtctgtaact gacgctgagg ctcgaaagcg tggggagcaa acaggattag 780
5 ataccctgggt agtccacgcc gtaaaccgat agtgctaagt gttggagggt ttccgccctt 840
cagtgctgca gcaaacgcat taagcactcc gcctggggag tacgaccgca aggttgaaac 900
tcaaaggaat tgacgggggc ccgcacaagc ggtggagcat gtggtttaat tcgaagcaac 960
gcgaagaacc ttaccaggtc ttgacatcct ttgaccactc tagagataga gctttccctt 1020
cggggacaaa gtgacagggt gtgcattggt gtcgtcagct cgtgctgta gatgttgggt 1080
10 taagtcccg c aacgagcgca acccttattg ttagtggcca tcatttagtt gggcactcta 1140
gcgagactgc cggtgacaaa ccggaggaag gtggggatga cgtcaaatca tcatgcccct 1200
tatgacctgg gctacacacg tgctacaatg gaagtacaa cgagtcgcta gaccgcgagg 1260
tcatgcaaat ctcttaaacg ttctctcagt tcaggattgca ggctgcaact cgctgcactt 1320
aagccggaat cgctagtaat cgcggatcag cagcccgcg tgaatacgtt cccggggcctt 1380
15 gtacacaccg cccgtcacac cacgagagtt tgtaacaccc gaagtcggtg aggtaacctt 1440
tttgagacc 1449

```

```

<210> 26
<211> 1548
20 <212> DNA
    <213> Lactococcus lactis

```

```

<400> 26
25 tttatttgag agtttgatcc tggctcagga cgaacgctgg cggcgtgcct aatacatgca 60
    agttgagcgc tgaagggttg tacttgtacc gactggatga gcagcgaacg ggtgagtaac 120
    gcgtggggaa tctgcctttg agcgggggac aacatttgga aacgaatgct aataccgcat 180
    aaaaacttta aacacaagtt ttaagtttga aagatgcaat tgcatactc aaagatgatc 240
    ccgcgttgta ttagctagtt ggtgaggtta aggctacca aggcgatgat acatagccga 300
    cctgagaggg tgatcggcca cattgggact gagacacggc ccaaactcct acgggaggca 360
30 gcagtaggga atcttcggca atggacgaaa gtctgaccga gcaacgccgc gtgagtgaag 420
    aagggttttcg gatcgtaaaa ctctgttggt agagaagaac gttggtgaga gtggaaagct 480
    catcaagtga cggtaactac ccagaaaggg acggctaact acgtgccagc agccgcggta 540
    atacgtaggt cccgagcggt gtccggattt attgggcgta aagcgagcgc aggtggttta 600
    ttaagtcctg tgtaaaaggc agtggctcaa ccattgtatg cattggaaac tggtagactt 660
35 gagtgcagga gaggagagtg gaattccatg tgtagcgggt aaatgcgtag atatatggag 720
    gaacaccggt ggcgaaagcg gctctctggc ctgtaactga cactgaggct cgaaagcggt 780
    gggagcaaac aggattagat accctggtag tcacgcgct aaacgatgag tgctagatgt 840
    agggagctat aagttctctg tatcgagct aacgcaataa gcaactccgc tggggagtac 900
    gaccgcaagg ttgaaactca aaggaattga cggggggccc cacaagcggg ggagcatgtg 960
40 gtttaattcg aagcaacgcg aagaacctta ccaggtcttg acatactcgt gctattccta 1020
    gagataggaa gttcccttcg gacacgggat acaggtggtg catggttgct gtcagctcgt 1080
    gtcgtgagat gttgggttaa gtcccgaac gagcgcaacc cctattgtta gttgccatca 1140
    ttaagttggg cactctaacg agactgccgg tgataaacg gaggaagggt gggatgacgt 1200
    caaatcatca tgccccttat gacctgggct acacacgtgc tacaatggat ggtacaacga 1260
45 gtcgcgagac agtgatgttt agctaattct ttaaaacat tctcagttcg gattgtaggc 1320
    tgcaactcgc ctacatgaag tcggaatcgc tagtaatcgc ggatcagcac gccgcgggtg 1380
    atacgttccc gggccttgta cacaccgcc gtcacaccac gggagttggg agtaccgaa 1440
    gtaggttgcc taaccgaag gagggcgctt cctaaggtta gaccgatgac tggggtgaag 1500
50 tcgtaacaag gtagccgtat cggaagggtg ggctggatca cctccttt 1548

```

```

<210> 27
<211> 1524
<212> DNA
55 <213> Listeria monocytogenes

```



<400> 27

	gcctgcaggt	cgacaacaga	gtttgatcat	ggctcaggac	gaacgctggc	ggcgtgccta	60
	atacatgcaa	gtcgaacgaa	cggaggaaga	gcttgctctt	ccaaagttag	tggcggacgg	120
5	gtgagtaaca	cgtgggcaac	ctgcctgtaa	gttggggata	actccgggaa	accgggggcta	180
	ataccgaatg	ataaagtgtg	gcgcatgccca	cgcttttgaa	agatggtttc	ggctatcgct	240
	tacagatggg	cccgcggtgc	attagctagt	tggtagggtta	atggcctacc	aaggcaacga	300
	tgcatagccg	acctgagagg	gtgatcggcc	acactgggac	tgagacacgg	cccagactcc	360
	tacgggaggc	agcagtaggg	aatcttccgc	aatggacgaa	agtctgacgg	agcaacgccg	420
	cgtgtatgaa	gaagggttttc	ggatcgtaaa	gtactgttgt	tagagaagaa	caaggataag	480
10	agtaactgct	tgtcccttga	cggtatctaa	ccagaaagcc	acggctaact	acgtgccagc	540
	agccgcggta	atacgtaggt	ggcaagcggt	gtccggattt	attgggcgta	aagcgcgcgc	600
	agggcgtctt	ttaagtctga	tgtgaaagcc	cccggcttaa	ccggggaggg	tcattggaaa	660
	ctggaagact	ggagtgcaga	agaggagagt	ggaattccac	gtgtagcgg	gaaatgcgta	720
	gatattgtga	ggaacaccag	tggcgaaggc	gactctctgg	tctgtaactg	acgctgaggg	780
15	gcgaaagcgt	ggggagcaaa	caggattaga	taccctggta	gtccacgccg	taaacgatga	840
	gtgctaagtg	ttaggggggtt	tccgccccctt	agtgtgtcag	ctaacgcatt	aagcactctg	900
	cctggggagt	acgaccgcaa	ggttgaaact	caaaggaatt	gacggggggc	cgcacaagcg	960
	tggagcatgt	ggtttaattc	gaagcaacgc	gaagaacctt	accaggtctt	gacatccctt	1020
	gaccactctg	gagacagagc	tttcccttcg	ggacaaagtg	acaggtgggtg	catggttgct	1080
20	gtcagctcgt	gtcgtgagat	gttgggttaa	gtcccgaac	gagcgcgaac	cttgatttta	1140
	gttgccagca	tttagttggg	cactctaaag	tgactgccgg	tgcaagccga	ggaaggtggg	1200
	gatgacgtca	aatcatcatg	ccccttatga	cctgggctac	acacgtgcta	caatggatag	1260
	tacaaagggt	cgcaagccg	cgaggtggag	ctaattccat	aaaactattc	tcagttcggg	1320
	ttgtaggctg	caactcgcct	acatgaagcc	ggaatcgcta	gtaatcggtg	atcagcatgc	1380
25	cacggtgagt	acgttcccgg	gccttgtaca	caccgcccgt	cacaccacga	gagtttgtta	1440
	cacccgaagt	cggtagggtta	acctttatgg	agccagccgc	cgaaggtggg	acagataatt	1500
	ggggtgaagt	cgtaacaagg	taaa				1524

30 <210> 28  
 <211> 1555  
 <212> DNA  
 <213> *Staphylococcus aureus*

35 <400> 28

	ttttatggag	agtttgatcc	tggctcagga	tgaacgctgg	cggcgtgcct	aatacatgca	60
	agtcgagcga	acggacgaga	agcttgcttc	tctgatgtta	gcggcggacg	ggtgagtaac	120
	acgtggataa	cctacctata	agactgggat	aacttcggga	aaccggagct	aataccggat	180
40	aatattttga	accgcatggt	tcaaaagtga	aagacggctc	tgctgtcact	tatagatgga	240
	tccgcgctgc	attagctagt	tggttaaggta	acggcttacc	aaggcaacga	tacgtagccg	300
	acctgagagg	gtgatcggcc	acactggaac	tgagacacgg	tccagactcc	tacgggaggg	360
	agcagtaggg	aatcttccgc	aatgggcaaa	agcctgacgg	agcaacgccg	cgtgagtgtg	420
	gaaggctctt	ggatcgtaaa	actctgttat	tagggaagaa	catatgtgta	agtaactgtg	480
	cacatcttga	cggtaacctaa	tcagaaagcc	acggctaact	acgtgccagc	agccgcggta	540
45	atacgtaggt	ggcaagcggt	atccggaatt	attgggcgta	aagcgcgcgt	aggcggtttt	600
	ttaagtctga	tgtgaaagcc	cacggctcaa	ccgtggaggg	tcattggaaa	ctggaaaact	660
	tgagtgcaga	agaggaaaagt	ggaattccat	gtgtagcgg	gaaatgcgca	gagatatgga	720
	ggaacaccag	tggcgaaggc	gactttctgg	tctgttaact	acgtgatgtg	gcgaaagcgt	780
	ggggatcaaaa	caggattaga	taccctggta	gtccacgccg	ttaaactgta	gtgctaagtg	840
50	ttaggggggtt	tccgccccctt	agtgtgtcag	ctaacgcatt	aagcactccg	cctggggagt	900
	acgaccgcaa	ggttgaaact	caaaggaatt	gacggggacc	cgcacaagcg	gtggagcatg	960
	tggtttaatt	cgaagcaacg	cgaagaacct	taccaaactt	tgacatcctt	tgacaactct	1020
	agagatagag	ccttccccctt	cgggggacaa	agtgacaggt	ggtgcatggt	tgctgtcagc	1080
	tcgtgtcgtg	agatgttggg	ttaagtcccg	caacgagcgc	aacccttaag	cttagttgcc	1140
55	atcattaagt	tgggcactct	aagttgactg	ccggtgacaa	accggaggaa	ggtggggatg	1200
	acgtcaaatc	atcatgcccc	ttatgatttg	ggctacacac	gtgctacaat	ggacaataca	1260

aagggcagcg aaaccgcgag gtcaagcaaa tcccataaag ttgttctcag ttcggattgt 1320  
 agtctgcaac tcgactacat gaagctggaa tcgctagtaa tcgtagatca gcatgctacg 1380  
 gtgaatacgt tcccgggtat tgtacacacc gcccgtcaca ccacgagagt ttgtaacacc 1440  
 cgaagccggt ggagtaacct tttaggagct agccgtcgaa ggtgggacaa atgattgggg 1500  
 5 tgaagtcgta acaaggtagc cgtatcggaa ggtgcggctg gatcacctcc tttct 1555

<210> 29  
 <211> 1551  
 10 <212> DNA  
 <213> *Streptococcus mutans*

<400> 29  
 15 agagtttgat cctggctcag gacgaacgct ggcggcgtgc ctaatacatg caagtgggac 60  
 gcaaggaaac acactgtgct tgcacaccgt gttttcttga gtcgcaacg ggtgagtaac 120  
 gcgtaggtaa cctgcctatt agcgggggat aactattgga aacgatagct aataccgcat 180  
 aatattaatt attgcatgat aattgattga aagatgcaag cgcataccta gtagatggac 240  
 ctgcgttgta ttagctagtt ggtaaggtaa gagcttacca aggcgacgat acatagccga 300  
 20 cctgagaggg tgatcgcca cactgggact gagacacggc ccagactcct acgggaggca 360  
 gcagtaggga atcttcggca atggacgaaa gtctgaccga gcaacgccgc gtgagtgaag 420  
 aaggttttcg gatcgtaaag ctctgttgta agtcaagaac gtgtgtgaga gtggaaagtt 480  
 cacacagtga cggtagctta ccagaaaggg acggctaact acgtgccagc agccgcggta 540  
 atacgtaggt cccgagcgtt gtccggattt attgggctga aaggagcgc aggcggctcag 600  
 gaaagtctgg agtaaaaggc tatggctcaa ccatagtgtg ctctggaaac tgtctgactt 660  
 25 gagtgcagaa ggggagagtg gaattccatg ttagcgggtg aaatgcgtag atatatggag 720  
 gaacaccagt ggcgaaagcg gctctctggt ctgtcactga cgtgaggct cgaaagcgtg 780  
 ggtagcgaa accgattagat accctggtag tccacgccgt aaacgatgag tgctagggtg 840  
 taggcccttt ccggggctta gtgccggagc taacgcaata agcactccgc ctggggagta 900  
 cgaccgcaag gttgaaactc aaaggaattg acggggggcc gcacaagcgg tggagcatgt 960  
 30 ggtttaattc gaagcaacgc gaagaacctt accaggtctt gacatcccga tgctattctt 1020  
 agagatagga agttacttcg gtacatcgga gacaggtggt gcatggttgt cgtcagctcg 1080  
 tgctgtgaga tggtgggtta agtcccgcaa cgagcgcaac ccttattggt agttgccatc 1140  
 attaatgttg gcactctagc gagactggcg gtaataaacc ggaggaaggt ggggatgacg 1200  
 tcaaatcatc atgcccctta tgacctgggc tacacacgtg ctacaatggt cggtaacaacg 1260  
 35 agttgcgagc cggtgacggc aagctaactc ctgaaagccg atctcagttc ggattggagg 1320  
 ctgcaactcg cctccatgaa gtccgaatcg ctagtaatcg cggatcagca cgccgcgggtg 1380  
 aatacgttcc cgggccttgt acacaccgcc cgtcacacca cgagagtttg taacaccgga 1440  
 agtcgggtgag gtaacctttt aagggccaa cgcctaagg tgggatggat gattgggggtg 1500  
 40 aagtcgtaac aaggtagccg tatcggaagg tgcggctgga tcacctcctt t 1551

<210> 30  
 <211> 1515  
 <212> DNA  
 45 <213> *Streptococcus pneumoniae*

<400> 30  
 50 atttgatcct ggctcaggac gaacgctggc ggcgtgccta atacatgcaa gtagaacgct 60  
 gaaggaggag cttgcttctc tggatgagtt gcgaacgggt gagtaacgcg taggtaacct 120  
 gcctggtagc gggggataac tattggaaac gatagctaata accgcataag agtggatgtt 180  
 gcatgacatt tgcttaaaag gtgcacttgc atcactacca gatggacctg cgttgtatta 240  
 gctagttggt ggggtaacgg ctcaccaagg cgacgataca tagccgacct gagaggggtga 300  
 tcggccacac tgggactgag acacgkccca gactcctacg ggaggcagca gtaggggaatc 360  
 55 ttccggcaatg gacggaagtc tgaccgagca acgcccgtg agtgaagaag gttttcggat 420  
 cgtaaagctc tggtgtaaga gaagaacgag tgtgagagt gaaagttcac actgtgacgg 480  
 tatcttacca gaaagggacg gctaactacg tgccagcagc cgcggaataa cgtaggtccc 540

5	gagcgttgtc	cggatttatt	gggcgtaaag	cgagcgcagg	cggttagata	agtctgaagt	600
	taaaggctgt	ggcttaacca	tagtaggctt	tggaaactgt	ttaacttgag	tgcaagaggg	660
	gagagtggaa	ttccatgtgt	agcggtgaaa	tgcgtagata	tatggaggaa	caccgggtggc	720
	gaaagcggct	ctctggcttg	taactgacgc	tgaggctcga	aagcgtgggg	agcaaacagg	780
	attagatacc	ctggtagtcc	acgctgtaaa	cgatgagtgc	taggtgttag	accctttccg	840
10	gggttagtg	ccgtagctaa	cgcattaagc	actccgcctg	gggagtagca	ccgcaaggtt	900
	gaaactcaga	ggaattgacg	ggggcccgca	caagcgggtg	agcatgtggt	ttaattcgaa	960
	gaacacgcga	gaaccttacc	aggtcttgac	atccctctga	ccgctctaga	gatagagttt	1020
	tccttcggga	cagaggtgac	aggtggtgca	tggttgctgt	cagctcgtgt	cgtgagatgt	1080
	tgggttaagt	cccgcacga	gcgcaacccc	tattgttagt	tgccatcatt	cagttgggca	1140
15	ctctagcgag	actgccggta	ataaacggga	ggaaggtggg	gatgacgtca	aatcatcatg	1200
	ccccttatga	cctgggctac	acacgtgcta	caatggctgg	tacaacgagt	cgcaagccgg	1260
	tgacggcaag	ctaatactctt	aaagccagtc	tcagttcgga	ttgtaggctg	caactcgctt	1320
	acatgaagtc	ggaatcgcta	gtaatcgcg	atcagcacgc	cgcgggtgaat	acgttcccgg	1380
	gccttgtaca	caccgcccg	cacaccacga	gagtttgtaa	caccgaagt	cggtgaggt	1440
	accgtaagga	gccagccgcc	taaggtggga	tagatgattg	gggtgaagtc	gtaacaaggt	1500
	cagccgtttg	ggaga					1515

```
20  <210> 31
    <211> 1335
    <212> DNA
    <213> Streptococcus pyogenes
```

[illegible]

```

50      <210> 32
        <211> 1465
        <212> DNA
        <213> Mycobacterium avium
55      <220>

```

<221> modified\_base

<222> (298)..(881)

<223> N = A, C, G or T/U

5 <400> 32  
ggcggcggtgc ttaacacatg caagtcgaac ggaaaggcct cttcggagggt actcagagtgg 60  
cgaacgggtg agtaacacgt gggcaatcta ccctgcactt cgggataagc ctgggaaact 120  
gggtctaata ccggatagga cctcaagacg catgtcttct ggtggaaagc ttttgcggtg 180  
tgggatgggc ccgcggccta tcagcttggt ggtgggggtga cggcctacca aggcgacgac 240  
10 gggtagccgg cctgagaggg tgtccggcca cactgggact gagatacggc ccagactnct 300  
acgggaggca gcagtgggga atattgcaca atgggcgcaa gcctgatgca gcgacgccgc 360  
gtgggggatg acggccttcg ggttgtaaac ctctttcacc atcgacgaag gtccgggttt 420  
tctcggattg acggtaggtg gagaagaagc accggccaac tacgtgccag cagccgagggt 480  
aatacgtagg gtgcgagcgt tgtccggaat tactgggcgt aaagagctcg taggtgggtt 540  
15 gtcgcgttgt tcgtgaaatc tcacggctta actgtgagcg tgcgngcgat acgggcagac 600  
tagagtactg caggggagac tggaaatcct ggtgtagcgg tggaaatgcgc agatatcagg 660  
aggaacaccg gtggcggaagg cgggtctctg gccagtaact gacgtgagg agcgaaagcg 720  
tggggagcga acaggattag ataccctggt agtccacgnc gtaaacgggtg ggtactaggt 780  
gtgggttttc ttccttgga tccgtgccgt agctaacgca ttaagtacct cgcctgggga 840  
20 gtacggnccg aaggctaata ctcaaaggaa ttgacggggg nccgcacaag cggcggagca 900  
tgtggattaa ttcgatgcaa cgcgaagaac cttacctggg tttgacatgc acaggacgcg 960  
tctagagata ggcgttcctt tgtggcctgt gtgcagggtg tgcattgctg tcgtcagctc 1020  
gtgtcgtgag atgttggtt aagtcccgcg acgagcgcaa cccttgctc atgttgccag 1080  
cgggtaatgc cggggactcg tgagagactg ccgggggtcaa ctcgagggaa ggtggggatg 1140  
25 acgtcaagtc atcatgcccc ttatgtccag ggcttcacac atgctacaat ggccggtaca 1200  
aagggtgctg atgcgctaag gttaagcgaa tctttttaa gccggtctca gttcggattg 1260  
gggtctgcaa ctcgacccca tgaagtcgga gtgcctagta atcgagatc agcaacgctg 1320  
cgtgtaatac gttcccggtc cttgtacaca ccgcccgtca cgtcatgaaa gtcggtaaca 1380  
cccgaagcca gtggcctaac ccttttgga gggagctgtc gaagggtgga tcggcgattg 1440  
30 ggacgaagtc gtaacaaggt agccg 1465

<210> 33

<211> 1536

35 <212> DNA

<213> Mycobacterium tuberculosis

<400> 33  
40 tttgtttgga gagtttgatc ctggctcagg acgaacgctg gcggcggtgt taacacatgc 60  
aagtcgaacg gaaagggtctc ttcggagata ctcgagtggc gaacgggtga gtaacacgtg 120  
ggtgatctgc cctgcacttc gggataagcc tgggaaactg ggtctaatac cggataggac 180  
cacgggatgc atgtcttggt gtgaaagcg ctttagcggt gtgggatgag cccgcggcct 240  
atcagcttgt tgggtgggtg acggcctacc aaggcgacga cgggtagccg gcctgagagg 300  
gtgtccggcc aactggggac tgagatacgg ccagactcc tacgggaggc agcagtgggg 360  
45 aatattgcac aatgggcgca agcctgatgc agcgacgccg cgtgggggat gacggccttc 420  
gggttgtaaa ctcttttcac catcgacgaa ggtccgggtt ctctcggatt gacggtaggt 480  
ggagaagaag caccggccaa ctacgtgccg gcagccgagg taatacgtag ggtgcgagcg 540  
ttgtccggaa ttactgggag taaagagctc tagggtggtt tgtcgcgttg ttcgtgaaat 600  
ctcacggctt aactgtgagc gtgcgggcga tacgggcaga cttagagtact gcaggggaga 660  
50 ctggaatttc tgggtgtagc gtggaatgcg cagatatcag gaggaacacc ggtggcgaa 720  
gcgggtctct gggcagtaac tgacgtgag gagcgaaagc gtggggagcg aacaggatta 780  
gataccctgg tagtccacgc cgtaaacggg ggtactagg tgtgggtttc cttccttggg 840  
atcctgtgcc tagctaacgc attaagtacc ccgctgggg agtacggccg caaggctaaa 900  
actcaaagga attgacgggg gcccgacaa gcggcgagc atgtggatta attcgatgca 960  
55 acgcgaagaa ccttacctgg gtttgacatg cacaggacgc gtctagagat aggcgttccc 1020  
ttgtggcctg tgtgcagggt gtgcattggct gtcgtcagct cgtgtcgtga gatgttgggt 1080

taagtcccg aacgagcgca acccttgtct catgttgcca gcacgtaatg gtggggactc 1140  
 gtgagagact gccggggtca actcggagga aggtggggat gacgtcaagt catcatgccc 1200  
 cttatgtcca gggcttcaca catgctacaa tggccgggtac aaagggctgc gatgccgcga 1260  
 5 gggttaagcga atccttaaaa gccggtctca gttcggatcg gggctctgcaa ctcgaccccc 1320  
 tgaagtcgga gtcgctagta atcgcagatc agcaacgctg cgggtgaatac gttccccggc 1380  
 cttgtacaca ccgcccgtca cgtcatgaaa gtcggtaaca cccgaagcca gtggcctaac 1440  
 cctcgggagg gagctgtcga aggtgggatc ggcgattggg acgaagtcgt aacaaggtag 1500  
 ccgtaccgga aggtgcggct ggatcacctc ctttct 1536

10 <210> 34  
 <211> 1536  
 <212> DNA  
 <213> Escherichia coli

15 <400> 34  
 tttgtttgga gagtttgatc ctggctcagg acgaacgctg gcggcggtgct taacacatgc 60  
 aagtccaacg gaaaggtctc ttcggagata ctcgagtggc gaacgggtga gtaacacgtg 120  
 ggtgatctgc cctgcacttc gggataagcc tgggaaactg ggtctaatac cggataggac 180  
 20 caccggatgc atgtcttggt gtggaagcgc ctttagcggg gtgggatgag cccgcggcct 240  
 atcagcttgt tgggtgggtg acggcctacc aaggcgacga cgggtagccg gcctgagagg 300  
 gtgtccggcc acactgggac tgagatacgg cccagactcc tacgggaggc agcagtgggg 360  
 aatattgcac aatggggcga agcctgatgc agcgacgccg cgtgggggat gacggccttc 420  
 gggttgtaaa cctctttcac catcgacgaa ggtccgggtt ctctcggatt gacggtaggt 480  
 25 ggagaagaag caccggccaa ctacgtgccg gcagccggcg taatacgtag ggtgcgagcg 540  
 ttgtccggaa ttactgggcg taaagagctc gtaggtggtt tgcgcgctg ttcgtgaaat 600  
 ctcacggctt aactgtgagc gtgcgggcca tacgggcaga cttaggtact gcaggggaga 660  
 ctggaattcc tgggtgtagc gtggaatgcg cagatatcag gaggaacacc ggtggcgaag 720  
 gcgggtctct gggcagtaac tgacgctgag gagcgaaagc gtggggagcg aacaggatta 780  
 30 gataccctgg tagtccacgc cgtaaagcgt gggtagtagg tgtgggtttc cttccttggg 840  
 atccgtgccg tagctaacgc attaatgacc ccgcctgggg agtacggccg caaggctaaa 900  
 actcaaagga attgacgggg gcccgacaaa gcggcgaggc atgtggatta attcgatgca 960  
 acgcgaagaa ccttacctgg gtttgacatg cacaggacgc gtctagagat aggcgttccc 1020  
 ttgtggcctg tgtgcaggtg gtgcaggtc gtcgtcagct cgtgtcgtga gatgttgggt 1080  
 35 taagtcccg aacgagcgca acccttgtct catgttgcca gcacgtaatg gtggggactc 1140  
 gtgagagact gccggggtca actcggagga aggtggggat gacgtcaagt catcatgccc 1200  
 cttatgtcca gggcttcaca catgctacaa tggccgggtac aaagggctgc gatgccgcga 1260  
 gggttaagcga atccttaaaa gccggtctca gttcggatcg gggctctgcaa ctcgaccccc 1320  
 tgaagtcgga gtcgctagta atcgcagatc agcaacgctg cgggtgaatac gttccccggc 1380  
 40 cttgtacaca ccgcccgtca cgtcatgaaa gtcggtaaca cccgaagcca gtggcctaac 1440  
 cctcgggagg gagctgtcga aggtgggatc ggcgattggg acgaagtcgt aacaaggtag 1500  
 ccgtaccgga aggtgcggct ggatcacctc ctttct 1536

45 <210> 35  
 <211> 1534  
 <212> DNA  
 <213> Klebsiella pneumoniae

50 <220>  
 <221> modified\_base  
 <222> (11)..(12)  
 <223> N = A, C, G or T/U

55 <400> 35  
 agagtttgat nntggctcag attgaacgct ggcggcaggc ctaacacatg caagtcgagc 60

```

5  ggtagcacag agagcttgct ctcgggtgac gagcggcgga cgggtgagta atgtctggga 120
   aactgcctga tggaggggga taactactgg aaacggtagc taataccgca taacgtcgca 180
   agaccaaagt gggggacctt cgggcctcat gccatcagat gtgcccagat gggattagct 240
   agtaggtggg gtaacggctc acctaggcga cgatccctag ctggtctgag aggatgacca 300
10 gccacactgg aactgagaca cgggtccagac tcctacggga ggcagcagtg gggaatattg 360
   cacaatgggc gcaagcctga tgcagccatg ccgcgtgtgt gaagaaggcc ttcgggttgt 420
   aaagcacttt cagcggggag gaaggcgatg aggttaataa cctcatcgat tgacgttacc 480
   ctgcagaaga agcaccggct aactccgtgc cagcagccgc ggtataacgg agggtgcaag 540
   cgttaatcgg aattactggg cgtaaagcgc acgcaggcgg tctgtcaagt cggatgtgaa 600
15 atccccgggc tcaacctggg aactgcattc gaaactggca ggctagagtc ttgtagaggg 660
   gggtagaatt ccagggtgtag cggtgaaatg cgtagagatc tggaggaata ccggtggcga 720
   aggcgggccc ctggacaaaag actgacgctc aggtgcgaaa gcgtggggag caaacaggat 780
   tagataccct ggtagtccac gccgtaaacg atgtcgattt ggaggttgtg cccttgaggc 840
   gtggcttccg gagctaacgc gttaaatcga ccgcctgggg agtacggccg caagggtaaa 900
15 actcaaataa attgacgggg gccgcacaa gcggtggagc atgtggttta attcgatgca 960
   acgcgaagaa ccttacctgg tcttgacatc cacagaactt tccagagatg gattgggtgc 1020
   ttcgggaact gtgagacagg tgctgcattg ctgtcgtcag ctcgtgttgt gaaatgttgg 1080
   gttaagtccc gcaacgagcg caacccttat cctttgttgc cagcggttag gccgggaact 1140
   caaaggagac tgccagtgat aaactggagg aaggtgggga tgacgtcaag tcatcatggc 1200
20 ccttacgacc agggctacac acgtgctaca atggcatata caaagagaag cgacctcgcg 1260
   agagcaagcg gacctcataa agtatgtcgt agtccggatt ggagtctgca actcgactcc 1320
   atgaagtcgg aatcgctagt aatcgtagat cagaatgcta cggatgaata gttcccgggc 1380
   cttgtacaca ccgcccgtca caccatggga gtgggttgca aaagaagtag gtagcttaac 1440
   cttcggggagg gcgcttacca ctttgtgatt catgactggg gtgaagtcgt aacaaggtaa 1500
25 ccgtagggga acctgcgggtt ggatcacctc cttt 1534

```

```

<210> 36
<211> 1485
30 <212> DNA
   <213> ACTINOBACCILUS ACTIN

```

```

<220>
<221> modified_base
35 <222> (208)..(1476)
   <223> N = A, C, G or T/U

```

```

<400> 36
40 attgaagagt ttgatcatgg ctcagattga acgctggcgg caggcttaac acatgcaagt 60
   cggacggtag caggagaaaag cttgctttct tgctgacgag tggcgggacg gtgagtaatg 120
   cttgggaatc tgtcttatgg agggggataa cgacgggaaa ctgtcgctaa taccgcgtag 180
   agtcgggaga cgaaagtgcg ggactttntg gccgcattgc atgagatgag cccaagtgtg 240
   attaggtagt tgggtgggga aaggcctacc aagccgacga tcgctagctg gtctgagagg 300
   atggccagcc acaccgggac tgagacacgg ccngactcc tacgggaggc agcagtgagg 360
45 aatattgcgc aatgggggca accctgacgc agccatgccg cgtgaatgaa gaaggccttc 420
   gggttgtaaa gttctttcgg tattgaggaa ggttgggtgt ttaatagcat gccaaattga 480
   cgttaaatca agaagaagca ccggtctaac ccgtgccagc agcccggtga atacgggggg 540
   tgcgagcgtt aatcggaata actgggcgta aagggcacgt aggcggacct ttaagtggag 600
   tgtgaaatcc ccgggcttaa cctgggnatt gcatttcata ctgggggtct ggagtacttt 660
50 ngggagggnt agaattccac gtgtagcggt gaaatgcgta gagatgtgga ggaataaccg 720
   aggcgaaggg agccccttgg ggatgtactg acgctgatgt gcgaaagcgt ggggagcaaa 780
   caggattaga taccctggta gtccacgctg taaacgggtg cgatttgggg attggggttt 840
   agccctggtg cccgaagcta acgtgataaa tcgaccgcct ggggagtagc gccgcaaggt 900
   taaaactcaa atgaattgac gggggcccgc acaagcgtg gagcatgtgg tttaattcga 960
55 tgcacacgca agaaccttac ctactcttga catccgaaga agaactcaga gatgggtttg 1020
   tgccttaggg agctttgaga cagggtgctgc atggcngtcg tcagctcgtg ttgtgaaatg 1080

```

5      ttgggttaag   tcccgcaacg   agcgcaaccc   ttatcctttg   tggccagcga   cgtgggtcggg   1140  
       aactcaaagg   agactgccgg   tgataaacgg   gaggaagggtg   gggatgacgt   caagtcatca   1200  
       tggcccttac   gagtagggct   acacacgtgc   tacaatggcg   tatacagagg   gtaaccaacc   1260  
       agcgatgggg   agtgaatctc   agaaagtgcg   tctaagttcg   gattggagtc   tgcaactcga   1320  
       ctccatgaag   tcggaatcgc   tagtaatcgc   gaatcagaat   gttgcgggtga   atacgttccc   1380  
       gggccttgta   cacaccgccc   gtcacaccat   gggagtgggt   tgtaccagaa   gtggatagct   1440  
       gaaccgagag   ggtggcggtt   accacggtat   gattcangac   tgggg   1485

10      <210> 37  
       <211> 1487  
       <212> DNA  
       <213> Haemophilus influenzae

15      <220>  
       <221> modified\_base  
       <222> (1)..(1387)  
       <223> N = A, C, G or T/U

20      <400> 37  
       naattgaaga   gtttgatcat   ggctcagatt   gaacgctggc   ggcaggctta   acacatgcaa   60  
       gtcgaacggt   agcaggagaa   agcttgcttt   cttgctgacg   agtggcggac   gggtagtaaa   120  
       tgcttgggaa   tctggcttat   ggagggggat   aacgacggga   aactgtcgct   aataccgcgt   180  
       attatcgga   gatgaaagtg   cgggactgag   aggccgcgatg   ccataggatg   agcccaagtg   240  
 25      ggattaggt   gttggtggg   taaatgccta   ccaagcctgc   gatctctagc   tggctctaga   300  
       ggatgaccag   ccacactgga   actgagacac   ggtccagact   cctacgggag   gcagcagtgg   360  
       ggaatattgc   gcnatggggg   gaaccctgac   gcagccatgc   cgcgtgaatg   aagaaggcct   420  
       tcgggttgta   aagttctttc   ggtattgagg   aaggttgatg   tgttaatagc   acatcaaatt   480  
       gacgttaaat   acagaagaag   caccggctaa   ctccgtgcc   gcagccgcgg   taatacggag   540  
 30      ngtgcgagcg   ttaatcgga   taactgggcg   taaagggcac   gcagggcggtt   atttaagtga   600  
       ggtgtgaaag   ccccgggcctt   aacctgggna   ttgcatttca   gactgggtaa   ctagagtact   660  
       ttagggaggg   gtgaattcc   acgtgtagcg   gtgaaatgcy   tagagatgtg   gaggaatacc   720  
       gaaggcgaag   gcagcccctt   gggaatgtat   tgacgctcat   gtgcgaaagc   gtggggagca   780  
       aacaggatta   gataccctgg   tagtccacgc   tgtaaacgct   gtcgatttgg   gggttggggg   840  
 35      ttaactctgg   caccctgtagc   taacgtgata   aatcgaccgc   ctggggagta   cggccgcaag   900  
       gttaaaactc   aaatgaattg   acggggggccn   gcacaagcgg   tggagcatgt   ggtttaattc   960  
       gatgcaacgc   gaagaacctt   acctactctt   gacatcctaa   gaagagctca   gagatgagct   1020  
       tgtgccttcg   ggaacttaga   gacaggtgct   gcatggctgt   cgtcagctcg   tgttgtagaa   1080  
       tgttgggtta   agtcccgcga   cgagcgcaac   ccttatectt   tgttgccagc   gacttggctg   1140  
 40      ggaactcaaa   ggagactgcc   agtgataaac   tggaggaagg   tngggatgac   gtcaagtcac   1200  
       catggccctt   acgagtaggg   ctacacacgt   ggtacaatgg   cgtatacaga   gggaagcgaa   1260  
       gctgcgaggt   ggagcgaatc   tcataaagta   cgtctaagtc   cggattggag   tctgcaactc   1320  
       gactccatga   agtcggaatc   gctagtaatc   gcgaatcaga   atgtcgcggt   gaatacgttc   1380  
       ccgggcnttg   tacacaccgc   ccgtcacacc   atgggagtg   gttgtaccag   aagtagatag   1440  
 45      cttaaccttt   tggagggcgt   ttaccacggt   atgattcatg   actgggg   1487

50      <210> 38  
       <211> 1532  
       <212> DNA  
       <213> Bordetella bronchiseptica

      <400> 38  
 55      tgaactgaag   agtttgatcc   tggctcagat   tgaacgctgg   cgggatgctt   tacacatgca   60  
       agtcggacgg   cagcacgggc   ttcggcctgg   tggcgagtg   cgaacgggtg   agtaatgtat   120  
       cggaacgtgc   ccagtagcgg   gggataacta   cgcgaaagcg   tggctaatac   cgcatagccc   180

ctacggggga aagcggggga ccttcggggc tgcactatt ggagcgggcg atatcggtt 240  
 agctagttagg tggggtaacg gcctaccaag ggcacgatcc gtagctgggt tgagaggacg 300  
 accagccaca ctgggactga gacacggccc agactcctac gggaggcagc agtggggaat 360  
 tttggacaat gggggcaacc ctgatccagc catcccgctg gtgcgatgaa ggccttcggg 420  
 5 tttgtaagca cttttggcag gaaagaaacg gcacgggcta atatcctgtg caactgacgg 480  
 tacctgcaga ataagcaccg gctaactacg tgccagcagc cgcggtaata cgtagggtgc 540  
 aagcgtaaat cgggaattact gggcgtaaaag cgtgcgcagg cggttcggaa agaaagatgt 600  
 gaaatcccag ggcttaacct tggaaactgca tttttaacta ccgggctaga gtgtgtcaga 660  
 gggaggtgga attccgcgtg tagcagtgaat atgcgtagat atgcggagga acaccgatgg 720  
 10 cgaaggcagc ctccctgggat aacactgacg ctcatgcacg aaagcgtggg gagcaaacag 780  
 gattagatag cctggtagtc cacgccctaa acgatgtcaa ctagctgttg gggccttcgg 840  
 gccttggtag cgcagctaac gcgtgaagtt gaccgcctgg ggagtacggg cgcaagatta 900  
 aaactcaaaag gaattgacgg ggacccgcac aagcgggtga tgatgtggat taattcgatg 960  
 caacgcgaaa aaccttacct acccttgaca tgtctggaat cccgaagaga tttgggagtg 1020  
 15 ctgcgaagag aaccggaaca caggtgctgc atggctgctg tcagctcgtg tcgtgagatg 1080  
 ttgggttaag tcccgcaacg agcgcaaccc ttgtcattag ttgctacgaa agggcactct 1140  
 aatgagactg ccggtgacaa accggaggaa ggtggggatg acgtcaagtc ctcatggccc 1200  
 ttatgggtag ggcttcacac gtcatacaat ggtcgggaca gaggtcgcc aaccgcgag 1260  
 ggggagccaa tcccagaaac ccgatcgtag tccggatcgc agtctgcaac tcgactgcgt 1320  
 20 gaagtgcgaa tcgctagtaa tcgcggtatca gcatgtcgcg gtgaatacgt tccccgggtc 1380  
 tgtacacacc gcccgtcaca ccatgggagt ggggtttacc agaagtagtt agcctaaccg 1440  
 caaggggggc gattaccacg gtaggattca tgactggggt gaagtcgtaa caagtagacc 1500  
 gtatcggaag gtgcggctgg atcacctcct tt 1532

25  
 <210> 39  
 <211> 1485  
 <212> DNA  
 <213> Bordetella parapertussis

30  
 <400> 39  
 attgaacgct ggcgggatgc tttacacatg caagtcggac ggcagcacgg gcttcggcct 60  
 ggtggcgagt ggcgaacggg tgagtaatgt atcggaacgt gccagtagc gggggataac 120  
 35 tacgcgaaaag cgtgggctaatt accgcatacg ccctacgggg gaaagcgggg gactttcggg 180  
 cctcgcacta ttggagcggc cgatatcgga ttagctagtt ggtggggtaa cggcctacca 240  
 aggcgacgat ccgtagctgg tttgagagga cgaccagcca cactgggact gagacacggc 300  
 ccagactcct acgggaggca gcagtgggga attttggaac atggggggcaa ccctgatcca 360  
 gccatcccgc gtgtgcgatg aaggccttcg ggttgtaaag cacttttggc aggaaagaaa 420  
 40 cggcacgggc taatatcctg tgcaactgac ggtacctgca gaataagcac cggctaacta 480  
 cgtgcccagca gccgcggtaa tacgtagggg gcaagcgtaa atcggaatta ctgggcgtaa 540  
 agcgtgcgca ggcgggttcgg aaagaaagat gtgaaatccc agggcctaac cttggaaactg 600  
 catttttaac taccgggcta gagtgtgtca gagggagggt gaattccgcg ttagcagtg 660  
 aaatgcgtag atatgcggag gaacaccgat ggcgaaggca gcctcctggg ataactactga 720  
 cgctcatgca cgaaagcgtg gggagcaaac aggattagat accctggtag tccacgccc 780  
 45 aaacgatgtc aactagctgt tggggccttc gggccttggg agcgcagcta acgcgtgaag 840  
 ttgaccgcct ggggagtacg gtcgcaagat taaaactcaa aggaattgac ggggacccgc 900  
 acaagcggtg gatgagtggg attaatcga tgcaacgcga aaaaccttac ctacccttga 960  
 catgtctgga atcccgaaga gatttgggag tgctcgcaag agaaccgga cagaggtgct 1020  
 gcatggctgt cgctcagctc gtgctgtgaga tgttgggtta agtcccgcaa cgagcgcaac 1080  
 50 ccttgtcatt agttgctacg aaagggcact ctaatgagac tgccgggttac aaaccggagg 1140  
 aaggtgggga tgacgtcaag tccctcatggc ccttatgggt agggccttcac acgtcataca 1200  
 atggctcggga cagagggtcg ccaacccgcg agggggagcc aatcccagaa acccgatcgt 1260  
 agtccggatc gcagtctgca actcgactgc gtgaagtcgg aatcgctagt aatcgcggt 1320  
 cagcatgtcg cgggtgaatac gttcccgggt cttgtacaca ccgcccgtca caccatggga 1380  
 55 gtgggtttta ccagaagtag ttagcctaag cgcaaggggg gggcgattac cacggttagga 1440  
 ttcagtactg ggggtgaagtc gtaacaaggt agccgtatcg gaagg 1485



<210> 40  
<211> 1464  
5 <212> DNA  
<213> Bordetella pertussis

<220>  
<221> modified\_base  
10 <222> (87) .. (1391)  
<223> N = A, C, G or T/U

<400> 40  
15 aactgaagag tttgatcctg gctcagattg aacgctggcg ggatgcttta cacatgcaag 60  
tcggacggca gcacgggctt cggcctngtg gcgagtggcg aacgggtgag taatgtatcg 120  
gaacgtgccc agtagcgggg gataactacg cgaaagcgta gctaataccg catacgccct 180  
acgggggaaa gcgggggacc ttccggcctc gcaactattg agcggccgat atcggattag 240  
ctngttggtg gggtaacggc ctaccaaggc gacgatccgt agctggtttg agaggacgac 300  
cagccacact gggactgaga cacggcccag nctcctacgg gaggcagcag tggggaattt 360  
20 tggacaatgg gggcaaccct gatccagcca tcccgcgtgt gcgatgaagg ccttcgggtt 420  
gtaaagcact tttggcagga aagaaacggc acgggcta atcctgtgca actgacggta 480  
cctgcagaat aagcaccggc taactacgtg ccagcagccg cggtaatacg tagggtgcaa 540  
gcgttaatcg gaattactgg gcgtaaagcg tgcgcaggcg gtccggaaag aaagatgtga 600  
aatcccaggg cttaaccttg gaactgcatt tttaactacc gggctagagt gtgtcagagg 660  
25 gaggtggaat tccgcgtgta gcagtgaat gcgtagatat gcggaggaac accgatggcg 720  
aaggcagcct cctgggataa cactgacgct catgcacgaa agtgtgggga gcaaacagga 780  
ttagataccc tggtagtcca cgccctaacc gatgtcaact agctgttggg gccttcgggc 840  
cttggtagcg cagctaacgc gtgaagtga ccgcctgggg agtacggtcg caagattaaa 900  
actcaaagga attgacgggg acccgcaaa gcggtggatg atgtggatta attcgatgca 960  
30 acgcgaaaaa ccttacctac ccttgacatg tctggaatcc cgaagagatt tgggagtgtc 1020  
cgcaagagaa ccggaacaca ggtgctgcat ggctgtcgtc agctcgtgtc gtgagatgtt 1080  
gggttaagtc ccgcaacgag cgcaaccctt gtcattagtt gctacgaaag ggcactctaa 1140  
tgagactgcc ggtgacaaac cggaggaagg tggggatgac gtgaagtcct catggccctt 1200  
attgggtaggg cttcacacgt catacaatgg tcgggacaga gggttgncaa cccgcgaggg 1260  
35 ggagccaatc ccagaaaccc ggtcgtngtc cggatcgcag tctgcaactc gactgcgtga 1320  
agtcggaatc gctagtaatc gcggatcagc atgtcgcggt gaatacgttc ccgggtcttg 1380  
tacacaccgc ncgtcacacc atgggagtgg gttttaccag aagtagttag cctaaccgca 1440  
aggggggcga ttaccacggt agga 1464

40  
<210> 41  
<211> 1535  
<212> DNA  
45 <213> Burkholderia cepacia

<400> 41  
50 taaactgaag agtttgatcc tggctcagat tgaacgctgg cggcatgctt aacacatgca 60  
agtgcgaacgg cagcaggggt gcttgacact ggtggcgagt ggcgaaacgg tgagtaatac 120  
atcggaacat gtcctgtagt gggggatagc ccggcgaaag ccggattaat accgcatacg 180  
atctacggat gaaagcgggg gaccttcggg cctcgcgcta tagggttggc gatggctgat 240  
tagctagtgt gtggggtaaa ggcctaccaa ggcgacgatc agtagctggt ctgagaggac 300  
gaccagccac actgggactg agacacggcc cagactccta cgggaggcag cagtggggaa 360  
ttttggacaa tgggcgaaag cctgatccag caatgccgcg tgtgtgaaga aggccttcgg 420  
gttgtaaaag acttttgtcc ggaaagaaat ccctggctct aatacagtcg ggggatgacg 480  
55 gtaccggaag aataagcacc ggctaactac gtgccagcag ccgcggtaat acgtagggtg 540  
caagcgttaa tcggaattac tgggcgtaaa gcgtgcgcag gcggtttgct aagaccgatg 600

5 tgaaatcccc gggctcaacc tgggaactgc attggtgact ggcaggctag agtatggcag 660  
 aggggggtag aattccacgt gtagcagtga aatgcgtaga gatgtggagg aataccgatg 720  
 gcgaaggcag cccctgggc caatactgac gctcatgcac gaaagcgtgg ggagcaaaca 780  
 ggattagata ccctggtagt ccacgcccata aacgatgtca actagtgtgt ggggattcat 840  
 10 ttccttagta acgtagctaa cgcgtgaagt tgaccgcctg gggagtacgg tcgcaagatt 900  
 aaaactcaaa ggaattgacg gggaccgcga caagcgggtg atgatgtgga ttaattcgat 960  
 gcaacgcgaa aaaccttacc tacccttgac atggtcggaa tcctgctgag aggtgggagt 1020  
 gctcgaaaga gaaccggcgc acaggtgctg catggctgtc gtcagctcgt gtcgtgagat 1080  
 gttgggttaa gtcccgaac gagcgcaacc cttgtcctta gttgctacgc aagagcactc 1140  
 15 taaggagact gccggtgaca aaccggagga aggtggggat gacgtcaagt cctcatggcc 1200  
 cttatgggta gggcttcaca cgtcatacaa tggtcggaac agagggttgc caaccgcga 1260  
 gggggagcta atcccagaaa acccatcgta gtccggattg cactctgcaa ctcgagtga 1320  
 tgaagctgga atcgtagta atcgcgacg agcatgccgc ggtgaatacg ttcccgggtc 1380  
 ttgtacacac cgcccgctac accatgggag tgggttttac cagaagtggc tagtctaacc 1440  
 20 gcaaggagga cggtcaccac ggtaggattc atgactgggg tgaagtcgta acaaggtagc 1500  
 cgtatcgga ggtgcggctg gatcacctcc tttct 1535

20 <210> 42  
 <211> 1488  
 <212> DNA  
 <213> Burkholderia mallei

25 <400> 42  
 agattgaacg ctggcggcat gccttacaca tgcaagtcga acggcagcac gggcttcggc 60  
 ctggtggcga gtggtgaacg ggtgagtaat acatcggaac atgtcctgta gtgggggata 120  
 gcccgcgcaa agccggatta ataccgcata cgatctgagg atgaaagcgg gggaccttcg 180  
 ggccctcgcc tatagggttg gccgatggct gattagctag ttggtggggt aaaggcctac 240  
 caaggcgacg atcagtagct ggtctgagag gacgaccagc cactactggga ctgagacacg 300  
 30 gccagactc ctacgggagg cagcagtggg gaattttgga caatgggcgc aagcctgatc 360  
 cagcaatgcc gcgtgtgtga agaaggcctt cgggttgtaa agcacttttg tccggaaaga 420  
 aatcattctg gctaataccc ggagtggatg acggtaccgg aagaataagc accggctaac 480  
 tacgtgccag cagccgcggg aatacgtagg gtgcgagcgt taattggaat tactgggcgt 540  
 aaagcgtgcg caggcgggtt gctaagaccg atgtgaaatc cccgggctca acctgggaac 600  
 35 tgcattgggt actggcaggc tagagtatgg cagagggggg tagaattcca cgtgtagcag 660  
 tgaatgcgt agagatgtgg aggaataccg atggcgaagg cagccccctg ggccaatact 720  
 gacgtcatg cacgaaagcg tggggagcaa acaggattag ataccctggt agtccacgcc 780  
 ctaaacgatg tcaactagtt gttggggatt catttcctta gtaacgtagc taacgcgtga 840  
 agttgaccgc ctggggagta cggtcgcaag attaaaaact aaaggaattg acggggaccc 900  
 40 gcacaagcgg tggtgatgtg ggattaattc gatgcaacgc gaaaaacctt acctaccctt 960  
 gacatggtcg gaagcccgat gagagtggg cgtgctcgaa agagaaccgg cgcacagggtg 1020  
 ctgcatggct gtcgtcagct cgtgtcgtga gatgttgggt taagtcccgc aacgagcgca 1080  
 acccttgtcc ttagttgcta cgcaagagca ctctaaggag actgccgggtg acaaaccgga 1140  
 ggaaggtggg gatgacgtca agtccctcat gcccttatgg gtagggcttc acacgtcata 1200  
 45 caatggctcg aacagagggt cgccaacccg cgagggggag ccaatcccag aaaaccgatc 1260  
 gtagtccgga ttgcaactct caactcgagt gcataagct ggaatcgcta gtaatcgcg 1320  
 atcagcatgc cgcggtgaat acgttcccgg gtcttgatca caccgcccgt cacaccatgg 1380  
 gagtgggttt taccagaagt ggctagtcta accgcaagga ggacgggtcac cacggtagga 1440  
 50 ttcatgactg ggtggaagtc gtaacaaggt agccgtatcg gaaggtgc 1488

55 <210> 43  
 <211> 1610  
 <212> DNA  
 <213> Burkholderia pseudomallei

<400> 43  
tctagatgcg tgctcgagcg gccgcccagt gctgcatgga tatctgctga attcggttg 60  
agcagtttga tcctgggtca gattgaacgc tggcggcagc ccttacacat gcaagtcgaa 120  
cggcagcacg ggcttcggcc tgggtggcgag tggcgaacgg gtgagttata catcggagca 180  
5 tgcctctgtag tgggggatag cccggcgaaa gccgaattaa taccgcatac gatctgagga 240  
tgaaagcggg ggaccttcgg gcctcgcgct atagggttg ccgatggctg attagctagt 300  
tgggtgggta aaggcctacc aaggcgacga tcagtagctg gtctgagagg acgaccagcc 360  
acactgggac tgagacacgg cccagactcc tacgggaggc agcagtgggg aattttggac 420  
aatgggcgca agcctgatcc agcaatgccg cgtgtgtgaa gaaggccttc gggttgtaaa 480  
10 gcacttttgt ccggaagaa atcattctgg ctaatacccc gagtggtatga cggtagccga 540  
agaataagca ccggctaact acgtgccagc agccgggttg atacgtaggg tgcgagcgtt 600  
aatcgggatt actgggcgta aagcgtgcgc aggcgggttg ctaagaccga tgtgaaatcc 660  
ccgggtcaca cctgggaact gcattgggtg ctggcaggct agagtatggc agaggggggt 720  
agaattccac gtgtagcagt gaaatgcgta gagatgtgga ggaataccga tggcgaaggc 780  
15 agccccctgg gccaaactg acgctcatgc acgaaagcgt ggggagaaaa caggattaga 840  
taccctggta gtccacgccc taaacgatgt caactagtgt ttggggattc atttccttag 900  
taacgtagct aacgcgcgaa gttgaccgcc tggggagtac ggtcgcaaga ttaaaactca 960  
aaggaattga cggggaccgg cacaagcggg ggatgatgtg gattaattcg atgcaacgcg 1020  
aaaaacctta cctacccttg acatggtcgg aagcccagat agagtggggc gtgctcgaaa 1080  
20 gagaaccggc gcacaggtgc tgcattggctg tcgtcagctc gtgtcgtgag atgttgggtt 1140  
aagtcccgcg acgagcgcaa ccttgtctct tagttgtctac gcaagagcac tctaaggaga 1200  
ctgccggtga caaacgggag gaagggtgggg atgacgtcaa gtccctcatgg cccttatggg 1260  
tagggcttca cacgtcatat aatggtcgga acagagggtc gccaacccgc gagggggagc 1320  
caatcccaga aaaccgatcg tagtccggat tgcactctgc aactcgagtg catgaagctg 1380  
25 gaatcgctag taatcgcgga tcagcatgcc gcggtgaata cgttcccggg tcttgtacac 1440  
accgcccgtc acaccatggg agtgggtttt accgaagtg gctagtctaa ccgcaaggag 1500  
gacggtcacc acggtaggat tcatgactgg ggtgaagtcg taacaaggta gccgtagaag 1560  
ccgaattcca gcacactggc ggccggttact actggatccg agctcgtacc 1610

30  
<210> 44  
<211> 1544  
<212> DNA  
<213> *Neisseria gonorrhoeae*

35  
<400> 44  
tgaacataag agtttgatcc tggctcagat tgaacgctgg cggcatgctt tacacatgca 60  
agtcggacgg cagcacaggg aagcttgctt ctcggggtggc gagtggcgaa cgggtgagta 120  
40 acatatcgga acgtaccggg tagcggggga taactgatcg aaagatcagc taataccgca 180  
tacgtcttga gagggaaaagc aggggacctt cgggccttgc gctatccgag cggccgata 240  
ctgattagct ggttggcggg gtaaaggccc accaaggcga cgatcagtag cgggtctgag 300  
aggatgatcc gccacactgg gactgagaca cggcccagac tcctacggga ggcagcagt 360  
gggaattttg gacaatgggc gcaagcctga tccagccatg ccgcgtgtct gaagaaggcc 420  
ttcgggttgt aaaggacttt tgtcagggaa gaaaaggctg ttgccaatat cggcggccga 480  
45 tgacgggtacc tgaagaataa gcaccggcta actacgtgcc agcagccgcg gtaatacgt 540  
gggtgcgagc gttaatcgga attactgggc gtaaagcggg cgcagacggt tacttaagca 600  
ggatgtgaaa tccccgggct caaccgggga actgcgttct gaactgggtg actcgagtgt 660  
gtcagaggga ggttgaattc cacgtgtagc agtgaaatgc gtagagatgt ggaggaatac 720  
cgatggcgaa ggtgaccttc tgggataaca ctgacgttca tgtccgaaag cgtgggtagc 780  
50 aaacaggatt agataccctg gtagtccacg ccctaaacga tgtcaattag ctgttgggca 840  
acttgattgc ttggtagcgt agctaacgcg tgaattgac cgcttgggga gtacggtcgc 900  
aagattaaaa ctcaaaggaa ttgacgggga cccgcacaag cgggtggatga tgtggattaa 960  
ttcgatgcaa cgccaagaac cttacctggt tttgacatgt gcggaatcct ccggagacgg 1020  
aggagtgcct tcgggagccg taacacaggt gctgcatggc tgtcgtcagc tcgtgtcgtg 1080  
55 agatgttggg ttaagtcccg caacgagcgc aacccttgct attagttgcc atcattcgtt 1140  
tgggcactct aatgagactg ccggtgacaa gccggaggaa ggtggggatg acgtcaagtc 1200

5 ctcatggccc ttatgaccag ggcttcacac gtcatacaat ggtcggtaca gagggtagcc 1260  
 aagccgcgag gcgagagccaa tctcacaataa ccgatcgtag tccggattgc actctgcaac 1320  
 tcgagtgcac gaagtcggaa tcgctagtaa tcgcaggtca gcatactgcg gtgaatacgt 1380  
 tcccgggtct tgtacacacc gcccgtcaca ccatgggagt gggggatacc agaagtaggt 1440  
 agggtaaccg caaggagtcc gcttaccacg gtatgcttca tgactggggg gaagtcgtaa 1500  
 caaggtagcc gtaggggaac ctgcggcttg atcacctcct ttct 1544

10 <210> 45  
 <211> 1544  
 <212> DNA  
 <213> *Neisseria meningitidis*

15 <400> 45  
 tgaacataag agtttgatcc tggctcagat tgaacgctgg cggcatgctt tacacatgca 60  
 agtcggacgg cagcacagag aagcttgctt ctccgggtggc gagtggcgaa cgggtgagta 120  
 acatatcgga acgtaccgag tagtggggga taactgatcg aaagatcagc taataccgca 180  
 tacgtcttga gagagaaaagc aggggacctt cgggccttgc gctattcgag cggccgatat 240  
 20 ctgattagct agttggtggg gtaaaggcct accaaggcga cgatcagtag cgggtctgag 300  
 aggatgatcc gccacactgg gactgagaca cggcccagac tcctacggga ggcagcagtg 360  
 gggaattttg gacaatgggc gcaagcctga tccagccatg ccgcgtgtct gaagaaggcc 420  
 ttccgggttg aaaggacttt tgtcagggaa gaaaaggctg ttgctaatat cagcggctga 480  
 tgacgggtacc tgaagaataa gcaccggcta actacgtgcc agcagccgcg gtaatacgt 540  
 ggggtgcgagc gttaatcgga attactgggc gtaaaaggcg cgcagacggg tacttaagca 600  
 25 ggatgtgaaa tccccgggct caaccgggga actgcgttct gaactgggtg actcagagtgt 660  
 gtcagaggga ggtagaattc cacgtgtagc agtgaaatgc gtagagatgt ggaggaatac 720  
 cgatggcgaa ggcagcctcc tgggacaaca ctgacgttca tgcccgaaag cgtgggtagc 780  
 aaacaggatt agataccctg gtagtccacg ccctaaacga tgtcaattag ctgttgggca 840  
 acctgattgc ttggtagcgt agctaaccgc tgaatttgac cgcttgggga gtacggtcgc 900  
 30 aagattaaaa ctcaaaggaa ttgacgggga cccgcacaag cgggtggatga tgtggattaa 960  
 ttcgatgcaa cgcgaagaac cttacctggt cttgacatgt acggaatcct ccggagacgg 1020  
 aggagtgcct tcgggagccg taacacaggt gctgcattggc tgcgtcagc tcgtgtcgtg 1080  
 agatgttggg ttaagtcccg caacgagcgc aacccttgc attagttgcc atcattcagt 1140  
 tgggcactct aatgagactg ccggtgacaa gccggaggaa ggtggggatg acgtcaagtc 1200  
 35 ctcatggccc ttatgaccag ggcttcacac gtcatacaat ggtcggtaca gagggtagcc 1260  
 aagccgcgag gcgagagccaa tctcacaataa ccgatcgtag tccggattgc actctgcaac 1320  
 tcgagtgcac gaagtcggaa tcgctagtaa tcgcaggtca gcatactgcg gtgaatacgt 1380  
 tcccgggtct tgtacacacc gcccgtcaca ccatgggagt gggggatacc agaagtaggt 1440  
 aggataacca caaggagtcc gcttaccacg gtatgcttca tgactggggg gaagtcgtaa 1500  
 40 caaggtagcc gtaggggaac ctgcggcttg atcacctcct ttct 1544

45 <210> 46  
 <211> 1537  
 <212> DNA  
 <213> *Pseudomonas aeruginosa*

50 <400> 46  
 gaactgaaga gtttgatcat ggctcagatt gaacgctggc agcagggggc ttcaacacat 60  
 gcaagtcgag cttatgaagg gagcttgctt tggattcagc ggcggacggg tgagtaatgc 120  
 ctaggaatct gcctggtagt gggggataac gtccggaaac ggccgcta at accgcatac 180  
 tcctgaggga gaaagtcggg gatcttcgga cctcacgcta tcagatgagc ctaggtcgga 240  
 ttagctagtt ggtggggtaa aggcctacca aggcgacgat ccgtaactgg tctgagagga 300  
 tgatcagtca cactggaact gagacacggc ccgactcct acgggaggca gcagtgggga 360  
 55 atattggaca atgggcgcaa gcctgatcca gccatgccgc gtgtgtgaag aaggctctcg 420  
 gattgtaaag cactttaagt tgggaggaag gccagtaagt taataccttg ctgtttgacg 480

5 ttaccaacag aataagcacc ggctaacttc gtgccagcag ccgcggtaat acgaaggggtg 540  
 caagcggttaa tcggaattac tgggcgtaaa gcgcgcgtaa gtggttcagc aagcttgatg 600  
 tgaatcccc gggctcaacc tgggaactgc atccaaaagc tactgagcta gagtacggta 660  
 gaggtggtag aatttcctgt gtagcgggtga aatgcgtaga tataggaagg aacaccagtg 720  
 gcgaaggcga ccacctggac tgtactgaca ctgaggtgag aaagcgtggg gagcaaacag 780  
 gattagatac cctgggtagtc cacgcgtaaa acgatgtcga ctagccgttg ggatccttga 840  
 gatcttagtg gcgcacgtaa cgcgataagt cgaccgcctg gggagtacgg ccgcaagggt 900  
 aaaactcaaa tgaattgacg ggggcccgcg caagcgggtg agcatgtggt ttaattcgaa 960  
 10 gcaacgcgaa gaaccttacc tggccttgac atgctgagaa ctttccagag atggattggt 1020  
 gccttcggga acagagacac aggtgctgca tggctgtcgt cagctcgtgt cgtgagatgt 1080  
 tgggttaagt cccgtaacga gcgcaaccct tgtccttagt taccagcacc tcgggtgggc 1140  
 actctaagga gactgccggt gacaaaccgg aggaaggtgg ggatgacgtc aagtcacat 1200  
 ggccttaccg ccacgggcta cacacgtgct acaatgggtc gtacaaaggg ttgccaagcc 1260  
 gcgagtggga gctaataccca taaaaccgat cgtagtccgg atcgcagtct gcaactcgac 1320  
 15 tgcgtgaagt cggaatcgct agtaatcggt aatcagaatg tcacggtgaa tacgtccccg 1380  
 ggcttgttac acaccgcccg tcacaccatg ggagtgggtt gctccagaag tagctagtct 1440  
 aaccgcaagg gggacgggtt ccacggagtg attcatgact ggggtgaagt cgtaacaagg 1500  
 tagccgtagg ggaacctgcg gctggatcac ctcctta 1537

20 <210> 47  
 <211> 1467  
 <212> DNA  
 <213> *Vibrio cholerae*

25 <220>  
 <221> modified\_base  
 <222> (928)..(1464)  
 <223> N = A, C, G or T/U

30 <400> 47  
 attgaagagt ttgatcctgg ctcagattga acgctggcgg caggcctaac acatgcaagt 60  
 cgagcggcag cacagaggaa cttgttcctt ggggtggcag cggcggacgg gtgagtaagt 120  
 ctggggaaat tgcccggtag aggggggataa ccattggaaa cgatggctaa taccgcataa 180  
 35 cctcgcaaga gcaaaagcagg ggaccttcgg gccttgcgct accggatatg cccaggtggg 240  
 attagctagt tggtgaggta agggctcacc aaggcgacga tccctagctg gtctgagagg 300  
 atgatcagcc aacttggaac tgagacacgg tccagactcc tacgggaggg agcagtgggg 360  
 aatattgcac aatgggcgca agcctgatgc agccatgccg cgtgtatgaa gaaggccttc 420  
 gggttgtaaa gtactttcag tagggaggaa ggtgggttaa ttaatacctt aatcatttga 480  
 40 cgttacctac agaagaagca ccggctaact ccgtgccagc agccgcggta atacggaggg 540  
 tgcaagcggt aatcggaatt actgggcgta aagcgcatgc aggtgggttg ttaagtcaga 600  
 tgtgaaagcc ctggggtcaa cctaggaatc gcatttgaaa ctgacaagct agagtactgt 660  
 agaggggggt agaatttcag gtgtagcggg gaaatgcgta gagatctgaa ggaataccgg 720  
 tggcgaaggc gggcccttgg acagatactg aactcagat gcgaaagcgt ggggagcaaa 780  
 45 caggattaga taccctggta gtccacgcgg taaacgatgt ctacttggag gttgtgccct 840  
 agagtcgtgg ctttcggagc taacgcgtta agtagaccgc ctggggagta cggtcgcaag 900  
 attaaaactc aaatgaattg acgggggncc gcacaagcgg tggagcatgt ggtttaattc 960  
 ganncaacgc gaagaacctt acctactctt gacatccaga gaatctagcg gagacgtgg 1020  
 agtgcccttc ggagctctga gacaggtgct gcatggctgt cgtcagctcg tgttggtgaa 1080  
 50 tgttgggtta agtcccgcaa cgagcgcaac ccttatcctt gtttgccagc acgtaatggt 1140  
 gggaaactca gggagactgc cggtgataaa ccggagggaag gtggggacga cgtcaagtca 1200  
 tcatggccct tacgagtagg gctacacacg tgctacaatg gcgtatacag agggcagcga 1260  
 taccgcgagg tggagcgaat ctacacaaag acgtcgtagt ccggattgga gtctgcaact 1320  
 cgactccatg aagtcggaat cgctagtaat cgcaaatcag aatgttgagg tgaatacgtt 1380  
 55 cccgggcctt gtacacaccg cccgtcacac catgggagtg ggctgcaaaa gaagcangta 1440  
 gtttaacctt cgggaggacg cttncce 1467

<210> 48  
<211> 1485  
5 <212> DNA  
<213> *Yersinia enterocolitica*

<220>  
<221> modified\_base  
10 <222> (1)..(1484)  
<223> N = A, C, G or T/U

<400> 48  
15 naattgaaga gtttgatcat ggctcagatn gaacgctggc ggcaggccta acacatgcaa 60  
gtcgaagcggc agcgggaagn agtttactac tttcngggcg agcggcggnac gggtagtaaa 120  
tgtctgggaa actgcctgat ggagggggat aactactgga aacggtagct aataccgcat 180  
aacgtcttcg gaccaaagtg ggggacctta gggcctcacg ccatcngatg tgcccagatg 240  
ggattagcta gtaggtgggg taatggctca cctaggcgac gatccctagc tggctctgaga 300  
ggatgaccag ccacactgga actgagacac ggtccagact cctacgggag gcagcagtgg 360  
20 ggaatattgc acaatgggcg caagcctgat gcagccatgc cgcgtgtgtg aagaaggcct 420  
tcgggttgta aagcactttc agcagaggag aaggccaata acttaatacg ttgttggatt 480  
gacgttactc gcagaagaag caccggctaa ctccgtgccg gcagccgagg taatacggag 540  
gggtgaagcg ttaatcggaa ttactgggcg taaagcgcac gcaggcgggt ttgttaagtca 600  
gatgtgaaat ccccgcgctt aacgtgggna cngcatattga aactggcaag ctagagtctt 660  
25 gtagaggggg gtagaattcc aggtgtagcg gtgaaatgag tagagatctg naggaataacc 720  
gggtggcgaag gcggccccct ggacaaagac tgacgctcag gtgcgaaagc gtggggagca 780  
aacaggatta gataccctgg tagtccacgc tgtaaacgat gtcgacttgg aggttgtgcc 840  
cttgaggcgt ggcttccgga gctaacgcgt taagtcgacc gcctggggag tacggccgca 900  
aggttaaaac tcaaatgaat tnnccggggc cngcacaagc ggtggagcat gtggtttaat 960  
30 tcgatgcaac gcgaagaacc ttacctactc ttgacatcca cggaatttag cagagatgct 1020  
ttagtgnctt cgggaaccgt gagacagggt ctgcatggct gtcgtcagct cgtgttgtga 1080  
aatgttgggt taagtcgccg aacgagcgca acccttatcc tttgttgcca gcacgtaatg 1140  
gtgggaactc aaaggagact gccggtgata aaccggagga aggtggggat gacgtcaagt 1200  
catcatggcc cttacgagta gggctacaca cgtgctacaa tggcagatac aaagtgaagc 1260  
35 gaactcgcga gagcaagcgg accacataaa gtctgtcgta gtccggattg gagtctgcaa 1320  
ctcgactcca tgaagtcgga atcgctagta atcgtagatc agaagctac ggtgaatacg 1380  
ttcccgggcc ttgtacacac cggcgtcac accntgggag tgggttgcaa aagaagtagg 1440  
tagcttaacn ttcgggaggg cgcgtaccac tttgtgattc nngnc 1485

40 <210> 49  
<211> 2927  
<212> DNA  
45 <213> *Bacillus subtilis*

<400> 49  
50 ggttaagtta gaaagggcgc acggtggatg ccttggcact aggagccgat gaaggacggg 60  
acgaacaccg atatgcttcg gggagctgta agcaagcttt gatccggaga ttccgaatg 120  
gggaaaccca ccactcgtaa tggagtggta tccatatctg aattcatagg atatgagaag 180  
gcagaccgag ggaactgaaa catctaagta cccggagaag agaaagcaaa tgcgattccc 240  
tgagttagcg cgacgaacac gggatcagcc caaaccaaga ggcttgctc tgtggttgta 300  
ggacactctg tacggagtta caaaagaacg aggtagatga agaggtctgg aaagggcccc 360  
ccataggagg taacagccct gtagtcaaaa ctctggttctc tcttgagtgg atcctgagta 420  
cggcggaaca cgtgaaattc cgtcggaatc cgggaggacc atctcccaag gctaaatact 480  
55 ccctagttag cgatagtga ccagtaccgt gagggaaagg tgaaaagcac cccggaaggg 540  
gagtgaaga gatcctgaaa ccgtgtgcct acaagtagtc agagcccgtt aacggtgatg 600

5 gcggtgccttt tgtagaatga accggcgagtg tacgatcccc tgcaagggtta agcagaagat 660  
 gcggagaccgc agcgaaaagcg agtctgaata gggcgcatga gtacgtgggtc gtagacccca 720  
 aaccagggtga tctacccatg tccagggtga agttcaggta acactgaatg gaggccccgaa 780  
 cccacgcacg ttgaaaagtg cggggatgag gtgtgggtag gggtgaaatg ccaatcgaac 840  
 ctggagatag ctggttctct ccgaaatagc tttagggcta gcctcaagggt aagagtcttg 900  
 gaggtagagc actgattgga ctaggggccc tcaccgggtt accgaattca gtcaaactcc 960  
 gaatgccaat gacttatcct tgggagtcag actgcgagtg ataagatccg tagtcgaaag 1020  
 ggaaacagcc cagaccgcca gctaagggtcc caaagtatac gttaagtgga aaaggatgtg 1080  
 gagttgctta gacaaccagg atgttggtt agaagcagcc accattttaa gagtgcgtaa 1140  
 10 tagctcactg gtcgagtgac tctgcgccga aaatgtaccg gggctaaacg tatcaccgaa 1200  
 gctgcggact gttcttcgaa cagtggtagg agagcggtct aagggtgtg aagccagacc 1260  
 ggaaggactg gtggacggct tagaagttag aatgccggta tgagtgcga aaagaggggt 1320  
 gagaatccct ccaccgaatg cctaagggtt cctgaggaag gtcggtccgc tcagggttag 1380  
 tcgggacctg agccgaggcc gaaaggcgta ggcgatggac aacagggtga tattcctgta 1440  
 15 ccacctctc accatttgag caatgggggg tcgcaggagg atagggttaag cgcggtattg 1500  
 gatatccgcg tccaagcagt taggctggga aataggcaaa tccgtttccc ataaggctga 1560  
 gctgtgatgg cgagcgaaat atagtagcga agttcctgat tccacactgc caagaaaagc 1620  
 ctctagcgag gtgagagggt cccgtaccgc aaaccgtcac aggtaggcga ggagagaatc 1680  
 ctaagggtgat cgagagaact ctcgtaagc aactcggcaa aatgacccc taacttcggg 1740  
 20 agaaggggtg ctctgttagg gtgcaagccc gagagagccg cagtgaatag gccaggcga 1800  
 ctgttttagca aaaacacagg tctctgcgaa gccgtaaggc gaagtatagg ggctgacgcc 1860  
 tgcccgggtg tggaagggtta agaggagcgc ttagcgtaag cgaagggtgcg aattgaagcc 1920  
 ccagtaaacg gcggccgtaa ctataacggt cctaaggtag cgaaattcct tgcgggttaa 1980  
 gtcccgacct gcacgaaagg cgcaacgata tgggcgctgt ctcaacgaga gactcgggtg 2040  
 25 aattatagta cctgtgaaga tgcagggttac ccgcgacagg acggaaagac cccgtggagc 2100  
 ttactgagc cctgatattg aatgttggtg cagcttgtag aggataggta ggagccttg 2160  
 aaaccggagc gccagcttcg gtggaggcat cggtgggata ctacctggc tgtattgacc 2220  
 ttctaaccct ccgcccctat cgggcgggga gacagtgtca ggtgggcagt ttgactgggg 2280  
 cggtcgctct ctaaaaggta acggaggcgc ccaaagggtc cctcagaatg gttggaaatc 2340  
 30 attcgagag tgtaaaggca caaggagct tgactgcgag acctacaagt cgagcaggga 2400  
 cgaaagtcgg gcttagtgat ccggtgggtc cgcaggaag ggccatcgct caacggataa 2460  
 aagctacccc ggggataaca ggcttatctc cccaagagc tccacatcga cggggagggt 2520  
 ttggacctct atgtcggctc atcgcatcct ggggtcttag tcggtcccaa ggggtgggt 2580  
 gtccgcccct taaagcggta cgcgagctgg gttcagaacg tcgtgagaca gttcgggtcc 2640  
 35 tatccgtcgc gggcgctgga aatttgagag gagctgtcct tagtacgaga ggaccgggat 2700  
 ggacgcaccg ctggtgtacc agttgttctg ccaagggtat cgctgggtag ctatgtgcgg 2760  
 acgggataag tgctgaaagc atctaagcat gaagcccccc tcaagatgag atttccatt 2820  
 ccgcaaggaa gtaagatccc tgaaagatga tcagggtgat aggtctgagg tggaagtgtg 2880  
 40 gcaacacatg gagctgacag atactaatcg atcgaggact taacct 2927

&lt;210&gt; 50

&lt;211&gt; 2922

&lt;212&gt; DNA

45 <213> *Bacillus anthracis*

&lt;400&gt; 50

50 gggttaagtta gaaagggcgc acggtggatg ccttgacact aggagtcgat gaaggacggg 60  
 actaacgcgc atatgcttcg gggagctgta agtaagcttt gatccgaaga tttccgaatg 120  
 gggaaaccca ccatacgtaa tgggtatggtg tccttatctg aatacatagg gtaagggaaga 180  
 cagaccagcg gaactgaaac atctaagtac ctggaggaag agaaagcaaa tgcgatttcc 240  
 tgagtgcgag cgagcgaaac ggaacatagc ccaaaccaag aggcttgctt cttgggggtg 300  
 taggacattc tatacggagt tacaaggaa cgaggtagac gaagcgacct ggaaagggtc 360  
 gtcgtagagg gtaacaaccc cgtagtcgaa acttcgttct ctcttgaaatg tatcctgagt 420  
 55 acggcggaac acgtgaaatt ccgtcggaat ctgggaggac catctcccaa ggctaaatac 480  
 tccctagtga tcgatagtga accagtaccg tgaggggaaag gtgaaaagca ccccggaagg 540

5 ggagtgaag agatcctgaa accgtgtgcc tacaaatagt cagagcccgt taacgggtga 600  
 tggcgtgcct tttgtagaat gaaccggcga gttacgatcc cgtgcgaggt taagctgaag 660  
 aggcggagcc gcagcgaaag cgagctctgaa tagggcggtt agtacgtggt cgtagacccg 720  
 aaaccagggt atctacccat gtccagggtg aagttcaggt aacctgaat ggaggcccg 780  
 10 acccagcac gttgaaaagt gcggggatga ggtgtgggta gcggagaaat tccaatcgaa 840  
 cctggagata gctggttctc cccgaaatag ctttagggct agccttaagt gtaagagtct 900  
 tggaggtaga gcaactgatt gactaggggt cctcatcgga ttaccgaatt cagtcaaaact 960  
 ccgaatgccat atgactttat cttaggagtc agactgcgag tgataagatc cgtagtcaaa 1020  
 agggaaacag cccagaccgc cagctaagggt cccaaagtgt gtattaagtg gaaaaggatg 1080  
 15 tggagttgct tagacaacta ggatgttggc ttagaagcag ccaccattta aagagtgcgt 1140  
 aatagctcac tagtcgagtg actctgcgcc gaaaatgtac cggggctaaa tacaccaccg 1200  
 aagctgcctg ttgataccaa tggatcaggt ggtaggggag cgttctaagg acagtgaagt 1260  
 cagaccggaa ggactggtgg agtgcttaga agtgagaatg ccggtatgag tagcgaaaga 1320  
 cgggtgagaa tcccgctccac cgaatgccta aggtttctct aggaaggctc gtccgctcag 1380  
 20 ggtagtcag gacctaagcc gagccgaca ggcgtaggcg atggacaaca ggttgatatt 1440  
 cctgtaccac ctcttttatc tttgagcaat ggagggacgc agaaggatag aagaagcgtg 1500  
 cgattggttg tgcacgtcca agcagttagg ctgataagta ggcaaaccg cttatcgtga 1560  
 aggtgagct gtgatgggga agctccttat ggagcgaagt ctttgattcc ccgctgcaa 1620  
 25 gaaaagcttc tagcgagata aaaggtgcct gtaccgcaa ccgacacagg taggcgagga 1680  
 gagaatccta aggtgtgcga gagaactctg gttaaagaa tcggcaaaat gaccccgtaa 1740  
 cttcgggaga aggggtgctt tcttaacgga aagccgcagt gaataggccc aagcgactgt 1800  
 ttagcaaaaa cacagctctc tgcgaagccg taaggcgaag tataggggtg gacacctgcc 1860  
 cgggtgctgga aggttaagga gaggggttag cgttaagcga gctctgaact gaagccccag 1920  
 30 taaacggcgg ccgtaactat aacggtccta aggttagcga attccttgtc gggtaagtct 1980  
 cgacccgcac gaaaggtgta acgatttggg cactgtctca accagagact cggtgaaatt 2040  
 atagtacctg tgaagatgca ggttaccgcg gacaggacgg aaagaccccg tggagcttta 2100  
 ctgtagcctg atattgaatt ttggtacagt ttgtacagga taggcgggag cttttgaaac 2160  
 cggagcgcta gcttcggtgg aggcgctggt gggataccgc cctgactgta ttgaaattct 2220  
 aacctacggg tcttatcgac ccgggagaca gtgtcagggt ggcagtttga ctggggcggt 2280  
 35 cgccctcctaa agtgtaacgg aggcgcccac aggttccctc agaattggtt gaaatcattc 2340  
 gtagagtgca aaggcataag ggagcttgac tgcgagacct acaagtcgag cagggacgaa 2400  
 agtcgggctt agtgatccgg tggttccgca tgggaaggcc atcgctcaac ggataaaaagc 2460  
 taccocgggg ataacaggct tatctccccc aagagtcac atcgacgggg aggtttggca 2520  
 cctcgatgct ggctcatcgc atcctggggc gttagtcggt cccaagggtt gggctgttccg 2580  
 40 cccattaaag cggtagcgca gctgggttca gaacgtcgtg agacagttcg gtccctatcc 2640  
 gtcgtgggcg taggaaattt gagaggagct gtccttagta cgagaggacc gggatggacg 2700  
 caccgctggt gtaccagttg ttctgccaag ggcatagctg ggtagctatg tgcggaaggg 2760  
 ataagtgtg aaagcatcta agcatgaagc cccctcaag atgagatttc ccatagcgta 2820  
 agctagtaag atccctgaaa gatgatcagg ttgatagggt cgaggtggaa gcatggtgac 2880  
 45 atgtggagct gacgaatact aatagatcga ggacttaacc at 2922

&lt;210&gt; 51

&lt;211&gt; 2912

45 &lt;212&gt; DNA

<213> *Enterococcus faecalis*

&lt;400&gt; 51

50 ggtaagtga ataagggcgc acggtggatg ccttggcact aggagccgat gaaggacggg 60  
 actaacaccg atatgctttg gggagctgta agtaagctat gatccagaga tttccgaatg 120  
 ggggaaccca atatctttta taggatatta cttttcagtg aatacatagc tgattagagg 180  
 tagacgcaga gaactgaaac atcttagtac ctgcaggaag agaaagaaaa ttcgattccc 240  
 tgagtagcgg cgagcgaaac gggaagagcc caaaccaaca agcttgcttg ttgggggttg 300  
 aggactccaa tatggttagt tggttagtata gttgaaggat ttggaaaatt ccgctaaaaga 360  
 55 ggggtgaaagc cccgtagacg aaatgctaac aacacctagg aggatcctga gtacggcgga 420  
 acacgagaaa ttccgtcgga atccgcgggg accatcccg aaggctaaat actccctag 480



5 gaccgatagt gaaccagttac cgtgagggaa aggtgaaaag caccgccgaa ggggagtgaa 540  
 atagatcctg aaaccgtgtg cctacaacaa gtcaaagctc gttaatgagt gatggcgtgc 600  
 cttttgtaga atgaaccggc gagttacgat tgcattgcgag gttaaagtcga agagacggag 660  
 ccgcagcgaa agcagagtctg aatagggcga atgagtatgt agtcgtagac ccgaaacccat 720  
 gtgatctacc catgtccagg ttgaaggtgc ggtaaaacgc actggaggac cgaacccacg 780  
 tacgttgaaa agtgccggga tgaggtgtgg gtacgggaga aattccaaac gaacttgag 840  
 atagctggtt ctctccgaaa tagctttagg gctagcctcg gaattgagaa tgatggagggt 900  
 agagcactgt ttggactagg ggcccatctc ggggttaccga attcagataa actccgaatg 960  
 10 ccattcattt atatccggga gtcagactgc gagtataaag atccgtagtc gaaagggaaa 1020  
 cagcccagac caccagctaa ggtcccaaaa tatatgtaa gtggaaaagg atgtgggggtt 1080  
 gcacagacaa ctaggatgtt ggcttagaag cagccacccat ttaaagagtg cgtaatagct 1140  
 cactagtcca gtgacctgc gccgaaaatg taccggggct aaacatatta ccgaagctgt 1200  
 ggactacacc attaggtgta gtggtaggag agcgttctaa gggcgttgaa ggtcgtatcg 1260  
 gaggcaggct ggagcgctta gaagttagaa tgcgggtatg agtagcgaaa gacaggtgag 1320  
 15 aatcctgtcc accgtatgac taagggttcc tggggaaggc tcgtccgcc aggggttagtc 1380  
 gggacctaag ccgaggccga taggcgtagg cgtgggaaa caggttgata ttctgtgacc 1440  
 agttgttttt gtttgagcaa tggagggacg cagtaggcta aggaatgcat gcgattggaa 1500  
 gtgcatgtcc aagcaatgag tcttgagtag agttaaagtc tttactctt aaggacaagt 1560  
 tgtgacgggg agcgaaataa tagtagcgaa gttcctgatg tcacactgcc aagaaaagct 1620  
 20 tctagtga aaacaactgc ccgtaccgta aaccgacaca ggtagtcgag gagagtatcc 1680  
 taaggtagc gagcgaactc tcgttaagga actcggcaaa atgaccccg aacttcggga 1740  
 gaaggggtgc tgacttcggt cagccgcagt gaataggccc aagcgactgt ttatcaaaaa 1800  
 cacaggtctc tgcaaaatcg taagatgaag tataggggct gacgcctgcc cggtgctgga 1860  
 aggttaagag gatggggttag ctccggcgaa gtcagaatt gaagccccag taaacggcgg 1920  
 25 ccgtaactat aacggtccta aggtagcgaa attccttgctc gggtaagttc cgacccgcac 1980  
 gaaaggcgta acgatttggg cactgtctca acgagagact cggtgaaatt ttagtacctg 2040  
 tgaagatgca ggttaccgc gacaggacgg aaagacccca tggagcttta ctgtagtttg 2100  
 atattgagtg tttgtaccac atgtacagga taggtaggag ccgatgagac cggaacgcta 2160  
 gtttcggagg aggcgctggt gggatactac ccttggtgta tgaaccctct aaccgcacc 2220  
 30 actaatcgtg gtgggagaca gtgtcagatg ggcagtttga ctggggcggt cgctcctaa 2280  
 aaggtaacgg aggcgcccga aggttccttc agaattggtg gaaatcattc gaagagtgt 2340  
 aaggcagaag ggagcttgac tgcgagacct acaagtcgag cagggacgaa agtcgggctt 2400  
 agtgatccgg tgggtccgca tgggaaggcc atcgctcaac ggtaaaagct accctgggga 2460  
 taacaggctt atctcccca agagtccaca tcgacgggga gggttggcac ctcgatgtcg 2520  
 35 gtcgtcgca tcctggggct gtagtcggtc ccaagggttg ggctgttcgc ccattaaagc 2580  
 ggcacgcgag ctgggttcag aacgtcgtga gacagttcgg tccctatccg tcgcgggctg 2640  
 tggaaatttg agaggagctg tccttagtac gagaggaccg ggatggactt accgctggtg 2700  
 taccagttgt tctgccaagg gcattgctgg gtgactatgt aggggaaggga taaacgctga 2760  
 aagcatctaa gtgtgaagcc cacctcaaga tgagatttcc catttcttta agaaagtaag 2820  
 40 acccctgaga gatgatcagg tagatagggt ggaagtggaa ggctagtgat agttggagcg 2880  
 gaccaatact aatcggtcga ggacttaacc aa 2912

45 <210> 52  
 <211> 2898  
 <212> DNA  
 <213> Lactococcus lactis

50 <400> 52  
 ggcaaagtta ataagggcgc acggtggatg ccttggcact aagagccgat gaaggacgtg 60  
 actaacgacg atattctagg gggagcagta agtacgcatt gatccctagg tctccgaatg 120  
 ggaaaaccca gctgctacta gcagttattc atgagtgaat acatagctca tgtaaaggta 180  
 acgcagagaa ctgaaacatc taagtacctg caggaagaga aagtaaaaac gatttcgtaa 240  
 gtagcggcga gcgaacgcga agaagggcaa accaagaagc ttgcttcttg ggggtgtagg 300  
 55 actgcaacgt ggacttaagc attatagtcg aataacctgg gaaggttaat caaagagggt 360  
 aataatccc tagacgaat agcgcttata ctagcagta tcctgagtag ggctggacac 420

5 gcgaaatcca gtttgaatcc gggaggacca tctcccaacc ctaaatactc cttagtgacc 480  
 gatagtgaac cagtaccgtg agggaaaggt gaaaagaacc cgagagggga gtgaaatagc 540  
 acctgaaacc gtgtgcctac aagaagttcg agcccgttaa tgggtgagag cgtgcctttt 600  
 gtagaatgaa ccggcgagtt acgttatgat gcgaggttaa gttgaagaga cggagccgta 660  
 gggaaaccga gtctgaatag ggcgacttag tatcatgatg tagaccgaa acctagtgc 720  
 ctatccatga cctagggtgaa ggtgtggtaa gacgcactgg agggccgaac caggacacgt 780  
 tgaaaagtgt ttggatgact tgtggatagc ggagaaatc caaacgaact gggagatagc 840  
 tggttctctc cgaaatagct ttagggctag cgtcgaaatg taagtgtatt ggaggtagag 900  
 cactgtttgg gtgaggggtc cgtctaggat taccaatctc agataaactc cgaatgctaa 960  
 10 tacacatggt cggcagtcag actgcgagtg ctaagatccg tagtcgaaag ggaacacagcc 1020  
 cagaccaaca gctaaggtcc caaaatatat gttaagtgga aaaggatgtg gggttgcaca 1080  
 gacaactagg atgttagctc agaagcagct atcattcaaa gagtgcgtaa tagctcata 1140  
 gtccgatgac cctgcccga aatgtaccg ggctaaaca tattaccgaa gctttggatt 1200  
 gatattttat caatggtagg agagcgttct taaccgcgat gaaggtatac cgtgaggagt 1260  
 15 gctggagcgt taagaagtga gaatgccggt atgagtagcg caagataagt gagaatctta 1320  
 tccaccgtaa gactaagggt tccaggggaa ggctcgtccg ccctgggtta gtcgggacct 1380  
 aaggcgaggc cgaaaggcgt agtcgatgga caactgggtg atattccagt actagatatg 1440  
 atcgtgatgg agggacgcag taggctaaga gatgccagtt aatggattct ggtctaagca 1500  
 gtgaggtgtg agatgtgtca aatgcatttc tctttaacat tgagctgtga tggggaagca 1560  
 20 actacggttg cgaactctct gatgtcacac tgccaagaaa agcttctagc gtaaaagcat 1620  
 atctaccctg accgcaaacc gacacaggtg gtcgaggcga gtacccctag gtgatcgaga 1680  
 gaactctcgt taaggaaact ggcaaaatag ccccgtactc tcgggagaag ggggtgctgg 1740  
 gtaaaagcca gccgcagtg ataggcccaa gcaactgttt atcaaaaaca cagctctctg 1800  
 ctaaacccga aggtgatgta taggggggtg cgcttgcccg gtgctggaag gttaaagagga 1860  
 25 gtgcttagac gtaagtcgaa ggtatgaatt gaagccccag taaacggcgg ccgtaactat 1920  
 aacggctcta aggtagcgaa attccttgtc gggtaaagtt cgaccgcac gaaaggcgta 1980  
 atgatttggg cactgtctca acgagagact cggtgaaatt ttagtacctg tgaagatgca 2040  
 ggttaccgcg gacaggacgg aaagacccca tggagcttta ctgtagtttg atattgagta 2100  
 cctgtaagtc atgtacagga taggtaggag ccattgaaat agggacgcta gtttctattg 2160  
 30 aggcgttggt gggatactac ccttgactta tggttactct aaccgcctgg cataatcggc 2220  
 caggagagaca gtgtctgacg gacagtttga ctggggcggt cgctcctaaa gagtaacgga 2280  
 ggcgctcaaa ggttgggtca gattgggttg aaatcaatcg tagagtgtaa aggtaaaagc 2340  
 cagcttgact gcgagagcta caactcgagc aggtaggaaa ctaggactta gtgatccggt 2400  
 ggtaccgcat ggaagggccca tcgctcaacg gataaaaagct accctgggga taacaggctt 2460  
 35 atctccccca agagttcaca tcgacgggga ggtttggcac ctcgatgtcg gctcgtcgca 2520  
 tcctggggct gtagtcggtc ccaaggggtg ggctgttcgc cattaaagcg gcacgcgagc 2580  
 tgggttcaga acgtcgtgag acagttcggg ccctatccgt cgcgggcgta ggtaatttga 2640  
 gaggatctgt ccttagtacg agaggaccgg gatggactta ccgctgggtg accagttgtt 2700  
 ccgccaggag cacggctgga tagctatgta gggaaaggat aagcgtgaa agcatctaag 2760  
 40 tgcgaagccc acctcaagat gagattaccc attcgtgaaga attaagagcc cagagagatg 2820  
 atctggtaga taggctggaa gtggaagagt tgcgagactt ggagcggacc agtactaatc 2880  
 gctcgaggac tttaacaa 2898

45 <210> 53  
 <211> 2932  
 <212> DNA  
 <213> *Listeria monocytogenes*

50 <400> 53  
 ggtaagtta gaaagggcgc acggtggatg ccttggcact aggagccgaa gaaggacggg 60  
 actaacaccg atatgctttg gggagctgta cgtaagcggt gatccagaga tttccgaatg 120  
 ggggaaccca ctatctttag tcggatagta tccttacgtg aatacatagc gtgaggaagg 180  
 cagacccagg gaactgaaac atctaagtag ctggaggaag agaaagaaaa atcgattttc 240  
 55 tgagtagcgg cgagcgaaac ggaaagagcc caaaccaaga agcttgcttc ttgggggtgt 300  
 aggacactct atacggagtt acaaaaagaa gttataaatg aagcgggtctg gaaaggcccc 360

5 ccaaagacgg taacagcccg gtagttgaaa tggctttccc tccagagtgg atcctgagta 420  
 cggcggaaca cgtgaaattc cgtcgggaatc cgggaggacc atctcccaag gctaaatact 480  
 ccctagtac cgtagtga cagtagccgt gagggaaagg tgaaaagcac cccggaaggg 540  
 gagtgaacaa gtctctgaaa ccgtgtgcct acaagtagtt agagcccgtt aatgggtgat 600  
 agcgtgacct ttgtagaatg aaccggcgag ttacgatttg ttgcaagggt aagcggaaaa 660  
 agcggagccg tagcgaagc gagtctgaat agggcgcata agtaacagggt cgtagaccgg 720  
 aaaccagggt atctacccat gtccaggatg aaggtaagggt aatacttact ggagggtccga 780  
 acccacgcac gttgaaaagt gcggggatga ggtgtgggta gcggagaaat tccaatcgaa 840  
 10 cttggagata gctggttctc tccgaaatag ctttagggct agcctcgagg taaagagtca 900  
 tggaggtaga gcaactgttg gactaggggc ctttctcggg ttaccgaatt cagataaact 960  
 ccgaatgcca tgtacttata ctcgggagtc agactgcgag tgataagatc cgtagtcgaa 1020  
 agggaaacga cccagaccac cagttaagggt ccccaaatat atgttaagt gaaaaggatg 1080  
 tggggttgct tagacaacca ggatgttggc ttagaagcag ccaccattga aagagtgcgt 1140  
 aatagctcac tggctcagtg accccgcgcc gaaaatgtac cggggctaaa catattaccg 1200  
 15 aaactgtgga tgaacctctt tagagggttc tggtaggaga gcgttctaag ggcggtgaag 1260  
 tcagaccgga aggactggtg gagcgcttag aagtgagaat gccggtatga gtagcgaaag 1320  
 aagggtgaga atcccttcca ccgaatatct aagggttctc gaggaagggt cgtccgctca 1380  
 gggttagtcg ggacctaaag cgaggccgat aggcgtaggc gatggacaac aggtagagat 1440  
 tctgtacca gtgctaattg tttaacccgat ggggtgacac agaaggatag ggaatcgac 1500  
 20 gaatggaaat gtgcgtccaa gcagtgaagt tgagaagtag gcaaatccgc ttctcacgaa 1560  
 gcatgagctg tgatggggaa ggaaattaag tacggaaagt cctgatttca cgctgtcaag 1620  
 aaaagcctct aggaagagta gtactgccc taccgcaaac cgacacaggt agatgaggag 1680  
 agaatcctaa ggtgagcgag agaactctcg ttaaggaaact cggcaaaatg accccgtaac 1740  
 ttccggagaa ggggtgctct attagggtgc aagcccgaga gagccgcagt gaataggccc 1800  
 25 aggcgactgt ttagcaaaaa cacaggcttc tgcaaaaccg taaggtagc tataggggct 1860  
 gacgcctgcc cgggtctgga aggttaagag gagtgccttag cttcggcgaa ggtacgaatt 1920  
 gaagccccag taaacggcgg ccgtaactat aacggtccta aggtagcgaa attccttgct 1980  
 gggtaagttc cgaccgcac gaaaggcgca acgatctggg cactgtctca acgagagact 2040  
 cggtgaaatt atagtacctg tgaagatgca ggttaccgc gacaggacgg aaagaccccc 2100  
 30 tggagcttta ctgcaacctg atatggaatg tttgtaccgc ttgtacagga taggtaggag 2160  
 ccgaagagac gtgtgcgcta gcatacgagg aggcaatggt gggatactac cctggctgta 2220  
 tgaccattct aaccgcgcac gcttagcgcg tggggagaca gtgtcagggt ggcagtttga 2280  
 ctggggcgggt cgcctcctaa agagtaacgg aggcgcctaa aggttccctc agaatggatg 2340  
 gaaatcattc gcagagtgt aaggcacaag ggagcttgac tgcgagactg acaagtgcag 2400  
 35 caggagcgaa agtcgggctt agtgatccgg tggttccgca tggaaaggcc atcgctcaac 2460  
 ggataaaaag taccgcgggg ataacagggt tatctcccc aagagtccac atcgacgggg 2520  
 aggtttggca cctcgatgtc ggctcgtcgc atcctggggc tgtagtcggt cccaagggtt 2580  
 gggctgttcg ccattaaag cggcacgcga gctgggttca gaacgtcgtg agacagttcg 2640  
 gtccctatcc gtgcggggcg caggaaattt gagaggagct gtccttagta cgagaggacc 2700  
 40 gggatggaca caccgctggt gtaccagttg ttccggcagg agcatcgtg ggtagctatg 2760  
 tgtggcaggg ataaacgctg aaagcatcta agcgtgaagc cccctcaag atgagatttc 2820  
 ccatttcttc ggaaagtaag atccctgaaa gatgatcagg tagatagggt tggagtggaa 2880  
 gtgtagcgat acatggagcg gacaaatact aatcgatcga ggacttaacc aa 2932

45 <210> 54  
 <211> 2923  
 <212> DNA  
 <213> Staphylococcus aureus

50 <400> 54  
 gattaagtta ttaagggcgc acgggtggatg ccttggcact agaagccgat gaaggacgtt 60  
 actaacgacg atatgctttg gggagctgta agtaagcttt gatccagaga tttccgaatg 120  
 gggaaaccca gcatagttta tgtcatgtta tcgatatgtg aatacatagc atatcagaag 180  
 55 gcacaccggg agaagtaaa catcttagta cccggaggaa gagaagaaa attcgatttc 240  
 cttagtagcg gcgagcgaaa cgggaagagc ccaaaccaac aagcttgctt gttgggggtt 300

taggacactc tatacggagt tacaaaggac gacattagac gaatcatctg gaaagatgaa 360  
 tcaaagaagg taataatcct gtagtcgaaa atgttgtctc tcttgagtgg atcctgagta 420  
 cgacggagca cgtgaaatcc cgtcgggaatc tgggaggacc atctcctaag gctaaatact 480  
 ctctagtgcg cgatagtga ccagtagcgt gagggaaagg tgaaaagcac cccggaaggg 540  
 5 gagtgaata gaacctgaaa ccgtgtgctt acaagtagtc agagcccggt aatgggtgat 600  
 ggctgcctt ttgtagaatg aaccggcgag ttacgatttg atgcaagggt aagcagtaaa 660  
 tgtggagccg tagcgaaagc gagtctgaat agggcggtta gtatttgggtc gtagaccgga 720  
 aaccagggtga tctacccttg gtcagggtta agttcaggta acactgaatg gaggaccgaa 780  
 ccgacttacg ttgaaaagtg agcggatgaa ctgagggtag cggagaaatt ccaatcgaac 840  
 10 ctggagatag ctggttctct ccgaaatagc tttagggcta gcctcaagtg atgattattg 900  
 gaggtagagc actgtttgga cgagggggccc ctctcgggtt accgaattca gacaaactcc 960  
 gaatgccaat taatttaact tgggagtcga aacatgggtg ataagggtccg tgttcgaaag 1020  
 ggaaacagcc cagaccacca gctaaggctc caaaatataat gttaagtggg aaaggatgtg 1080  
 gcgttgcccc gacaactagg atgttggcctt agaagcagcc atcatttaaa gagtgcgtaa 1140  
 15 tagctcacta gtcgagtgc actgcgcga aaatgtaccg gggctaaaca tattaccgaa 1200  
 gctgtggatt gtcccttgga caatggtagg agagcggtct aagggcggtg aagcatgatc 1260  
 gtaaggacat gtggagcgct tagaagttag aatgccgggt tgagtagcga aagacgggtg 1320  
 agaatcccg ccaccgattg actaagggtt ccagaggaag gctcgtccgc tctgggttag 1380  
 tcgggtccta agctgaggcc gacaggcgta ggcgatggat aacagggtga tattcctgta 1440  
 20 ccacctataa tcgttttaac cgatgggggg ttacgtagg ataggcgaag cgtgcgattg 1500  
 gattgcacgt ctaagcagta aggtcgagta ttaggcaaat ccggtactcg ttaaggctga 1560  
 gctgtgatgg ggagaagaca ttgtgtcttc gagtgcgtga ttccactg ccgagaaaag 1620  
 cctctagata gaaaataggt gcccgtagc caaacgaca caggtagtca agatgagaat 1680  
 tctaaggtag gcgagcgaac tctcgtaag gaactcggca aaatgacccc gtaacttcgg 1740  
 25 gagaaggggt gctcttttag gttaacgccc agaagagccg cagtgaatag gccaagcga 1800  
 ctgtttatca aaaacacagg tctctgctaa accgtaaggat gatgtatagg ggctgacgcc 1860  
 tgcccggtgc tggaaaggta agaggagtg tttagctctg cgaagctacg aatcgaagcc 1920  
 ccagtaaacg gcggccgtaa ctataacggt cctaaggtag cgaaattcct tgcgggtaa 1980  
 gttccgaccc gcacgaaagg cgtaacgatt tgggcactgt ctcaacgaga gactcgggtga 2040  
 30 aatcatagta cctgtgaaga tgcaggttac ccgacgagc acggaaagac cccgtggagc 2100  
 ttactgttag cctgatattg aaattcggca cagcttgtag aggataggta ggagcctttg 2160  
 aaacgtgagc gctagcttac gtggaggcgc tggtgggata ctaccctagc tgtgttggt 2220  
 ttctaaccgc caccattat cggtgtggga gacagtgtca ggcgggcagt ttgactggg 2280  
 cggctgcctc ctaaaaggta acggaggcgc tcaaagggtt cctcagaatg gttggaaatc 2340  
 35 attcatagag tgtaaaggca taaggagct tgaactgcag acctacaagt cgaagcgggt 2400  
 cgaaagacgg acttagtgat ccggtgggtc cgcagtggaag ggccatcgct caacggataa 2460  
 aagctacccc ggggataaca ggcttatctc cccaagagt tcacatcgac ggggaggttt 2520  
 ggacactcga tgcgggtca tgcacatcct gggctgtagt cggccccaaag ggttgggctg 2580  
 40 ttcgcccatt aaagcggtag gcgagctggg ttcagaacgt cgtgagacag ttcgggtccct 2640  
 atccgtcgtg ggcgtaggaa atttgagagg agctgtcctt agtacgagag gaccgggatg 2700  
 gacatacctc tgggtgacca gttgtcgtgc caacggcata gctgggtagc tatgtgtgga 2760  
 cgggataaagt gctgaaagca tctaagcatg aagccccct caagatgaga tttcccaact 2820  
 tcgggtataa gatccctcaa agatgatgag gttaataggt tcgaggtgga agcatggtga 2880  
 45 catgtggagc tgacgaatac taatcgatcg aagacttaat caa 2923

&lt;210&gt; 55

&lt;211&gt; 2900

&lt;212&gt; DNA

50 &lt;213&gt; Streptococcus mutans

&lt;400&gt; 55

55 gttaaggttaa taaggcgca cggtagatgc ctaggcacta ggagccgatg aaggacgtga 60  
 cgaacgacga catgcttttg ggagctgtaa gtaagccttg atccagagat atccgaatgg 120  
 gggaacccaa caggtaatgc ctgttatcca taactgttaa ggttatgaga aggaagacgc 180  
 agtgaactga aacatctcag tagctgcagg aagagaaagc aagagcgatt gcctcagtag 240

5 cggcgagcga agaggcagga gggcaaacca gagtgtttac actctggggg ttaggactg 300  
 cgataaagca gccaaaggaa tagaagaaga ctctgggaag agtcgccaga gagagtaaga 360  
 gcctcgtatt tgaaattcac ttgatgccaa gcaggatcct gactacggcg ggacacgagg 420  
 aatcccgcg gaactcggga ggcccatctc ccaaccctaa atactcccta gtgaccgata 480  
 gtgaaccagt accgtgagg aaaggtagaa agtaccgcg aaggggagtg aaagagaacc 540  
 tgaaaccgtg tgcttacaag aagttcgagc ccgttaatgg gtgagagcgt gccttttgta 600  
 gaatgaaccg gcgagttacg tttacgtgcg aggttaagtt gaagagacgg agccgtaggg 660  
 aaaccgagtc tgaaaagggc gggttaagtag gtagatgtag acccgaaacc aagtgcacta 720  
 cccatgagca gggtgaaggt gcggtaaaac gactggagg accgaaccag gacacgttga 780  
 10 aaagtgtttg gatgacttgt gggtagcgga gaaattccaa acgaacttgg agatagctgg 840  
 ttctctccga aatagcttta gggtagcgt cggtcgcgag actcttgag gtgagcacta 900  
 gtttgattga ggggtccatc ccggttacc aatctcagat aaactccgaa tgccaacgag 960  
 ttaagaccgg cagtcagact gcgagtgcta agatccgtag tcgaaaggga aacagccag 1020  
 accaccagct aagggtccca aataattggt aagtggaaaa ggatgtgggg ttgcacagac 1080  
 15 aactaggatg ttagcttaga agcagctatt cattcaaaga gtgcgtaata gctcactagt 1140  
 cgagtgacct tgcgccgaaa atgtaccggg gctgaaacaa tttaccgaag ctgtggatcc 1200  
 cttaggggat ggtaggagag cgttctatgt gcgcagaagg tgtaccgcaa ggagcgctgg 1260  
 agtgcataga agtgagaatg ccggtatgag tagcgtaga caggtgagaa tctgtccac 1320  
 cgtaagacta aggattccag gggaaggctc gtccgcctg ggtagtcgg gacctaagga 1380  
 20 gagaccgata ggtgtatccg atgggcaaca ggttgatatt cctgtactag agtattgagt 1440  
 gaaggaggga cgcagcaggc taactagagc gtgcgattgg aagagcacgt ccaagcagt 1500  
 aggtgaggac tgagtcaaat gcttagttct gcgccaccaa gctgtgacgg ggagcgaagt 1560  
 ttagtagcga agctagtgat gtcactctgc caagaaaagc ttctagcgtt aatgaatact 1620  
 ctaccctgac cgcaaaccga cacaggtagt cgaggcgagt agcctcaggt gatcgagcga 1680  
 25 actctcgtta aggaactcgg caaaatggcc ccgtaacttc gggagaaggg gcgctggcga 1740  
 taagtcagcc gcagtgaata ggcccaagca actgtttatc aaaaacacag ctctctcgca 1800  
 aatcgtaaga tgaagtatag ggggtgacgc ctgcccgggtg ctggaagggtt aagaggagcg 1860  
 cttagacgtt tgtcgaagggt gtgaattgaa gccccagtaa acggcgggcg taactataac 1920  
 ggtcctaagg tagcgaatc ccttgctcgg taagtccga cccgcacgaa aggcgtaatg 1980  
 30 atttgggcac tgtctcaacg agagactcgg tgaaatttta gtacctgtga agatgcaggt 2040  
 taccgcgcac aggacggaaa gaccccatgg agctttactg cagtttgata ttgcgtatct 2100  
 gttacacatg tacaggatag gtaggagcca aggaagagt aacgctagtt tacttgagg 2160  
 cgttggtggg atactaccct tgtgtgatgg ctactctaac ccggtagggt gatcatctac 2220  
 ggagacagtg tctgacgggc agtttgactg gggcggtcgc ctctaaagc gtaacggagg 2280  
 35 cgcccaaagg ttccctcaga ctggttgga atcagtcgta gagtgtaaag gtataaggga 2340  
 gcttgactgc gagacagaca agtcgagcag ggacgaaagt cgggcttagt gatccgggtg 2400  
 taccgtatgg aagggccatc gctcaacgga taaaagctac cctggggata acaggcttat 2460  
 ctcccccaag agttcacatc gacggggagg tttggcacct cgatgtcggc tcgtcgcac 2520  
 ctggggctgt agtcgggtccc aagggttggg ctgttcgccc attaaagcgg cacgcgagct 2580  
 40 ggggttcagaa cgtcgtgaga cagttcggtc cctatccgtc gcgggcgaag gaaatttgag 2640  
 aggatctgct cctagtacga gaggaccaga gtggacttac cgctgggtga ccagttgttc 2700  
 tgccaagagc atcgtcgggt agctaagtag ggaggggata aacgctgaaa gcatctaagt 2760  
 gtgaagcccc cctcaagatg agatttccca taacgttcag ttagtaagag ccctgaaaga 2820  
 45 agaacaggtg gataggttgg gagtggaaagc gttgtgagac gtgaagcgga ccaataactaa 2880  
 tcgctcgagg acttatccaa 2900

&lt;210&gt; 56

&lt;211&gt; 2902

50 &lt;212&gt; DNA

&lt;213&gt; Streptococcus pneumoniae

&lt;400&gt; 56

55 gggttaagtta ataagggcgc acgggtggatg ccttggcact aggagccgac gaaggacgtg 60  
 acaaacgacg atatgccttg ggtagctgta agtaagcgat gatccaggga tttccgaatg 120  
 ggggaaccca acaggtaata cctgttacc acatctgtta aggatgtgag gaggaagacg 180

5 cagtgaactg aaacatctaa gtagctgcag gaagagaaa caaaagcgat tgccttagta 240  
 gcggcgagcg aaacggcaga agggcacaacc gaagagttta ctcttcgggg ttgtaggact 300  
 gcaatgtgga ctcaaagatt atagaagaat gattttggaa gatcagccaa agagagtaat 360  
 agcctcgtat ttaaaatagt ctttgtactt agcagtatcc tgagtacggc gggacacgtg 420  
 aaatcccgtc ggaatctggg aggaccatct cccaacccta aatactccct agtgaccgat 480  
 agtgaaccag tacctgtagg gaaagggtgaa aagcaccocg ggaggggagt gaaatagaac 540  
 ctgaaaccgt gtgcctacaa caagttcgag ccggttaatg ggtgagagcg tgccttttgt 600  
 agaatgaacc ggcgagttac gttatgatgc gaggttaagt tgaagagacg gagccgtagg 660  
 gaaaccgagt ctgaataggg cgcttagta tcatgacgta gacccgaaac catgtgacct 720  
 10 acccatgagc aggttgaagg tgcggttaaga cgcactggag gaccgaacca gggcacgttg 780  
 aaaagtgcct ggatgacttg tgggtagcgg agaaattcca aacgaacttg gagatagctg 840  
 gttctctccg aaatagcttt agggctagcg tcgacattag agattcttgg aggtagagca 900  
 ctgtttgggt taccgggtcca tcccggatta ccaatctcag ataaactccg aatggcaatg 960  
 aattatgggtc ggcagtcaga ctgcgagtcg taagatccgt agtcgaaagg gaaacagccc 1020  
 15 agaccaccag ctaagggtccc aaaataattg ttaagtggaa aaggatgtgg ggttgacag 1080  
 acaactagga tgttagctta gaagcagcta ttcatcaca gagtgcgtaa tagctcacta 1140  
 gtcgagtgac cctgcgccga aaatgtaccg gggctaaaac aatttaccga agctgtggat 1200  
 acctttatag gtatggtagg agagcgcttc atgtgtgatg aagggtatacc gtgaggagt 1260  
 ctggaacgca tagaagttag aatgccggta tgagtgcga aagacagggt agaaccctgt 1320  
 20 ccaccgtaag actaagggtt ccagggggaa cctcgctccg cctgggttag tcgggacctt 1380  
 aggagagacc gaaagggtga tccgatggac aacagggtta tattcctgta ctagagtatg 1440  
 tagtgatgga gggacgcagt aggctaacta aagcagacga ttggaagagt ctgtctaagc 1500  
 agtgagggtg gaattgagtc aaatgcttaa ttctataaca ttgagctgtg atggggagcg 1560  
 aagtttagta gcgaagttag tgacgtcaca ctgccaaaga aagcttctag cgtttaaaca 1620  
 25 tactctaccc gtaccgcaaa ccgacacagg tagtcgagggc gagtagcctc aggtgagcga 1680  
 gagaactctc gttaaggaac tcggcaaaaac gaccccgtaa cttcggggaga aggggtgctg 1740  
 acttaaagtc agccgcagtg aataggccca agcaactgtt tatcaaaaac acagctctct 1800  
 gctaaatcgt aagatgatgt ataggggggtg agccctgccc ggtgctggaa ggttaagagg 1860  
 agtgcttagc gtaagcgaag gtatgaattg aagccccagt aaacggcggc cgtaactata 1920  
 30 acggctcctaa ggtagcgaat ttcttctgct ggtaagttcc gacccgcacg aaaggcgtaa 1980  
 tgatttgggc actgtctcaa cgagagactc ggtgaaattt tagtacctgt gaagatgcag 2040  
 gttacccgcg acaggacgga aagaccccat ggagctttac tgcagtttga tattgagtgt 2100  
 ctgtaccaca tgtacaggat aggtaggagt ctaagagatc gggacgccag tttcgaagga 2160  
 35 gacgtgtgtg ggatactacc ctgtgtttat ggccactcta acccagatag gtgatcccta 2220  
 tcggagacag tgtctgacgg gcagtttgac tggggcggtc gcctcctaaa aggtaacgga 2280  
 ggcgccccaa ggttccctca gaatgggttg aaatcattcg cagagtgtaa aggtataagg 2340  
 gagcttgact gcgagagcta caactcgagc agggacgaaa gtcgggctta gtgatccggt 2400  
 ggttccgtat ggaagggcca tcgctcaacg gataaaagct accctgggga taacaggctt 2460  
 40 atctccccc agagttcaca tcgacgggga ggtttggcac ctcgatgtcg gctcgtcgca 2520  
 tcctgggggt gtagtcggtc ccaagggttg ggctgttcgc ccattaaagc ggcacgcgag 2580  
 ctgggttcag aacgtcgtga gacagttcgg tccctatccg tcgcgggcgt aggaaatttg 2640  
 agaggatctg ctcttagtac gagaggacca gagtggactt accgctggtg taccagttgt 2700  
 cttgccaaag gcatcgctgg gtagctatgt agggaaaggga taaacgctga aagcatctaa 2760  
 gtgtgaaacc cacctcaaga tgagatttcc catgattata tatcagtaag agccctgaga 2820  
 45 gatgatcagg tagataggtt agaagtggaa gtgtggcgac acatgtagcg gactaatact 2880  
 aatagctcga ggacttatcc aa 2902

50 <210> 57  
 <211> 2901  
 <212> DNA  
 <213> Streptococcus pyogenes

55 <400> 57  
 ggtaagtta ataagggcgc acggtggatg ccttggcact agaagccgaa gaaggacgtg 60  
 actaacgacg aaatgctttg gggagctgta agtaagcgct gatccagaga tgtccgaatg 120

5 ggggaacccg gcatgtaatg catgtcatcc atgactgtta aggtcatgag aaggaagacg 180  
 cagtgaactg aaacatctaa gtagctgcag gaagagaaag caaacgcgat tgccttagta 240  
 gcggcgagcg aaacggcagg agggcaaacg gaggagttta ctccctcgagg ttgtaggact 300  
 gcgaagtggg acataaagtt aatagaagaa ttacctggga aggtaagcca aagagagtaa 360  
 cagcctcgta tttaaaattg acttttagccc tagcagtatc ctgagtacgg cgagacacgc 420  
 gaaatctctg cggaaatctgg gaggaccatc tcccaaccct aaatactctc tagtgaccga 480  
 tagtgaacca gtaccgtgag ggaaagggtg aaagcaccct gggaggggag tgaatataga 540  
 cctgaaacccg tgtgcctaca acaagttcga gcccgtaat gggtagagac gtgccttttg 600  
 tagaatgaac cggcgagttg cgatatgatg cgaaggtaag ttgaagagac ggagccgtag 660  
 10 ggaaaccgag tcttaatagg gcgtcatagt atcatgttgt agaccgaaa ccatgtgacc 720  
 taccatgag caggttgaag gtgtggtaaa acgcactgga ggaccgaacc agggcacgtt 780  
 gaaaagtgtc tggatgactt gtgggtagcg gagaaattcc aaacgaactt ggagatagct 840  
 ggttctctcc gaaatgactt tagggctagc gtcgagtgtt agtctcttgg aggtagagca 900  
 ctgtttgggt gaggggtcca tcccggatta ccaatctcag ataaactccg aatgccaacg 960  
 15 agatataatc ggcagtcaga ctgcgagtgc taagatccgt agtcgaaagg gaaacagccc 1020  
 agaccaccag ctaagggtccc aaaataactg ttaagtggaa aaggatgtgg ggttgccacg 1080  
 acaactagga tgttagctta gaagcagcta ttcatcctaa gagtgcgtaa tagctcacta 1140  
 gtcgagtgc cctgcgcgga aaatgtaccg gggctaaaac agtttaccga agctgtggat 1200  
 gacacaaaag tgtcatggta ggagagcggt ctatgtgtga agaagggtga ccgtgaggag 1260  
 20 cgctggaacg catagaagtg agaatgccgg tatgagtgc gaaagacagg tgagaatcct 1320  
 gtccaccgta agactaaggt ttccagggtg aggtctgtcc gccctgggtt agtcgggacc 1380  
 taaggagaga ccgaaagggt tatccgatgg ccaacagggt gatattcctg tactagagta 1440  
 tatagtgatg gagggacgca gtaggctaac taaaccggac gattggaaga gtccggctaa 1500  
 gcagtgaggt gtaagatgag tcaaatgctt atctttataa cattgagctg tgatggggag 1560  
 25 cgaatttttag tagcgaagtt agtcatgtca cactgccaaag aaaagcttct agcgtttaat 1620  
 gatactctac ccgtaccgca aaccgacaca ggtagtcgag gcgagttagc tcaggtgac 1680  
 gagagaactc tcgttaagga actcggcaaa aacttcggga gaaggggtgc 1740  
 tgacttaggt cagccgcagt gaataggccc aagcaactgt ttatcaaaaa cacagctctc 1800  
 tgctaaatcg taagatgatg tataggggtt gacgcctgcc cgggtgctgga aggttaagag 1860  
 30 gaggggttag cgcaagcgaa gatctgaatt gaagccccag taaacggcgg ccgtaactat 1920  
 aacggtccta aggttagcgaa attccttgctc gggtaagttc cgaccgcac gaaaggcgta 1980  
 atgatttggg cactgtctca acgagagact cggtgaaatt ttagtacctg tgaagatgca 2040  
 ggttaccgcg gacaggacgg aaagacccca tggagcttta ctgcagtttg atattgagta 2100  
 tctgtaccac atgtacagga taggtaggag ccattgactt cgggacgcca gtttcgaatg 2160  
 35 aggcgttgtt gggatactac ccttgtgtta tggctactct aaccagata ggttatccct 2220  
 atcggagaca gtgtctgacg ggcagtttga ctggggcggt cgcctcctaa agagtaacgg 2280  
 aggcgcccga aggttccctc agattgggtt gaaatcaatc gcagagtgtg aaggatataag 2340  
 ggagcttgac tgcgagagct acaactcgag cagggacgaa agtcgggctt agtgatccgg 2400  
 tggtagcgaa tggaaaggcc atcgtcaac ggataaaagc taccctgggg ataacaggct 2460  
 40 tatctcccc aagagttcac atcgacgggg aggtttggca cctcgatgtc ggctcgtcgc 2520  
 atcctggggc tgtagtcggt cccaagggtt gggctgttcg cccattaaag cggcacgcga 2580  
 gctgggttca gaacgtcgtg agacagttcg gtccctatcc gtcgcgggcg taggaaattt 2640  
 gagaggatct gctcctagta cgagaggacc agagtggact taccgctggt gtaccagttg 2700  
 tcttgccaaa ggcacgtctg ggtagctatg tagggaaggg ataagcgtg aaagcatcta 2760  
 45 agtgcgaaag cccctcaag atgagatttc ccatgatttt atatcagtaa gagccctgag 2820  
 agatgatcag gtagataggt taggagtgtg agtgtagcga tacatgtagc ggactaatac 2880  
 taatagctcg aggacttatc c 2901

50 <210> 58  
 <211> 3107  
 <212> DNA  
 <213> Mycobacterium avium

55 <400> 58  
 tgtgtgtaag taagtgttta agggcgcatg gtggatgcct tggcatcgag agccgatgaa 60

ggacgtggga ggctgcgata tgcctcgggg agctgtcaac cgagcattga tccgaggatt 120  
 tccgaatggg ggaacccagc acgagtgatg tctgtgtacc cgtatctgaa tatataggg 180  
 gcgggaggtg acgcggggaa gtgaaacatc tcagtaccgc taggagaaga aaacaattgt 240  
 5 gattcccgta gtagtggcga gcgaaccgga acaggctaaa ccgcatgcat ggacaaccgg 300  
 gtaggggttg tgtgtgcggg gttgtgggat tgatatgtct cagctctacc tggctgaggg 360  
 gtagtcagaa agtgtcgtgg ttagcggaag tggcctggga cggcccgccg tagacgggtga 420  
 gagcccggtg cgcgaaaacc cggcacctgc cttatatcaa cacccgagta gcagcgggcc 480  
 cgtggaatct gctgtgaatc tgccggggacc acccggtaa cctaaatact tctcgatgac 540  
 cgatagcgga ttagtaccgt gagggaaatgg tgaagagta cccgggaggg agtgaaatag 600  
 10 tacctgaaac cgtgtgccta caatccgtca gagcctcctc gtgggggtgat ggcggtgcctt 660  
 ttgaagaatg agcctgagag tcagggacac gtcgcgaggt taacccgtgc ggggtagccg 720  
 cagcgaaagc gagtctgaat agggcgcac ccttttgggg ttagtgaggc tgttctggac 780  
 ccgaagcgga gtgatctacc catggccagg gtgaagccg cgtggagccc 840  
 cgaacccact taggttgaag actgagggga ttagctgtgg gtaggggtga aaggccaatc 900  
 15 aaactccgtg atagctgggt tccccgaaa tgcatttagg tgcagcgttg cgtgggtcac 960  
 cacggaggtg gagctactgg atggccgatg ggccctacta ggttactgac gtcagccaaa 1020  
 ctccgaatgc cgtggtgtaa aagcgtggca gtgagacggc gggggataag ctccgtacgt 1080  
 cgaaagggaa acagcccaga tcgcccggta agggccctaa gcgtgtgcta agtggaaaag 1140  
 gatgtgtagt cgcagagaca accaggaggt tggcttagaa gcagccatcc ttgaaagagt 1200  
 20 gcgtaatagc tcaactggta agtgattatg cggcgataat gtagcggggc tcaagcacac 1260  
 cgccgaagcc gcggcacatt catctttacg gtggatgtgg gtaggggagc gtccccatt 1320  
 cagcgaagct ccgggtgacc ggtggtggag ggtgggggag tgagaatgca ggcatgagta 1380  
 gcgataagcc aagtgagaac cttgcccgc gtaagaccaa gggttcctgg gccaggccag 1440  
 tccgcccagg gtgagtcggg acctaaggcg aggcgcagag ggtagtcgat ggacaacggg 1500  
 25 ttgatattcc cgtacccgtg tatgggcgtc cctgatgaat cagcgggtact aaccacccaa 1560  
 aaccggatcg accattcccc ttcgggggag tggcgattcg gggctgcgtg ggaccttcgc 1620  
 tggtagtagt caagcaatgg ggtgacgcag gaagcgagcc gtaccagtca gtggtaatc 1680  
 tggggcaagc cgttagagag cgtataggca atccgtcgtc cactaatcct gagaggtgat 1740  
 gcatagccgg ttgaggcgaa ttcggtgatc ctctgctgcc aagaaaagcc tctagcgagc 1800  
 30 acatacacgg cccgtacccc aaaccaacac aggtggtcag gtagagaata ccaaggcgta 1860  
 cgagataact atgggttaagg aactcggcaa aatgcccccg taacttcggg agaagggggc 1920  
 ccggaatacc gtgaacaccc ttgcgggtgg agcgggattc ggcccgagaa accagtgggt 1980  
 agcgactggt tactaaaaac acaggtccgt gcgaagtcgc aagacgatgt atacggactg 2040  
 acgcctgccc ggtgctggaa ggttaagagg acccgttaac ccgtaagggg gaagcggaga 2100  
 35 atttaagccc cagtaaacgg cggtggtaac tataaccatc ctaaggtagc gaaattcctt 2160  
 gtcgggtaag ttccgacctg cacgaatggc gtaacgactt cccaactgtc tcaaccatag 2220  
 actcggcgaa attgcactac gagtaagat gctcgttacg cgcggcagga cgaaaagacc 2280  
 ccgggacctt cactacaact tggatttggt gttcggtacg gtttgtgtag gataggtggg 2340  
 agactttgaa gcacagacgc cagtttgtgt ggagtcgttg ttgaaatacc actctgatcg 2400  
 40 tattggacac ctaacgtcga acccttatcg ggttcacgga cagtgcctgg cgggtagttt 2460  
 aactggggcg gttgcctcct aaaatgtaac ggaggcgccc aaagggttccc tcaacctgga 2520  
 cggcaatcag gtggcgagtg taagtgcaca agggagcttg actgcgagac ttacaagtca 2580  
 agcagggagc aaagtccgga ctagtgatcc ggcacccccg agtggagggg gtgtcactca 2640  
 acggataaaa ggtaccccgg ggataacggg ctgatcttcc ccaagagtc atacgacgg 2700  
 45 gatggtttgg cacctcgatg tcggctcgtc gcacctcggg gctggagcag gtcccaagg 2760  
 ttgggctggt cgcccattaa agcggcacgc gagctgggtt tagaacgtcg tgagacagtt 2820  
 cgttctctat ccgcccgcgc cgtcagaaac ttgaggaaac ctgtccctag tacgagagga 2880  
 ccgggacgga cgaacctctg gtataccagt tgtccacca ggggcacggc tggatagcca 2940  
 50 cgttcggaca ggaataaccg tgaaagcatc taagcgggaa accttctcca agatcaggtt 3000  
 tctcaccctt tttagaggat aaggccccc gcagaccacg ggattgatag gccagacctg 3060  
 gaagctcagt aatgagtga ggaactggc actaactggc cgaaagc 3107

&lt;210&gt; 59

55 &lt;211&gt; 3138

&lt;212&gt; DNA



## &lt;213&gt; Mycobacterium tuberculosis

&lt;400&gt; 59

	ttgtaagtgt	ctaagggcgc	atgggtggatg	ccttggcatc	gagagccgat	gaaggacgtg	60
5	ggaggctgcg	atatgcctcg	gggagctgtc	aaccgagcgt	ggatccgagg	atbtcggaat	120
	ggggaaaccc	agcacgagtg	atgtcgtgct	accgcacatc	gaatatatag	ggtgcgggag	180
	ggaacgcggg	gaagtgaaac	atctcagtac	ccgtaggagg	agaaaacaat	tgtgattccg	240
	caagtagtgg	cgagcgaacg	cggaaacaggc	taaaccgcac	gcatgggtaa	ccgggtaggg	300
	gttggtgtgtg	cggggttgtg	ggaggatatg	tctcagcgct	acccggctga	gaggcagtca	360
10	gaaagtgtcg	tggttagcgg	aagtggcctg	ggatgggtctg	ccgtagacgg	tgagagcccc	420
	gtacgcgaaa	acccggcacc	tgcttagtat	caattcccga	gtagcagcgg	gcccgtggaa	480
	tccgctgtga	atccgcggg	accaccgggt	aagcctaaat	actcctcgat	gaccgatagc	540
	ggattagtag	cgtgagggaa	tgggtgaaaag	taccccgga	ggggagtga	agagtacctg	600
	aaaccgtgtg	cctacaatcc	gtcagagcct	ccttttcctc	tccggaggag	ggtggtgatg	660
15	gcgtgccttt	tgaagaatga	gcctgcgagt	cagggacatg	tcgcaagggt	aaccctgtgtg	720
	gggtagccgc	agcgaaagcg	agtctgaata	ggcgaccca	cacgcgcata	cgcgctgtgtg	780
	aatagtggcg	tgttctggac	ccgaagcggg	gtgatctacc	catggccagg	gtgaagcgcg	840
	ggtaagaccg	cgtggaggcc	cgaacccact	taggttgaag	actgagggga	tgagctgtgg	900
	gtaggggtga	aaggccaatc	aaactccgtg	atagctgggt	ctccccgaaa	tgcatctagg	960
20	tgcaagcgtg	cgtgggttcac	cgcgagggtg	gagctactgg	atggccgatg	ggccctacta	1020
	ggttactgac	gtcagccaaa	ctccgaatgc	cgtggtgtaa	agcgtggcag	tgagacggcg	1080
	ggggataagc	tccgtacgtc	gaaagggaaa	cagcccagat	cgccggctaa	ggcccccagg	1140
	cgtgtgctaa	gtgggaaagg	atgtgcagtc	gcaaaagaaa	ccaggagggt	ggcttagaag	1200
	cagccaccct	tgaagagagt	cgtaatatgct	cactggtcaa	gtgattgtgc	gccgataatg	1260
25	tagcggggct	caagcacacc	gccgaagccg	cggcacatcc	accttgttgt	gggtgtgggt	1320
	aggggagcgt	ccctcattca	gcgaagccac	cgggtgaccg	gtggtggagg	gtgggggagt	1380
	gagaatgcag	gcctgagtag	cgacaaggca	agtgagaacc	ttgcccgcg	aaagaccaag	1440
	ggttcctggg	ccaggccagt	ccgcccaggg	tgagtcggga	cctaaggcga	ggccgacagg	1500
	cgtagtcgat	ggacaacggg	ttgatattcc	cgtaccctgt	tgtgggcgcc	cgtgacgaat	1560
30	cagcgggtact	aaccacccaa	aaccggatcg	atcactcccc	ttcgggggtg	tggagtctctg	1620
	gggctgcgtg	ggaacttcgc	tggtagtagt	caagcgaagg	ggtgacgcag	gaaggtagcc	1680
	gtaccagtca	gtggtaacac	tggggcaagc	cggtaggagg	agcgataggc	aaatccgtcg	1740
	ctcactaatc	ctgagaggtg	acgcataatc	ggttgaggcg	aattcgggtg	tcctctgctg	1800
	ccaagaaaag	cctctagcga	gcacacacac	ggcccgtacc	ccaaaccgac	acaggtgggtc	1860
35	aggtagagca	taccaaggcg	tacgagataa	ctatgggtta	ggaactcggc	aaaatgcccc	1920
	cgtaacttcg	ggagaagggg	gaccggaata	tcgtgaacac	ccttgcggtg	ggagcgggat	1980
	ccggtcgcag	aaaccagtga	ggagcgcactg	tttactaaaa	acacagggtcc	gtgcgaagtc	2040
	gcaagacgat	gtatacggac	tgacgcctgc	ccggtgctgg	aagggttaaga	ggaccctgta	2100
	acccgcaagg	gtgaagcggg	gaatttaagc	cccagtaaac	ggcgggtggt	actataacca	2160
40	tcctaaggta	gcgaaattcc	ttgtcgggta	agttccgacc	tgacgaatg	gcgtaacgac	2220
	ttctcaactg	tctcaaccat	agactcggcg	aaattgcact	acgagtaaa	atgctcggtta	2280
	cgcgcgccag	gacgaaaaga	ccccgggacc	ttcactacaa	cttgggtattg	atgttcggta	2340
	cggtttgtgt	aggataggtg	ggagactgtg	aaacctcgac	gccagttggg	gcggagtcgt	2400
	tgttgaaata	ccactctgat	cgatattgggc	atctaacctc	gaaccctgaa	tcgggttttag	2460
45	ggacagtgcc	tggcgggtag	tttaactggg	gcggttgcc	cctaaaatgt	aacggaggcg	2520
	cccaaagggt	ccctcaacct	ggacggcaat	caggtggcga	gtgtaaatgc	acaagggagc	2580
	ttgactgcga	gactttaca	tcaagcaggg	acgaaagtcg	ggattagtga	tccggcacc	2640
	ccgagtgga	ggggtgtcgc	tcaacggata	aaagggtacc	cggggataac	aggctgatct	2700
	tccccaagag	tccatatacg	cgggatgggt	tggcacctcg	atgtcggctc	gtcgcaccc	2760
50	ggggctggag	caggtcccaa	gggttgggct	gttcgccc	taaagcggca	cgcgagctgg	2820
	gtttagaacg	tcgtgagaca	gttcgggtctc	tatccgcgcg	gcgcgtcaga	aacttgaggga	2880
	aacctgtccc	tagtacgaga	ggaccgggac	ggacgaacct	ctgggtgcacc	agttgtccc	2940
	ccagggggcac	cgctggatag	ccacgttcgg	tcaggataac	cgctgaaagc	atctaagcgg	3000
	gaaaccttct	ccaagatcag	gtttctcacc	cacttgggtg	gataaggccc	cccgcagaac	3060
55	agggttccaa	taggtcagac	ctggaagctc	agtaatgggt	gtaggggaact	ggtgctaacc	3120
	ggccgaaaac	ttacaaca					3138

5 <210> 60  
 <211> 2903  
 <212> DNA  
 <213> Escherichia coli

<400> 60  
 10 gggttaagcga ctaagcgtac acggtggatg ccctggcagt cagaggcgat gaaggacgtg 60  
 ctaatctgcg ataagcgtcg gtaagggtgat atgaaccggt ataaccggcg atttccgaat 120  
 ggggaaaccc agtgtgattc gtcacactat cattaactga atccataggt taatgaggcg 180  
 aaccggggga actgaaacat ctaagtaccc cgaggaaaag aaatcaaccg agattccccc 240  
 agtagcggcg agcgaaacggg gaggagccca gagcctgaat cagtgtgtgt gttagtggaa 300  
 15 gcgtctggaa aggcgcgcga tacagggtga cagccccgta cacaaaaatg cacatactgt 360  
 gagctcgatg agtagggcgg gacacgtggt atcctgtctg aatatggggg gaccatcctc 420  
 caaggctaaa tactcctgac tgaccgatag tgaaccagta ccgtgaggga aaggcgaaaa 480  
 gaaccccgcg gaggggagtg aaaaagaacc tgaaccggtg tacgtacaag cagtggggagc 540  
 ctcttttatg gggtgactgc gtaccttttg tataatgggt cagcgactta tattctgtag 600  
 caagggttaac cgaatagggg agccgaaggg aaaccgagtc ttaaccgggc gtttaagttgc 660  
 20 aggggtataga cccgaaaccc ggtgatctag ccatgggcag gttgaagggt gggtaacact 720  
 aactggagga ccgaaccgac taatgttgaa aaattagcgg atgacttgtg gctgggggtg 780  
 aaaggccaat caaacgggga gatagctggt tctccccgaa agctatttag gtagcgctc 840  
 gtgaattcat ctccgggggt agagcactgt ttcggcaagg gggcatccc gactaccaaa 900  
 ccgatgcaa actgcgaata ccggagaatg ttatcacggg agacatacgg cgggtgctaa 960  
 25 cgtccgctcg gaagagggaa acaaccagga ccgccagcta aggtcccaaa gtcattggtta 1020  
 agtgggaaac gatgtgggaa ggcccagaca gccaggatgt tggcttagaa gcagccatca 1080  
 tttaaagaaa gcgtaatagc tcactggctg agtcggcctg cgcggaagat gtaaccggggc 1140  
 taaaccatgc accgaagctg cggcagcgac actgtgtgtt gttgggtagg ggagcgttct 1200  
 gtaagcctgt gaaggtgtac tgtgagggtat gctggaggta tcagaagtgc gaatgctgac 1260  
 30 ataagtaacg ataaagcggg tgaaaagccc gctcgccgga agaccaaggg ttctgtgcca 1320  
 acgttaatcg gggcaggggt agtcgacccc taaggcagag ccgaaaggcg tagtcgatgg 1380  
 gaaacagggt aatattcctg tacttgggtg tactgcgaag gggggacgga gaaggctatg 1440  
 ttggccggggc caggttgtgc ccggtttaag cgtgtaggct ggttttccag gcaaatccgg 1500  
 35 aaaaacaagg ctgaggcgtg ctgacgaggg actacgggtg tgaagcaaca aatgccctgc 1560  
 ttccaggaaa agcctctaag catcaggtaa catcaaatcg taccctaaac cgacacaggt 1620  
 ggtcaggtag agaataccaa ggcgcttgag agaactcggg tgaaggaaact aggcaaatg 1680  
 gtgccgtaac ttccgggagaa ggcacgctga tatgtagggt aagtcctcgc cggatggagc 1740  
 tgaaatcagt cgaagatacc agctgggtgc aactgtttat taaaaacaca gcaactgtgca 1800  
 aacacgaaag tggacgtata cgggtgtgac cctgcccggg gccggaagggt taattgatgg 1860  
 40 ggtcagcgca agcgaagctc ttgatcgaag ccccggtaaa cggcggccgt aactataacg 1920  
 gtcctaagggt agcgaattc cttgtcgggt aagttccgac ctgcacgaat ggcgtaata 1980  
 tggccaggct gtctccaccc gagactcagt gaaattgaac tcgctgtgaa gatgcagtgt 2040  
 acccgcgga agacggaaag acccgtgaa cctttactat agcttgacac tgaacattga 2100  
 gccttgatgt gtaggatagg tgggaggcct tgaagtgtgg acgccagtc gcatggagcc 2160  
 45 gaccttgaaa taccaccctt taatgtttga tgttctaacg tggacccgtg atccgggttg 2220  
 cggacagtgt ctggtgggta gtttgactgg ggcggtctcc tcctaaagag taaccggagga 2280  
 gcacgaagggt tggctaattc tggtcggaga tcaggagggt agtgcaatgg cataagccag 2340  
 ctgtactgcg agcgtgacgg cgcgagcagg tgcgaaagca ggtcatagt atccgggtgt 2400  
 50 tctgaatgga agggccatcg ctcaacggat aaaagggtact ccgggggataa caggctgata 2460  
 ccgccaaga gttcatatcg acggcgggtg ttggcacctc gatgtcggct catcacatcc 2520  
 tggggctgaa gtaggtccca agggatatggc tgttcgcat taaagtggg acgcgagctg 2580  
 ggtttagaac gtcgtgagac agttcgggtc ctatctgccg tgggcgctgg agaactgagg 2640  
 ggggtgctc ctagtacgag aggaccggag tggacgcac actggtgttc ggggtgtcat 2700  
 55 gccaatggca ctgcccggta gctaaatcgc gaagagataa gtgctgaaag catctaagca 2760  
 cgaaacttgc ccgagatga gttctcctg accctttaag ggtcctgaag gaacgttgaa 2820  
 gacgacgacg ttgataggcc ggggtgtgtaa gcgcagcgat gcgttgagct aaccgggtact 2880

aatgaaccgt gaggcttaac ctt

2903

&lt;210&gt; 61

5 &lt;211&gt; 2903

&lt;212&gt; DNA

<213> *Klebsiella pneumoniae*

&lt;400&gt; 61

10	ggttaagcga	ctaagcgtag	acgggtggatg	ccctggcagat	cagagggcgat	gaaggacgtg	60
	ctaactctgcg	aaaagcgtag	gtaaggtgat	atgaaccggt	ataaccggcg	atgtccgaat	120
	ggggaaaccc	agtgaattc	gttgactat	cgttaactga	atacataggt	taacgaggcg	180
	aaccggggga	actgaaacat	ctaagtaccc	cagggaaaag	aaatcaaccg	agattccccc	240
	agtagcggcg	agcgaacggg	gagcagccca	gagtctgaat	cagcttgtgt	gttagtgga	300
15	cggctctggaa	agtccgacgg	tacaggggtga	tagtcccgtg	caccaaagt	cacaggtgt	360
	gaactcgaag	agtagggcg	gacacgtggt	atcctgtctg	aatatggggg	gaccatcctc	420
	caaggctaaa	tactcctgac	tgaccgatag	tgaaccagta	ccgtgaggga	aaggcgaaaa	480
	gaaccccgcc	gaggggagtg	aaaaagaacc	tgaaccggtg	tacgtacaag	cagtgggagc	540
	accttcgggt	gtgactgcgt	accttttcta	taatgggtca	gcgacttata	ttctgtagca	600
20	aggttaaccg	tataggggag	ccgcaggga	accgagtcct	aaactgggct	taagttgcag	660
	ggtatagacc	cgaaaccccg	tgatctagcc	atgggcaggt	tgaaggttgg	gtaacactaa	720
	ctggaggacc	gaaccgacta	atgttgaaaa	attagcggat	gacttgtggc	tgggggtgaa	780
	aggccaatca	aaccgggaga	tagctgggtc	tccccgaaag	ctatttaggt	agcgctcgt	840
	gaactcatct	tcgggggtag	agcactgttt	cggttagggg	gtcatcccca	cttaccaacc	900
25	cgatgcaaac	tacgaatacc	gaagaatgtt	atcacgggag	acacacggcg	ggtgctaacc	960
	tccgtcgtga	agagggaaac	aaccagacc	gccagctaag	gtcccaaagt	catggttaag	1020
	tgggaaacga	tgtgggaagg	cacagacagg	caggatgttg	gcttagaagc	agccatcatt	1080
	taaagaaagc	gtaatagctc	actggtcgag	tcggcctgag	cggaagatgt	aacggggcta	1140
	aaccatgcac	cgaagctgag	gcagcgacac	tatgtgttgt	tgggtagggg	agcgttctgt	1200
30	aagcctgcga	aggtgtgctg	tgaggcatgc	tggaggtatc	agaagtgcga	atgctgacat	1260
	aagtaacgat	aaagcgggtg	aaaagcccgc	tcgcccgaag	accaagggtt	cctgtccaac	1320
	gttaatcggg	gcaggggtgag	tcgaccccta	aggcgaggcc	gaaaggcgta	gtcgatggga	1380
	aacagggttaa	tattcctgta	cttggtgtta	ctgcgaaggg	gggacggaga	aggctatgtt	1440
	agccggggcg	cggttgtccc	ggtttaagca	tgtaggctgg	ttgtccaggc	aaatccggat	1500
35	aatcaaggct	gaggtgtgat	gacgaggcac	tacggtgctg	aagtaacaaa	tgctctgctt	1560
	ccaggaaaag	cctctaagca	tcaggtaaca	tcaaatcgta	ccccaaaccg	acacaggtgg	1620
	tcaggtagag	aataccaagg	cgcttgagat	aactcgggtg	aagggaactag	gcaaaatggt	1680
	gccgtaactt	cgggagaagg	cacgctgggt	tgtagggtgaa	gcccctgccg	ggtggagctg	1740
	agaccagtcg	aagataaccg	ctggctgcaa	ctgtttatta	aaaacacagc	actgtgcaaa	1800
40	cacgaaagtg	gacgtatacg	gtgtgacgcc	tgcccgggtg	cggaagggtta	attgatgggg	1860
	ttatccgtaa	ggagaagctc	ttgatcgaag	ccccggtaaa	cggcggccgt	aactataacg	1920
	gtcctaaggt	agcgaaattc	cttgtcgggt	aagttccgac	ctgcacgaat	ggcgtaatga	1980
	tggccaggct	gtctccaccc	gagactcagt	gaaattgaac	tcgctgtgaa	gatgcagtgt	2040
	acccgcggca	agacggaaaag	accccgtgaa	cctttactat	agcttgacac	tgaacattga	2100
45	gccttgatgt	gtaggatagg	tgggaggcct	tgaagcgtgg	acgccagctc	gcgtggagcc	2160
	aaccttgaaa	taccaccctt	taatgtttga	tggtctaacg	ttggccccctc	accgggggtt	2220
	cggacagtgt	ctggtgggta	gtttgactgg	ggcggtctcc	tcccaaagcg	taacggagga	2280
	gcacgaaggt	tagctaattc	tggctcggaca	tcaggagggt	agtgcgaatg	cataagctag	2340
	cttgactgcg	agcgtgacgg	cgcgagcagg	tgcgaaagca	ggtcatagtg	atccggtggt	2400
50	tctgaatgga	agggccatcg	ctcaacggat	aaaagggtact	ccgggggataa	caggctgata	2460
	ccgcccaga	gttcatatcg	acggcggtgt	ttggcacctc	gatgtcgggt	catcacatcc	2520
	tggggctgaa	gtaggtccca	aggggtatgg	tggtcgccat	ttaaagtggg	acgcgagctg	2580
	ggtttagaac	gtcgtgagac	agttcgggtc	ctatctgccg	tgggcgctgg	agaattgagg	2640
	ggggctgctc	ctagtacgag	aggaccggag	tggacgcac	actggtgttc	gggttgctat	2700
55	gccaatggga	ctgcccggta	gctaaatgcg	gaagagataa	gtgctgaaag	catctaagca	2760
	cgaacattgc	cccagatgta	gttctccctg	agactttaag	tctcctgaag	gaacgttgaa	2820

gacgacgacg ttgataggcc ggggtgtgtaa gcgcagcgat gcgttgagct aaccgggtact 2880  
aatgaaccgt gaggcttaac ctt 2903

5 <210> 62  
<211> 2897  
<212> DNA  
<213> Haemophilus influenzae

10 <400> 62  
gtatagttaa gtgactaagc gtacaagggt gatgccttgg caatcagagg cgaagaagga 60  
cgtgctaatac tgcgaaaagc ttggatgagt cgataagagg cgtttaatcc aagatatccg 120  
aatggggaaa ccagtagat gaagaatcta ctatcaacaa gtgaattcat agcttggtga 180  
ggcaaaccgg gagaactgaa acatctaagt accccgagga aaagaaatca accgagattt 240  
15 cgtcagtagc ggcgagcgaa agcgaaagag ccagtaagt atagcaatat agtgaggaga 300  
atgtgttggg aagcacaatc aaagaggggtg ataatcccgt atctaaaaac catattgtgg 360  
tactaagcta acgagaagta gggcgggaca cgtgatatcc tgtttgaaga agggggggccc 420  
atcctccaag gctaaatact cctgattgac cgatagtga cagtagtgaa ccagtactgt gaaggaaagg 480  
cgaaaagaa cccggtgagg ggagtgaat agaacctgaa accttgtagc tacaagcagt 540  
20 gggagcaggg gcaaccttgt gactgcgtac cttttgtata atgggtcagc gacttatatt 600  
ttgtagcgag gttaaccgaa taggggagcc gaagggaac cgagtcttaa ctgggcgaat 660  
agttgcaagg tatagaccgg aaaccggtg atctagccat gggcaggttg aagggtgggt 720  
aacactaact ggaggaccga accgactaat gttgaaaaat tagcggatga cttgtggctg 780  
ggggtgaaag gccaatcaaa ccgggagata gctggttctc cccgaaatct atttaggtag 840  
25 agccttgagg tgacacctt gggggtagag cactgtttcg gctagggggc catcccggt 900  
taccaaccgg atgcaaaacta cgaataccaa agagtgtatc tcaggagaca cacggcgggt 960  
gctaacgtcc gtcgtggaga gggaaacaac ccagaccgcc agctaaggct cccaagtcta 1020  
tattaagtgg gaaacgaagt gggaaggctt agacagctag gatgttggct tagaagcagc 1080  
catcatthaa agaaagcgta atagctcact agtcgagtcg gcctgcgcgg aagatgtaac 1140  
30 ggggctgaaa tatagaccgg aagctgcggc atcagaatth attctgttgg gtaggggagc 1200  
gttgtgtaag cggagaaggg ttcatcgaga ggtgggctgg acgtatcaca agtgcgaaatg 1260  
ctgcataaag taacgataaa acgggtgaaa aaccggttcg ccggaagacc aagggttctc 1320  
gtccaacgtt aatcggggca gggtagtcg gctcctaagg cgaggctgaa aagcgtagtc 1380  
gatgggaaac aggttaatat tcctgtactt ggtaaagctg cgatgtgggg acggagtagg 1440  
35 ttaggttatc gcaactgttg atatgtgcgt ttaagttggt aggtgggaag ttaggcaaaa 1500  
tcgggacttc cttaacacag agagatgatg acgaggctct acggagctga agtaactgat 1560  
accacacttc caggaaaagc cactaagcga aaggctttac taaaccgtac tgaaaaccga 1620  
cacaggtggt caggtagaga atactcaggc gcttgagaga actcgggtga aggaactagg 1680  
caaaatagca ccgtaacttc gggagaaggt gcgcccggcg agattgtaag ggctagcccc 1740  
40 tgaaggttga accggtcgaa gataccagct ggctgcaact gtttattaaa aacacagcac 1800  
tctgcaaaaca cgaaagtgga cgtatagggt gtgatgcctg cccggtgctg gaaggttaat 1860  
tgatggtgtc atcgaaagag aagcacctga tcgaagcccc agtaaacggc ggccgtaact 1920  
ataacggtcc taaggtagcg aaattccttg tcgggttaagt tccgacctgc acgaatggca 1980  
taatgatggc caggctgtct ccacccgaga ctgagtgaaa ttgaaatcgc cgtgaagatg 2040  
45 cgggtgacct gcggctagac ggaaagacct cgtgaacctt tactatagct tgacactgaa 2100  
cattgaattt tgatgtgtag gatagggtgg agcctttgaa gcagtgcgc cagtcattgt 2160  
ggaggcgacc ttgaaatacc accctttaac gtttgatgtt ctaacgaaga tgacgaaacg 2220  
tggctcggga cagtgtctgg tgggtagttt gactggggcg gtctcctccc aaagcgtaac 2280  
ggaggagcac gaaggtttgc taatcacggt cgacatcgat gaggttagtg caatgggtata 2340  
50 agcaagctta actgcgagac agacaagtcg agcaggtacg aaagtaggtc atagtgatcc 2400  
ggtggttctg aatggaaggg ccacgcgtca acggataaaa ggtactccgg ggataacagg 2460  
ctgataccgc ccaagagttc atatcgacgg cgggtgttgg cacctcgatg tcggctcatc 2520  
acatcctggg gctgaagtag gtcccaaggg tatggctgtt cgccatttaa agtggtagcg 2580  
gagctgggtt tagaacgtcg tgagacagtt cggtccttat ctgcccgtgg cgtaggatga 2640  
55 ttgattgggg tagctcctag tacgagagga ccggagtgga cgcactactg gtgttccgg 2700  
tgtgtcgcca gacgcattgc cgggtagcta aatgcggaag agataagtgc tgaaagcatc 2760

taagcacgaa acttgccaag agatgagtc tccctgactt taagtcagta aggggtgttg 2820  
tagactacga cgtagatagg ttgggtgtgt aagtgatgtg agtcattgag ctaaccaata 2880  
ctaattgccc gagagggc 2897

5

<210> 63  
<211> 2865  
<212> DNA  
<213> Bordetella bronchiseptica

10

<220>  
<221> modified\_base  
<222> (622)  
<223> N = A, C, G or T/U

15

<400> 63  
gatcaagcga ctaagtgcac atggtggatg ccttggcgat cacaggcgga tgaaggacgt 60  
agtagcctgc gaaaagctgc ggggagctgg caaacaagca ttgatccgca gatatccgaa 120  
tggggaaacc caccggcaagc ggtatccctg gctgaataca taggccagtg gaggcgaacc 180  
20 ggggtgaactg aaacatctca gtagctcgag gaaaagaaat caaccgagat tccgaaagta 240  
gtggcgagcg aaatcggaag agcctttacg atttagcatt ttgcatagtc gaacggaatg 300  
gaaagtccgg ccgtagcagg ttagtagccct gtagacgaat gcagagtgtg gaactaggcg 360  
taagagaagt agggcgggac acgtgaaatc ctgtctgaag atgggggggac catcctccaa 420  
ggctaaatac tcgtgatcga ccgatagtga accagtaccg tgaggaaagg cgaaaagaac 480  
25 cccggaagga gtgaaataga tcctgaaacc gtatgcatac aacagtcgga gcctctttat 540  
ggggtgacgg cgtacctttt gtataatggg tcagcgactt acattcagtg gcagcttaac 600  
cgaataggga aggcgtcaga anagcagtcg gaataggggc ttccagtcgc tgggtgtaga 660  
cccgaacca gatgatctac ccatggccag gttgaaggca cggtaacacg tgctggagga 720  
ccgaaccac tagtggtgaa aaactagggg atgagctgtg gataggggtg aaaggctaaa 780  
30 caaatctgga aatagctggt tctctccgaa aactatntag gtagtgccctc aagtattact 840  
gcagggggta gagcactggt atggctaggg ggtcatggcg acttaccaaa ccatggcaaa 900  
ctccgaatac ctgcaagtac agcttgggag acagacgacc ggggtgctaac gtccggactc 960  
aagagggaaa caaccagac cgccagctaa ggtcccgaat tctcgctaag tgggaaacga 1020  
agtgggaagg catagacagt caggagggtg gcttagaagc agccaccctt taaagaaagc 1080  
35 gtaatagctc actgatcgag tcgtcctgag cggaagatgt aacggctaag cgataaaccg 1140  
aagctgcggg tgtgcacttt tagtgacgag gtaggagagc gttctgtaag cctgcgaagg 1200  
tggcttgtaa aggctgctgg aggtatcaga agtgcgaaat ctgacatgag tagccataaa 1260  
gggggtgaaa agccccctcg ccgtaagtcc aagggttctc gcgcaacgtt catcggcgca 1320  
gggtgagtcg gcccttaagg cgaggcagag atgcgtagct gatgggaagc tgggttaatat 1380  
40 tccagcaccg tcgtacagtg cgatgggggg acggatcgcg gaaggctatc aggggtgttg 1440  
acgtccctgt tgctgcattg aagatggcgc ttaggcaaat ccggggcgca gaatcaaggg 1500  
tgtggcacga gcgagcaagt ctgcgcaagt gattggaagt ggttccaaga aaagcctcta 1560  
agcttcagct gtacgagacc gtaccgcaaa ccgacacagg tgggacggga tgaatattcc 1620  
aaggcgcttg agagaactca ggagaaggaa ctccggcaaat tgataccgta acttcgggag 1680  
45 aaggatatac ctggtagtgt gaagcctgag cgctgagcat gaaggggtcg cagagaatcg 1740  
gtggctgcga ctgtttatta aaaacacagc actctgcaaa gacgaaagtc gacgtatagg 1800  
gtgtgacgcc tgcccgtgac cggaagggtt agtgatgggg tgcaagctct tgatcgaagc 1860  
cccggtaaac ggccggccgta actataacgg tcctaaggta gcgaaattcc ttgtcgggta 1920  
agttccgacc tgcacgaatg gcgtaacgat ggccacactg tctcctctg agactcagcg 1980  
50 aagttgaagt gtttgtgatg atgcaatcta ccgcgggcta gacggaaaga ccccatgaac 2040  
ctttactgta gctttgcatt ggactgtgaa ccggcctgtg taggatagggt gggaggcgca 2100  
gaactcgagt cgccagattc gagggagcca tccttgaaat accaccctgg tttgtttgag 2160  
gttctaacct tgggtccgta tccggatcgg ggacagtga ttgtaggcag tttgactggg 2220  
gcggtctcct cccaaagcgt aacggagggg ttcgaaagta cgctaggtag ggtcggaaat 2280  
55 cgtgctgata gtgcaatggc ataagcgtgc ttgactgtga gactgacagt gaacagggtg 2340  
gaacgggaca tagtgatccg gtggttctga tgggaaggcc atcgctcaac ggataaagggt 2400

5 actctgggat aacaggctga taccgcccga gagttcatat cgacggcggt gtttggcacc 2460  
 tcgatgtcgg ctcatctcat cctgggggctg tagccgggtcc aagggtatgc tgttcgccat 2520  
 ttaaagaggt acgtgagctg ggttttagaaa cgtcgtgaga cagtttggtc cctatctgcc 2580  
 gtgggcggtg gatacttgaa caggagcctg ctcctagtac gagaggaccg gagtggacgt 2640  
 5 acctctggtg taccggttgt catgccaatg gcattgccgg gtagctaagt acggaagaga 2700  
 taaccgctga aggcattctaa gcgggaaaact cgtctgaaga ttaggtatcc cggggactag 2760  
 atccccctga agggctcgttc gagaccagga cgttgatagg tcgggtgtgg aagcgcagta 2820  
 atgcgttaag ctaaccgata ctaattgccc gtgaggctta atcct 2865

10 <210> 64  
 <211> 2865  
 <212> DNA  
 <213> Bordetella parapertussis

15 <220>  
 <221> modified\_base  
 <222> (624)  
 <223> N = A, C, G or T/U

20 <400> 64  
 gatcaagcga ctaagtgcac atggtgggat ccttggcgat cacaggcgat gaaggacgta 60  
 gtagcctgcg aaaagctgcg gggagctggc aaacaagcat tgatccgcag atatccgaat 120  
 25 ggggaaaccc acggcaagcg gtatccctgg ctgaatacat aggccagtgg aggcgaaccg 180  
 ggtgaactga aacatctcag tagctcgagg aaaagaaatc aaccgagatt ccgaaagtag 240  
 ttggcgagcga aatcggaaga gcctttacga tttagcattt tgcatagtcg aacggaatgg 300  
 aaagtccggc cgtagcaggt gatagccctg tagacgaaat gcagagtgtg gaactaggcg 360  
 taagagaagt agggcgggac acgtgaaatc ctgtctgaag atggggggac catcctccaa 420  
 ggctaaatac tcgtgatcga ccgatagtga accagtagcg tgaggaaagg cgaaaagaac 480  
 30 cccggaagga gtgaaataga tcctgaaacc gtatgcatac aaacagtcgg agcctcttta 540  
 tgggggtgacg gcgtaccttt tgtataatgg gtcagcgact tacattcagt ggcgagctta 600  
 accgaatagg gaaggcgctc gaanagcagt ccgaataggg cgtccagtcg ctgggtgtag 660  
 acccgaaacc agatgatcta cccatggcca ggttgaaggc acggtaacac gtcgtggagg 720  
 accgaaccga ctagtggtga aaaactaggg gatgagctgt ggataggggt gaaaggctaa 780  
 35 acaaatctgg aaatagctgg ttctctccga aaactattta ggtagtgctt caagtattac 840  
 tgcagggggg agagcactgt tatggctagg gggtcatggc gacttaccaa accatggcaa 900  
 actccgaata cctgcaagta cagcttggga gacagacgac cgggtgctaa cgtccggact 960  
 caagagggaa acaaccaga ccgccagcta aggtcccga ttatcgctaa gtgggaaacg 1020  
 aagtgggaag gcatagacag tcaggaggtt ggcttagaag cagccaccct taaagaaag 1080  
 40 cgtaatatag cactgatcga gtcgtcctgc gcggaagatg taacggctaa gcgataaacc 1140  
 gaagctgcgg gtgtgcactt ttagtgacgc ggtaggagag cgttctgtaa gcctgcgaag 1200  
 gtggcttgta aaggctgctg gaggtatcag aagtgcgaat gctgacatga gtagcgataa 1260  
 aggggggtgaa aagccccctc gccgtaagtc caaggtttcc tgcgcaacgt tcacggcgcg 1320  
 aggggtgagtc ggcccctaag gcgaggcaga gatgcgtagc tgatgggaag ctggttaata 1380  
 45 ttccagcacc gtcgtacagt gcgatggggg gacggatcgc ggaaggatcat cagggtgttg 1440  
 gacgtccctg ttgctgcatt gaagatggcg cttaggcaaa tccgggcgcg agaataaagg 1500  
 gtgtggcagc agcgagcaag tctcgcgaag tgattggaag tggttccaag aaaagcctct 1560  
 aagcttcagc gtagcagac cgtaccgcaa accgacacag gtgggacggg atgaatatct 1620  
 caaggcgctt gagagaactc aggagaagga actcggcaaa ttgataccgt aacttcggga 1680  
 50 gaaggatata cctggtagtg tgaagcctgc gcgctgagca tgaaggggtc gcagagaatc 1740  
 ggtggctgcg actgtttatt aaaaacacag cactctgcaa agacgaaagt cgacgtatag 1800  
 ggtgtgacgc ctgcccgggt ccggaagggt aagtgatggg gtgcaagctc ttgatcgaag 1860  
 ccccggtaaa cggcgccgct aactataacg gtcctaaggt agcgaaatct cttgtcgggt 1920  
 aagttccgac ctgcacgaat ggcgtaacga tggccacact gtctcctcct gagactcagc 1980  
 55 gaagttgaag gtgtttgtat gatgcaatct acccgggct agacggaaag accccatgaa 2040  
 cctttactgt agctttgcat tggactgtga accggcctgt gtaggatagg tgggaggcgc 2100

5 agaactcgag tcgccagatt cgagggagcc atccttgaaa taccaccctg gtttgtttgc 2160  
 ggttctaacc ttgggtccgtt atccggatcg gggacagtgc atggtaggca gtttgactgg 2220  
 ggcggtctcc tcccaaagcg taacggagga gttcgaaggt acgctaggta cggtcggaaa 2280  
 tcgtgctgat agtgcaatgg cataagcgtg cttgactgtg agactgacag tcgaacaggt 2340  
 10 gcgaacggga catagtgate cgggtggttct gatggaaggg ccatcgctca acggataaag 2400  
 gtactctggg ataacaggct gataccgccc aagagttcat atcgacggcg gtgtttggca 2460  
 cctcgatgtc ggctcatctc atcctggggc tgtagccggt ccaagggtat gctgttcgcc 2520  
 atttaaagag gtacgtgagc tgggtttaga aacgtcgtga gacagtttgg tccctatctg 2580  
 ccgtgggctg tggatacttg aacaggagcc tgctcctagt acgagaggac cggagtggac 2640  
 15 gtacctctgg tgtaccggtt gtcattgcaa tggcattgcc gggtagctaa gtacggaaga 2700  
 gataaccgct gaaggcatct aagcggaaac tcgtctgaag attaggtatc ccgggactag 2760  
 atccccctga agggctcgtt gagaccagga cgttgatagg tcgggtgtgg aagcgcagta 2820  
 atgctgttaag ctaaccgata ctaattgccc gtgaggcttg atcct 2865

15 <210> 65  
 <211> 2864  
 <212> DNA  
 <213> Bordetella pertussis

20 <220>  
 <221> modified\_base  
 <222> (624)  
 <223> N = A, C, G or T/U

25 <400> 65  
 gatcaagcga ctaagtgcatt atgggtggatg ccttggcgat cacaggcgat gaaggacgta 60  
 gtagcctgcg aaaagctgcg gggagctggc aaacaagcat tgatccgcag atatccgaat 120  
 30 ggggaaaccc acggcaagcg gtatccctgg ctgaatacat aggccagtgg aggcgaaccg 180  
 ggtgaactga aacatctcag tagctcgagg aaaagaaatc aaccgagatt ccgaaagtag 240  
 tggcgagcga aatcggaaga gcctttacga ttagcattt tgcatagtcg aacggaatgg 300  
 aaagtccggc cgtagcaggt gatagccctg tagacgaaat gcagagtgtg gaactaggcg 360  
 taagagaagt agggcgggac acgtgaaatc ctgtctgaag atggggggac catcctccaa 420  
 35 ggctaaatc tcgtgatcga ccgatagtag accagtaccg tgaggaaagg cgaaaagaac 480  
 cccggaagga gtgaaataga tctgaaacc gtatgcatac aaacagtcgg agcctcttta 540  
 tggggtgacg gcgtacctt tgtataatgg gtcagcgact tacattcagt ggcgagctta 600  
 accgaatagg gaaggcgtca gaanagcagt ccgaataggg cgtccagtcg ctgggtgtag 660  
 acccgaaacc agatgatcta cccatggcca ggttgaaggc acggtaacac gtcgtggagg 720  
 accgaaccca ctagtgttga aaaactaggg gatgagctgt ggataggggt gaaaggctaa 780  
 40 acaaatctgg aaatagctgg ttctctccga aaactattta ggtagtgcct caagtattac 840  
 tgcagggggg agagcactgt tatggctagg gggctatggc gacttaccaa accatggcaa 900  
 actccgaata cctgcaagta cagcttggga gacagacgac cgggtgctaa cgtccggact 960  
 caagagggaa acaaccagga ccgccagcta aggtcccga ttatcgctaa gtgggaaacg 1020  
 aagtgggaag gcatagacag tcaggagggt ggcttagaag cagccaccct ttaaagaaag 1080  
 45 cgtaatagct cactgatcga gtcgtcctgc gcggaagatg taacggctaa gcgataaacc 1140  
 gaagctgcgg gtgtgcactt ttagtgacgc ggtaggagag cgttctgtaa gcctgcgaag 1200  
 gtggcttgta aaggctgctg gaggtatcag aagtgcgaat gctgacatga gtacgataa 1260  
 aggggggtgaa aagccccctc gccgtaagc caaggtttcc tgcgcaacgt tcatcggcgc 1320  
 50 aggggtgagtc ggcccctaag gcgaggcaga gatgcgtagc tgatgggaag ctgggttaata 1380  
 ttccagcacc gtcgtacagt gcgatggggg gacggatcgc ggaaggatcat cagggtgttg 1440  
 gacgtccctg ttgctgcatt gaagatggcg cttaggcaaa tccgggcgcg agaacaagg 1500  
 gtgtggcacg agcgagcaag tctcgcaag tgattggaag tggttccaag aaaagcctct 1560  
 aagcttcagc tgtacgagac cgtaccgcaa accgacacag gtgggacggg atgaatatct 1620  
 caagggcgtt gagagaatc aggagaagga actcggcaaa ttgataaccg aacttcggga 1680  
 55 gaaggtatac cctggtagtg tgaagcctgc gcgctgagca tgaaggggtc gcagagaatc 1740  
 ggtggctgcg actgtttatt aaaaacacag cactctgcaa agacgaaagt cgacgtatag 1800

5 ggtgtgacgc ctgcccgggtg ccggaagggtt aagtgatggg gtgcaagctc ttgatcgaag 1860  
 ccccggtaaa cggcggccgt aactataacg gtcctaaggt agcgaaatcc cttgtcgggt 1920  
 aagttccgac ctgcacgaat ggcgtaacga tggccacact gtctcctcct gagactcagc 1980  
 gaagttgaag tgtttgtgat gatgcaatct acccgcggt agacggaaag accccatgaa 2040  
 cctttactgt agctttgcat tggactgtga accggcctgt gtaggatagg tgggaggcgc 2100  
 agaactcgag tcgccagatt cgaggggagcc atccttgaaa taccaccctg gtttgtttgc 2160  
 ggttctaacc ttgggtccgtt atccggatcg gggacagtgc atggtaggca gtttgactgg 2220  
 ggcggtctcc tcccaaagcg taacggagga gttcgaaggt acgctaggta cggtcggaaa 2280  
 10 tcgtgctgat agtgcaatgg cataagcgtg cttgactgtg agactgacag tcgaacagggt 2340  
 gcgaacggga catagtgatc cggtggttct gatggaaggg ccatacgctca acggataaag 2400  
 gtactctggg ataacaggct gataccgccc aagagttcat atcgacggcg gtgtttggca 2460  
 cctcgatgac ggctcatctc atcctggggc tbtagccggg ccaaggggat gctgttcgcc 2520  
 atttaaagag gtacgtgagc tgggtttaaa acgtcgtgag acagtttggt ccctatctgc 2580  
 cgtgggcgtt ggatacttga acaggagcct gtccttagta cgagaggacc ggagtggacg 2640  
 15 tacctctggt gtaccggttg tcatgccaat ggcattgccg ggtagctaag tacggaagag 2700  
 ataaccgctg aaggcatcta agcggaaact cgtctgaaga ttaggatatcc cgggactaga 2760  
 tccccctgaa gggtcggttcg agaccaggac gttgataggt cgggtgtgga agcgcagtaa 2820  
 tgcgttaagc taaccgatac taattgcccc tgaggcttga tcct 2864

20 <210> 66  
 <211> 2878  
 <212> DNA  
 <213> Burkholderia cepacia

25 <400> 66  
 ggtcaagcga acaagtgcac gtggtgggat ccttggcgat cacaggcgat gaaggacgcg 60  
 gtgacctgcg aaaagctacg gggagctggc aaacaagctt tgatccgtag atgtccgaat 120  
 30 ggggaaaccc actccttttg gagtatccat ggctgaatac ataggccatg cgaaggaacg 180  
 cggtagaactg aaacatctaa gtaaccgcag gaaaagaaat caaccgagat tcccaaagta 240  
 gtggcgagcg aaatgggatg agccttgcac tctttatttg tattgttagc cgaacgctct 300  
 ggaaagtgcg gccatagcag gtgatagccc tbtaggcgaa aacagtatga aagaactagc 360  
 tgtgcgacaa gtagggcggg acacgtgaaa tctgtctga agatgggggg accatcctcc 420  
 aaggctaaat actcgtgatc gaccgatagt gaaccagtac cgtgagggaa aggcgaaaag 480  
 35 aaccccgga ggggagtga atagatcctg aaaccgcag catacaaaaca gtcggagcct 540  
 cgtaaggggt gacggcgtag cttttgtata atgggtcagc gacttacgtt cagtagcaag 600  
 cttaacgcta tagggcaggg gtaggaaagg agtccgaata gggcgttcag ttgctgggcg 660  
 tagaccgaa accagggtgat ctatccatgg ccaggatgaa ggtgcggtaa cacgtactgg 720  
 aggtccgaac cactaacgt tgaaaagtta ggggatgagc tbtggatagg ggtgaaaggc 780  
 40 taaacaaacc tggaaatagc tggttctctc cgaaaactat ttaggtagtg cctcgtgtct 840  
 caccttcggg ggttaggcac tgtcatggtt ggggggtcta ttgcagatta ccccgccata 900  
 gcaaaactcg aataccgaag agtgcaatca cgggagacag acatcgggtg ctaacgtccg 960  
 gtgtcaagag ggaacaacc cagaccgcca gctaagggtc ccaaatatag ctaagtggga 1020  
 aacgaagtgg gaaggctaaa acagtcagga ggttggctta gaagcagcca ccctttaaag 1080  
 45 aaagcgtaat agctcactga tgcagtcgtc ctgcgcggaa gatgtaacgg ggctaagcta 1140  
 tataccgaag ctgcggatgc gtgctttgca cgatggtagg agagcgttcc gtaagcctgc 1200  
 gaaggtgcct tgtaaagggt gctggaggta tcggaagtgc gaatgctgac atgagtagcg 1260  
 ataaaggggg tgaaaggccc cctcgccgta agcccaagg ttcctacgca acgttcactc 1320  
 gcgtagggtg agtcggcccc taaggcgagg cagaaatgcg tagctgatgg gaagcaggct 1380  
 50 aatattcctg caccattgtt agatgcgatg gggggacgga tcgcggaagg ttgtccgggt 1440  
 gttggaagtc ccggtcgctg cattggagaa ggcgcttagg caaatccggg cgcagaattc 1500  
 aaggggtgtg cgcgagctcc ttcgggagcg aagcaattgg aagtgggtcc aagaaaagcc 1560  
 tctaagcttc agtctaacga tgaccgtacc gcaaacgcac acagggtgggc gagatgagta 1620  
 ttctaaggcg cttgagagaa ctcgggagaa ggaactcggc aaattggtag cgtaacttcg 1680  
 55 ggataaggta cgcccttgta gcttgactgg cctgcgccag gaggtggaag gggttgcaat 1740  
 aaactgggtg ctgcgactgt ttaataaaaa cacagcactc tgcaaacacg aaagtggacg 1800



tataggggtgt gacgcctgcc cgggtgccga agattaaatg atgggggtgca agctcttgat 1860  
 tgaagtcoccg gtaaacggcg gccgtaacta taacgggtcct aaggtagcga aattccttgt 1920  
 cgggtaagtt ccgacctgca cgaatggcgt aacgatggcc aactgtctc ctcccagac 1980  
 tcagcgaagt tgaagtgttt gtgatgatgc aatctaccg cggctagacg gaaagacccc 2040  
 5 atgaaccttt actgtagctt tgcattggac tttgaaccga tctgtgtagg ataggtggga 2100  
 ggctatgaaa ccggaacgct agtttcgggt gagccgtcct tgaataacca ccctggtttg 2160  
 tttgaggttc taaccttggc ccgtgatccg ggtcggggac agtgcattgt aggcagtttg 2220  
 actggggcgg tctcctocca aagcgtaacg gaggagtacg aaggtagcgt aggtacggtc 2280  
 ggaaatcgtg ctgatatgtc aatggcataa gcgtgcttaa ctgcgagacc gacaagtcca 2340  
 10 gcagggtgca aagcaggcca tagtgatccg gtggttctgt atggaagggc catcgctcaa 2400  
 cggataaaag gtactctggg gataacaggc tgataccgcc caagagttca tatcgacggc 2460  
 ggtgttttggc acctcgatgt cggctcatct catcctgggg ctgtagccgg tcccaagggt 2520  
 atggctgttc gccatttaaa gaggtacgtg agctgggttt aaaacgtcgt gagacagttt 2580  
 ggtccctatc tgcctggggc gttggatatt tgaagggggc tgctcctagt acgagaggac 2640  
 15 cggagtggac gaacctctgg tgtaccgggt gtcacgccag tggcatcgcc gggtagctat 2700  
 gttcgggaaga gataaccgct gaaagcatct aagcgggaaa ctgccttaa gatgagatat 2760  
 ccctggggac tagatccctt tgaagggtcg ttcgagacca ggacgttgat aggtcagggt 2820  
 tgtaagcgca gtaatgcgtt cagctaactg atactaattg cccgtaaggc ttgatcct 2878

20 <210> 67  
 <211> 2882  
 <212> DNA  
 <213> Burkholderia mallei

25 <400> 67  
 ggtcaagcga acaagtgcatt gtggtggatg ccttggcgat cacaggcgat gaaggacggc 60  
 gtagcctgcg aaaagctacg gggagctggc aaacgagctt tgatccgtag atgtccgaat 120  
 ggggaaaccc ggcccttttg ggtcatccta gactgaatac ataggtctag tgaggcgaac 180  
 30 gcggtgaact gaaacatcta agtaaccgca ggaagaaaa tcaaccgaga ttcccaaagt 240  
 agtggcgagc gaaatgggaa gagcctgtac tctttatttg tattgttagc cgaacgctct 300  
 ggaaagtgcg gccatagcag gtgatagccc tgtagggcaa aacagtatga aagaactagg 360  
 tgtacgacaa gtagggcggg acacgtgaaa tctgtctga agatgggggg accatcctcc 420  
 aaggctaaat actcgtgac gaccgatagt gaaccagtag cgtgagggaa aggcgaaaaa 480  
 35 aaccccgga ggggagtgaa atagatcctg aaaccgcatg catacaaaac gtcggagcct 540  
 cttcgggggt gacggcgtac cttttgtata atgggtcagc gacttacgtt cagtagcaag 600  
 cttaaccgaa tagggcaggc gtagcgaaag cgagtcgcaa tagggcgttc agttgctggg 660  
 cgtagaccgg aaaccagggt atctatccat ggcaggatg aagggtgcgt aacacgtact 720  
 ggaggtccga acccactaac gttgaaaagt taggggatga gctgtggata ggggtgaaag 780  
 40 gctaaacaaa cctggaaata gctggttctc tccgaaaact atttaggtag tgctcgtgt 840  
 ctcaacctcg ggggtagagc actgtcatgg ttgggggggtc tattgcagat taccgcccca 900  
 tagcaaaactc cgaataccga agagtgcatt cacgggagac agacatcggg tgctaacgtc 960  
 cgggtgtcaag agggaaacaa cccagaccgc cagctaaggt ccccaaatat ggctaagtgg 1020  
 gaaacgaagt gggaaggcta aaacagtcag gaggttggct tagaagcagc caccctttta 1080  
 45 agaaagcgta atagctcact gatcgagtcg tcctgcgcgg aagatgtaac ggggctaagc 1140  
 catataccga agctgcggat gcgagctagt ctgcgatggt aggagagcgt tccgtaagcc 1200  
 tgcaaggtg cgttgaaaag cgtgctggag gtagcggaag tgcgaatgct gacatgagta 1260  
 gcgataaaag ggtgaaaagg cccctcggc gtaagcccaa ggtttcctac gcaacgttca 1320  
 tcggcgtagg gtgagtcggc ccctaaggcg aggcagaaat gcgtagctga tgggaagcag 1380  
 50 gtcaatattc ctgcaccgtc gtttagatgc atggggggac ggatcgcgga aggttgctcg 1440  
 ggtgttgaa gtcccggtcg ctgcattgga gaaggcgctt aggcgaatcc gggcgaggga 1500  
 ttcaagggtg tggcgcgagc tccttcggga gcgaagcaat tgggaagtgg tccaagaaaa 1560  
 gcctctaagc ttcagtctaa cgatgaccgt accgcaaacc gacacagggt ggcgagatga 1620  
 gtattctaag gcgcttgaga gaactcggga gaaggaactc ggcaaatttg taccgtaact 1680  
 55 tcgggataag gtacgacctg gtagcttgac tggcctgcgc cagaagggtg aaggggttgc 1740  
 aataaactgg tggctgcgac tgtttaataa aaacacagca ctctgcaaac acgaaagtgg 1800

5 acgtataggg tgtgacgcct gcccgggtgcc ggaagattaa atgatgggggt gcaagctcct 1860  
 gattgaagtc ccggtaaacg gcggccgtaa ctataacggt cctaaggtag cgaaattcct 1920  
 tgtcgggtaa gttccgacct gcacgaatgg cgtaacgatg gccacactgt ctccctccga 1980  
 gactcagcga agttgaagtg tttgtgatga tgcaatctac ccgcggttag acggaagac 2040  
 cccatgaacc ttactgttag ctttgcattg gactttgaac cgatctgtgt aggatagggtg 2100  
 ggaggctatg aaaccggaat gctagtttcg gtggagccgt ccttgaaata ccaccctgggt 2160  
 ttgtttgagg ttctaacctt ggcccggtgat ccgggtcggg gacagtgcac ggtaggcagt 2220  
 ttgactgggg cgtctcctc ccaaagcgta acggaggagt acgaaggtag gctagggtacg 2280  
 gtcggaatc gtgctgatag tgcaatggca taagcgtgct taactgcgag accgacaagt 2340  
 10 cgagcagggtg cgaagcagg tcatagtgat ccggtgggtc tgtatggaag ggccatcgct 2400  
 caacggataa aagggtactct ggggataaca ggctgatacc gcccaagagt tcatatcgac 2460  
 ggcggtgttt ggcacctcga tgcgggtca tctcactctg gggctgtagc cgggtcccaag 2520  
 ggtagtggctg ttcggccattt aaagaggtag gtgagctggg tttaaaacgt cgtgagacag 2580  
 tttggtccct atctgccgtg ggcgttggaa gtttgaaggg ggctgctcct agtacgagag 2640  
 15 gaccggagtg gacgaacctc tgggtgacct gttgtgacgc cagtcgcacg gccgggtagc 2700  
 tatgttcgga agagataacc gctgaaagca tctaagcggg aaactcgcct taagatgaga 2760  
 ctccccggg gacttgatcc ccttgaaggg tcgttcgaga ccaggacgtt gatagggtcgg 2820  
 gtgtgtaagc gcagtaatgc gttcagctaa ccgatactaa ttgcccgtac ggcttgatcc 2880  
 20 ta 2882

&lt;210&gt; 68

&lt;211&gt; 2882

&lt;212&gt; DNA

25 <213> Burkholderia pseudomallei

&lt;400&gt; 68

30 ggtcaagcga acaagtgcac gtggtggatg ccttggcgat cacaggcgat gaaggacgag 60  
 gtagcctgag aaaagctacg gggagctggc aaacgagctt tgatccgtag atgtccgaat 120  
 ggggaaaccc ggcctctttt ggtcatccta gactgaatac ataggtctag tgaggcgaac 180  
 gcggtgaact gaaacatcta agtaaccgca gaaaaagaaa tcaaccgaga ttcccaaagt 240  
 agtggcgagc gaaatgggaa gagcctgtac tctttatttg tattgttagc cgaacgctct 300  
 ggaaagtgcg gccatagcag gtgatagccc tgtaggcgaa aacagtatga aagaactagg 360  
 35 tgtacgacaa gtaggcgagg acacgtgaaa tctgtctga agatgggggg accatcctcc 420  
 aaggctaaat actcgtgatc gaccgatagt gaaccagtac cgtgagggaa aggcgaaaag 480  
 aaccccgga ggggagtga atagatcctg aaaccgcatg catacaaaca gtcggagcct 540  
 cttcgggggg gacggcgtag cttttgtata atgggtcagc gacttacgtt cagtagcaag 600  
 ctaaacgaa tagggcaggg gttagcgaaa cgagtcgcaa tagggcggtc agttgctggg 660  
 40 cgtagaccgg aaaccagggt atctatccat ggccaggatg aagggtgcgg aacacgtact 720  
 ggaggtccga acccactaac gttgaaaagt taggggatga gctgtggata ggggtgaaag 780  
 gctaaacaaa cctgggaaata gctggttctc tccgaaaact atttaggtag tgcctcgtgt 840  
 ctcaccttcg ggggtagagc actgtcatgg ttgggggggtc tattgcagat taccctcgca 900  
 tagcaaacct cgaataaccga agagtgaat cacgggagac agacatcggg tgctaacgtc 960  
 45 cgtgtgcaag agggaaacaa cccagaccgc cagctaagggt ccccaaatat ggctaagtgg 1020  
 gaaacgaagt gggaaggcta aaacagtcag gagggttggc tagaagcagc caccctttta 1080  
 agaaagcgta atagctcact gatcgagtcg tcttgcgcgg aagatgtaac ggggctaagc 1140  
 catataccga agctgaggat gcgagctagt ctcgcattgt aggagagcgt tccgtaagcc 1200  
 tgcgaaaggt cgttgaaaag cgtgctggag gtatcggaag tgcgaatgct gacatgagta 1260  
 50 gcgataaagg ggggtgaaag cccctcgcg gtaagcccaa ggtttcctac gcaacgttca 1320  
 tcggcgtagg gtgagtcggc ccctaaggcg aggcagaaat gcgtagctga tgggaagcag 1380  
 gtcaatatct ctgcaccgtc gttagatgcg atggggggac ggatcgcgga aggttgtccg 1440  
 ggtgttggaa gtccccggtc ctgcattgga gaaggcgctt agggcaaatcc gggcgagga 1500  
 ttcaagggtg tggcgcgagc gctctagggc gcgaagcaat tggaagtggg tccaagaaaa 1560  
 55 gcctctaagc ttcagtctaa cgatgaccgt accgcaaac gacacagggt ggcgagatga 1620  
 gtattctaag gcgcttgaga gaactcgga gaaggaaact taccgtaact 1680  
 tcgggataag gtacgccctg gtagcttgac tggcctgcgc cagaagggtg aagggggttc 1740

5 aataaactgg tggctgcgac tgtttaataa aaacacagca ctctgcaaac acgaaagtgg 1800  
 acgtataggg tgtgacgcct gcccggtgcc ggaagattaa atgatggggg gcaagctcct 1860  
 gattgaagtc ccggtaaacc gcggccgtaa ctataacggt cctaaggtag cgaaattcct 1920  
 tgtcgggtaa gttccgacct gcacgaatgg cgtaacgatg gccacactgt ctctcccga 1980  
 gactcagcga agttgaagtg tttgtgatga tgcaatctac ccgcggttag acggaaagac 2040  
 cccatgaacc ttactgttag ctttgcattg gactttgaac cgatctgtgt aggatagggtg 2100  
 ggaggctatg aaaccggaac gctagtttcg gtggagccgt ccttgaaata ccaccctggt 2160  
 ttgtttgagg ttctaaccct ggcccgtgat ccgggtcggg gacagtgcac ggtaggcagt 2220  
 ttgactgggg cggctcctc ccaaagcgta acggaggagt acgaaggtag gctagggtacg 2280  
 10 gtcggaaatc gtgctgatag tgcaatggca taagcgtgct taactgcgag accgacaagt 2340  
 cgagcagggt gaaagcagg tcatagtcat ccggtggttc tgtatggaag ggccatcgct 2400  
 caacggataa aaggtactct ggggataaca ggctgatacc gcccaagagt tcatatcgac 2460  
 ggcggtgttt ggcactcga tctcggctca tctcatcctg gggctgtagc cgggtcccaag 2520  
 ggtatggctg ttccgccattt aaagaggtag gtgagctggg tttaaaacgt cgtgagacag 2580  
 15 tttggctcct atctgccgtg ggcgttggaa gtttgaaggg ggctgctcct agtacgagag 2640  
 gaccggagtg gacgaacctc tgggtgaccg gttgtgacgc cagtcgcacg gccgggtagc 2700  
 tatgttcgga agagataacc gctgaaagca tctaagcggg aaactcgcct taagatgaga 2760  
 cttccccggg gacttgatcc ccttgaaggg tcgttcgaga ccaggacgtt gatagggtcgg 2820  
 20 gtgtgtaagc gcagtaatgc gttcagctaa ccgatactaa ttgcccgtag ggcttgatcc 2880  
 ta

&lt;210&gt; 69

&lt;211&gt; 2890

25 &lt;212&gt; DNA

<213> *Neisseria gonorrhoeae*

&lt;400&gt; 69

30 ggtcaagtga ataagtgcac caggcgggat ccttggcgat gataggcgac gaaggacgtg 60  
 taagcctgcg aaaagcgcgg gggagctggc aataaagcta tgattccgag atgtccgaat 120  
 ggggaaaccc actgcattct gtgcagtatc ctaagttgaa tacataggct tagagaagcg 180  
 aacccggaga actgaacct ctaagtacc' ggaggaaaag aaatcaaccg agattccgca 240  
 agtagtgggc agcgaacgag gaggagcctg tacgtaataa ctgtcgagat agaagaacaa 300  
 35 aactgggaagc ttgaccatag cgggtgacag tcccgattc gaaatctcaa cagcgggtact 360  
 aagcgtacga aaagttagggc gggacacgtg aaatcctgtc tgaatatggg gggaccatcc 420  
 tccaaggcta aatactcatc atcgaccgat agtgaaccag taccgtgagg gaaaggcgaa 480  
 aagaaccccg ggagggaagt gaaacagaac ctgaaacctg atgcatacaa acagtgggag 540  
 cgccctagtg gtgtgactgc gtaccttttg tataatgggt caacgactta cattcagtag 600  
 cgagcttaac cggatagggg aggcgtaggg aaaccgagtc ttaatagggc gatgagttgc 660  
 40 tgggtgtaga cccgaaaccg agtgatctat ccatggtcag gttgaagggt ccgtaacagg 720  
 tactggagga ccgaaccac gcatgttgca aaatgcgggg atgagctgtg ggtaggggtg 780  
 aaaggctaaa caaactcgga gatagctggt tctccccgaa aactatttag gtagtgctc 840  
 gagcaagaca ctgatggggg taaagcactg ttatggctag ggggttattg caactacca 900  
 acccatggca aactcagaat accatcaagt ggttcctcgg gagacagaca gcgggtgcta 960  
 45 acgtccgttg tcaagaggga aacaacccag accgcggct aagggtccaa atgatagatt 1020  
 aagtggtaaa cgaagtggga aggcacagac agccaggatg ttggcttaga agcagccatc 1080  
 atttaaagaa agcgtaatag ctactggtc gagtgcctc gcgcggaaga tgtaacgggg 1140  
 ctcaaatcta taaccgaagc tgcggatgcc ggtttaccgg catggtaggg gagcgttctg 1200  
 tagctgtatg aagggtgcatt gtaaagtgtg ctggagggtat cagaagtgcg aatggtgaca 1260  
 50 tgagtagcga taaagcgggt gaaaagcccg ctgcgcgaaa gcccaagggt tcctacgcaa 1320  
 cgttcatcgg cgtagggtaa gtcggccctt aaggcgaggc agaaatgcgt agtcgatggg 1380  
 aaacagggtt atattcctgt acttgattca aatgcgatgt ggggacggag aagggttaggt 1440  
 tggcaagctg ttggaatagc ttgtttaagc cggtaggtgg aagacttagg caaatccggg 1500  
 ttttcttaac accgagaagt gatgacgagt gtctacggac acgaagcaac cgataccacg 1560  
 55 cttccaggaa aagccactaa gcttcagttt gaatcgaacc gtaccccaaa ccgacacagg 1620  
 tgggtaggat gagaattcta aggcgcttga gagaactcgg gagaaggaac tcggcacaatt 1680

5 gataccgtaa cttcgggaga aggtatgccc tctaagggtta aggacttgct ccgtaagccc 1740  
 cggagggtcg cagagaatag gtggctgcga ctgtttatta aaaacacagc actctgcca 1800  
 cacgaaagt gacgtatagg gtgtgacgcc tgcccgggtgc cggaggtta attgaagatg 1860  
 tgcaagcatc ggatcgaagc cccggtaaac ggcggccgta actataacgg tcctaaggta 1920  
 gcgaaattcc ttgtcgggta agttccgacc cgcacgaatg gcgtaacgat ggccacactg 1980  
 tctcctcccg agactcagcg aagttgaagt ggttgtgaag atgcaatcta cccgctgcta 2040  
 gacggaaaga ccccgtaac ctttactgta gctttgcatt ggactttgaa gtcacttggtg 2100  
 taggataggt gggaggcttg gaagcagaga cgccagtctc tgtggagtcg tccttgaaat 2160  
 10 accaccctgg tgtctttgag gttctaacc cagcccgta tccgggtcgg ggaccgtgca 2220  
 tggtaggcag tttgactggg gcggtctcct cccaaagcgt aacggaggag ttcgaagggt 2280  
 acctaggctc ggtcggaaat cggactgata gtgcaatggc aaaaggtagc ttaactgcga 2340  
 gaccgacaag tcgggcaggt gcgaaagcga gacatagtga tccggtgggt ctgtatggaa 2400  
 gggccatccg tcaacggata aaaggtaact cggggataac aggtcgattc cgcccaagag 2460  
 ttcatatcga cggcggagtt tggcacctcg atgtcggctc atcacatcct ggggctgtag 2520  
 15 tcgggtccaa gggataggct gttcgccatt taaagtggta cgtgagctgg gtttaaacg 2580  
 tcgtgagaca gtttggtccc tatctgcagt ggcgttgga gtttgacggg gctgctccta 2640  
 gtacgagagg accggagtgg acgaacctct ggtgtaccgg ttgtaacgcc agttgcatag 2700  
 ccgggttagct aagttcggaa gagataagcg ctgaaagcat ctaagcgca aactcgctg 2760  
 aagatgagac ttcccttgcg gtttaaccgc actaaagggt cgttcgagac caggacgtt 2820  
 20 atagggtggg tgtggaagcg cggtaacgcg tgaagctaac ccatacta atgcccgtgag 2880  
 gcttgactct 2890

<210> 70

25 <211> 2891

<212> DNA

<213> *Neisseria meningitidis*

<400> 70

30 gtcaagtga taagtgcac aggtggatgc cttggcgatg ataggcgacg aaggacgtgt 60  
 aagcctgcga aaagcgcggg ggagctggca ataaagcaat gatcccgca tgtccgaatg 120  
 gggaaaccca ctgcattctg tgcagtatcc taagttgaat acatagactt agagaagcga 180  
 acccgagaa ctgaaccatc taagtaccgc gaggaaga aatcaaccga gattccgcaa 240  
 35 gtatggcga gcgaacgcgg aggagcctgt acgtaataac tgtcgagata gaagaacaa 300  
 ctgggaagct tgaccatagt gggtagacgt cccgtattcg aaatctcaac agcggtaacta 360  
 agcgtacgaa aagtagggcg gggcacgtga aatcctgtct gaatatgggg ggaccatcct 420  
 ccaaggctaa atactcatca tcgaccgata gtgaaccagt accgtgaggg aaaggcgaaa 480  
 agaaccgccg gaggggagtg aaacagaacc tgaaacctga tgcatacaaa cagtgggagc 540  
 gccctagtgg tgtgactgcg taccttttgt ataatgggtc aacgacttac attcagtagc 600  
 40 gagcttaacc gaatagggga ggcgtaggga aaccgagctc taatagggcg atgagttgct 660  
 ggggttagac ccgaaccga gtgatctatc catggccagg ttgaagggtc cgtaacaggt 720  
 actggaggac cgaaccacg catggttgca aatgcgggga tgagctgtgg ataggggtga 780  
 aaggctaaac aaactcggag atagctgggt ctccccgaaa actatttagg tagtgcctcg 840  
 agcaagacac tgatgggggt aaagcactgt tatggctagg gggttattgc aacttaccaa 900  
 45 cccatggcaa actaagaata ccatcaagt gttcctcggg agacagacag cgggtgctaa 960  
 cgtccgttgt caagagggaa acaaccagga ccgccagcta aggtcccaaa tgatagatta 1020  
 agtggtaaac gaagtgggaa ggcccagaca gccaggatgt tggcttagaa gcagccatca 1080  
 tttaagaaaa gcgtataagc tctactgctc cgcggaagat gtaacggggc 1140  
 tcaaatctat aaccgaagct gcggatgccg gtttaccggc atggtagggg agcgttctgt 1200  
 50 aggtgatga aggtgcattg taaagtgtgc tggaggtatc agaagtgcga atgttgacat 1260  
 gagtagcgat aaagcgggtg aaaagcccgc tcgccgaaag cccaaggttt cctgcgcaac 1320  
 gttcatcgcc gtaggggtgag tcggccccta aggcgaggca gaaatgcgta gtcgatggga 1380  
 aacagggtta tattcctgta cttgattcaa atgcgatgtg gggacggaga aggttaggtt 1440  
 ggcaagctgt tggaatagct tgtttaagcc ggtaggtgga agacttaggc aaatccgggt 1500  
 55 cttcttaaca ccgagaagt acgacgagtg tctacggaca cgaagcaacc gataccacgc 1560  
 ttccaggaaa agccactaag cttcagtttg aatcgaaccg taccgcaaac cgacacaggt 1620

	gggcaggatg	agaattctaa	ggcgcttgag	agaactcagg	agaaggaact	cggcaaattg	1680
	ataccgtaac	ttcgggagaa	ggtatgccct	ctaagggttaa	ggacttgctc	cgtaagcccc	1740
	ggaggggtcg	agagaatagg	tggtgcgac	tgtttattaa	aaacacagca	ctctgctaac	1800
	acgaaagtgg	acgtataggg	tgtgacgcct	gcccggtgct	ggaagggttaa	ttgaagatgt	1860
5	gagagcatcg	gatcgaagcc	ccagtaaacy	gcggccgtaa	ctataacggg	cctaaggtag	1920
	cgaaattcct	tgctgggtaa	gttccgaccc	gcacgaatgg	cgtaacgatg	gccacactgt	1980
	ctcctcctga	gactcagcga	agttgaagtg	gttgtgaaga	tgcaatctac	ccgctgctag	2040
	acggaaagac	cccgtgaacc	tttactgtag	ctttgcattg	gactttgaag	tcacttggtg	2100
	aggataggtg	ggagggttag	aagcagagac	gccagtctct	gtggagccgt	ccttgaaata	2160
10	ccaccctggt	gtctttgagg	ttctaaccga	gacccgtcat	ccgggtcggg	gaccgtgcat	2220
	ggtaggcagt	ttgactgggg	cggtctcctc	ccaaagcgta	acggaggagt	tcgaagggtta	2280
	cctagggtccg	gtcgggaatc	ggactgatag	tgcaatggca	aaaggtagct	taactgcgag	2340
	accgaacaagt	cgagcaggtg	cgaaagcagg	acatagtgat	ccgggtggtc	tgtatggaag	2400
	ggccatcgct	caacggataa	aagggtactcc	ggggataaca	ggctgattcc	gcccagaggt	2460
15	tcataatcgac	ggcggagttt	ggcacctcga	tgctgggtca	tcacatcctg	gggctgtagt	2520
	cggtcccaag	ggtatggctg	ttcgccattt	aaagtggtag	gtgagctggg	tttaaaacgt	2580
	cgtagagacag	tttgggtccct	atctgcagtg	ggcgttgga	gtttgacggg	ggctgctcct	2640
	agtacgagag	gaccggagtg	gacgaacctc	tggtgtaccg	gttgaacgc	cagttgcata	2700
	gccgggtagc	taagtccgga	agagataagc	gctgaaagca	tctaagcgcg	aaactcgccct	2760
20	gaagatgaga	cttcccttgc	ggtttaaccg	cactaaagag	tcgttcgaga	ccaggacgtt	2820
	gataggtggg	gtgtggaagc	gcggtaacgc	gtgaagctaa	cccatactaa	ttgctcgtga	2880
	ggcttgactc	t					2891
25	<210> 71						
	<211> 2891						
	<212> DNA						
	<213> Pseudomonas aeruginosa						
30	<400> 71						
	ggtcaagtga	agaagcgcat	acgggtggatg	ccttggcagt	cagaggcgat	gaaagacgtg	60
	gtagcctgcy	aaaagcttcc	gggagtcggc	aaacagactt	tgatccggag	atctctgaat	120
	gggggaaccc	acctaggtata	acctaggtat	cttgtactga	atccataggt	gcaagaggcg	180
	aaccaggggga	actgaaacat	ctaagtaccc	tgaggaaaaag	aaatcaaccg	agattccctt	240
35	agtagtgggc	agcgaacggg	gatttagccct	taagcttcat	tgatttttagc	ggaacgctct	300
	ggaaagtgcg	gccatagtgg	gtgatagccc	cgtacgcgaa	aggatctttg	aagtgaatc	360
	gagtaggacg	gagcacgaga	aactttgtct	gaacatgggg	ggaccatcct	ccaaggctaa	420
	atactactga	ctgaccgata	gtgaaccagt	accgtgaggg	aaaggcgaaa	agaacccccg	480
	agaggggagt	gaaatagaac	ctgaaaccgt	atgcgtacaa	gcagtgggag	cctacttggt	540
40	aggtagactgc	gtaccttttg	tataatgggt	cagcgactta	tattcagtgg	caagcttaac	600
	cgtatagggg	aggcgtagcg	aaagcgagtc	ttaatatggg	gttttagtcg	tgggtataga	660
	cccgaacccg	ggcgatctat	ccatgagcag	gttgaagggt	aggtaacact	gactggagga	720
	ccgaacccac	tcccgttgaa	aaggtagggg	atgacttggt	gatcggagtg	aaaggctaat	780
	caagctcgga	gatagctggt	tctcctcgaa	agctattttag	gtagcgccct	atgtatcact	840
45	ctgggggggta	gagcactggt	tcggctaggg	ggctcatccc	acttaccaaa	ccgatgcaaa	900
	ctccgaatac	ccagaagtgc	cgagcatggg	agacacacgg	cggggtgctaa	cgctccgtcgt	960
	gaaaaggggaa	acaacccaga	ccgccagcta	agggtcccaa	gttgtgggtta	agtggtaaac	1020
	gatgtggggaa	ggcttagaca	gctaggaggt	tggtctagaa	gcagccaccc	tttaagaaa	1080
	gcgtaaatagc	tcactagtcg	agtcggcctg	cgcggaagat	gtaacggggc	tcaaacacaca	1140
50	caccgaagct	gcgggtgtca	cgtaagtgc	gcggtagagg	agcgttctgt	aagcctgtga	1200
	aggtaggttg	agaagcttgc	tggaggtatc	agaagtgcga	atgctgacat	gagtaacgac	1260
	aatgggtgtg	aaaaacaccc	acgccgaaag	accaagggtt	cctgcgcaac	gttaatcgac	1320
	gcagggttag	tcggttccta	aggcgaggct	gaaaagcgta	gtcgatggga	aacagggttaa	1380
	tattcctgta	cttctgggtta	ctgcgatgga	gggacggaga	aggctaggcc	agcttggcgt	1440
55	tggttggtcca	agtttaagggt	ggtaggtgga	aatcttaggt	aaatccgggg	tttcaaggcc	1500
	gagagctgat	gacgagtcgt	cttttagatg	acgaagtgggt	tgatgccatg	cttccaagaa	1560

	aagcttctaa	gcttcaggta	accaggaacc	gtaccccaaa	ccgacacagg	tggctcgggta	1620
	gagaatacca	aggcgcttga	gagaactcgg	gtgaaggaa	taggcaaaat	ggcaccgtaa	1680
	cttcggggaga	agggtcgccg	gctagggtga	aggatttact	ccgtaagctc	tggctggtcg	1740
	aagataccag	gccgtgcgca	ctgtttatta	aaaacacagc	actctgcaaa	cacgaagtg	1800
5	gacgtatagg	gtgtgacgcc	tgcccgggtg	cggaaaggtta	attgatgggg	ttagcgcaag	1860
	cgaagctctt	gatcgaagcc	ccggtaaacg	gcgcccgtaa	ctataacggt	cctaaggtag	1920
	cgaatttcct	tgctgggtaa	gttccgacct	gcacgaatgg	cgtaacgatg	gcgccgctgt	1980
	ctccaccgga	gactcagtga	aattgaaatc	gctgtgaaga	tgcatgtgat	ccgcggctag	2040
	acggaaagac	cccgtgaacc	tttactgtag	ctttgcactg	gactttgagc	ctgcttgtgt	2100
10	aggatagggtg	ggaggctttg	aagcgtggac	gccagttcgc	gtggagccat	ccttgaaata	2160
	ccaccctggc	atgcttgagg	ttctaactct	ggcccgtaat	ccggtcgcag	gacagtgtat	2220
	gttggggcagt	ttgactgggg	cggctctcctc	ctaaagagta	acggaggagt	acgaagggtg	2280
	gctcagaccg	gtcggaaatc	ggtcgcagag	tataaaggca	aaagcgcgct	tgactgagag	2340
	acagacacgt	cgagcaggta	cgaaagtagg	tcttagtgat	ccggtgggtc	tgatggaag	2400
15	ggccatcgct	caacggataa	aaggtagctc	ggggataaca	ggctgatacc	gccaagagt	2460
	tcatatcgac	ggcgggtgtt	ggcacctcga	tgctggctca	tcacatcctg	gggctgaagc	2520
	cgggtcccaag	ggtatggctg	ttcgccattt	aaagtggtag	gcgagctggg	tttagaacgt	2580
	cgtgagacag	ttcgggtccct	atctgcccgtg	gacgtttgag	atttgagagg	ggctgctcct	2640
	agtacgagag	gaccggagtg	gacgaacctc	tggtgttccg	gttgtcacgc	cagtggcatt	2700
20	gccgggtagc	tatgttcgga	aaagataacc	gctgaaagca	tctaagcggg	aaacttgctt	2760
	caagatgaga	tctcactggg	aacttgattc	ccctgaaggg	ccgtcgaaga	ctacgacgtt	2820
	gataggctgg	gtgtgtaagc	gttgtgaggc	gttgagctaa	ccagtactaa	ttgcccgtag	2880
	ggcttgacca	t					2891
25	<210> 72						
	<211> 2886						
	<212> DNA						
	<213> Vibrio cholerae						
30	<400> 72						
	ggttaagtga	ctaagcgtac	acgggtggatg	cctggggcagt	cagaggcgat	gaaggacgta	60
	ctaacttgcg	ataagcgcag	ataaggcagt	aagagccgtt	tgagtctgcg	atttccgaat	120
	ggggaaaccc	aactgcataa	gcagttactg	ttaactgaat	acatagggtta	acagagcaaa	180
35	ccgggggaac	tgaaacatct	aagtaccccc	aggagaagaa	atcaaccgag	attccggtag	240
	tagcggcgag	cgaacctgga	ttagccctta	agcactcggg	gaagtaggtg	aacaagctgg	300
	aaagcttggc	gatacagggg	gatagccccg	taaccgacgc	ttcatcgagc	gtgaaatcga	360
	gtaggggcgg	acacgtgata	tctgtcttga	atatgggggg	accatcctcc	aaggctaaat	420
	actcctgact	gaccgatagt	gaaccagtag	cgtgaggaaa	ggcgaaaaga	accctctgtg	480
40	ggggagtga	atagaacctg	aaaccgtgta	cgtacaagca	gtaggagcac	cttcgtgggtg	540
	tgactgcgta	ccttttgtat	aatgggtcag	cgacttatat	tcagtggcaa	ggttaaccgt	600
	ataggggagc	cgtagcgaaa	gcgagtctta	actgggcgct	cagtctcttg	atatagacct	660
	gaaaccgggt	gatctagcca	tgggcagggt	gaaggttgag	taacatcaac	tgagggaccg	720
	aaccgactaa	tgttgaaaaa	ttagcggatg	acttgtggct	aggggtgaaa	ggccaatcaa	780
45	actcggagat	agctggttct	ccccgaaagc	tatttaggtg	gcgcctcgga	cgaatactac	840
	tgggggtaga	gcaactgtta	ggctaggggg	tcaccccgac	ttaccaaccc	tttgcaaaact	900
	ccgaatacca	gtaagtacta	tccggggagc	acacggcggg	tgctaacgtc	cgtcgtggag	960
	ggggaaacaa	ccagacccgc	cagctaaggt	cccaaagtat	tgctaagtgg	gaaacgatgt	1020
	gggaaggctc	agacagctag	gatgttggct	tagaagcagc	catcatttaa	agaaagcgta	1080
50	atagctcact	agtcgagtcg	gcctgcgcgg	aagatgtaac	ggggctaagc	aatacaccga	1140
	agctgcggca	atatctttta	gatattgggt	aggggagcgt	tctgtaagcc	ggtgaagggtg	1200
	aatcgtaagg	tttgctggag	gtatcagaag	tgcgaaatgct	gacatgagta	acgacaaagg	1260
	gggtgaaaaa	cctcctcgcc	ggaagaccaa	gggttcctgt	ccaacgttaa	tcggggcagg	1320
	gtgagtcgac	ccctaagggt	aggccgaaag	gcgtaatcga	tgggaaacgg	gttaatatct	1380
55	ccgtacttct	gactattgct	atggggggac	ggagaaggct	aggtgggcca	ggcgacgggt	1440
	gtcctgggttc	aagtgcgtag	gcttgagagt	taggtaaatc	cggctctctc	taaggctgag	1500

5 acacgacgtc gagctactac ggtagtgaag tcattgatgc catgcttcca ggaaaagcct 1560  
 ctaagcttca gatagtcagg aatcgtaccc caaaccgaca cagggtggtcg ggtagagaat 1620  
 accaaggcgc ttgagagaac tcgggtgaag gaactaggca aaatgggtacc gtaacttcgg 1680  
 gagaaggtag gctcttgatg gtgaagtccc tcgcggatgg agctgacgag agtcgcagat 1740  
 accaggtggc tgcaactgtt tattaataaac acagcactgt gcaaaatcgc aagatgacgt 1800  
 atacggtgtg acgcctgccc ggtgccgga ggtaattga tgggggttagc gcaagcgaag 1860  
 ctcttgatcg aagccccggt aaacggcggc cgtaactata acggtcctaa ggtagcgaaa 1920  
 ttcttgatcg ggtaagttcc gacctgcacg aatggcgtaa tgatggccac gctgtctcca 1980  
 cccgagactc agtgaaattg aaatcgctgt gaagatgcag tgtaccgcg gctagacgga 2040  
 10 aagaccccggt gaacctttac tacagcttgg cactgaacat tgaacctaca tgtgtaggat 2100  
 aggtgggagg ctatgaagac gtgacgccag ttgcgttga gccgtccttg aaataccacc 2160  
 ctgtgatgtt tgatgttcta acttagacct gttatccggg ttgaggacag tgcctggtgg 2220  
 gtagtttgac tggggcggtc tcctcccaaa gagtaacgga ggagcacgaa ggtgggctaa 2280  
 tcacggttgg acatcgtgag gttagtgcag tggcataagc ccgcttaact gcgagaatga 2340  
 15 cggttcgagc aggtgcgaaa gcaggtcata gtgatccggt gggtctgtat ggaagggcca 2400  
 tcgctcaacg gataaaagggt actccgggga taacaggctg ataccgcca agagttcata 2460  
 tcgacggcgg tggttgccac ctcgatgtcg gctcatcaca tcctggggct gaagtcgggtc 2520  
 ccaagggtat ggctgttcgc catttaaagt ggtacgcgag ctgggtttag aacgtcgtga 2580  
 gagagttcgg tccttatctg ccgtgggctg ttggaagattg aagggggctg ctccctagat 2640  
 20 gagaggaccg gagtgagcga acctctgggt ttcgggttgt gtcgccagac gcattgcccg 2700  
 gtagctaagt tcggaattga taagcgctga aagcatctaa gcgcgaagcg agccctgaga 2760  
 tgagtcttcc ctgacagttt aactgtccta aaggggttgt cgagactaga acgttgatag 2820  
 gcagggtgtg taagcgttgt gaggcgttga gctaacctgt actaattgcc cgtgaggctt 2880  
 aaccat 2886

25

&lt;210&gt; 73

&lt;211&gt; 2906

&lt;212&gt; DNA

30 <213> *Yersinia enterocolitica*

&lt;220&gt;

&lt;221&gt; modified\_base

&lt;222&gt; (1168)..(1178)

35 &lt;223&gt; N = A, C, G or T/U

&lt;400&gt; 73

40 ggtaagcga ccaagcgtac acgggtggat cctaggcagt cagaggcgat gaaggacgtg 60  
 ctaatctcg aaaagcgtcg gtaagggtgat atgaaccgtt ataaccgacg ataccggaat 120  
 ggggaaaccc agtgcaattc gttgcactat tgcatgggtga atacatagcc atgcaaggcg 180  
 aaccggggga actgaaacat ctaagtaccc cgaggaaaag aaatcaaccg agattcccc 240  
 agtagcggcg agcgaacggg gaggagccca gaacctgaat cagcgtatgt gttagtggaa 300  
 gcgtctggaa agtcgcacgg tacagggtga tagtcccgt cacaataatg catatgttgt 360  
 gagttcgatg agtagggcgg gacacgtgac atcctgtctg aatatggggg gaccatcctc 420  
 45 caaggctaaa tactcctgac tgaccgatag tgaaccagta ccgtgaggga aaggcgaaaa 480  
 gaaccccggc gaggggagtg aaacagaacc tgaaaccgtg tacgtacaag cagtgggagc 540  
 accttcgtgg tgtgactgcg taccttttgt ataattgggtc agcgacttat atttttagc 600  
 aagggttaacc gaataaggga gccgtaggga aaccgagtct taactgggag aatagttgca 660  
 aggtatagac ccgaaaccgg gtgatctagc cctgggcagg ttgaagggtg ggtaacacta 720  
 50 actggaggac cgaaccgact aatggtgaaa aattagcgga tgacttgtgg ctgggggtga 780  
 aaggccaatc aaaccgggag atagctggtt ctccccgaaa gctatttagg tagcgctcgc 840  
 tgaactcatc ttcgggggta gagcactgtt tcggctaggg ggcatcccg acttaccaaa 900  
 ccgatgcaaa ctccgaatac cgaagaatgt tatcacggga gacacacggc ggggtgctaac 960  
 gtccgctcgtg aagagggaaa caaccagac cgccagctaa ggtcccaaag tcatgggtta 1020  
 55 gtgggaaacg atgtgggaag gcacagacag ccaggatgtt ggcttagaag cagccatcat 1080  
 ttaaagaaag cgtaatatgct cactgggtcga gtcggcctgc gcggaagatg taacggggct 1140

aaaccatgca ccgaagctgc ggcagcgnnn nnnnnnnnnn nnnnnnnngg ggagcggttct 1200  
 gtaagccggt gaaggtgacc tgtgaggggt gctggaggta tcagaagtgc gaatgctgac 1260  
 ataagtaacg ataatgcggg tgaaaaaccc gcacgcggga agaccaaggg ttcctgtcca 1320  
 acgttaatcg gggcaggggt agtcgacccc taaggcgagg ctgaaaggcg tagtcgatgg 1380  
 5 gaaacaggtt aatattcctg tacttggtgt tactgcgaag gggggacgga gaaggctatg 1440  
 ctagccgggc gacggttgct ccggtttaag catgtaggcg gagtgaccag gtaaatccgg 1500  
 ttgcttatca acgctgaggt gtgatgacga gtcactacgg tgatgaagta gttgatgcca 1560  
 tgcttccagg aaaagcctct aagcatcagg taacatgaaa tcgtacccca aaccgacaca 1620  
 ggtgggtcagg tagagaatac tcaggcgctt gagagaactc ggggtgaagga actaggcaaa 1680  
 10 atgggtgccgt aacttcggga gaaggcacgc tgacacgtag gtgaagcggg ttaccctggg 1740  
 agctgaagtc agtcgaagat accagctggc tgcaactggt tattaataaac acagcactgt 1800  
 gcaaacacga aagtggacgt atacgggtgt acgcctgccc ggtgctggaa ggttaattga 1860  
 tggggtcacg gcaagcgaag ctcttgatcg aagccccggt aaacggcggc cgtaactata 1920  
 acggctcctaa ggtagcgaag ttcttgctcg ggtaagttcc gacctgcacg aatggcgtaa 1980  
 15 tgatggccag gctgtctcca cccgagactc agtgaaattg aactcgctgt gaagatgcag 2040  
 tgtaccgcg gcaagacgga aagaccctgt gaacctttac tatagcttga cactgaacat 2100  
 tgagccttga tgtgtaggat aggtgggagg catagaagtg tggacgccag tctgcatgga 2160  
 gccaaccttg aaataaccacc cttaaatggt tgatgttcta actcggcccc gtaatccggg 2220  
 gtgaggacag tgtcaggtgg gtagtttgac tggggcggtc tcctcccaa gagtaacgga 2280  
 20 ggagcacgaa ggttagctaa tcacggtcgg acatcgtag gttagtgaag aggcataagc 2340  
 tagcttcaat gcgagagtga cggctcgagc aggtacgaaa gtaggtctta gtgatccgg 2400  
 ggttctgaat ggaagggcca tcgctcaacg gataaaagg actccgggga taacaggctg 2460  
 ataccgcccc agagttcata tcgacggcgg tggttgccac ctcgatgtcg gctcatcaca 2520  
 tcctggggct gaagtaggtc ccaagggtat ggctgttcgc catttaaagt ggtacgcgag 2580  
 25 ctgggttttag aacgtcgtga gacagttcgg tccttatctg ccgtgggcgy tggarraytg 2640  
 agrggggctg ctccatagta gagaggaccg gagtggacgm atcactggtg ttcgggttgt 2700  
 catgccaatg gcaytgcccc gtagctaaat kcggaagaga taasygctga aagcatctaa 2760  
 gcrsgaaact tgccycgaga tgagttctcc ctgagactac aagtctcctg aaggaacggt 2820  
 gaagacgacg acgttgatag gcygggtgtg taagcgcgag ttggcggtga gctaaccggt 2880  
 30 actaatgaac cgtgaggctt aacctt 2906

<210> 74  
 <211> 23  
 35 <212> DNA  
 <213> Artificial Sequence

<220>  
 40 <223> Description of Artificial Sequence: Synthetic  
 Primer

<400> 74  
 gggttgcgct cgttacggga ctt 23

45 <210> 75  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence

50 <220>  
 <223> Description of Artificial Sequence: Synthetic  
 Primer

55 <400> 75  
 gggttgcgct cgttgccgga ctt 23



5 <210> 76  
<211> 23  
<212> DNA  
<213> Artificial Sequence

10 <220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

<400> 76  
tccccactgc tgcctcccgt agg 23

15 <210> 77  
<211> 23  
<212> DNA  
<213> Artificial Sequence

20 <220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

25 <400> 77  
caacatctca cgacacgagc tga 23

30 <210> 78  
<211> 23  
<212> DNA  
<213> Artificial Sequence

35 <220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

40 <400> 78  
tccccactgc tgcctcccgt agg 23

45 <210> 79  
<211> 22  
<212> DNA  
<213> Artificial Sequence

50 <220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

<400> 79  
ttaccgcggc tgctggcacg ga 22

55 <210> 80  
<211> 23

<212> DNA  
<213> Artificial Sequence

5 <220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

10 <400> 80  
ccccgtcaat tcctttgagt ttc 23

15 <210> 81  
<211> 23  
<212> DNA  
<213> Artificial Sequence

20 <220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

25 <400> 81  
caacatctca cgacacgagc tga 23

30 <210> 82  
<211> 23  
<212> DNA  
<213> Artificial Sequence

35 <220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

40 <400> 82  
tttcaccttt ccctcacggt act 23

45 <210> 83  
<211> 23  
<212> DNA  
<213> Artificial Sequence

50 <220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

55 <400> 83  
ggttcttttc acctttccct cgc 23

<210> 84  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
Primer

5 <400> 84  
tggtttcagg ttctatttca ctc 23

10 <210> 85  
<211> 22  
<212> DNA  
<213> Artificial Sequence

15 <220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

<400> 85  
tttaaccgac aaggaatttc gc 22

20 <210> 86  
<211> 23  
<212> DNA  
<213> Artificial Sequence

25 <220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

30 <400> 86  
ggttcttttc acctttccct cgc 23

35 <210> 87  
<211> 15  
<212> DNA  
<213> Artificial Sequence

40 <220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

45 <400> 87  
taacctggtc gtaac 15

50 <210> 88  
<211> 14  
<212> DNA  
<213> Artificial Sequence

55 <220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

<400> 88

cccccccccc cccc 14

5 <210> 89  
<211> 16  
<212> DNA  
<213> Artificial Sequence

10 <220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

15 <400> 89  
gccctaacc tcgtcg 16

20 <210> 90  
<211> 26  
<212> DNA  
<213> Artificial Sequence

25 <220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

30 <400> 90  
cgccctagc cgggtcgtag ctccgg 26

35 <210> 91  
<211> 26  
<212> DNA  
<213> Artificial Sequence

40 <220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

45 <400> 91  
cgccctaac ctggtcgtaa ctccgg 26

50 <210> 92  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
Primer

<400> 92  
aggcttcgat cccgggatcc gcg 23